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Glossary
The following abbreviations have been used throughout this thesis
5FU 5-Fluorouracil
adjOR Adjusted odds ratio
AgNORs Argyrophilic nucleolar organizer regions
AJCC American Joint Committee on Cancer
AMT Amniotic membrane transplant
ART Antiretroviral Therapy
ASR Age-standardised incidence rate
ATRA All-trans retinoic acid
BCPB British Council for Prevention of Blindness
BCRP Breast cancer resistance protein
BD Twice daily (12 hourly)
CD Cluster of designation
CI Confidence interval
CIN Conjunctival Intraepithelial Neoplasia
CIS Carcinoma-in-situ
CK Cytokeratin
CMV Cytomegalovirus
CONSORT Consolidated Standards of Reporting Trials
CPD Cyclobutane pyrimidine dimers
CsA Cyclosporin A
DFID Department for International Development
DNA Deoxyribonucleic acid
DSMB Data safety and monitoring board
E6 Early protein 6 (of human papilloma virus)
E7 Early protein 7 (of human papilloma virus)
EBV Epstein Barr Virus
EDTA Ethylenediaminetetracetic acid (an anticoagulant)
EGF-R Epidermal growth factor receptor
EQA External quality assurance
F- False negative
F+ False positive
FDA Food and drug administration
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FdUMP Fluorodeoxyuridine monophosphate
FdUTP Fluorodeoxyuridine triphosphate
FUTP Fluorouridine triphosphate
G1, G2 Growth phases of the cell cycle
GCLP Good clinical laboratory practice
GCP Good clinical practice
GDP Gross Domestic Product
Gy Grays (units of radiation)
H&E Haematoxylin and eosin
HAART Highly Active Antiretroviral Therapy
HACM HIV/AIDS Cancer Match study
HC-2 Hybrid Capture 2
HEED Health education and Early Detection study
HGF Hepatocyte growth factor
HIV Human Immunodeficiency Virus
HPLC High-performance liquid chromatography
HPSG Heparin sulphate proteoglycan
HPV Human Papilloma Virus
HR Hazard ratio
HSV Herpes Simplex Virus
IAPB International Agency for Prevention of Blindness
IARC International Agency for Research in Cancer
ICD International Classification of Diseases
ICMJE International Council of Medical Journal Editors
IFN Interferon
IQR Interquartile range
ISCO International Standard Classification of Occupations
IU International units
IVCM in vivo confocal microscopy
JAMA Journal of the American Medical Association
k Kappa statistic (for inter-observer agreement)
KAIS Kenya AIDS indicator survey
KAVI Kenya AIDS Vaccine Institute
KDH Kitale District Hospital
KDHS Kenya Demographic and Health Survey
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KEU Kikuyu Eye Unit
KGF-R Keratinocyte growth factor receptor
KNH Kenyatta National Hospital
KNOCS Kenya National Occupation Classification System
KSHV Kaposi’s Sarcoma-associated Herpes Virus
L1, L2 Late proteins (of human papilloma virus)
LESC Limbal epithelial stem cells
LR Likelihood ratio
LSHTM London School of Hygiene & Tropical Medicine
M:F ratio Male to female ratio
MBASIC Multilevel Biological And Social Integrative Construct
MMC Mitomycin C
MMP Matrix Metalloproteinase
MOH Ministry of Health
M-phase Mitotic phase of the cell cycle
MRC Medical Research Council (UK)
MSVI Moderately severe visual impairment
MU Mega Units
Mutp53 Mutated p53 gene
NC ratio Nuclear to cytoplasm ratio
NGF Nerve growth factor
NHS National health service
NSOPS National specialist ophthalmic pathology service
OA Ophthalmic assistant
OCO/CS Ophthalmic clinical officer/Cataract surgeon
OCT Optical coherence tomography
OD Once daily
ON Ophthalmic nurse
OR Odds ratio
OSSN Ocular surface squamous neoplasia
PAS Periodic acid Schiff
PCEA Presbyterian Church of East Africa
PCNA Proliferating cell nuclear antigen
PCR Polymerase Chain Reaction
PEPFAR President’s Emergency Fund for AIDS Relief
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PMC Post-mitotic cells
pRB Retinoblastoma gene
PV- Predictive value of a negative test
PV+ Predictive value of a positive test
QID Four times daily (6 hourly)
qRT-PCR Quantitative Reverse Transcriptase Polymerase Chain Reaction
RCT Randomised controlled trial
RNA Ribonucleic acid
ROC curve Receiver operator characteristic curve
ROS Reactive oxygen species
SCC Squamous Cell Carcinoma
SCCC Squamous Cell Carcinoma of the Conjunctiva
SD Standard deviation
SE Standard error
SEH Sabatia Eye Hospital
SIR Standardised Incidence Rate
SOP Standard operating procedure
S-phase Synthesis phase of the cell cycle
SSA Sub-Saharan Africa
STI Sexually transmitted infections
TAC Transient amplifying cells
TDRC Tropical Diseases Research Centre
Th1 T-Helper 1 Lymphocytes
TID Three times daily (8 hourly)
TIL Tumour infiltrating lymphocytes
TIMP Transient Inhibitors of Matrix Metalloproteinase
ToB Toluidine Blue
UHR-OCT Ultra-high resolution Optical coherence tomography
UK United Kingdom
UON University of Nairobi
USA United States of America
UV Ultraviolet
UVR Ultraviolet radiation
WHO World Health Organization
XP Xeroderma pigmetosum
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Abstract
Introduction
Ocular surface squamous neoplasia (OSSN) is a spectrum of disease that ranges from non-
invasive intra-epithelial dysplasia of the conjunctival and cornea (CCIN), through to invasive
squamous cell carcinoma (SCC). It often presents with unilateral tumours on the eyeball. The
tumours may cause blindness, disfigurement and even death. In East Africa, OSSN is
relatively common and aggressive, affecting younger adults and proportionally more women
than in other parts of the world. The management of OSSN is challenging for various reasons.
Its risk factors are not clearly understood. Studies have implicated HIV, human papilloma virus
(HPV) and solar radiation however about 30% of cases are HIV-negative while some studies
have implicated HPV and others found no association. The importance of vitamin A for a
healthy ocular surface is known, yet its role in OSSN has not been studied. Early diagnosis
relies on the clinical impression yet OSSN appears similar to other conjunctival tumours and
histopathology services are generally unavailable in Africa. Surgery is the mainstay of
treatment but recurrence is an issue. There is no trial evidence for the various treatments used
in HIV-infected persons. This project was an integrated set of studies to improve our
understanding of the epidemiology and management of OSSN in Kenya.
Methods
We conducted three systematic reviews on the epidemiology of OSSN in Africa, the
pathophysiology of OSSN and updated a Cochrane review on the interventions for OSSN in
HIV-infected individuals. Working in four eye care centres in Kenya between July 2012 and
July 2015, we conducted the following six studies: (i) clinical assessment of a series of patients
with conjunctival lesions to describe OSSN to determine how OSSN may differ clinically from
benign lesions, (ii) evaluated vital staining with a special dye called Toluidine Blue (ToB) for
making the diagnosis of OSSN, (iii) developed a diagnostic algorithm based on clinical
features and vital staining, (iv) conducted a large case-control study to investigate risk factors
that may contribute to the development of OSSN, (v) investigated the care-seeking journey of
OSSN patients to assess referral pathway and treatment delay, and finally, (vi) conducted a
randomised placebo-controlled trial of 5-Fluorouracil (5FU) chemotherapy eyedrops given
after surgery to investigate if this can reduce recurrence of the lesions.
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Results
Meta-analysis of data from cancer registries worldwide showed that Africa has the highest
incidence of OSSN in the world with a peak at latitude 160 South and males and females are
equally affected, unlike other continents where male disease predominates. Here the age-
standardized rate in cases/year /100,000 population (95%CI) is 1.38 (1.00–3.75) and 1.18
(1.08–3.43) in males and females, respectively (p=0.853). Incidence rises with increasing
exposure to direct sunlight (2–4 h, OR = 1.7, 95% CI: 1.2–2.4 and ≥5 h OR = 1.8, 95% CI: 
1.1–3.1) and outdoor occupations (OR = 1.7, 95% CI: 1.1–2.6). Fixed-effect meta-analysis
shows a strong association with HIV (6 studies: OR = 6.17, 95% CI: 4.83–7.89) but not
cigarette smoking (2 studies: OR = 1.40, 95% CI: 0.94–2.09). HPV shows heterogeneous
association (random effects meta-analysis of 7 studies: OR = 2.64, 95% CI: 1.27–5.49).
The pathophysiology review concluded that limbal epithelial stem cells are the likely progenitor
cells of OSSN. UV radiation probably causes DNA damage via pyrimidine dimers (involving
the p53 tumour suppressor gene), photo-immunosuppression and reactivates latent HPV.
HPV E6 inhibits p53 gene allowing DNA-damaged cells past the G1-S checkpoint of the cell
cycle. HPV E7 inhibits the retinoblastoma (pRB) gene anti-transcription at G1 so infected cells
continue replicating. HIV, photo-immunosuppression and vitamin A deficiency may impair
tumour surveillance.
The Cochrane review found no trials for the interventions used in OSSN in HIV-infected
populations. There was one trial in Australia that found topical Mitomycin C (MMC) effective.
The results from case series reviewed were difficult to compare. They reported a wide variety
of combinations of surgery and adjuvant treatment used during surgery or post operatively;
varying doses of adjuvant agents used; different inclusion criteria of patients and recurrences
reported at varying periods after treatment. Surgery with adjuvant 5FU or MMC was often
associated with recurrences of 11% to 67% about 30 months later.
We enrolled 496 adults with any conjunctival lesions requiring excision and 131 controls.
OSSN was the most common lesion diagnosed in 187 (38%). Patients with OSSN were slightly
older (mean [SD] age, 41 [11.6] vs 38 [10.9] years; p =0.002) and tended to have lower levels
of education than patients with benign lesions (p = 0.001). Females predominated (67% of
OSSN vs 64% of benign lesions; p = 0.65). HIV infection was common among patients with
OSSN (74%). Although some clinical signs were more frequent in OSSN, all OSSN signs were
also observed in benign lesions. OSSN and benign conjunctival lesions have overlapping
phenotypes and cannot always be reliably distinguished on clinical grounds. The positive
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predictive value of clinical appearance in identifying OSSN was 54%. Inter-observer
agreement was modest (κ= 0.1-0.4).  
Any blue colour on vital staining with ToB 0.05% had a sensitivity of 92%, specificity of 31%,
positive predictive value of 41%, and negative predictive value of 88% for OSSN. Inter-
observer agreement was substantial for staining (k=0.8) and moderate for overall diagnosis
(OSSN or benign) (κ =0.4). Use of ToB caused mild discomfort in 88 (21%) patients; mild
superficial punctate keratopathy seen in 7 (1.7%) and no histological evidence of corneal
toxicity was observed. ToB had a high rate of false positives (69%).
We developed a simple probability-tree clinical algorithm that shows the probability of OSSN
with various combinations of clinical features. A multivariable regression model found 8
features strongly associated with OSSN; prior excision, corneal involvement, feeder vessels,
dark blue ToB staining, papillary or gelatinous tumour surface, severe inflammation, anti-
retroviral therapy and temporal or circumlimbal tumours. Using a cut-off of any 3 of these
features, the sensitivity was 89%, specificity 50%, and 65% of lesions were correctly classified.
This specificity was higher than any blue ToB staining (31%) but lower than clinical photo-
examination (60%).
A total of 131 cases were frequency-matched to 131 controls by age, sex and eye center. Risk
factors for OSSN were HIV infection without antiretroviral therapy (ART) use (OR=48.30;
95%CI 7.53-309.90) and with ART use (OR=19.02; 95%CI 6.55-55.26), longer duration of
exposure to the sun in the main occupation (6.9 hrs/day vs. 4.6 hrs/day, OR=1.23; 95%CI
1.08-1.39) and a history of allergic conjunctivitis (OR=80.20; 95%CI 8.62-746.29). Wearing
hats was protective (OR=0.21; 95%CI 0.07-0.63).
We studied the care-seeking journey followed by 158 new OSSN patients. About half (88/158,
[56%]) presented directly to the study centres while the rest were referred. Indirect presenters
sought care earlier than direct presenters (median 2.0 months vs 5.5 months) and travelled a
shorter distance to the first health facility (median 20km vs 30km) but had surgery later
(median 12.5 months vs 5.5 months). Visits beyond the first health facility for indirect
presenters markedly increased delay (median 7.3, 29.0, 37.9, and 32.0 months for 1-4
facilities, respectively). Delay was associated with number of health facilities visited (adjusted
ordered OR=9.12; 95%CI 2.83-29.4, p<0.001) and being female (adjusted ordered OR=2.42;
95%CI 1.32-4.44, p=0.004).
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In the randomized placebo-controlled trial we randomly allocated 49 participants to 5FU and
49 to placebo. Four participants were lost to follow-up. Treatment with 5FU was associated
with fewer OSSN recurrences: there were 5/47 (10·6%) recurrences in the 5FU arm and 17/47
(36·2%) in the placebo arm (odds ratio 0·21; 95%CI 0·07-0·63, p=0·01). There was little effect
from adjusting for passive smoking and antiretroviral therapy imbalance (adjOR=0·23; 95%CI
0·07-0·75, p=0·02). Adverse effects were transient, mild and more frequent with 5FU: ocular
discomfort (43 [88%] vs 36 [73%]), epiphora (24 [49%] vs 5 [10%]), and eyelid skin
inflammation (7 [14%] vs 0).
Conclusions
The clinical impression alone is unreliable for distinguishing OSSN from benign lesions.
Toluidine Blue (ToB) staining is less specific and predictive than clinical examination by an
Ophthalmologist. However, ToB may be a useful tool for other health care workers, with less
ophthalmic training who might be involved in screening patients for the disease, as when there
is no staining the disease is unlikely to be malignant. An algorithm that combines clinical
features and ToB staining improves the specificity to 50%, is reasonably accurate (65%) for
distinguishing OSSN from non-OSSN and shows the probability of disease with various
combinations of clinical features. This algorithm cannot replace histopathology. Measures to
prevent and control HIV, prevent sun exposure such as wearing hats, and control allergic
conjunctivitis are recommended. Referral introduces significant delay before patients receive
definitive treatment for OSSN. Women were more likely to experience delay. Despite regular
contact with the health system for those with known HIV infection, delays occurred. Training
in recognition and referral of OSSN cases, particularly in the HIV service, might lead to shorter
delays before presentation. Post-operative topical 5FU substantially reduced recurrence of
OSSN, was well-tolerated, and its use recommended in this context.
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Format of the thesis
The thesis for this PhD utilises the “research papers” format, recently introduced by the
London School of Hygiene and Tropical Medicine. It therefore includes a number of papers
which are either published, accepted or in submittable format for publication in peer-reviewed
journals. The chapters listed in italics in the Contents are in this research/review paper format,
and each chapter includes publication details in a cover sheet, including acknowledgement of
the contributions of other people.
The other chapters of the thesis are composed of “linking material” which includes
information/data not covered in the research papers and helps to make the thesis a coherent
body.
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Introduction
Ocular surface squamous neoplasia (OSSN) is a spectrum of disease that ranges from non-
invasive intra-epithelial dysplasia of the conjunctival and cornea (CCIN), through to invasive
squamous cell carcinoma (SCC).1 In recent decades OSSN has undergone an
epidemiological shift. In more temperate countries, it remains a rare, slow growing tumour of
elderly males.2 In contrast, in tropical countries, particularly in Eastern Africa, it is now more
common, more aggressive, affects younger people and with a higher incidence in women here
than in other parts of the world.3-6 It seems likely that much of this increased burden of disease
is attributable to the HIV/AIDS epidemic.7 Even though OSSN is not a target condition within
Vision 2020, it frequently leads to a poor quality of life, visual disability and death. In
September 2010 the “IAPB/Vision2020 Workshop on Research for Global Blindness
Prevention” identified specific research priorities.8 It was recognised that for Africa there was
a need for research on HIV-related conditions to better define the epidemiology and determine
context-specific management approaches.
Prevalence and Incidence
Reliable prevalence and incidence estimates of the numbers of individuals affected have been
difficult to ascertain and vary considerably. At one extreme, in one study from Kenya based in
a HIV testing clinic, 7.8% of HIV-infected adults were found to have conjunctival lesions which
were found to be OSSN on histopathology.5 The Kenyan national HIV prevalence is 6% (2.28
million out of 38 million) so it was suggested that over 170,000 Kenyans might have some
degree of OSSN. In contrast, a relatively low annual incidence estimate of 2.2/100,000 has
been suggested in a study from Tanzania, based on the number of cases being operated in
eye units.6 From the clinical perspective OSSN represents a significant component of the
ophthalmic “work-load” in East Africa. About 5% of all ophthalmic surgery in Kenya is for OSSN
(Table 1 on page 18) and is associated with a high level of morbidity for the patient, as
exenteration is often needed for those with late presentation or recurrent disease. However,
OSSN receives little or no attention from either ophthalmic or HIV care programs.
Risk factors and Aetiology
The risk factors and aetiology of OSSN in East Africa are not well understood. There is an
association with HIV; however, a significant proportion (~30%) of people with OSSN are not
infected with HIV, suggesting that other factors also contribute to the excess burden of disease
in this region.7, 9-11 Despite the association with HIV, a dose-response effect where lower
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CD4+ T-lymphocyte levels in HIV+ individuals is associated with more severe OSSN has not
been described. The relationship between human papilloma virus (HPV) and OSSN remains
unclear; some studies have reported associations and others have not.12-17 This is probably
because of variations in methodology and the specific HPV types that have been looked for.
Generally only a very limited sub-set of the many different HPV types have been investigated.
It seems plausible that ultraviolet solar radiation also plays a major role; a specific mutation
associated with UV radiation has been found more frequently in OSSN tissue.18 The
importance of vitamin A in maintaining the health of the ocular surface is established and its
deficiency leads to goblet cell loss, desquamation and keratinization of the ocular surface.19
Studies in the pre-HAART era found vitamin A deficiency (serum retinol <30 µg/dL or <1.05
µmol/L) common in HIV patients.20 The potential role of vitamin A deficiency in OSSN has not
previously been investigated.
Diagnosis
Histopathology is the gold standard for diagnosing OSSN and determining the stage of the
disease. However, generally in sub-Saharan Africa there is very limited access to pathology
services, such that most probable OSSN lesions are excised without pathological confirmation
of the diagnosis or complete excision of the lesion. A simple and cheap diagnostic aid would
be of considerable help to the clinician. Vital stains are used to colour living tissues; various
dyes are used extensively in ophthalmic surgery.21 Toluidine blue (ToB) is a vital dye that
stains abnormal tissue. It has been used for many years to help support the clinical diagnosis
of oral, oesophageal and cervical dysplasia and carcinoma and to demarcate lesions during
surgical excision.22 There is one case report describing the use of ToB vital staining of OSSN.23
The dye was reported to clearly demarcate the abnormal tissue, assisting the excision. The
authors commented that they also found ToB did not stain other conjunctival lesions such as
pterygium (no data presented) and did not cause any toxicity to the ocular surface.
Treatment
A Cochrane systematic review found no randomised controlled clinical trials of any
interventions for the treatment of OSSN in HIV-infected people.24 Most lesions are surgically
excised (very large tumours that have spread to the orbit are usually managed by
exenteration). However, results in terms of OSSN recurrence rates are very variable. Although
one series by a very experienced surgeon reported low recurrence rates (3.2%),11 under
routine operational conditions in Africa and elsewhere the recurrence rates are much higher:
reports generally range between 30% and 66%.5, 25-27 To try to reduce recurrence rates various
adjuvant chemotherapy treatments are sometimes used: mitomycin-C, 5-fluorouracil (5-FU)
or interferon-2β.28 A recent case-series study of the long-term efficacy and safety of topical 5-
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FU 1% given alone or as adjuvant therapy following surgical excision reported recurrence
rates of <10% and no evidence of toxicity.29 Adjuvant therapy is rarely used in sub-Saharan
Africa, although 5-FU is available and affordable. Randomized controlled trials are needed to
identify the optimal treatment for this condition to minimise recurrence rates, visual loss and
death from conjunctival SCC in the East African setting.
Research and Thesis Overview
This research project consisted of an integrated set of studies to improve our understanding
of the epidemiology and management of OSSN in Kenya. We conducted a systematic review
of the epidemiology of OSSN in Africa and updated an earlier conducted Cochrane review of
the interventions of OSSN in HIV-infected populations. We also reviewed what is known about
the pathophysiology of OSSN. There is a linking chapter on the diagnostic methods used for
OSSN. The research setting where the project was conducted is described followed by an
overview of the research project design. The data chapters consist of reports on the clinical
presentation of OSSN in Africa with an emphasis on the features that may distinguish OSSN
from benign lesions; a diagnostic test study of toluidine blue vital staining; a clinical algorithm
for diagnosis of OSSN; a case control study of risk factors of OSSN; an evaluation of factors
that may contribute to delay in presentation and treatment of patients with OSSN and finally a
randomized controlled trial of 5-Fluorouracil adjuvant therapy to try and reduce recurrence
rates after surgical excision of OSSN tumours.
Table 1. The clinical workload attributable to Ocular Surface Squamous Neoplasia
(OSSN) in Kenya.This data was obtained from the Ophthalmic Services Unit database
in the Ministry of Health
Year 2008 2009 2010 2011
Total no. of patients seen 376,174 448,923 474,216 454,439
Patients with conjunctival lesions 4,860 7,867 8,198 8,054
Estimated no. with OSSN (38% of lesions) 571 689 740 639
Total no. of eye surgeries 30,701 37,935 36,625 28,897
Total no. of conjunctival excisions 1,428 1,722 1,850 1,597
% of total patients seen estimated to have OSSN 1.3 1.8 1.7 1.8
% of total surgeries estimated due to OSSN 4.7 4.5 5.1 5.5
FOOTNOTE: This data did not include exenterations but shows that the surgical volume attributed to
OSSN is increasing over the years. In 2015 Sabatia Eye Hospital, one of our study centers performed
296 conjunctival excisions and 3 exenterations. OSSN was confirmed in 82 patients (29%)
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Systematic Review
Epidemiology of ocular surface squamous neoplasia in Africa
Stephen Gichuhi1,2, Mandeep S. Sagoo3,4, Helen A. Weiss2 and Matthew J. Burton2,3
1 Department of Ophthalmology, University of Nairobi, Nairobi, Kenya
2 London School of Hygiene and Tropical Medicine, London, UK
3 Moorfields Eye Hospital, London, UK
4 UCL Institute of Ophthalmology, University College London, UK
Abstract objectives To describe the epidemiology and an aetiological model of ocular surface squamous
neoplasia (OSSN) in Africa.
methods Systematic and non-systematic review methods were used. Incidence was obtained from
the International Agency for Research on Cancer. We searched PubMed, EMBASE, Web of Science
and the reference lists of articles retrieved. Meta-analyses were conducted using a fixed-effects model
for HIV and cigarette smoking and random effects for human papilloma virus (HPV).
results The incidence of OSSN is highest in the Southern Hemisphere (16 South), with the highest
age-standardised rate (ASR) reported from Zimbabwe (3.4 and 3.0 cases/year/100 000 population for
males and females, respectively). The mean ASR worldwide is 0.18 and 0.08 cases/year/100 000
among males and females, respectively. The risk increases with exposure to direct daylight (2–4 h,
OR = 1.7, 95% CI: 1.2–2.4 and ≥5 h OR = 1.8, 95% CI: 1.1–3.1) and outdoor occupations
(OR = 1.7, 95% CI: 1.1–2.6). Meta-analysis also shows a strong association with HIV (6 studies:
OR = 6.17, 95% CI: 4.83–7.89) and HPV (7 studies: OR = 2.64, 95% CI: 1.27–5.49) but not
cigarette smoking (2 studies: OR = 1.40, 95% CI: 0.94–2.09). The effect of atopy, xeroderma
pigmentosa and vitamin A deficiency is unclear.
conclusions Africa has the highest incidence of OSSN in the world, where males and females are
equally affected, unlike other continents where male disease predominates. African women probably
have increased risk due to their higher prevalence of HIV and HPV infections. As the survival of
HIV-infected people increases, and given no evidence that anti-retroviral therapy (ART) reduces the
risk of OSSN, the incidence of OSSN may increase in coming years.
keywords ocular surface squamous neoplasia, conjunctival intraepithelial neoplasia, conjunctival
intraepithelial dysplasia, ocular surface epithelial dysplasia, conjunctival squamous cell carcinoma,
risk factors, incidence
Introduction
Ocular surface squamous neoplasia (OSSN) is the most
common ocular surface tumour (Grossniklaus et al.
1987). Other synonymous terms include ‘conjunctival
epithelial neoplasia’, ‘ocular surface epithelial dysplasia’
and ‘conjunctival squamous cell neoplasia’ (Lee & Hirst
1992; McDonnell et al. 1992; Tulvatana 2003). OSSN
covers a spectrum of disease ranging from non-invasive
intra-epithelial dysplasia of the conjunctiva and cornea
(CCIN) to invasive squamous cell carcinoma (Lee &
Hirst 1995).
Clinical features
The disease may present with irritation, red eye, raised
gelatinous mass and leucoplakia (Tunc et al. 1999). In
Africans, it is often pigmented brown (Figure 1). OSSN is
usually unilateral (Chisi et al. 2006) and arises at the
limbus – the junction between the cornea and conjunctiva
(Lee & Hirst 1997). Most lesions occur within the
exposed part of the eyeball between the lids (Ateenyi-
Agaba 1995; McKelvie 2002; Waddell et al. 2006). Up
to 31.2% of cases seen are recurrent lesions (Chisi et al.
2006). Late stages present with a large fungating oculo-
orbital mass (Ogun et al. 2009). Early lesions resemble
1424 © 2013 The Authors. Tropical Medicine and International Health published by John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Tropical Medicine and International Health doi:10.1111/tmi.12203
volume 18 no 12 pp 1424–1443 december 2013
24
benign growths such as pterygia and pingueculae. OSSN
can be the first manifestation of HIV infection in about
50% of cases in HIV-endemic settings (Porges &
Groisman 2003; Spitzer et al. 2008).
Histopathology
Histologically, OSSN may be classified into 3 forms:
benign, pre-invasive and invasive (Table 1; Basti &
Macsai 2003). The term OSSN usually excludes the
benign forms. The term ‘invasive’ indicates infiltration
through the basement membrane of the conjunctival
epithelium into the underlying stroma (Basti & Macsai
2003; Shields & Shields 2004).
Epidemiology overview
Two disease patterns of OSSN are recognised: older,
predominantly male in temperate climates, not associated
with HIV or human papilloma virus (HPV); and younger
men and women, in tropical climates, associated with
HIV and HPV. The latter represents a public health chal-
lenge in Africa in relation to the HIV pandemic and late
presentation of large tumours (Ukponmwan et al. 2002;
Chisi et al. 2006; Ogun et al. 2009), diagnostic difficul-
ties (Furahini & Lewallen 2010), malignant transforma-
tion and high recurrence rates after treatment (1-year
recurrence of 16.6% reported in Tanzania; Makupa et al.
2012). Experienced surgeons report lower recurrences
(3.2%) after excision (Waddell et al. 2006). Trial data to
guide management in this context are lacking (Gichuhi &
Irlam 2013). For the temperate pattern of disease, one
randomised controlled crossover trial in Australia
compared mitomycin-C with placebo in participants
(a) Small lesion with leuloplakia (b) Medium sized lesion with 
pigmentation
(c) Large lesion with corneal extension
but not involving the fornices
(d) Very large lesion extending into the
 orbit
Figure 1 A range of clinical
presentations of ocular surface squamous
neoplasia (OSSN) in East Africa. (a)
Small lesion with leukoplakia; (b)
Medium sized lesion with pigmentation;
(c) Large lesion with corneal extension
but not involving the fornices; (d) Very
large lesion extending into the orbit.
Table 1 Histopathological classification of ocular surface squa-
mous neoplasia (OSSN), Basti & Macsai (2003) and American
Joint Committee on Cancer (2010)
Benign
Squamous papilloma
Pseudoepitheliomatous hyperplasia
Benign hereditary intraepithelial dyskeratosis
Pre-invasive
Conjunctival intraepithelial neoplasia (CIN)
CIN I (mild dysplasia) – confined to the basal third of the
conjunctival epithelium
CIN II (moderate dysplasia) – extends into the middle third
of the conjunctival epithelium
CIN III (severe dysplasia) – extends into the superficial third
of the conjunctival epithelium
CIS (carcinoma-in-situ) – full thickness dysplasia*
Invasive
Squamous cell carcinoma
GX – grade cannot be defined
G1 – Well differentiated
G2 – Moderately differentiated
G3 – Poorly differentiated
G4 – undifferentiated
Mucoepidermoid carcinoma
*The American Joint Committee on Cancer (AJCC) staging
manual 2010 classifies CIS under CIN.
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whose average age was 67 years (Hirst 2007). There was
a significant treatment effect on clinically assessed com-
plete resolution of lesions (P = 0.0005), but no effect on
histologically assessed complete resolution (P = 0.49).
Incidence rates and geographical variation
Incidence estimates for OSSN are difficult to ascertain
and vary regionally (Table 2). The first paper to examine
this used cancer registry data from International Agency
for Research on Cancer (IARC; Newton et al. 1996). A
subset of these data were used in a subsequent publica-
tion looking at variation in incidence across the USA
(Emmanuel et al. 2012). However, published results need
to be interpreted with caution – firstly, all eye cancers are
classified together by the International Classification of
Diseases for Oncology (ICD-O-3 C.69) while other
databases classify squamous cell carcinoma of the
conjunctiva (SCCC) with head and neck cancers (Lee
et al. 2000; Curado et al. 2007; Parkin et al. 2010).
OSSN is not recognised as a separate entity. Squamous
cell carcinomas that are site-coded for the eye (C69)
probably include some cancers that originate in the eyelid
skin (WHO 2000, 2010; Curado et al. 2007). Secondly,
the availability of histopathology services to confirm
OSSN diagnosis is often limited in low- and middle-
income countries (Furahini & Lewallen 2010). Thirdly,
health information systems tend to capture invasive squa-
mous cell carcinoma (SCC) but not earlier stages. Coun-
tries reporting higher rates of SCC (mostly in Africa)
only started sending cancer registry data to IARC in the
mid-1980s (Curado et al. 2007). Completeness of the
current IARC database is hampered in that only data
from 80 countries were submitted, of which 75% was of
acceptable quality, and not all countries had data on
squamous cell carcinoma in the eye under code C69.
Africa had the lowest level of acceptable quality of data
(36%). Fourthly, crude incidence rates can be influenced
by population structure, a problem often addressed by
reporting age-standardised incidence rates. Finally, in
areas with limited health facilities for cancer treatment
where a large number of patients are treated outside the
reference area, incidence may be underestimated.
Moreover, in defining incidence from different sources, it
may be difficult to distinguish between recurrence or
extension of an existing cancer on one hand and the
development of a new primary on the other. Analysis of
incidence time trends is also difficult if geographical
coverage, ICD revisions and disease definitions in a
registry change.
Methods for this review
Systematic and non-systematic review methods were
used. No a priori systematic review protocol had been
published. Incidence data were obtained from the cur-
rent IARC report (9th Volume) covering the period
1998–2002. The IARC collates data from cancer regis-
tries worldwide. The report uses ICD codes to show the
age-standardised incidence per 100 000 population strat-
ified by sex and histological type. Under code C.69
where eye cancers are reported, the four main groups
are retinoblastoma, malignant melanoma, carcinomas
(11.4% of all eye cancers), sarcoma and other unspeci-
fied tumours. Under carcinomas, there are three sub-
groups – SCC (principally tumours of the conjunctiva
and cornea, comprising 70% of the carcinoma sub-
group), other specified carcinoma (adenocarcinomas of
the lacrimal gland and lacrimal duct) and unspecified
carcinomas. We extracted data from the SCC subgroup.
Table 2 Age-standardized incidence rates of squamous cell carcinoma in the eye (ICD-O-3 C.69) by continent for the period 1998–
2002 (Curado et al. 2007)
Region
Age-standardized incidence rate (cases/year/100 000 pop)
P-valueMales mean (95% CI) Females mean (95% CI)
Africa 1.38 (1.00 to 3.75) 1.18 (1.08 to 3.43) 0.853
Central & South America 0.48 (0.33 to 0.62) 0.21 (0.10 to 0.33) 0.005
Oceania 0.28 (0.14 to 0.41) 0.05 (0.01 to 0.10) 0.002
North America 0.08 (0.06 to 0.10) 0.00 (0.00 to 0.01) <0.001
Asia 0.08 (0.01 to 0.14) 0.05 (0.00 to 0.09) 0.416
Europe 0.05 (0.02 to 0.08) 0.01 (0.00 to 0.03) 0.033
Southern Hemisphere 0.61 (0.14 to 1.09) 0.33 (0.12 to 0.78) 0.355
Northern Hemisphere 0.10 (0.06 to 0.14) 0.05 (0.00 to 0.08) 0.045
Worldwide estimate 0.18 (0.09 to 0.26) 0.08 (0.01 to 0.15) 0.091
CI = confidence interval.
1426 © 2013 The Authors. Tropical Medicine and International Health published by John Wiley & Sons Ltd.
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The coordinates locating each registry were obtained
from http://itouchmap.com/latlong.html.
We searched PubMed, EMBASE and Web of Science
for systematic reviews, meta-analysis and case–control
studies using ‘OSSN’, ‘conjunctival squamous cell carci-
noma’, ‘risk factors’ and their synonyms as key words
with no language restrictions. Abstracts were assessed
and studies were selected if they reported analysis of
known or suspected risk factors. The search was con-
ducted on 2 January 2013 and updated on 31 May 2013.
Data were extracted from the full texts of articles and
additional articles obtained from their reference lists.
Meta-analyses were conducted where appropriate. A
fixed-effects model was used for HIV and cigarette
smoking. A random-effects model was chosen for HPV
after investigation of heterogeneity.
Results and discussion
Africa has the highest age-standardised incidence rate of
ocular SCC followed by Central and South America then
Oceania (Australia, New Zealand and Hawaii), respec-
tively (Table 2 and Figure 2). The rate in Africa is about
9–10 times higher than in Europe and North America.
The highest incidence rate is 3.4 cases/year/100 000
among males and 3.0 cases/year/100 000 among females
in Zimbabwe (Curado et al. 2007). Uganda follows with
1.6 cases/year/100 000 for males and females. Australia
comes third with 0.3–0.5 cases/year/100 000 in parts of
that country. Other countries have rates between 0 and
0.1 cases/year/100 000. The rates have a right-skewed
bell-shaped distribution peaking at latitude 16 South
(Figure 3). Incidence rates are higher in the Southern
Hemisphere than the Northern Hemisphere, with male
ASR = 0.61 cases/year/100 000 (95% CI: 0.14–1.09) and
female ASR = 0.33 (95% CI: 0.12 to 0.78) in the
Southern Hemisphere, compared with male ASR = 0.10
(95% CI: 0.06–0.14) and female ASR = 0.05 (95% CI:
0.00–0.08) in the Northern Hemisphere.
The high rates in Africa are consistent with other esti-
mates from the region. A Tanzanian study estimated the
incidence of suspected OSSN from 2006 to 2008 using
operating theatre records across the country. Although
there was no histological confirmation in all cases, the inci-
dence was found to be 2.2 cases/year/100 000 (Furahini &
Lewallen 2010). Uganda reported a peak incidence of 3.5
cases/year/100 000 in 1992 (Ateenyi-Agaba 1995). More
recent data from the Kampala Cancer Registry also show a
marked increase, although it is reported as ocular cancer,
rather than specifically as OSSN (Wabinga et al. 2000).
Cancer registry data in two African countries show
that OSSN has become more prevalent with time. In
Zimbabwe, the age-adjusted annual incidence rates of
SCCC underwent a more than 10-fold increase from 0.17
to 1.8/100 000 between 1990 and 1999 (Masanganise
et al. 2008) while the prevalence of OSSN among ocular
KEY:  Dot size is directly proportional to incidence. Males are shown in blue and females in red.
Overlaps between males and females appear purple in colour
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surface tumour biopsy specimens increased from 33% in
1996 to 58% by 2000 (Pola et al. 2003).
OSSN is the most common indication for orbital exentera-
tion performed in adults in Africa (Table 3; Pola et al 2003).
This surgical procedure to excise all the orbital tissue includ-
ing stripping the periosteum from the orbital walls is per-
formed in cases with advanced disease. More than half
(≥57%) the exenterations performed in Africa are for OSSN
compared with 32% in Australia and 9–15% in Europe and
India. Although available data does not clearly distinguish
those performed for primary eyelid disease from conjunctival
disease, SCC still emerges as an important cause in Africa.
Eyelid SCC is uncommon in Africa (Templeton 1967, 1973).
Incidence of OSSN by age and sex
In temperate countries, OSSN remains a rare, slow-
growing tumour of elderly males (70–80% are males
with a mean age of about 60 years; Lee & Hirst 1997;
Tunc et al. 1999). In contrast, in tropical countries,
particularly in Eastern and Southern Africa, the preva-
lence is highest among young people in their 30s and
among women (50–70%; Table 4; Poole 1999; Pola
et al. 2003; Chisi et al. 2006; Furahini & Lewallen
2010). Within East Africa, the pattern of SCCC in the
1960s differed to that seen today. In 1967, the average
age of affected patients was 48 years, and males were
four times more frequently affected than females
(Templeton 1967).
Worldwide, IARC data show that the overall incidence
is higher in males than females but the difference is not
statistically significant (Figure 3 and Table 2). The mean
male ASR worldwide is 0.18 cases/year/100 000 (95%
CI: 0.09–0.26) and 0.08 (95% CI: 0.01–0.15) among
females (P = 0.09). Incidence is significantly higher in
males than females except in Africa and Asia where both
4
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Figure 3 The age-standardized incidence
rates (ASR) of squamous cell carcinoma
of the eye (ICD-O-3 C.69) for the period
1998–2002 (Curado et al. 2007).
Table 3 The proportion of orbital exenterations performed due to ocular squamous cell carcinoma in different regions of the world
Year (ref.) Country No. of exenterations (N) No. due to SCCC (n) Proportion (n/N) (%)
2011 (Ackuaku-Dogbe 2011) Ghana 25 19 76
2001 (Masanganise & Magava 2001) Zimbabwe 23 13 57
2007 (Nemet et al. 2007) Australia 38 12 32
2004 (Pushker et al. 2004) India 26 3 15
2008 (Croce et al. 2008) Italy* 6 1 13
2005 (Rahman et al. 2005) UK† 69 6 9
*Included children.
†Mainly elderly patients.
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sexes are equally affected (Table 2). Prevalence in Africa
is higher in females than males (Table 4). This may be
related to Africa having the highest prevalence of both
HIV and HPV, which may increase the risk of OSSN in
women and gender differences in mortality of HIV-
infected adults. In South Africa, HIV-infected females
have a longer life expectancy than HIV-infected males
(Cornell et al. 2012; Johnson et al. 2013; Maskew et al.
2013). Men present in later stages of HIV/AIDS for anti-
retroviral therapy (ART) and possibly have poorer adher-
ence to ART (Taylor-Smith et al. 2010). This has also
been observed in Latin America, China and Lao (Dou
et al. 2011; Gonzalez et al. 2011; Bastard et al. 2013). In
Europe, the response to ART and mortality is similar for
both sexes (Perez-Molina et al. 2012; Thorsteinsson et al.
2012).
Variation in disease severity
There may be variation in disease stage at presentation,
with more advanced disease present at time of surgery in
East Africa, compared with other regions (Table 5; Chisi
et al. 2006; Waddell et al. 2010; Kao et al. 2012;
Makupa et al. 2012). This may reflect delayed presenta-
tion to ophthalmic services in this region, leading to more
advanced pathology by the time of surgery. Histopatho-
logical reporting is also subjective, and pathologists may
not always grade tumours the same way (Margo et al.
2002). Alternatively, the disease may be intrinsically
more aggressive in the East African region or HIV
worsens disease progression.
Risk factors
Various factors are thought to influence the causation of
OSSN, but it is not clear how they interact or which is
the most potent. The rising incidence of OSSN in recent
decades may be driven by increased prevalence of these
factors. We found no systematic reviews of risk factors
for OSSN after the literature search. Of the case–control
studies found, two in Uganda and Australia examined the
association with solar exposure; six in Africa examined
the association with HIV; sixteen examined the associa-
tion with HPV; seven in Africa, five in Asia, one in
Brazil, two in USA and one in Australia. Two studies
examined cigarette smoking in Uganda.
Ultraviolet solar radiation. Several cutaneous malignan-
cies, including melanoma and SCC, have a strong associ-
ation with solar radiation. It was first noted in the 1960s
that SCCC was relatively common in East Africa, and
this apparent excess risk was attributed to higher expo-
sure to sunlight (Templeton 1967). There is a strong rela-
tionship between the incidence of SCCC and increasing
Ultraviolet (UV) levels (Newton et al. 1996). Using IARC
data and published measurements of ambient solar ultra-
violet light, the incidence of SCCC was found to reduce
by 49% for every 10° increase in latitude from 1.2 cases/
year/100 000 (Table 7) in Uganda (latitude 0.3°) to
<0.02/year/100 000 in the UK (latitude > 50°). More
recently, the National Institutes of Health/American
Association of Retired Persons (NIH-AARP) Diet and
Health Study in the USA found a slightly lower risk of
SCCC in those who lived >35° compared with ≤35° from
the equator, although this was not statistically significant
(adjusted Hazard Ratio = 0.92, 95% CI: 0.49–1.71; Em-
manuel et al. 2012). The USA has comparatively lower
HIV prevalence, solar irradiance and incidence of OSSN
than Africa, which is bisected by the equator. The high
incidence of ocular SCC near the equator may be related
to high solar irradiance (the amount of solar radiant
energy incident on a surface per unit area and per unit
time) in the world (World Energy Council 2007).
A case–control study in Uganda adjusted for age, sex,
residential district, and HIV serostatus demonstrated that
the risk of OSSN was higher with increasing time spent
Table 4 The age and sex of patients affected by ocular surface squamous neoplasia (OSSN)
Year (ref.) Country Mean age (years) Male (%) Female (%) Male:Female ratio
1995 (Ateenyi-Agaba 1995) Uganda 33 52 48 1:2.3
2008 (Spitzer et al. 2008) Malawi 33 42 58 1:2.1
2010 (Simbiri et al. 2010) Botswana 39 39 61 1:1.6
2003 (Pola et al. 2003) Zimbabwe 35 30 70 1:1.4
2002 (Mahomed & Chetty 2002) S. Africa 37 50 50 1:1.3
2006 (Chisi et al. 2006) Kenya 38 50 50 1:1
2012 (Makupa et al. 2012) Tanzania 39 32 68 1:1
2009 (Ogun et al. 2009) Nigeria 54 43 57 1:0.9
1999 (Tunc et al. 1999) USA 64 70 30 1:0.4
2002 (McKelvie 2002) Australia 69 77 23 1:0.3
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in daylight (Waddell et al. 2010). Compared with those
who reported spending up to 1 h a day in direct sunlight,
the odds ratio (OR) for those who spent 2–4 h was 1.7
(95% CI: 1.2–2.4), and for those who spent 5 or more
hours a day, it was 1.8 (95% CI: 1.1–3.1). A case–con-
trol study in Australia reported that the strongest risk
factor was a past history of skin cancer (OR = 15, 95%
CI: 2.0–113.6), although other factors, including outdoor
activity, pale skin and irides and propensity to burn, were
also important (Lee et al. 1994).
More direct evidence for UV radiation induced damage
in the pathophysiology of SCCC was described in another
case–control study in Uganda in which 52% of the cases
had mutations in the tumour suppressor gene TP53
compared with 14% of controls (Ateenyi-Agaba et al.
2004a). The mutations were mainly of the CC TT type,
consistent with UV-induced mutagenesis. This gene also
downregulates the replication of HPV type 16 via the
viral E2 protein, suggesting that its mutation may allow
replication of HPV particles (Brown et al. 2008). Further,
exposure to UV radiation is associated with altered
expression of matrix metalloproteinases (MMPs) and the
tissue inhibitors of these metalloproteinases (TIMPs),
molecules that may be responsible for tissue invasion and
metastasis of tumours (Ng et al. 2008).
In addition, OSSN lesions occur more often at the
limbus. A study in Uganda demonstrated that tumours
almost always occur in sun-exposed areas of the eye
(Waddell et al. 2006). It is thought that the human eye is
more exposed laterally, making this a large collecting
zone of peripheral sunlight, which, depending on the
incident angle and radius of curvature of the cornea, is
focused on the limbus, lens and lid margin, which are the
main foci of sun-related eye diseases such as pterygium,
OSSN, cataract and lid malignancies (Maloof et al.
1994). Low doses of ambient sunlight received on every
day exposure inhibit immunity in the skin and internal
organs (Halliday et al. 2012).
HIV. There is strong evidence that HIV is a major risk
factor for OSSN. Uganda, which had a cancer registry
since 1951, was the first country to report a dramatic
increase in the annual incidence of SCCC shortly after the
outbreak of HIV/AIDS. There was a sixfold increase from
0.6 cases/year/100 000 between 1970 and 1988 to 3.5/
year/100 000 by 1992 (Figure 4; Ateenyi-Agaba 1995). A
marked rise was also observed in the USA with the onset
of the HIV pandemic (Guech-Ongey et al. 2008). At the
same time, a US study observed a strong association in an
HIV-infected cohort (OR = 13.0, 95% CI: 4–34; Goedert
& Cote 1995). In Tanzania, regional incidence rates were
significantly correlated with regional HIV prevalence
(Pearson’s r = 0.53, P = 0.03; Furahini & Lewallen
2010). The majority of patients (60–77%) with OSSN
seen in Africa are HIV-infected (Table 6). A meta-analysis
of 6 case–control studies (Table 7) in Uganda, Rwanda
and Zimbabwe shows a strong association with HIV infec-
tion (pooled OR = 6.17, 95% CI: 4.83–7.89; Figure 5).
The association with HIV suggests that immunosup-
pression plays a role in OSSN; however, a linear associa-
tion between the CD4 lymphocyte count and OSSN has
not been confirmed. A cross-sectional study conducted in
Tanzania found a median CD4 cell count of 71 cells/ll
among HIV-infected individuals with OSSN (Makupa
et al. 2012). HIV-infected cases tended to have larger
lesions: 71% had lesions >5 mm in diameter vs. 27%
among HIV-negative individuals (OR = 3.13, 95% CI:
1.5–6.5). HIV-infected cases were also more likely to
develop recurrent tumours within a year of excision (82%
vs. 18%; OR = 3.54, 95% CI: 1.12–11.2). However,
there was no significant trend found between CD4 count
and the grade of OSSN (P = 0.94). In a Ugandan study,
Table 5 Stages of ocular surface squamous neoplasia (OSSN) seen at presentation in Africa and USA
Country year (ref.)
Stage of OSSN, n (%)
Mild
dysplasia
(CIN I)
Moderate
dysplasia
(CIN II)
Severe
dysplasia
(CIN III)
Carcinoma
in situ (CIS)
Well
differentiated
SCC
Moderately
differentiated
SCC
Poorly
differentiated
SCC
Kenya 2006 (Chisi et al. 2006) 7 (21.9) 1 (3.1) 9 (28.1) 15 (46.9)
Uganda 2008 (de Koning et al. 2008) 17 (21.0) 18 (22.2) 22 (27.2) 0 (0) 24 (29.6)
Uganda 2010
(Ateenyi-Agaba et al. 2010)
39 (29.3) 94 (70.7)
Uganda 2010 (Waddell et al. 2010) 48 (15.1) 66 (20.8) 81 (25.5) 0 (0) 123 (38.7)
Tanzania 2012 (Makupa et al. 2012) 28 (21.2) 73 (55.3) 0 (0) 31 (23.5)
Malawi 2013 (Tiong et al. 2013) 1 (2.0) 5 (10.2) 9 (18.4) 17 (34.7) 17 (34.7)
USA 2012 (Kao et al. 2012) 48 (8.1) 98 (16.4) 59 (9.9) 322 (54.0) 69 (11.6)
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among 112 HIV-infected cases of CIN and invasive SCC,
the median CD4 count at diagnosis was 111 cells/lL
(IQR; 62–221; Waddell et al. 2006). Excess risks standar-
dised incidence ratio (SIR = 19.5, 95% CI: 6.3–45.5) have
also been observed among a cohort of kidney transplant
recipients in Australia suggesting that immune suppression
from other causes may play a role (Vajdic et al. 2007).
HAART does not reduce the incidence of SCCC
according to data from the US HIV/AIDS Cancer Match
(HACM) Study (Guech-Ongey et al. 2008) which
compared SIRs in the pre-HAART and HAART eras
among 491 048 adults aged ≥15 years with HIV/AIDS
diagnosed from 1980 to 2004. The SIRs here estimate
the excess risk of SCCC attributable to HIV/AIDS com-
pared with a population with negligible HIV/AIDS preva-
lence and were similar at 12.0 (95% CI: 5.5–22.8) and
12.6 (95% CI: 4.6–27.4) in the pre- and post-HAART
eras, respectively (P = 0.79). There is, however, a case
report of ART causing tumour regression in an otherwise
inoperable case (Holkar et al. 2005).
Human papilloma virus. The relationship between
human papilloma virus (HPV) and OSSN is rather
controversial with variable results. (Tulvatana 2003;
Moubayed et al. 2004; Sen et al. 2007; de Koning et al.
2008; Guthoff et al. 2009; Simbiri et al. 2010; Yu et al.
2010). A review of 12 case series and 17 case–control
studies concluded that there was no causal association
between mucosal HPV types and OSSN while the role of
cutaneous types was uncertain (de Koning et al. 2008).
The studies included used different methods for testing of
HPV (including PCR and serology), and different HPV
types were examined. Conversely, a random-effects
meta-analysis of various case–control studies shows that
OSSN is associated with HPV infection in sub-Saharan
Africa (pooled OR = 2.64, 95% CI: 1.27–5.49) and
worldwide (pooled OR = 4.00, 95% CI: 2.11–7.57; Fig-
ure 6). The prevalence of HPV in OSSN ranges from 0%
to 100% depending on geographical region with subtypes
HPV18 and HPV16 being the most common (Table 8; di
Girolamo 2012). Most African studies report prevalence
of 75–85% (Ateenyi-Agaba et al. 2004b; Simbiri et al.
2010; Yu et al. 2010). HPV is more commonly isolated in
OSSN than pterygium – on average, considering studies
from different regions of the world, 33.8% of OSSN
lesions and 18.6% of pterygia are HPV positive (di Girol-
amo 2012). There may be a true geographical variation in
the prevalence of HPV in OSSN.
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Figure 4 Sudden rise in the annual
incidence rates of conjunctival SCCC in
Kampala with the onset of the HIV
pandemic – number of cases shown
(Ateenyi-Agaba 1995).
Table 6 Prevalence of HIV infection in cases of squamous cell carcinoma of the conjunctiva in Africa
Year (ref.) Country Study period HIV prevalence in SCCC cases (%)
2012 (Makupa et al. 2012) Tanzania 2005–2008 60
2011 (Osahon et al. 2011) Nigeria 1999–2009 75
2002 (Mahomed & Chetty 2002) South Africa 1995–1997 71
1995 (Ateenyi-Agaba 1995) Uganda 1990–1991 75
1996 (Waddell et al. 1996) Uganda 1993–1994 71
2003 (Porges & Groisman 2003) Zimbabwe 1993–1995 91
2001 (Newton et al. 2001) Uganda 1994–1998 77
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Differences in HPV prevalence in OSSN may be influ-
enced by patient selection, sample handling in the operat-
ing theatre, preparation, storage, overseas shipping and
the detection method. Variations may also be due to
different testing methodology and the specific HPV types
tested for. Most existing molecular diagnostic tests
applied in OSSN testing for HPV were developed for
cervical tissue testing. The sensitivity and specificity of
various polymerase chain reaction (PCR) tests varies and
may be influenced by various factors including the PCR
design (nested, broad spectrum or type-specific), size of
amplified product and choice of polymerase used (Munoz
et al. 2012; Mesher et al. 2013). Detection of E6/E7
mRNA transcripts by quantitative reverse transcriptase–
PCR (qRT-PCR) has been proposed as the gold standard
for HPV testing (Smeets et al. 2007). However, RNA is
unstable limiting this test to fresh frozen tissue (Kim
et al. 2013). Testing for HPV DNA by PCR from paraf-
fin-embedded archived tumour blocks may be compli-
cated by contamination between samples at the time of
initial tissue sectioning for DNA harvest (Boyd et al.
1996; Iftner & Villa 2003).
Generally, only a limited subset of HPV types has been
investigated among OSSN cases. There are 170 genotypes
of HPV described to date, which are broadly subdivided
into cutaneous and mucosal types (de Villiers 2013).
There are conflicting reports on which of these two are
more commonly associated with OSSN. One study
conducted in Uganda reported that among OSSN cases,
the prevalence of mucosal types was higher than cutane-
ous types (38% vs. 22%) while from another study in
the same population, the prevalence of cutaneous types
was higher than mucosal types (43.6% vs. 6.8%;
Table 8; de Koning et al. 2008; Ateenyi-Agaba et al.
2010). Multiple HPV types have been found in individual
patients with OSSN tumours. One Ugandan study
reported multiple HPV types in 57.1% of SCCC and
75% of dysplasia cases by PCR (Ateenyi-Agaba et al.
2010). In Botswana, multiple HPV types were identified
in all OSSN and all pterygium specimens by DNA
sequencing (Simbiri et al. 2010). The HPV types found
by sequencing ranged from 4 to 21 types per sample. The
same study also described co-infection with multiple
other viral types per individual in 17 of 18 (94%) histo-
logically proven OSSN specimens by PCR; 83% were
positive for Epstein–Barr virus (EBV), 72% were HPV
positive, 67% were Kaposi’s sarcoma-associated herpesvi-
rus (KSHV) positive, 67% were herpes simplex virus
(HSV-1/2) positive and 56% were cytomegalovirus
(CMV) positive. All the pterygium specimens from that
study similarly had multiple viruses; 75% were positive
for each of EBV, KSHV, CMV and HSV while 50% were
Overall  (I-squared = 52.7%, P = 0.060)
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Figure 5 Meta-analysis of case-control studies of HIV infection in ocular surface squamous neoplasia (OSSN) in Africa (fixed effect).
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HPV positive. The proportion of HPV infection in this
series was much higher than any other studies in the
region have reported raising the question whether this
could be due to the methodology used.
The mechanism by which HPV is associated with
OSSN is unknown. HPV is associated with causation of
metaplasia in squamocolumnar epithelial transition zones
such as the corneoscleral limbus and eyelid skin of the
eye, the cervix and anus where there is active cell turn-
over and continuous cell division to replace desquamated
cells (Chow et al. 2010). HPV also promotes degradation
of the p53 gene (Scheffner et al. 1990).
The epidemiology of OSSN is closely related to that of
cervical cancer with respect to high incidence in Africa
and the association with HIV and HPV mainly types 18
and 16 (Sun et al. 1997; Clifford et al. 2003; Stanley
2010). A meta-analysis of HPV prevalence reports world-
wide shows that Africa has the highest adjusted preva-
lence (22.1%; 95% CI: 20.9–23.4%) among women with
cytologically normal cervical pap smears using
PCR-based or high-risk Hybrid Capture 2 (HC-2) tech-
nology to detect HPV DNA (de Sanjose et al. 2007).
Whether vaccination against HPV may help to reduce the
incidence of OSSN remains to be seen (Hughes et al.
2008).
Occupation. Outdoor occupations have been associated
with OSSN, probably related to UV solar radiation
exposure. In Uganda, those with outdoor occupations
had an OR of 1.7 (95% CI: 1.1–2.6) compared to those
with indoor occupations (Waddell et al. 2010). Another
in Uganda reported that 74% of 133 patients with
SCCC or dysplasia had outdoor occupations (Ateenyi-
Agaba et al. 2010). In Japan, exposure to petroleum
products was also described as a risk factor for conjunc-
tival intraepithelial neoplasia (synonym of OSSN) in a
Table 7 Characteristics of case–control studies included in the meta-analysis of HIV as a risk factor of ocular surface squamous
neoplasia (OSSN)
Study period (ref.), Country Cases Controls
1989–1990
(Kestelyn et al. 1990),
Rwanda
11 patients with clinical evidence of conjunctival
dysplasia or malignancy seen at
Centre Hospitalier de Kigali
22 controls. 2 controls per case
from the same area matched for age
and sex within 5 years. Referrals from
elsewhere were excluded
1990–1991
(Ateenyi-Agaba 1995),
Uganda
48 patients with conjunctival growths who presented
to the eye clinic at Mulago Hospital, Kampala
48 patients matched for age and sex
attending the same eye clinic with
other eye diseases
1993–1994
(Waddell et al. 1996),
Uganda
38 patients in seven countrywide eye clinics including
New Mulago Hospital, Kampala who had suspicious
conjunctival lesions had excision biopsy of the lesion
76 controls. 2 controls per case matched
for age and sex. 16 Controls were
patients in the eye clinic without
neoplasia or clinical features of HIV
disease; the remainder were general
(non-eye clinic) anonymous outpatients
at the same health units
1993–1995
(Porges & Groisman 2003),
Zimbabwe
13 cases from patients who underwent excisional biopsy
for conjunctival lesions at Bindura Provincial Hospital
(Mashonaland Central, Zimbabwe)
7 controls. Patients were from the same
group as cases but had benign lesions
on histology
1994–1998
(Newton et al. 2001),
Uganda
22 cases. Patients aged >15 years with a provisional
diagnosis of cancer from all wards and out-patient
clinics of the 4 main hospitals in Kampala: Mulago,
Nsambya, Mengo and Rubaga
112 controls. 93 patients with tumours
not suspected to be of infectious
aetiology and 19 with non-malignant
conditions
2001–2005
(Waddell et al. 2010),
Uganda
318 cases recruited from country-wide ophthalmology
clinics in Uganda. Anyone with a suspected OSSN
was offered surgical treatment and histology,
together with enrolment into a case-control study
762 controls were recruited from 2 sources.
The first group comprised patients
attending the ophthalmology clinics
with concerns or conditions other than
OSSN. This group also included those
individuals who were originally recruited
as cases, but where histology subsequently
revealed another diagnosis. The second
group comprised people who were
recruited through the voluntary HIV
counselling and testing (VCT) service
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small age–sex-matched case–control study (Napora et al.
1990). Exposure to smoke from burning wood in the
kitchen was described as a risk factor for cervical cancer
among HPV-infected women in Honduras (Velema et al.
2002).
Cigarette smoking. Cigarette smoking is implicated in
other squamous cell cancers (Haverkos 2004). There is,
however, evidence of no effect from smoking on OSSN in
Africa. In Uganda, two case–control studies showed that
current smokers were not at a significantly higher risk for
OSSN than non-smokers (Waddell et al. 2010; Ateenyi-
Agaba et al. 2010; pooled OR = 1.40; 95% CI: 0.94–
2.09; Figure 7). In a Nigerian series of 37 SCCC cases,
only two patients (5.4%) had a history of cigarette smok-
ing (Ogun et al. 2009) while in a series from Australia, 5
of 11 cases of SCCC (45%) were smokers (McKelvie
2002).
Allergy. There is little evidence that allergic conjunctivi-
tis is a risk factor. Among 215 SCCC cases in Tanzania,
1.9% had allergic conjunctivitis (Poole 1999). In
Rwanda, allergic conjunctivitis was found in 4% of chil-
dren and was responsible for 3–6% of hospital visits of
all ages (de Smedt et al. 2013). In a case–control study in
Uganda, none of the cases of OSSN had a history of
allergic eye disease (Waddell et al. 2010). However, a
case series of SCCC from Germany reported that 6/10
cases had atopic eczema, so this may be of more
importance in temperate climates (Heinz et al. 2003).
NOTE: Weights are from random effects analysis
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Figure 6 Meta-analysis of case-control studies of human papilloma virus (HPV) infection in ocular surface squamous neoplasia
(OSSN) (random effects).
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Xeroderma pigmentosum. Xeroderma pigmentosum
(XP), a rare, inherited skin disease characterised by high
sensitivity to UV damage is associated with a high preva-
lence (40%) of specific mutations of the TP53 tumour
suppressor gene (Dumaz et al. 1993). Over a 25-year
period in Zimbabwe, in a series of 12 cases, 2 had SCCC
while the rest had SCC of the skin, lip or tongue (Chid-
zonga et al. 2009). From a series of 7 XP cases in India,
6 of the 14 eyes (42.9%) had invasive SCC and eight eyes
(57.1%) had CIN (Gupta et al. 2011). A larger series of
32 cases in France found that 59% of them had ocular
and periocular malignancies (Touzri et al. 2008).
Vitamin A deficiency. The importance of vitamin A in
maintaining the health of the ocular surface is well
known, but the role of vitamin A deficiency in OSSN has
not been established. Deficiency of vitamin A induces
keratinisation of the ocular surface (Beitch 1970; Pfister
& Renner 1978). Keratinisation is commonly observed as
leucoplakia in OSSN lesions (Figure 1). There is a syner-
gistic interaction between vitamin A and zinc in mainte-
nance of the corneal and conjunctival epithelium
(Kanazawa et al. 2002). In South Africa, it was shown
that 54% of HIV-infected adults are deficient in vitamin
A (plasma retinol <1.05 lM) and 33% deficient in zinc
(<10.7 lM; Visser et al. 2003). In Ethiopia, 53% of
HIV-infected adults were deficient in vitamin A (Fufa
et al. 2009). As most patients with OSSN are also
HIV-infected, it is plausible that vitamin A deficiency
contributes to the aetiology.
Other risk factors. There is limited evidence of a role for
exposure to dust, ocular trauma and pre-existing benign
conjunctival lesions such as pterygia and pingueculae
(Templeton 1967; Margo & Groden 1986; Waddell et al.
2010).
Protective factors. One of the Ugandan case–control
studies found that some factors are associated with a
lower risk for SCCC such as higher personal income
(adjusted OR = 0.4, 95% CI: 0.3–0.7) and decreasing
age at leaving home (P = 0.05), perhaps reflecting less
exposure to sunlight consequent to rural-to-urban
migration (Newton et al. 2002).
Aetiological model of OSSN
Various models have been proposed to simultaneously
address the role of two or more risk factors in cancer
causation within hierarchical levels (Victora et al. 1997).
Most such models focus on social and environmental
hypothesis but do not incorporate biological factors. A
recently proposed framework called Multi-level Biological
And Social Integrative Construct (MBASIC) includes
Overall  (I-squared = 69.0%, P = 0.072)
Study
Ateenyi 2010
Waddell 2010
Cases
133
299
Controls
284
754
1.40 (0.94, 2.09)
OR (95% CI)
0.90 (0.48, 1.72)
1.92 (1.15, 3.22)
100.00
Weight
%
50.89
49.11
.5 1 2 3 4
Odds ratio
Favours no association Favours association
Figure 7 Meta-analysis of case-control studies in Uganda on cigarette smoking and ocular surface squamous neoplasia (OSSN) in
Africa (fixed effect).
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biological factors together with macro-environmental and
individual level factors (Lynch & Rebbeck 2013). Using
the existing evidence reviewed in this article, we propose
an aetiological model that might explain how the risk
factors discussed may be involved development of OSSN
(Figure 8).
Conclusions
OSSN is a disease of increasing importance in Africa. A
triad of ultraviolet solar radiation, HIV and HPV form
the major risk factors and this may explain the high inci-
dence rates in Africa. There is evidence from case–control
studies that exposure to UV radiation, outdoor occupa-
tions – perhaps due to exposure to sunlight, HIV and
HPV infection are associated with a higher risk for
OSSN. These studies also show no evidence of effect of
cigarette smoking. Dust, ocular trauma and pre-existing
benign conjunctival tumours may play a role. Although
mentioned in the literature, the effect of atopy and xero-
derma pigmentosa is unclear. The effect of vitamin A
deficiency has not been examined in case–control studies.
The highest incidence of OSSN is found in Africa, where
males and females are equally affected, unlike other conti-
nents where male disease predominates. This probably
reflects that African women have increased risk due to their
higher prevalence of HIV and HPV infections. As people
with HIV are living longer, and given no evidence that
ART reduces risk of OSSN, one could expect incidence of
OSSN to increase in Africa in coming years.
Residence near
     equator
Outdoor
occupation
Solar UV
radiation
Altered expression of
MMPs and TIMPs
p 53 genetic mutations
& degradation
Impaired tumor
suppressive effect
Impaired
downregulation of
HPV E2 proteins
HPV infection or
reactivation of
latent infection
Metaplasia at squamo-columnar
transition epithelia eg. limbus
?
Vitamin A deficiency
Atopy
Cigarette smoking
Unknown
No evidence of effect
Tissue invasion and spread
of malignant cells (OSSN)
MMPs - matrix metalloproteinases
TIMPs - tissue inhibitors of metalloproteinases
HPV E6 protein
promotes degradation
of p53 gene
Immune
suppression
Impaired surveillance
of mutated or virus-
infected cells
   HIV
infection
Xeroderma
pigmentosum
Extreme sensitivity to
UV radiation damage
Figure 8 An aetiological model
illustrating how ocular surface squamous
neoplasia (OSSN) might develop. MMPs,
matrix metalloproteinases; TIMPs, tissue
inhibitors of metalloproteinases.
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Currently, the best available options for OSSN control
remain early detection and effective treatment. However,
there are no early non-invasive diagnostic methods in use
and no trial evidence to guide treatment. OSSN is
currently largely neglected by both eye and HIV care
programmes. Eye care programmes prioritise preventable
blindness while OSSN often in early stages does not
affect vision. OSSN may, however, lead to facial disfig-
urement and death in late stages. In Africa, a key
research question is whether scale-up of ART and HPV
vaccination will impact on OSSN.
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The incidence of ocular surface squamous neoplasia (OSSN) is strongly associated with solar ultraviolet
(UV) radiation, HIV and human papilloma virus (HPV). Africa has the highest incidence rates in the world.
Most lesions occur at the limbus within the interpalpebral ﬁssure particularly the nasal sector. The nasal
limbus receives the highest intensity of sunlight. Limbal epithelial crypts are concentrated nasally and
contain niches of limbal epithelial stem cells in the basal layer. It is possible that these are the progenitor
cells in OSSN. OSSN arises in the basal epithelial cells spreading towards the surface which resembles the
movement of corneo-limbal stem cell progeny before it later invades through the basement membrane
below. UV radiation damages DNA producing pyrimidine dimers in the DNA chain. Speciﬁc CC/ TT base
pair dimer transformations of the p53 tumour-suppressor gene occur in OSSN allowing cells with
damaged DNA past the G1-S cell cycle checkpoint. UV radiation also causes local and systemic photo-
immunosuppression and reactivates latent viruses such as HPV. The E7 proteins of HPV promote pro-
liferation of infected epithelial cells via the retinoblastoma gene while E6 proteins prevent the p53
tumour suppressor gene from effecting cell-cycle arrest of DNA-damaged and infected cells. Immuno-
suppression from UV radiation, HIV and vitamin A deﬁciency impairs tumour immune surveillance
allowing survival of aberrant cells. Tumour growth and metastases are enhanced by; telomerase reac-
tivation which increases the number of cell divisions a cell can undergo; vascular endothelial growth
factor for angiogenesis and matrix metalloproteinases (MMPs) that destroy the intercellular matrix
between cells. Despite these potential triggers, the disease is usually unilateral. It is unclear how HPV
reaches the conjunctiva.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Ocular surface squamous neoplasia (OSSN) comprises of a
spectrum of tumours that affect the ocular surface ranging histo-
logically from intraepithelial neoplasia to different grades of inva-
sive squamous cell carcinoma (Lee and Hirst, 1995). Early lesions of
varying size usually occur at the limbus, the area of transition be-
tween the cornea and conjunctiva (Lee and Hirst, 1997; Waddell
et al., 2006). Advanced stages may involve the eyelids and mayEye Health (ICEH), London
, WC1E 7HT London, UK.
. Gichuhi), s.ohnuma@ucl.ac.
matthew.burton@lshtm.ac.uk
r Ltd. This is an open access article
47invade the orbit. Curiously OSSN usually affects only one eye (Chisi
et al., 2006).
OSSN occurs worldwide but the peak incidence is found at a
latitude of 16 South (Gichuhi et al., 2013). The mean age-
standardised incidence rate worldwide is 0.18 and 0.08 cases/
year/100,000 among males and females, respectively and the
highest incidence rate is found in Africa (1.38 and 1.18 cases/year/
100,000 in males and females) (Gichuhi et al., 2013). In temperate
countries OSSN predominantly affects males while in Africa both
sexes are affected equally. Systematic reviews and meta-analysis
show that the main risk factors are solar ultraviolet (UV) radia-
tion, HIV and human papilloma virus (HPV); while vitamin A
deﬁciency is a potential risk factor but has not been investigated
(Gichuhi et al., 2013; Carreira et al., 2013). This paper reviews the
pathophysiological mechanisms underlying the development of
OSSN.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The ocular surface consists of the cornea, limbus and con-
junctiva but in a wider anatomical and embryological sense the
mucosa of the ocular adnexa (lacrimal gland and lacrimal
drainage system) is included. The epithelia of the cornea, con-
junctiva and eyelid are formed from differentiation of the surface
ectoderm during embryonic development. The corneal endo-
thelium and the corneal stroma, conjunctiva and eyelids are
formed when periocular mesenchymal cells of neural crest origin
migrate and differentiate (Cvekl and Tamm, 2004; Kao et al.,
2008).
The cornea has a stratiﬁed squamous non-keratinizing epithe-
lium with ﬁve to seven cell layers. It is immunologically privileged
due to its lack of blood vessels and lymphatics, with dendritic cells
present usually only in the peripheral cornea (Akpek and Gottsch,
2003).
The limbal epithelium is 8e10 cells thick and is constantly being
replenished from stem cells in the basal layer (Schermer et al.,
1986). The limbal basement membrane has undulating peg-like
inter-digitations into the underlying stroma called the palisades
of Vogt, which increase the surface area and protect against
shearing forces (Fig. 1). The palisades are unique for individuals
(like ﬁngerprints) and have distinct radial vascular loops that leak
ﬂuorescein in the late phase of angiography suggesting a protective
function for stem cells (Goldberg and Bron, 1982). The basal cells
are protected from UV light by melanin within deep limbal crypts,
where melanocytes contain melanin granules oriented towards the
apex of each cell, acting as a pigmented cap facing the ocular sur-
face (Higa et al., 2005). Among darker pigmented races the limbus
is heavily pigmented, perhaps offering greater protection from UV
radiation.Fig. 1. Anatomy o
48The conjunctiva consists of an epithelium on a basement
membrane and underlying loose connective tissue called the lam-
ina propria. The lamina propria is loosely anchored to the episclera
and sclera making the conjunctiva easily mobile. The epithelium
varies between 2e3 and 10e12 cell layers, depending onwhether it
is the bulbar, fornix or tarsal portion. Lymphocytes and plasma cells
are abundant in the conjunctiva (Hingorani et al., 1997). They form
the conjunctiva-associated lymphoid tissue (CALT) in the lamina
propria (Knop and Knop, 2007).
3. Limbal stem cell biology
Stem cell biology is a rapidly progressing ﬁeld. A stem cell is a
special undifferentiated progenitor cell capable of giving rise to
many more cells of the same type, and from which other kinds of
cells arise by differentiation. There are three types of stem cells.
Embryonic stem cells originate frompre-implantation embryos and
can develop into tissues that belong to one of the three germ layers
(Martin, 1981). Non-embryonic adult stem cells (termed somatic)
are undifferentiated cells found in special niches of various organs
where they divide and differentiate to replace damaged tissuewhile
some may transdifferentiate to other tissues (Gonzalez and Bernad,
2012). Their origin remains unclear. Limbal epithelial cellswould fall
in this category. Lastly, induced pluripotent stem cells are created in
the lab by genetically reprogramming somatic cells to an embryonic
stem cell-like state (Takahashi et al., 2007; Obokata et al., 2014).
Corneo-limbal lineage is distinct from conjunctival lineage (Wei
et al., 1996). Evidence suggests the existence of corresponding stem
cell reservoirs. Corneo-limbal epithelial stem cells are located in the
limbal basal layer while conjunctival stem cells are distributed
throughout the bulbar and forniceal conjunctiva, but some propose
that they are concentrated in the fornix (Nagasaki and Zhao, 2005;f the limbus.
S. Gichuhi et al. / Experimental Eye Research 129 (2014) 172e182174Sun et al., 2010; Pellegrini et al., 1999; Wei et al., 1995). Stem cells
are also found in the corneal stroma and mucocutaneous junction
of the lid margin (Du et al., 2005; Wirtschafter et al., 1997). The
molecular structure of the basement membrane and extracellular
matrix at the cornea, limbus and conjunctiva differ from each other
and this is thought to play a role in regulation of epithelial differ-
entiation (Kolega et al., 1989; Schlotzer-Schrehardt et al., 2007).
Various markers have been studied in the ocular surface to deter-
mine which are more concentrated at the limbus (Table 1)
(Schlotzer-Schrehardt and Kruse, 2005). There are no speciﬁc lim-
bal stem cell markers or any that distinguishes stem cells from their
early progeny (Chee et al., 2006).
Limbal stem cells are found in special niches in the basal region
called limbal epithelial crypts which are cords of epithelial cells
extending from the palisades of Vogt into the underlying stromaTable 1
Molecular markers for limbal stem cells (Schlotzer-Schrehardt and Kruse, 2005).
Characterization Example
Cytoskeletal proteins
- proteins that form intermediate ﬁlaments in epithelial cells
i) Cytok
It is a
ii) Vime
limba
Cytosolic proteins
- associated with cellular metabolic functions
a) enzym
i) c
ii) c
iii) a
b
iv) p
in
v) a
vi) tr
b) Cell-c
i) Cy
ii) Ki
c) Meta
d) Invol
kerat
e) calciu
f) prote
proce
Nuclear proteins p63 is a
Although
stem cel
Cell surface proteins
a) Cellecell and cellematrix interaction molecules
b) Growth factor receptors
c) Transporter molecules
d) Cell surface glycoconjugates
i) Con
low
ext
ii) Cad
cell
iii) Inte
con
bas
iv) epi
v) ker
vi) Trk
vii) hep
viii) Tra
ix) tran
x) ABC
pro
of t
wh
dru
loca
epi
xi) a-2
Neuronal markers
- human corneal and limbal cells may exhibit neuronal
properties characteristic of their neuroectodermal origin
i) Nesti
excep
ii) trans
Hematopoietic stem cell markers i) CD34
ii) CD13
a In the original article cytokeratins were abbreviated as K. We have modiﬁed that to
49(Dua et al., 2005). The crypts are most abundant nasally in the mid-
or distal limbus (Shanmuganathan et al., 2007). Stem cells within
the crypts have the followingmarker proﬁle; CK3/CK19þ/CD34/
Vimentinþ/p63þ/Connexin43þ/Ki67 (Shanmuganathan et al.,
2007). Stem cells represent less than 10% of the limbal basal cell
population (Lavker et al., 1991). They are characterised by; low level
of differentiation, slow cell-cycle, long life-span, high proliferative
potential and self-renewal (ability to produce more stem cells)
(Schlotzer-Schrehardt and Kruse, 2005; Dua and Azuara-Blanco,
2000). The limbus creates a barrier to prevent extension of
conjunctival epithelium and blood vessels into the cornea (Osei-
Bempong et al., 2013). Clinical features of limbal stem cell deﬁ-
ciency disorders thus include corneal epithelial defects, conjunc-
tival epithelial migration onto the cornea and corneal
neovascularization (Sejpal et al., 2013).s
eratinsa (CK3, CK12, CK5, CK14, CK19) e CK3/CK12 pair is lacking in the limbus.
marker of corneal phenotype
ntin fastens limbal stem cells to their local environment. It is localised in
l basal cells
es
ytochrome oxidase e Na/K-ATPase
arbonic anhydrase
-enolase (initially thought to be a glycolytic enzyme it acts as a plasminogen
inding receptor)
rotein kinase C (PKC), a key enzyme controlling signal transduction pathways
growth and differentiation.
ldehyde dehydrogenase (ALDH)
ansketolase (TKT)
ycle associated proteins
clins
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G2, a member of the ATP binding cassette transporters. ABCG2 has been
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ich causes resistance to certain chemotherapeutic drugs. It is a multi-resistance
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3 a transmembrane glycoprotein
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constantly lost and are replaced by basal cells entering the dif-
ferentiation pathway. To replenish the corneal epithelium, corneal
epithelial stem cells undergo mitosis producing a progeny of fast-
dividing transient amplifying cells (TAC) that make up the ma-
jority of the proliferating cell population in the epithelium
(Castro-Munozledo, 2013). TAC migrate superﬁcially to the
suprabasal limbus and centripetally towards the centre of the
cornea to form the basal layer of the corneal epithelium (Lehrer
et al., 1998). They undergo a limited number of divisions then
differentiate into post-mitotic cells (PMC) and further into
terminally differentiated cells (TDC) that migrate superﬁcially to
the corneal surface (Lehrer et al., 1998). It takes 14e21 days for
complete renewal of the rabbit corneal epithelium (Haddad,
2000). In humans it takes 5e7 days (Hanna and O'Brien, 1960).
For conjunctival renewal, cells stream centrifugally (instead of
centripetally as occurs in the cornea) at 10.5 ± 2.4 mm/day then
superﬁcially at 9.3 ± 5.4 mm/day with a cell-cycle time of 8.3 days
in rats (Zajicek et al., 1995). Stem cells have a slower passage
through the cell cycle than the other basal cells of the cornea and
conjunctiva (Lavker et al., 1991). In mice they take 4e8 weeks and
are preferentially stimulated by wounding and tumour promoting
compounds (Cotsarelis et al., 1989). Intact innervation of the
ocular surface is needed to maintain the stem cell niche (Ueno
et al., 2012).4. Cancer stem cells
The term cancer stem cell is a relatively new one in cancer
biology, though this is a concept known for many years (Wicha
et al., 2006). In malignant tumours there is frequently a subpopu-
lation of cells that responds poorly to treatment such as chemo-
therapy and radiotherapy, divides at a slower rate than other cancer
cells, and is less affected by hypoxia (Moore and Lyle, 2011; Lin and
Yun, 2010). This subpopulation is thought to drive tumour growth
and is the subject of much debate and much investigation for
different tumour types. The origin of these cells is controversial and
their interaction with non-stem cancer cells has been variously
studied using mathematical models (Wang et al., 2014).
Cancer stem cells comprise less than 5% of the cell population in
most tumours (Yang and Chang, 2008). They are found in various
cancers including breast, brain, gastric, pancreatic and liver (Al-Hajj
et al., 2003; Yuan et al., 2004; Takaishi et al., 2008; Lee et al., 2008;
Sell and Leffert, 2008). In high-grade cervical intraepithelial
neoplasia (CIN) associated with carcinogenic HPV types they are
found at the squamo-columnar junction but rarely in ectocervical/Fig. 2. Location of 352 OSSN tumours in Uganda showing most lesions occurred within th
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50transformation zone CINs or those associated with non-
carcinogenic HPVs (Herfs et al., 2012).
Their existence could help to explain the clinical observation of
the inaction of conventional cancer chemotherapy and radio-
therapy in some instances since these treatments target rapidly
dividing cells yet stem cells by nature are slow-cycling. For
example, treatment with ﬂuorouracil (5-FU) selects and enriches
the cancer stem cell population since the rapidly dividing cells
would be killed while slow-cycling ones incorporate the drug at a
lower rate (Shi et al., 2013; Wang et al., 2006). Potentially, therapies
targeting cancer stem cells could be more effective (Duggal et al.,
2014).
5. Patterns of ocular surface dysplastic and neoplastic disease
The clinical presentation of ocular surface dysplastic and
neoplastic diseases provides clues to the pathophysiology of OSSN.
Firstly, OSSN, pterygium, pingueculae, climatic droplet keratopathy
and actinic keratosis are usually located within the interpalpebral
ﬁssure, the space between the open upper and lower eyelid that is
exposed to UV radiation (Waddell et al., 2006; Sudhalkar, 2012;
Shields et al., 2004; Gray et al., 1992). Secondly, most OSSN le-
sions arise from the limbus particularly the nasal quadrant (Fig. 2)
(Waddell et al., 2006). A similar observation was made of pterygia
in India where all the lesions in a study of 427 participants were
nasal (Sudhalkar, 2012). This is the area with the highest concen-
tration of limbal epithelial crypts (Shanmuganathan et al., 2007).
Thirdly, the disease may involve the circumferential limbus with
relatively little involvement of the cornea or fornix (Fig. 3). Lastly,
intraepithelial neoplasia begins in the basal cells and spreads up-
wards, a pattern reﬂected in the histological grading (Basti and
Macsai, 2003; American Joint Committee on Cancer, 2010). This
resembles the spreading waves of limbal stem cells and their
progeny described in biology above suggesting that the diseasemay
be of stem cell origin. It remains unclear why OSSN is often uni-
lateral since exposure to UV radiation, HIV and HPV has no
laterality.
6. Vulnerability of the limbus
The limbus receives direct sunlight temporally which is focused
nasally (Fig. 4). As the human eye is more exposed laterally, the
large temporal visual ﬁeld becomes a collecting zone of peripheral
light, which, depending on the angle of incidence (q) and the
corneal central radius of curvature (r0), is intensely focused onto
the nasal limbus, lid margin or lens with up to a 20-fold increase ine interpalpebral ﬁssure with a higher concentration in the nasal sector.
06
Fig. 3. A lesion of OSSN lesion in Kenya showing a circum-limbal growth pattern
involving almost the entire circumference of the limbus. The margins are drawn in a
black dotted line to show extension into the cornea and bulbar conjunctiva.
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the anterior chamber strikes the nasal limbal cells basally where
there is less melanin. These foci coincide with the usual site for
pterygium, OSSN, lid malignancy and cataract.
Limbal basal cells remain quiescent but proceed more rapidly
through the cell cycle when there is an insult to the ocular surface
such as a wound or tumour promoter (Cotsarelis et al., 1989).
Quiescent adult stem cells accumulate DNA damage making them
vulnerable to neoplastic transformation (Mohrin et al., 2010).
Others however suggest that slow-cycling protects them from
cancer (Wodarz, 2007). Quiescence may create a reservoir of latent
virus infection, which can persist for long periods before reac-
tivation following immunosuppression (Maglennon et al., 2011). In
skin hair follicle stem cells the papilloma virus oncogenes, E6 and
E7, can compromise stem cell quiescence by promoting their
aberrant mobilization (Michael et al., 2013).
7. Key events in the aetiology of OSSN
7.1. DNA damage: genetic and epigenetic changes
At the heart of carcinogenesis is non-lethal DNA damage. DNA
damage can be genetic (mutations of the DNA nucleotide
sequence) or epigenetic (variations in gene expression that do
not involve changing the nucleotide sequence). DNA damageFig. 4. Light from a torch shining on the temporal side of the eye to illustrate that the
limbus receives direct sunlight temporally which is focused nasally. Notice the glow in
the nasal limbus.
51affects genome stability and stem cell function leading to cancer
(Xu and Taylor, 2014). Mutations may affect oncogenes (genes
that facilitate cell division) or tumour suppressor genes (that
slow down or stop cell division). Epigenetic modiﬁcations can
take three different forms (Walters, 2013). Firstly, DNA methyl-
ation where cytosine nucleotides (C) are found adjacent to gua-
nine nucleotides (G) called CpG sites, which shuts down RNA
transcription. Secondly, modifying histones (e.g. acetylation and
methylation) around which DNA is wrapped allowing uncon-
trolled access to DNA by transcription factors. Thirdly, silencing
micro RNA (miRNA) genes which regulate cell processes such as
proliferation, differentiation, and apoptosis by binding the 30
untranslated region of target mRNA. Epigenetic changes are often
reversible (Delcuve et al., 2009). Although distinct from each
other, epigenetic changes and mutations are related because
epigenetic changes may lead to mutations and cancer (Feinberg
et al., 2006). Ocular surface DNA damage is probably mainly
caused by solar UV radiation (UVR), although HPV may also play a
role.
7.1.1. Effects of solar ultraviolet radiation
7.1.1.1. Genetic and epigenetic changes. Ambient UVR can be
broadly divided into UVA (320e400 nm, approximately 90%) and
UVB (290e320 nm, approximately 5%) wavebands (Diffey, 2002).
UVC (200e290 nm) is largely prevented from reaching the earth's
surface by the ozone layer in the atmosphere.
UVB radiation causes direct DNA damage by crosslinking adja-
cent bases to form cyclobutane pyrimidine dimers (CPDs) and 6-4
photoproducts (6-4 PPs) (Pfeifer et al., 2005). The most commonly
seen are CPDs and are considered the hallmarks of UV damage
(Besaratinia et al., 2011). Pyrimidine dimers are formed when
adjacent bases (thymine-T or cytosine-C) on the same DNA strand
absorb energy from UV light and form crosslinks via carbon-to-
carbon covalent bonds (Rastogi et al., 2010). CPDs and 6-4PPs
distort DNA's structure and block DNA synthesis by preventing the
replicative DNA polymerases from moving along a template strand
(Ikehata and Ono, 2011). CPDs are also resistant to hydrolysis
(Yamamoto et al., 2014). Speciﬁc CC/ TT dimer transitions of the
p53 tumour-suppressor gene have been observed in OSSN lesions
in Uganda (Ateenyi-Agaba et al., 2004). p53 mutations occur in
different phases of the multistepmalignant transformation and can
be found in precancerous lesions such as actinic keratosis (Rivlin
et al., 2011). The effects of p53 mutation are discussed later in
this article.
UVA causes indirect DNA damage via reactive oxygen species
(ROS), like OH (hydroxyl radical), O2 (superoxide radical anion) or
H2O2 (hydrogen peroxide) leading to DNA strand breaks (Cortat
et al., 2013; Greinert et al., 2012; Cadet et al., 2009). No studies
have demonstrated DNA strand breaks in OSSN. Cells have greater
ability to repair UVA effects than UVB (Besaratinia et al., 2008).
7.1.1.2. Reactivation of latent HPV infection. Exposure to UVB reac-
tivates latent HPV(Zhang et al., 1999), HIV(Breuer-Mcham et al.,
2001), varicella-zoster (shingles) (Zak-Prelich et al., 2002; Rice,
2011) and herpes simplex (cold sores) (Blatt et al., 1993; Miller
et al., 1993). HPV is a small DNA virus. Asymptomatic HPV infec-
tion is widespread with an estimated global prevalence of 11.7% in
women and 1.3%e72.9% in men (Bruni et al., 2010; Dunne et al.,
2006). HPV is epitheliotropic for squamous epithelia especially
transitional mucosae and is implicated in the aetiology of various
squamous cell carcinomas including cervical (summary OR ¼ 70.0,
95% CI; 57.0e88.0), colorectal (summary OR ¼ 10.0, 95% CI;
3.7e27.5), laryngeal (summary OR ¼ 5.4, 95% CI; 3.3e8.9), OSSN
(summary OR ¼ 4.0, 95% CI; 2.1e7.6), oesophageal (summary
OR ¼ 3.3, 95% CI; 2.3e4.9) and bladder (summary OR ¼ 2.8, 95% CI;
Fig. 5. The cell division cycle.
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2011; Gichuhi et al., 2013; Li et al., 2014, Li et al., 2011).
Much of what is known about the pathophysiology of HPV in
cancer is derived from cervical studies. HPV invades the basement
membrane through micro abrasions where it initially binds to
heparin sulphate proteoglycan (HSPG) (Johnson et al., 2009; Sapp
and Bienkowska-Haba, 2009). It does not bind intact epithelia
(Johnson et al., 2009). The basement membrane is not merely a
passive reservoir of virus but is involved in viral processing. Here
the viral capsids undergo a conformational change where the L2
epitope is cleaved by a protease and exposure of its N-terminal
leads to the transfer of capsids to the epithelial cell surface (Kines
et al., 2009). After internalization, the virus is disassembled and
the DNA enters the nucleus by a mechanism that is still not well
understood where it replicates producing extra-chromosomal
copies of viral DNA (Sapp and Bienkowska-Haba, 2009). However
the genome of high-risk HPV has been found incorporated into
speciﬁc preferential sites of the host DNA in cervical lesions (Li
et al., 2013a). During differentiation of epithelial cells, virions
mature and are carried towards the surface (Doorbar, 2005). In
normal uninfected epithelia, as cells leave the basal layer, they exit
the cell cycle but infected cells remain active due to E7 (Longworth
and Laimins, 2004). E7 inactivates the retinoblastoma gene (pRB)
which usually acts in the G1 phase of the cell cycle where it binds
transcription factors, thus infected cells remain in a proliferative
state while E6 binds the p53 protein preventing it from suppressing
replication of such DNA-defective cells (Lehoux et al., 2009). In
high-risk HPV types, E6 and E7 also cause genomic instability; E7
causes centriole over-duplication and disturbs mitotic ﬁdelity
while E6 causes structural chromosomal alterations and DNA
breakage (Korzeniewski et al., 2011). The effects on p53 and pRB are
considered the molecular signatures of HPV-induced carcinogen-
esis (Buitrago-Perez et al., 2009). Regression of HPV-induced le-
sions is mediated by a T-helper 1 lymphocyte (Th1) cell mediated
immune response (Stanley, 2012). HPV latency may arise in two
ways; (i) low titre infection that is too low to complete the life cycle
or (ii) clearance of lesions by the adaptive immune system followed
by persistence of low-level viral gene expression, which is reac-
tivated by immunosuppression (Doorbar, 2013).
How HPV initially reaches the conjunctiva is not clear. The
prevalence of HPV in OSSN tissue is heterogeneous, varying widely
from zero to 100% (Gichuhi et al., 2013).
HPV infection is associated with an increased incidence of HIV
acquisition (summary OR¼ 1.96; 95% CI; 1.55e2.49) (Lissouba et al.,
2013).
7.2. Failure of DNA repair mechanisms
Several mechanisms prevent UV-induced DNA mutations from
being incorporated into the genome and UV-damaged cells from
establishing themselves. Cells can correct carcinogen-induced DNA
damage; severely damaged cells are eliminated from healthy tis-
sues by processes that trigger apoptosis; and abnormal cells are
recognized, targeted and destroyed by immune surveillance (Di
Girolamo, 2010).
The cell-division cycle involves duplication of the genome and
intracellular organelles (Imoto et al., 2011). The stages of the cycle
can be visualised directly by high-resolution imaging (Hesse et al.,
2012). Nuclear DNA is synthesized during a stage of interphase
called the S phase which is followed by a gap (G2), then mitosis (M
phase) in which nuclear and cell division occur and another gap
(G1) before the next S phase (Fig. 5).
DNA damage activates checkpoint pathways that regulate spe-
ciﬁc DNA repair mechanisms in the different phases of the cell cycle
(Branzei and Foiani, 2008). There are three important cell-cycle52checkpoints (Sancar et al., 2004). The G1-S checkpoint prevents
cells with damaged DNA from entering the S phase by inhibiting
the initiation of replication. The intra-S-phase checkpoint deals
with DNA damage that may occur during S-phase or unrepaired
damage that escaped the G1-S checkpoint. The G2-M checkpoint
prevents cells with damaged DNA from undergoing mitosis.
The molecular mechanisms that repair UVR-induced DNA
damage include excision repair, mismatch repair, strand break
repair, and cross-link repair (Rastogi et al., 2010). During excision
repair sections of damaged DNA are replaced by a nucleotide or
base (Sinha and Hader, 2002). The nucleotide excision repair (NER)
pathway is primarily responsible for repairing CPDs in humans
(Sancar et al., 2004). There are two types of NER; general excision
repair which removes lesions from the whole genome and
transcription-coupled repair which works on damage in tran-
scribed DNA strands. The latter is not clearly understood but the
former is performed through a series of special proteins and pro-
ceeds through four discrete steps; recognition of the damage;
excision of the section of DNA that includes and surrounds the er-
ror; ﬁlling in of the resulting gap by DNA polymerase; and sealing of
the nick between the newly synthesized and older DNA by DNA
ligase (Hu et al., 2013; Reardon and Sancar, 2005).
Base excision repair (BER) is the predominant pathway against
lesions caused by ROS, ionizing radiation and strong alkylating
agents (Svilar et al., 2011). It proceeds through 5 steps as follows;
DNA glycosylases remove damaged or modiﬁed bases; the apuri-
mic/apyrimidinic site is removed by an endonuclease or lyase; the
remaining phosphate residue is removed by a phosphodiesterase;
the gap is ﬁlled by a DNA polymerase and the strand sealed by a
DNA ligase (Hegde et al., 2008).
7.2.1. The p53 tumour-suppressor system
The p53 tumour-suppressor gene is found on the short arm of
chromosome 17 (17p13.1) (Mcbride et al., 1986). P53 is a phos-
phoprotein found in the nucleus which regulates the cell cycle to
protect cells from the effects of DNA damage (Ford, 2005; Jin and
Robertson, 2013; Borras et al., 2011). It is thus described as the
‘guardian of the genome’ (Lane, 1992). Once p53 is activated by a
stress signal it binds to speciﬁc DNA elements in the genome with
various primary and secondary response effects (Levine et al.,
2006). The primary responses include; cell cycle arrest at the G1-
S checkpoint; irreversible withdrawal of cells from the cycle into
a terminal state of senescence or programmed cell death
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come from p53-regulated gene products that prevent DNA damage
(sestrins) or aid in DNA repair; mediate communication between
the cell and its neighbours, the extracellular matrix or more distant
cells; or create intracellular or extracellular p53 feedback loops that
modulate p53 activity. In addition, deacetylation of p53 facilitates
autophagy (autophagocytosis by controlled lysosomal degradation)
(Contreras et al., 2013). Mutated p53 (Mutp53) leads to further
genomic instability (Meek, 2009).
7.3. Reduced immunity
Tumour immunology presumes that tumour cells express anti-
gens such as mutp53 and HPV proteins that distinguish them from
non-transformed cells. The immune system prevents tumour for-
mation in 3 ways (i) elimination or suppression of viral infection (ii)
preventing establishment of a pro-inﬂammatory environment and
(iii) speciﬁcally identifying and eliminating cells that express
tumour-speciﬁc antigens or molecular signals of cellular stress
before they cause harm (Schreiber et al., 2011). The latter is part of a
more general process called tumour immuno-editing. Immuno-
editing is a dual process in which the immune system may either
suppress tumour growth by destroying or inhibiting growth of
cancer cells or inadvertently promote tumour progression by
selecting tumour cells that aremore likely to survive. It has 3phases:
elimination, equilibrium and escape (Schreiber et al., 2011). In the
elimination phase the immune system recognizes tumour cells and
initiates cell death eliminating themcompletely before theybecome
clinically apparent. If not fully eliminated the remaining tumour
cells enter a state of temporary equilibrium between the immune
system and the developing tumour in which the tumour cells
remain dormant or continue to accumulate further genetic and
epigenetic changes. Finally if the immune system fails to contain the
tumour at this phase, surviving tumour cell variants escape causing
uncontrolled tumour expansion. The quantity, quality and distri-
bution of tumour inﬁltrating lymphocytes (TILs) such as CD8þ
cytotoxic T lymphocytes (CTL), CD4þ T helper lymphocytes (Th),
CD4þ regulatory T lymphocytes (Treg) and CD3þ lymphocytes in-
ﬂuence prognosis. A meta-analysis showed that improved survival,
measured by the deathHazard ratio (HR),was associatedwith CD3þ
TIL inﬁltration (HR ¼ 0.58, 95% CI; 0.43e0.78) and CD8þ TIL
(HR ¼ 0.71, 95% CI; 0.62e0.82) (Gooden et al., 2011). However TIL
counts alone may overestimate this effect and ratios between TIL
subsets CD8þ/FoxP3þ (effector:regulatory ratio) and CD8þ/CD4þ
(effector:helper ratio) may be more informative. Natural killer cells
are another important component of cancer immunosurveillance
and immuno-editing (Gross et al., 2013).
7.3.1. Photoimmunosuppression
Ambient UV radiation suppresses cell-mediated immunity
(Clydesdale et al., 2001). UVB is a more potent immunosuppressor
than UVA (Poon et al., 2005). This phenomenon referred to as
photoimmunosuppression is not limited to exposed cutaneous
tissues but is also systemic, affecting internal organs (Gibbs and
Norval, 2013). The immunosuppressive effect of UVB is used in
phototherapy of skin conditions such as psoriasis (Chen et al.,
2013). In the skin, UVB stimulates migration of epidermal Langer-
hans cells, which present antigens to lymphocytes in the draining
lymph nodes promoting a Th2 and regulatory T cells (Treg) domi-
nated response that suppresses local immune responses (Taguchi
et al., 2013; Schwarz and Schwarz, 2011; Norval et al., 2008).
7.3.2. HIV
HIV preferentially infects helper T cells (CD4þ), inducing their
apoptosis (Lundin et al., 1987; Cloyd et al., 2001; Alimonti et al.,532003). The virus establishes latency in resting memory T cells,
which explains why combination antiretroviral therapy (ART) is not
curative; interruption of treatment inevitably results in rebound
viraemia (Van Lint et al., 2013) (van Der Sluis et al., 2013). HIV may
weaken tumour immunosurveillance (Mbulaiteye et al., 2003). A
meta-analysis found an increased incidence of cancers among both
HIV/AIDS patients and immunosuppressed transplant recipients,
however, therewas no signiﬁcant difference in the risk between the
two groups suggesting that it is primarily the immunosuppression,
rather than another action of HIV that is responsible for the
increased risk of cancer (Grulich et al., 2007).
HIV potentiates the oncogenic action of other viruses such as
HPV, Kaposi sarcoma-associated herpes virus (KSHV) and Eps-
teineBarr virus (EBV) by enhancing their transmission to target
cells (Aoki and Tosato, 2004). A report from Botswana reported
multiple oncogenic viruses (EBV, HPV, KSHV, HSV1/2 and CMV) in
cases of OSSN and pterygium (Simbiri et al., 2010). In rabbits
immunosuppression induced by T-cell depletion facilitated reac-
tivation of latent HPV infection leading to a 3 to 5 log increase in the
number of viral copies to levels associated with productive infec-
tion (Maglennon et al., 2014).
Lastly, HIV induces a state of persistent inﬂammation (Hunt,
2012). Markers of inﬂammation such as C-reactive protein and
interleukin-6 are elevated in HIV patients particularly those on ART
even when viral loads are undetectable (Neuhaus et al., 2010). In-
ﬂammatory microenvironments have tumour-promoting effects
(Mantovani et al., 2008). One proposed mechanism is via over-
expression of microRNA-155 (MiR155), which increases sponta-
neous mutation rates (Tili et al., 2011; Valeri et al., 2010).
7.3.3. Vitamin A deﬁciency
Vitamin A helps to maintain the integrity of the ocular surface
(Kanazawa et al., 2002). Its deﬁciency is associated with squamous
metaplasia of the conjunctiva (Mckelvie, 2003). Vitamin A also acts
as a mucosal and systemic immune enhancer through immuno-
homeostasis of CD4þ helper T cells and Treg cells (Hall et al.,
2011; Pino-Lagos et al., 2011; Ross, 2012). These cells are part of
tumour immuno-surveillance. Retinoids are reported to prevent
various cancers in the skin and liver (Alizadeh et al., 2014). They
promote stem cell differentiation through epigenetic modiﬁcations
of histones or by altering chromatin structure to remove the stem
cell from the self-renewing pluripotential state to a differentiated
one (Gudas, 2013). Loss of the differentiated phenotype can lead to
generation of cancer stem cells (Gudas, 2013). Retinoids activate
DNA transcription in stem cells via retinoic acid receptors (RAR
a,b,g), retinoid X receptors (RXR a,b,g) and other transcription
factor regulatory proteins (Gudas and Wagner, 2011).
A study in Kenya found that HIV-positive women had a higher
prevalence of vitamin A deﬁciency (<30 mg/dL) than HIV-negative
women (59% vs 29%, p < 0.001) (Baeten et al., 2002).
We hypothesize that vitamin A deﬁciency has three effects; it
compromises the integrity of the surface epithelium creating
micro-abrasions for HPV entry, it leads to cell-mediated immuno-
deﬁciency, and dysregulation of stem cell differentiation.
8. Downstream events after initiation of neoplasia
8.1. Uncontrolled cell replication
Human somatic cells can only undergo a limited number of cell
divisions (50e70) then arrest, an event related to shortening of
telomeres (Gomez et al., 2012). In comparison, epidermal stem cells
can divide for more than 150 generations in vitro (Mathor et al.,
1996). Telomeres are a repetitive sequence of nucleotides rich in
guanidine, synthesized by the enzyme telomerase, that cap the
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(Blackburn and Gall, 1978). Usually telomeres shorten during each
round of DNA replication but in advanced cancers telomerase is
reactivated to maintain telomere length allowing many more cell
divisions (Artandi and DePinho, 2010; Prescott et al., 2012).
Downregulation of 14-3-3s protein in keratinocytes maintains
telomerase activity allowing them to escape replicative senescence
(Dellambra et al., 2000).
8.2. Angiogenesis
Neovascularization occurs to meet the increased tumour
metabolic demand. Tumours overproduce vascular growth factors
such as vascular endothelial growth factor (VEGF) (Aonuma et al.,
1999). In conjunctival tumours this manifests clinically as feeder
vessels, enlarged blood vessels in the conjunctiva that perfuse the
growth. In a Tanzanian study 88% of OSSN lesions and 61% of benign
tumours had feeder vessels (Nguena et al., 2014).
8.3. Metastasis
Metastasis is considered a hallmark of malignancy. Cells loose
adherence with each other and secrete proteolytic enzymes such as
matrix metalloproteinases (MMPs) that degrade the extracellular
matrix (Chiang and Massague, 2008). UVB radiation alters the
balance between MMPs and tissue inhibitors of matrix metal-
loproteinases (TIMPs) (Ng et al., 2008). When exposed to UVB,
cultured human dysplastic conjunctival epithelial cells show
increased expression of MMP-1 and MMP-3 with little change in
TIMP-1 unlike normal conjunctival cells (Ng et al., 2008). Increased
MMP activity upsets cell-to-cell adhesion and promotes carcino-
genesis and tumour invasion into surrounding tissues (Johansson
et al., 2000). In lesions of squamous cell carcinoma of the con-
junctiva MMPs and TIMP are overexpressed compared to normal
conjunctiva and cornea (Di Girolamo et al., 2013).
9. Are cancer stem cells central to OSSN?
The short lifespan of ocular surface cells means that epithelial
cells with DNA mutations do not last long enough to have an effect,
as they are constantly being shed from the surface. The longevity of
stem cells however gives them enough time to accumulate muta-
genic insults. Why tumours are heterogeneous yet originating from
the same stem cells could partly be explained by ongoing muta-
genesis (Pardal et al., 2003).
The location of stem cells on the ocular surface coincides with
the position of OSSN tumours while the growth pattern of lesions
(from base upwards) is consistent with the stem cell theory. A study
in Australia described concurrent existence of features of OSSN and
primary acquired melanosis and stem cells arranged in micro-
clusters in the basal epithelium in 12% of pterygiums (Chui et al.,
2011). Focus would necessarily have to shift to ocular surface lim-
bal epithelial stem cells (LESCs) as the potential progenitors of
OSSN to consider new explanations for tumour formation, new
diagnostic methods to detect the LESCs and new treatments that
target LESCs.
10. Conclusion
The known risk factors of OSSN e solar UV radiation, HIV and
HPV are implicated in the aetiology. The pattern of distribution of
OSSN lesions within the interpalpebral ﬁssure of the ocular surface
at the limbus, particularly the nasal side provides further clues. The
site is highly vulnerable to solar UVR and has a high concentration
of stem cells in the basal epithelium. Stem cells in the limbal54epithelial crypts are the likely originators of this disease, and may
take on cancer stem cell properties.
Neoplasia is probably initiated when background solar UV ra-
diation causes various forms of genetic and epigenetic DNA dam-
age. UVBmainly creates pyrimidine dimers. Speciﬁc dimer CC/ TT
transformation, a signature UV mutation, occurs at the p53 gene, a
tumour suppressor that maintains cell-cycle arrest at the G1-S
checkpoint. UV radiation also reactivates latent viruses such as
HPV. HPV's E7 protein keeps infected cells in a proliferative state
while E6 inhibits cell cycle arrest of DNA-damaged cells. Immu-
nosuppression caused by UV radiation, HIV and vitamin A deﬁ-
ciency weakens the tumour surveillance system and allows DNA-
damaged cells to proliferate into tumours. Vitamin A deﬁciency
interferes with ocular surface integrity creating micro-abrasions
through which HPV may invade the conjunctival basement mem-
brane and epithelial cells. Cancer cells reactivate telomerase which
maintains long telomeres increasing the number of cell divisions a
cell can undergo. Further tumour expansion and metastasis is
enhanced by angiogenesis and increased matrix metal-
loproteinases (MMPs) which destroy the intercellular matrix.
Despite these advances in our understanding there remain gaps,
which are areas for further research. For example, there is no
explanation why the disease is mostly unilateral despite both eyes
receiving equal sunlight exposure. Equally the route of trans-
mission of HPV to the conjunctiva is unknown. The drivers on a
molecular level which convert intraepithelial neoplasia to squa-
mous cell cancer are also out with our current understanding of the
disease.
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Chapter 3. Diagnosis of ocular surface
squamous neoplasia
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The following is a review of current diagnostic methods for OSSN and the related challenges.
1. Clinical diagnosis
Many clinicians rely on their clinical impression to make a diagnosis of OSSN. A standard of
care survey in the USA found that only about half the ophthalmologists always perform a
biopsy before instituting topical therapy for suspected OSSN lesions.1
Red eye, photophobia, irritation, foreign body sensation and a whitish painless progressive
growth are common presenting symptoms.2-4 Various clinical features may be seen in OSSN.
Most lesions occur in the interpalpebral fissure especially on the nasal side.5 They involve the
conjunctiva and may extend onto the peripheral cornea so visual acuity is often normal in the
early lesions. For reasons that are unclear, most lesions are unilateral.6 Bilateral cases are
rare.7 Perhaps an immune response to the first tumour prevents further tumour establishment
in the fellow eye, however, this remains to be proven. The surface may be gelatinous,
papillomatous or fibrovascular.8 There may be accompanying inflammation of the ocular
surface, leukoplakia and markedly dilated blood vessels referred to as feeder vessels.9 The
lesions may be flat or raised and of variable size. Late lesions present as large fungating
orbital masses. At this stage a diagnosis of OSSN seems obvious as few other diseases
present that way.
A study in Tanzania evaluated various symptoms and signs that may distinguish OSSN from
benign lesions and found that OSSN tumours were more likely to have a shorter mean duration
than benign lesions (3.7 months vs 8.8 months, p=0.029), show feeder vessels (p=0.034) and
have a gelatinous surface (p=0.055) than benign lesions (Table 3.1).10 Studies have also
evaluated features that may distinguish different grades of OSSN. A study in USA found that
male gender, temporal and superior locations, lack of corneal involvement, papillomatous and
nodular appearance were associated with higher-grade OSSN lesions.11 A second study in
Tanzania found that the patients’ age, size of lesion and lesion pigmentation were associated
with the degree of malignancy defined by histological grade of OSSN (Table 3.2).12
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Table 3.1 Clinical features of OSSN and other benign conjunctival tumours are similar
in a Tanzania study.10
OSSN
(N=34)
Benign Lesions*
(N=18)
P-value
Symptom
Irritated red eye 21 (61.7%) 8 (44.4%) 0.26
Discharge 20 (58.8%) 11 (61.1%) 1.00
Foreign body sensation 14 (41.1%) 10 (55.5%) 0.39
Decreased vision 8 (23.5%) 3 (16.6%) 0.73
Pain 5 (14.7%) 5 (27.7%) 0.29
Proptosis 5 (14.7%) 1 (5.5%) 0.65
Itchy 2 (5.8%) 1 (5.5%) 1.00
Mean duration in months,
(95%CI)
3.7 (2.4-5.8) 8.8 (3.9-19) 0.029a
Sign
Feeder vessel 30 (88.2%) 11 (61.1%) 0.034
Limbal involvement 26 (76.4%) 9 (50.0%) 0.07
Leukoplakia 15 (44.1%) 3 (16.6%) 0.07
Gelatinous 13 (38.2%) 2 (11.1%) 0.055
Pedunculated 4 (11.7%) 2 (11.1%) 1.00
Papilliform 2 (5.8%) 1 (5.5%) 1.00
Orbital invasion 2 (5.8%) 0 (0.0%) 0.54
Fibrovascular tissue 1 (2.9%) 7 (44.4%) 0.001
* Including one lymphoma case
a p-values calculated using Fisher exact test for variables except duration, which was calculated by
Wilcoxon rank-sum test.
Table 3.2. Clinical features that distinguish various grades of OSSN12
Feature
Histological grade of OSSN
p-value aMild-moderatedysplasia
n(%) or mean(SD)
Severe dysplasia
n(%) or mean(SD)
Squamous cell
carcinoma
n(%) or mean(SD)
Mean age, (SD),y 34.8 (8.6) 38.1 (11.4) 43.6 (14.9) 0.016
Lesion size (mm)
     ≤5 
>5
17 (30.9%)
11 (14.3%)
33 (60.0%)
40 (52.0%)
5 (9.1%)
26 (33.7%)
0.002
Lesion pigmentation 4 (10%) 22 (55%) 14 (35%) 0.036
a the paper did not report how p-values were calculated
However the predictive value of the clinical features has not been formally assessed. Clinically
it is difficult to distinguish dysplasias from invasive squamous cell carcinomas. Also the
appearance of OSSN overlaps with several other lesions of the conjunctiva including benign
changes such as pterygium and pinguecula, or premalignant lesions such as actinic keratosis
(Table 3.1 and Figure 3.1).13 In addition, OSSN lesions especially in Africans are often
pigmented and the conjunctival nevi seen can be fleshy with leukoplakia, which makes
distinction between OSSN and nevi difficult. In a study of 287 cases of conjunctival squamous
carcinoma in Mexico, clinical diagnosis was correct in only 41% of them.14
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Figure 3.1 This montage shows lesions that may mimic OSSN. All the lesions in the left
column (A, C, E) are moderately differentiated squamous cell carcinoma (SCC), while
the lesions in the right column are not OSSN, but appear similar. (A) SCC with a
gelatinous surface, (B) pterygium, (C) SCC with leukoplakia, (D) actinic keratosis with
leukoplakia, (E) SCC with pigmentation and (F) a nevus.
2. Histopathology
The normal conjunctiva is divided into 3 regions: (1) the palpebral (tarsal) conjunctiva on the
inner aspect of the upper lid has stratified columnar epithelial cells with little substantia propria,
(2) the fornix has abundant goblet cells, loose stroma, lymphatics and accessory lacrimal
glands of Krause, and (3) the bulbar conjunctiva on the eyeball, in which the epithelium
changes from stratified columnar to stratified squamous near the limbus and has few goblet
cells and melanocytes (Figure 3.2a). Where the lesion is excised with a 2-4 mm margin of
normal tissue, an abrupt transition can be seen between the tumour and adjoining normal
tissue (Figure 3.2b).9
F
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Figure 3.2a. Histology of the conjunctiva showing the normal limbus. The cornea is to the left
and conjunctiva and sclera to the right of the picture. Cells at the base of the conjunctiva appear
more columnar but get more rounded as you move towards the surface where they appear
flattened. (H&E x10)
Figure 3.2b. This picture shows conjunctival intraepithelial neoplasia on the left hand side where
the conjunctiva appears thickened. Notice the loss of normal cell orientation in the lesion with
some rounded cells seen in superficial areas. The lesion involves the full thickness of the
epithelium but does not erode through the basement membrane into the underlying stroma. The
space between the epithelium and the stroma is an artefact created during slide preparation.
(H& E x20)
62
The histological features of OSSN depend on the stage of disease and include:
• Dysplasia – disorderly maturation of epithelium with loss of polarity, cytological atypia
(increased nuclear/cytoplasmic ratio, hyperchromatic pleomorphic nuclei and mitotic figures)
as the cells rise from the basement membrane towards the epithelial surface. The degree of
dysplasia depends on the level and thickness of epithelial involvement. Thus the lesion may
be classified as conjunctival intraepithelial neoplasia (CIN) I, II or III (Figure 3.2c-e). When this
invades the underlying basal epithelium into the substantia propria this is called invasive
squamous cell carcinoma (Figure 3.2f).
• Epithelial hyperkeratosis – thickening of the keratin layer, clinically this is seen as leukoplakia
• Dyskeratosis – keratin formation within the basal cell layer or deeper
• Penetration through the basement membrane by malignant cells seen in invasive squamous
cell carcinoma (SCC)
Figure 3.2c. CIN 1 showing dysplastic cells in the deep 1/3 of the conjunctival epithelium. (H&E
x10)
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Figure 3.2d. CIN 2 showing dysplasia in the deep 2/3 closer to the epithelial surface. (H&E x10)
Figure 3.2e. CIN 3 showing dysplasia involving the whole thickness of the conjunctiva.
(H&E10)
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Figure 3.2f. Invasive well differentiated squamous cell carcinoma. (H&E x10)
Basti originally suggested a classification for OSSN into benign, pre-invasive and invasive
stages (Table 3.3).15 The American Joint Committee on Cancer (AJCC) has suggested both
a clinical and pathological staging (Table 3.4).16
Table 3.3 Classification of OSSN after Basti & Macsai.15
Benign
Papilloma
Pseudoepitheliomatous hyperplasia
Benign hereditary intraepithelial dyskeratosis
Pre-invasive
Conjunctival/corneal intraepithelial neoplasia (CIN) grades I-III
CIN I (mild dysplasia) - confined to the lower third of the conjunctival epithelium
CIN II (moderate dysplasia) - extends into the middle third of the conjunctival epithelium
CIN III (severe dysplasia) – full thickness of the conjunctival epithelium also referred to
as CIS (carcinoma-in-situ)
Invasive
Squamous cell carcinoma
Mucoepidermoid carcinoma
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Table 3.4 American Joint Committee on Cancer (AJCC) staging of carcinoma of the
conjunctiva.16
Tumour (T) size
TX primary tumour cannot be assessed
T0 no evidence of primary tumour
Ti carcinoma in situ
T1 tumour ≤5mm in greatest dimension 
T2 tumour >5mm in greatest dimension without invading
adjacent structures a
T3 tumour invades adjacent structures (excluding the orbit)
T4 tumour invades the orbit ±further extension
Regional lymph nodes (N)
NX
N0
N1
regional lymph nodes cannot be assessed
no regional lymph node metastasis
regional lymph node metastasis
Distant metastasis (M)
MX distant metastasis cannot be assessed
M0 no distant metastasis
M1 distant metastasis
Histopathologic type
CIN including carcinoma in situ
Squamous cell carcinoma
Mucoepidermoid carcinoma
Spindle cell carcinoma
Sebaceous gland carcinoma including
pagetoid (conjunctival) spread
Basal cell carcinoma
Histologic grade (G)
GX grade cannot be defined
G1 Well differentiated
G2 Moderately differentiated
G3 Poorly differentiated
G4 undifferentiated
Biomarker (Ki-67 growth fraction)
Is Ki-67 growth fraction <5%?
Is Ki-67 growth fraction between 5% and <10%?
Is Ki-67 growth fraction between 10% <20%?
Is Ki-67 growth fraction between 20% and 50%?
Is Ki-67 growth fraction >50%?
a Adjacent structures include the cornea (3,6,9 or 12 o’clock hours), intraocular compartments,
forniceal conjunctiva, palpebral conjunctiva, tarsal conjunctiva, lacrimal punctum and canaliculi, plica,
caruncle, posterior eyelid lamellar, anterior eyelid lamellar, and/or eyelid margin
The term actinic keratosis is not used much nowadays. Some pathologists classify these
lesions with CIN however the diagnosis of actinic keratosis is based on the presence of
elastotic stromal degeneration, acanthosis, hyperkeratosis and parakeratosis in the presence
of normal cellular polarity. By the accepted criteria for dysplasia, such lesions are classified
as CIN only if there is loss of polarity. An example of the histology of actinic keratosis is shown
in Figure 3.2g.
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Figure 3.2g. Actinic keratosis showing hyperkeratosis on the surface. (H&E x10)
Histopathology is considered the gold-standard for cancer diagnosis but has a number of
shortcomings. It requires surgical intervention. The service is also in short supply in high-
incidence areas. In 2012 Kenya had 40 pathologists (1 pathologist to 1 Million population).17
In most of Sub-Saharan Africa there were 1 million to 5 million people per pathologist.
Histopathology is also subject to individual interpretation and discordance may arise at two
levels (i) between pathologists and (ii) between pathologists and clinical observations.18 In
addition immediately after excision, the specimen often rolls up if put in formalin immediately.
This is often counteracted by first placing the tissue on a sterile piece of flat paper or suture
packing for a few minutes before putting it in formalin containers.9 Labelling and orientation
need to be indicated to the pathologist to aid interpretation. Fragmentation of small tumour
specimens may also occur. During section preparation not all conjunctival layers may be
represented on the slide mounts. Some of the tissue may shear off making assessment of the
depth of involvement difficult (Figure 3.2b and 3.2h). Lastly, an adequate margin may not be
included at the time of surgical excision. Further, the term OSSN is not used in the AJCC
manual which raises questions of consistent comparisons and clinical interpretation.19
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Figure 3.2h. This lesion is graded as CIN 3 but the shearing off during section preparation may
make it difficult to grade the depth of involvement. (H&E x5)
Histopathology may be augmented with immunocytochemistry. A study in Japan found that
proliferating cell nuclear antigen (PCNA) immunostaining, p53 immunostaining, and
argyrophilic nucleolar organizer regions (AgNORs) staining in formalin-fixed and paraffin-
embedded tissues could be used as markers of proliferative potency and cell differentiation.
The PCNA-positive staining proportion was highest in SCC, followed by severe dysplasia and
mild dysplasia. P53-positive staining was highest in severe dysplasia, followed by mild
dysplasia, and was negative in SCC. AgNORs-count increased with advancing histological
grade of malignancy.20
3. Vital staining
Vital stains are used to colour living tissues; various dyes are used extensively in
ophthalmology including rose Bengal, fluorescein, methylene blue and toluidine blue.21,22
Toluidine blue (ToB) is a vital dye that stains abnormal tissue dark royal blue by penetrating
into cancerous tissue where it has a selective affinity for nucleic acids (Figure 3.3).23 ToB has
been used safely for many years to help support the clinical diagnosis of oral, oesophageal
and cervical carcinoma and to demarcate tumours during surgical excision.24-28 Animal safety
studies found that intraocular injection (as opposed to topical use) of 1% and 2% ToB caused
irreversible damage to all the corneal layers; 0.5% damaged the stromal keratocytes and
corneal endothelium but 0.25% stained the lens capsule and did not damage the cornea layer
or trabecular meshwork.29 Wander et al conducted animal safety studies in rabbits and guinea
pigs applying eye drops of 0.01%, 0.1%, 0.25%, 0.5%, and 1.0% toluidine blue applied to stain
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corneal epithelial cells. The cells picked up the vital dye within 5 minutes. Wash out time was
rapid and no toxic effects were observed.30 There is one case report describing the use of
topical / extraocular 0.05% ToB vital staining of OSSN.31 The dye was reported to clearly
demarcate the abnormal tissue, assisting the excision. The authors commented that they also
found ToB did not stain other conjunctival lesions such as pterygium (no data presented) and
it did not cause any toxicity to the ocular surface at a concentration of 0.05%.
A recent study in Brazil evaluated 1% topical Toluidine Blue eyedrops in diagnosis of OSSN
and found that all OSSN lesions stained blue while 90% of pterygiums did not and there were
no adverse events reported.32 The sensitivity was 100%, specificity 90%, predictive value
positive 96.4% and predictive value negative 96%. However the performance of diagnostic
tests vary with disease prevalence so in East Africa it may be different. Further, we do not
know the effect of lesion pigmentation on staining - lesions in Africans tend to have more
brown pigmentation. A similar study in South Africa evaluated 1% methylene blue vital staining
for diagnosis of OSSN and found a sensitivity of 97% but a low specificity of 50%, a predictive
value positive of 50% and predictive value negative of 96%.33 However, the classification of
OSSN in the two studies was different.
Figure 3.3 Conjunctival lesions before and after vital staining with 0.05% Toluidine blue. The
pictures in the left column are before staining and those on the right after staining. (A and B)
Moderately differentiated squamous cell carcinoma, showing deep royal blue staining. (C and
D) Actinic keratosis, showing mixed staining (margin and parts of the lesion). (E and F)
Pterygium, showing no staining.
A B
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4. Cytology
Superficial cellular tissue from the ocular surface may be obtained by conjunctival impression
cytology or exfoliative cytology. Impression cytology has been used for the diagnosis of ocular
lesions for a number of decades.34,35 There are minor variations in the techniques for
impression cytology of the ocular surface.36 Cellulose acetate filter paper strips or special
biopore membranes are used to obtain superficial cells.37 The technique involves gently
pressing the paper or membrane on the surface of the eyeball and collecting the cells that
stick to it. The paper is fixed in acetic acid, formaldehyde, and ethyl alcohol in a 1:1:20 volume
ratio, rehydrated with 70% ethyl alcohol, then taken through cycles of washing in periodic acid
Schiff reagent, sodium metasulfite, Gill’s haematoxylin, and Scott’s tap water substitute for 2
minutes each, before rinsing in tap water and staining the cell surface of the filter paper. 36
Xylene is used in the final step to make the filter paper transparent to allow examination of the
morphology of these cells under a microscope. For exfoliative cytology a brush is used to
obtain the tissue.38 The most commonly used staining methods are Papanicolaou39, periodic
acid Schiff (PAS) with haematoxylin and eosin (H&E)40 or Giemsa41.
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An Australian study identified a number of cytomorphological features associated with
OSSN.42 About 50% of CIN cases had keratinized dysplastic cells often accompanied by
hyperkeratosis, large syncytial-like groups in about 35% and individual non-keratinized
dysplastic cells in 10%, while 70% of invasive SCC had significant keratinization. In alcohol-
fixed Papanicolaou stained smears, squamous dysplasia or malignancy was indicated by
nuclear hyperchromasia, high nuclear/cytoplasmic ratio and pleomorphism.43 Conjunctival
impression cytology has been reported to have a sensitivity of 85% and specificity of 90% in
Thailand and USA.44 45 Recently a scoring system was proposed that identifies
cytomorphological features, which may help to reliably differentiate invasive conjunctival
squamous cell carcinoma from pre-invasive lesions.46 In that study the following seven
cytological parameters were found to be predictive of malignancy:
i) nuclear size enlargement >x3
ii) hyperchromasia (dark staining nuclei which is usually due to increased DNA content)
iii) prominent nucleoli
iv) syncytial-like groupings
v) increased nuclear-to-cytoplasm (NC) ratio - it is considered a slightly increased NC
ratio when the cell has an NC ratio of 2:1 or a marked increase in NC ratio when the
cell has an NC ratio up to 2:1
vi) eosinophilic cytoplasmic stain
vii) absence of distinct cytoplasmic borders
Each feature was given a score based on a logistic regression model. A score of 4.25 was the
best cut-off for malignancy.
The following 4 parameters were not predictive:
i) cell disposition - single or individual cells, cells within sheets or cells inside keratin
plaques
ii) cell size - very small or very large
iii) the presence of a regular or irregular nuclear contour
iv) cytoplasmic area - significant reduction in mean cytoplasmic area when the nucleus
fills at least two-thirds of the cell or increased cytoplasmic area when the nucleus
occupies less than half the total area of the cytoplasm
Cytology has also been applied in diagnosis of other diseases of the ocular surface such as
limbal stem-cell deficiency, viral keratoconjunctivitis, allergic/inflammatory
keratoconjunctivitis, vitamin A deficiency and melanocytic lesions.36,37
Impression cytology has a number of shortcomings. It is constrained by the need for
specialised equipment and personnel and this may not be easily available in peripheral care
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centres. Inter- and intra-observer variation may occur. It is also likely to miss CIN as the
abnormal cells are deeper down. In one Australia study it was difficult to distinguish between
carcinoma-in-situ and minimally invasive disease.47
5. Confocal microscopy
Unlike conventional light microscopes whose image is degraded by reflections and light
scattering by objects outside of the focal plane, in in vivo confocal microscopy, light from a
point source is focused on a tissue and the light reflected from this focal point is collected by
a parallel objective lens and focused onto a duplicate pinhole aperture. Light that passes this
second aperture is collected by a detector. Both the illuminating point source and the
observation aperture of the detector are conjugate with the same point in the tissue, and are
said to be confocal.48 Initially it was used for corneal examination but later extended to
conjunctival studies such as trachoma.49 Confocal microscopy is non-invasive and may allow
serial visualization of the same living tissue down to the cellular level (hence the term in vivo
confocal microscopy – IVCM) over time unlike histology.
Several studies have evaluated the use of IVCM for the diagnosis of OSSN with differing
results. A study of 10 cases from Italy found that the main pathological features include:
cytonuclear atypias, epithelial folds into an inflammatory and vascularised conjunctival stroma,
fine vessels perpendicular to the surface, clear limit with normal epithelium, papillomatous
organization, and abnormal keratinisation.50 A study of 5 cases in China found cellular
anisocytosis (variation in cell size) and enlarged nuclei with high nuclear to cytoplasmic ratio
in 3 cases of CIN and nests partially formed by isolated keratinized, binucleated, and actively
mitotic dysmorphic epithelial cells in the other 2 cases diagnosed as carcinoma in situ (CIS).51
However, more recently we looked at a larger series of 52 cases of conjunctival lesions in
Tanzania and found that IVCM features such as hyper-reflective cells, anisocytosis and starry
night appearance of basal cells could not reliably distinguish OSSN from benign conjunctival
pathology because of an overlap in the features (see appendix 1).10
6. Anterior segment Optical Coherence Tomography (OCT)
OCT is a computer assisted optical instrument that produces cross-sectional images
(tomograms) similar to B-mode ultrasound only that it uses light instead of sound. A low
coherence infra-red light (820nm) is directed at a target tissue and the amount and position of
backscattered light displayed according to the optical properties of the structure in question. It
has the advantages of fast image acquisition speed and non-contact and is non-invasive with
some referring to it as a non-excisional 'optical biopsy'.52 It has been suggested that ultra-high
resolution anterior segment optical coherence tomography (UHR OCT) may be used in
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diagnosis and follow up of OSSN however the studies in this area are small. One study showed
that UHR OCT images of the lesions showed a thickened hyper-reflective epithelium and
abrupt transition from normal to hyper-reflective epithelium in all 7 cases.53 In a study to
distinguish OSSN from pterygium, there was a statistically significant difference in the
epithelial thickness with an average 346µm (standard deviation [SD], 167) in 17 OSSN
patients and 101 µm (SD, 22) in 17 pterygium patients (p<0.001). By receiver operating
characteristic curve, the sensitivity and specificity of UHR OCT for differentiating between
OSSN and pterygia was found to be 94% and 100%, respectively, using a cut-off value of 142
µm.54
One of the major shortcomings of ultraound and OCT is the cost of equipment and the effect
of rapidly changing technology that may render it obsolete in a few years. In practice the
reliability of this technique is yet to be proven.
Conclusions
OSSN has serious consequences associated with recurrence and local metastasis that may
lead to death. Early diagnosis may reduce this. There seems to be a mismatch between
availability of diagnostic facilities and where OSSN is most frequently found. Highly affected
areas have short supply of diagnostic capability.
Some clinicians make management decisions without a tissue diagnosis but clinical signs are
not very reliable for diagnosis due to the overlap between the features of OSSN and other
conjunctival lesions. There is a risk of misclassification and inappropriate treatment with this
practice. Patients with benign disease would inappropriately be subjected to chemotherapy
and live with a diagnosis of ‘cancer’ and fear of recurrence.
Histology is the gold standard but is subjective and prone to inter-observer variability. Tissue
samples are small and may roll up if put in formalin immediately after excision making
orientation and interpretation of slides difficult. During tissue section preparation the surface
epithelium may be sheared off making classification by depth of involvement difficult.
Vital staining with toluidine blue is promising as a non-invasive diagnostic tool. Formal
evaluation in areas of differing prevalence is needed as the performance of diagnostic tests is
affected by disease prevalence. Toluidine blue vital staining may be useful for marking the
extent of tumour to aid surgical excision. Brown pigmentation of lesions however obscures the
dye. In addition, this will not replace a tissue diagnosis.
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Cytology is a less invasive tissue diagnostic method. Scoring systems using cytology are
reliable. However cytology may miss CIN as it would not pick the deeper epithelial cells. There
are also relatively few trained cytologists.
In-vivo confocal microscopy, ultrasound and anterior segment optical coherence tomography
(OCT) are modern technologies that promise to circumvent surgical excision and facilitate
primary topical treatment. However there is overlap in the appearance of OSSN and other
conjunctival lesions so IVCM cannot reliably distinguish between the two. The technology is
very expensive and prone to short lifespans due to rapid new developments that may render
existing equipment obsolete. They are currently not a suitable option in Africa where OSSN
mainly occurs.
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A B S T R A C T
Background
Squamous cell carcinoma of the conjunctiva is described in the ophthalmic literature as a rare, slow-growing tumour of the eye, normally
affecting elderly men around 70 years of age. In Africa, however, the disease is different. The incidence is rising rapidly, affecting young
persons (around 35 years of age), and usually affecting women. It is more aggressive, with amean history of threemonths at presentation.
This pattern is related to the co-existence of the HIV/AIDS pandemic, high HPV exposure, and solar radiation in the region. Various
interventions exist, but despite therapy, there is a high recurrence rate (up to 43%) and poor cosmetic results in late disease. This review
was conducted to evaluate the interventions for treatment of conjunctival squamous cell carcinoma in HIV-infected individuals.
Objectives
To evaluate the effect of interventions for treating squamous cell carcinoma of the conjunctiva in HIV-infected individuals on local
control, recurrence, death, time to recurrence, and adverse events.
Search methods
Using a sensitive search strategy, we attempted to identify all relevant trials, regardless of language or publication status, from the
following electronic databases; PubMedPubMed, EMBASE and The Cochrane Library. We also searched clinical trial registries; WHO
International Clinical Trials Registry Platform (ICTRP) and the US National Institutes of Health Clinicaltrials.gov. We searched the
international conference proceedings of HIV/AIDS and AIDS-related cancers from the AIDS Education Global Education System
(AEGIS). Searches were conducted between January and February 2012.
Selection criteria
Randomised controlled trials (RCTs) involving HIV-infected individuals with ocular surface squamous neoplasia.
Data collection and analysis
We independently screened the results of the search to select potentially relevant studies and to retrieve the full articles.We independently
applied the inclusion criteria to the potentially relevant studies. No studies were identified that fulfilled the selection criteria.
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Main results
No RCTs of interventions currently used against conjunctival squamous cell carcinoma in HIV-infected individuals were identi-
fied.There is one ongoing RCT in Kenya that was registered in July 2012.
Authors’ conclusions
Implications for practice:
Current clinical practice in treatment of squamous cell carcinoma of the conjunctiva rests on a weak evidence base of case series and
case reports.
Implications for research:
Randomised controlled trials for treatment of this disease are needed in settings where it occurs most frequently. Preventive interventions
also need to be identified. HIV/AIDS research has not focused on treatment of this tumour.
P L A I N L A N G U A G E S U M M A R Y
Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Conjunctival squamous cell carcinoma, a tumour of the thin membrane that covers the white of the eye, is becoming more common,
more aggressive, and affectingmore young people, especially women. This pattern is associated with theHIV/AIDS pandemic, exposure
to solar radiation, and infection with human papilloma virus (HPV). Various treatment modalities exist, but the recurrence rate is high
and the cosmetic outcome of late disease unsightly (Figure 1). Death may occur when the disease spreads to the surrounding structures
and the brain. This review was conducted to evaluate the effects of the current interventions. No randomised controlled trials of any
interventions for this cancer were found. Current clinical practice appears to be based on case series and case reports. These are weak
sources of evidence for the effectiveness of a treatment. Randomised controlled clinical trials are needed.
B A C K G R O U N D
Definition
Squamous cell carcinoma of the conjunctiva (SCC) is the end stage
of a spectrumof conditions called ocular surface squamous neopla-
sia (OSSN). Histologically, OSSN varies from a benign form that
includes papilloma, pseudoepitheliomatous hyperplasia and be-
nign hereditary intraepithelial dyskeratosis, through a pre-invasive
form called conjunctival intraepithelial neoplasia (CIN) graded as
I,II or III depending on depth of involvement and finally the in-
vasive form that includes squamous cell carcinoma and mucoepi-
dermoid carcinoma (Basti 2003).When the dysplastic changes are
confined to the basal one third of the epithelium, this is termed
CIN I or mild dysplasia, when they extend into the middle third
of the epithelium this is termed CIN II or moderated dysplasia
and when they extend into the superficial third of the epithelium
this is termed CIN III or severe dysplasia. Full thickness dysplasia
is also referred to as carcinoma-in-situ (CIS). Invasive squamous
cell carcinoma of the conjunctiva refers to the infiltration through
the basement membrane to involve the underlying stroma (Basti
2003; Shields 2004). Clinically, these stages may be indistinguish-
able except by histology.
Clinical features
The tumour may be asymptomatic or present with redness, irrita-
tion, severe pain, and visual loss (Tunc 1999). It commonly affects
the visible area between the upper and lower eyelids (interpalpe-
bral conjunctiva), usually on the nasal side at the margin of the
conjunctiva and the cornea (limbus). This slow-growing tumour
can present as a solitary or diffuse growth. Solitary tumours can
be nodular or gelatinous and may have a whitish plaque (leuko-
plakia). The lesionmimics benign conjunctival degenerations such
as pterygium and pinguecula. Most cases are unilateral(Cervantes
2002; Chisi 2006).
The morbidity from squamous cell carcinoma of the conjunctiva
relates to the effects of the disease and its treatment. It may ex-
tend into the eyeball, orbit, regional lymph nodes, surrounding
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paranasal sinuses and the brain. Death may result from regional
or distant metastases, as well as intracranial spread.
Aetiology
The aetiology of SCC has been associated with HIV infection
(Ateenyi-Agaba 1995;Waddell 1996), human papilloma virus
(HPV) infection (Waddell 1996;Nakamura 1997;Newton 2002),
immunosuppression in organ transplant recipients (Macarez
1999), and exposure to ultraviolet B rays of the sun (Ateenyi-Agaba
2004; Ng 2008; ). Chronic conjunctival diseases, such as aller-
gic conjunctivitis and trachoma, have also been implicated (Poole
1999).
The majority of affected persons in Africa are HIV-positive; 71%
in Uganda, 86% in Malawi (Waddell 1996) ,70.6% in South
Africa (Mahomed 2002) and 75% in Nigeria (Osahon 2011). In
a smaller study in Zimbabwe, 12 out of 13 persons with SCC or
CIS (92.3%) were HIV-positive (Porges 2003). Many ophthal-
mologists in Africa now consider SCC in young adults to be a
marker for HIV infection. The relationship between SCC and
HPV is less clear. Some case-control studies have found an as-
sociation (Moubayed 2004; de Koning 2008) while some have
not (Sen 2007; Guthoff 2009). Among HIV-infected people with
SCC, cutaneous types of HPV are detected more frequently than
the mucosal types (de Koning 2008; Ateenyi-Agaba 2010). In
another Ugandan study, HPV was detected more frequently in
the low-grade conjunctival neoplasias than in more advanced dis-
ease (Tornesello 2006). Ultraviolet solar radiation causes tissue
damange mediated through mutation of the tp53 tumour-sup-
pressor gene and tissue matrix metalloproteinases (Ateenyi-Agaba
2004; Ng 2008).
It is plausible that the aetiology involves an interaction of these
factors in a yet to be determined model.
Epidemiology
The epidemiology of SCChas transformed in the last few decades.
It used to be an uncommon slow-growing tumour found in elderly
males (Lee 1997; McKelvie 2002), but in Africa it is becoming
more common, more aggressive, and more likely to affect young
persons, especially females (Ateenyi-Agaba 1995). This pattern is
related to the co-existence of theHIV/AIDS pandemic, high HPV
exposure, and solar radiation in the region. The HIV pandemic
is mainly centered in Africa. In 2009 22.5 million of the 33.3
million infected people worldwide were living in Africa (UNAIDS
2010). Africa also has the highest prevalence of HPV infection in
the world, with an age-adjusted prevalence of 25.6% in women
of age 15 to 74 years, followed by South America (14.3%), Asia
(8.7%) and Europe (5.2%). (Clifford 2005). The equator bissects
the continent and over 75% of the continent is within the tropics
with consequent high ambient solar exposure all year round.
The Kampala Cancer Registry in Uganda recorded a six-fold in-
crease in the incidence of conjunctival squamous cell carcinoma,
from an average of six per million per year between 1970 and
1988, to 35 per million per year in 1992 (Ateenyi-Agaba 1995).
A study in Australia found that 78.5% of affected persons were
elderly males with a mean age of 60 years (Lee 1997). Similarly,
in Britain, 77% were males and 69% of them were more than
60 years old (McKelvie 2002). In contrast, a study in Zimbabwe
found that 70% of patients were young females with a median
age of 35 years (Pola 2003), while in South Africa the mean age
was 37 years (Mahomed 2002). In Tanzania the tumour has been
observed to be more aggressive than it was previously. The mean
length of history on presentation is three months (Poole 1999).
SCC is a common tumour of the ocular surface among adults in
Africa. Pola 2003 In Tanzania 45.8% of 168 conjunctival biopsies
seen between 1996 and 1997 were squamous cell carcinomas,
while 35% were pingueculum or pterygium (Poole 1999).
The prevalence of SCC in a hospital-based HIV-positive popula-
tion in Kenya was 7.8% (Chisi 2006).
Diagnosis
Most cases are diagnosed on clinical impression after a person
presents with a growth on the eyeball, which is then excised and
sent for histology to get a definitive diagnosis (Shields 1997).
Histopathology is the commonest mode of diagnosis in practice.
Although regarded as the gold standard, histopathological diag-
noses are subject to discordant interpretation (Margo 2002). Cy-
tology has also been used, especially for the follow-up of people
treated using chemotherapy or immune therapy to monitor re-
currence, since malignant cells are poorly adherent to each other
(McKelvie 2001).
Other methods include the use of DNA cytometry to identify tu-
mour-cell regression (Nadjari 1999); immunostaining for certain
molecular genetic markers, such as proliferating cells nuclear anti-
gens (PCNA), Ki67 expression, tp53 gene mutations, and argy-
rophilic nucleolar organiser regions (AgNORs) (Aoki 1998); and
toluidine blue staining to mark tumour margins for surgical exci-
sion (Kaji 2006).
Treatment options
The treatment of this condition since the pre-HIV era has been
simple: surgical excision alone or with additional adjunctive ther-
apy. The main objective of surgical excision is complete removal
of the tumour to minimise recurrence (Shields 1997). The result-
ing surface defect may need reconstruction using amniotic mem-
brane transplantation (Espana 2002; Gunduz 2005) or limbal au-
tografts (Copeland 1990). Adjunctive therapies augment surgical
excision. These include cryotherapy, chemotherapy, radiotherapy,
immune therapy, and amniotic membrane transplants. They work
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by killing residual malignant cells at the excision margins or any
that may be seeded during excision, although there are also re-
ports of their use as primary therapy (Cerezo 1990; Karp 2001;
Barbazetto 2004). Cidofovir, an antiviral active against human pa-
pilloma virus, has been described as a primary therapy, and was
reported to cause tumour regression (Sherman 2002). It under-
goes phosphorylation to active diphosphates independent of viral
enzymes, which act as both inhibitors and alternative substrates
of viral DNA polymerase, thus inhibiting DNA synthesis (Safrin
2004). A list of these interventions is shown in Table 1.
Cryotherapy kills malignant cells by repeated cycles of freezing
and thawing (Peksayar 1989). Chemotherapy involves using a class
of drugs called antimetabolites. They act by interfering with the
enzymes involved in the intermediary metabolism of replicating
cancer cells. An example is 5-Fluorouracil (5-FU) and mitomycin
C. The former (5-FU), is a prodrug, which means it is converted
to active molecules. One of them, 5- fluoro-2’- deoxyuridine-5’-
monophosphate (FdUMP), binds to the enzyme thymidylate syn-
thetase critical for the synthesis of thymidylate, which results in
the inhibition ofDNA synthesis. Another one, 5-fluorouridine-5’-
triphosphate (FUTP) interferes with RNA synthesis (Chu 2004).
It is cell-cycle specific and acts in the S phase of the cell cycle. In
one study, 1% 5-FU eyedrops were used alone without concur-
rent surgery or radiotherapy to treat a recurrent tumour (Midena
2000). Mitomycin C is an antibiotic which acts by interfering
with the DNA of tumour cells. It undergoes metabolic activation,
which generates an alkylating agent that cross-links DNA,making
the cell unable to replicate (Chu 2004). It is a cycle-non-specific
agent that is most effective in the G1 and S phases. Radiotherapy
destroys the DNA and RNA of dividing cells (Goldberg 1963).
The source of beta radiation is strontium 90 (Cerezo 1990). Pho-
todynamic therapy combines a drug (called a photosensitizer or
photosensitizing agent) with light of a specific wavelength to pro-
duce activated oxygen species that promote tumour destruction
(Castano 2005). Another treatment option is amniotic membrane
transplantation. It is one of the layers of the placenta and is ob-
tained after electiveCaesarean section. It has anti-angiogenic, anti-
scarring, and anti-inflammatory properties (Hao 2000). Immune
therapy for this condition involves the use of interferon alpha.
Interferon alpha is part of a group of proteins called cytokines. It
has three-pronged action with antiviral and oncostatic effects and
also activates natural killer cells, which are cells of the immune
system that are able to recognise and destroy tumour cells (Lake
2004). The exact mechanism of action is not known. Cidofovir,
an antiviral that is active against human papilloma virus, has been
reported to cause regression of this tumour (Sherman 2002). It
undergoes phosphorylation to active diphosphates independent of
viral enzymes, which act as both inhibitors and alternative sub-
strates of viral DNA polymerase, thus inhibiting DNA synthesis
(Safrin 2004).
Advanced disease where the tumour has spread requires removal
of the eyeball (modified enucleation) or the entire orbital contents
(exenteration) in an attempt to save life (Shields 1991).
Despite therapy, up to 43% of treated patients experience recur-
rence at variable times (but usually within two years) (Peksayar
1989; Tabin 1997; Yeatts 2000). Simple excision has a higher rate
of recurrence. A study inAustralia reported 23%(Lee 1997). In the
USA, it was 28.5%, but was 7.7% when combined with cryother-
apy (Sudesh 2000). In one series of 17 cases treated with mito-
mycin C eye drops, 15 of them had undergone one to four surgi-
cal procedures before the mitomycin C treatment and six (35%)
recurred within six months (Frucht-Pery 1997). The efficacies of
treatment reported in the literature need to be interpreted cau-
tiously, since some of the treated cases have recurrences from prior
surgical excision (Frucht-Pery 1997; Midena 2000). The recur-
rence rate may be higher in Africa due to late presentation, expo-
sure to solar radiation, and lack of many of the adjunctive thera-
pies. Only cryotherapy and chemotherapy are likely to be found
in advanced centres.
It is not clear whether the efficacy of these interventions is dif-
ferent in people with HIV infection. The effect, if any, of highly
active antiretroviral therapy (HAART) on this condition is also
not clearly known.
Clinical and public health importance of this review
Although the number of people living with HIV infection world-
wide seems to have stabilized Africa remains the global epicentre
of the AIDS pandemic (UNAIDS 2010). The region also has the
highest prevalence of HPV in the world and high solar ultraviolet
exposure year-round (Clifford 2005). If this triad of risk factors
remains, the number of cases of conjunctival squamous cell carci-
noma is expected to remain high. The effect of HPV vaccination
in children on OSSN if any will take a long time to determine.
Recurrences still occur after surgical excision. Most of the cur-
rent adjunctive therapies described are not readily available in low-
income countries. They are expensive and inconvenient to use.
Cryotherapy requires special probes and canisters of liquid nitro-
gen gas that need refilling. Amniotic membrane transplantation
requires tissue banks to process and preserve the transplant mate-
rial. Medications for chemotherapy are not widely available, but
are probably the easiest to obtain and use in such settings, since
they are packed in small vials and do not require stringent storage
conditions.
The cosmetic outcome of advanced disease and its treatment is
very poor and leaves patients with an empty socket (Figure 1).
Patients who undergo orbital exenteration often experience social
problems because of their facial disfigurement leading to limited
social interaction (Bonanno 2010). Facilities for cosmetic surgery
and orbital implants in low-income countries are often unavail-
able.
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Figure 1.
With antiretroviral therapy, HIV-infected people can now enjoy
an improved physical appearance and quality of life, but unsightly
lesions on the face such as those caused by conjunctival squa-
mous cell carcinoma unmask what would otherwise be a ’hidden’
HIV infection. This potentially exposes the affected persons to the
stigma and discrimination associated with HIV infection.
Effective evidence-based interventions that allow early diagnosis
and treatment are therefore needed.
O B J E C T I V E S
To evaluate interventions for treating squamous cell carcinoma of
the conjunctiva in HIV-infected individuals (see Table 1 for list
of interventions).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCT).
Types of participants
HIV-positive people with ocular surface squamous neoplasia
(OSSN), whose diagnosis of HIV infection is based on either an-
tibody or antigen tests, and whose OSSN is determined by histol-
ogy, conjunctival impression cytology, or immunostaining.
Types of interventions
Any intervention used for treatingOSSN, including the following:
• surgical excision, modified enucleation, and exenteration
• adjunctive therapies such as cryotherapy, chemotherapy,
radiotherapy, amniotic membrane transplants , and immune
therapies, such as interferon therapy
• cidofovir
• different regimens of HAART
• combinations of the above
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We were interested in trials that compared any of the interven-
tions with another intervention or a placebo, or trials comparing
different dosages or regimens of the same intervention.
Types of outcome measures
Primary outcomes
• local control, defined as a tumour-free period of two years
• recurrence at six months, then at six-month intervals
thereafter until two years after treatment, diagnosed by
histopathology, conjunctival impression cytology, or
immunostaining
• death
Secondary outcomes
• time to recurrence
• adverse events
Search methods for identification of studies
The HIV/AIDS review group search methods were used. We
searched electronic databases and abstracts of conference proceed-
ings. There were no language restrictions. The key words used in
the search included:
ocular surface squamous neoplasia, squamous cell carcinoma, con-
junctiva, carcinoma in situ, conjunctival intraepithelial neoplasia,
HIV, AIDS, excision, enucleation, exenteration, chemotherapy,
cryotherapy, interferon, immunetherapy, radiotherapy,
A search had been conducted in December 2009 using search
terms from the first edition of this review and found no trials. We
conducted an updated search beginning January 2010.
• Electronic databases
The following electronic databases were searched.
1. PubMed - from January 2010 to 27th January 2012
2. EMBASE - from January 2010 to 10th February 2012
3. The Cochrane Library - from January 2010 to 3rd February
2012
• Clinical trial registers
We searched theWHO International Clinical Trials Registry Plat-
form (ICTRP) on 10th February 2012 (WHO ICTRP 2012).We
also searched the clinical trial register of the USNational Institutes
of Health (NIH) www.clinicaltrials.gov website (NIH 2012) on
12th February 2012. This database includes trials registered with
the US National Eye Institute (NEI) and US National Cancer In-
stitute (NCI).
• Conference proceedings
We searched abstracts of the proceedings of the HIV/AIDS con-
ferences covered in the AIDS Education Global Education System
(AEGIS) database (http://www.aegis.com/search).
This search covered all the following conferences which also shows
the latest conference abstracts available in the AEGIS database:
1. International AIDS conference by the the International AIDS
Society (IAS) upto the conference held from 18th-23rd August
2010
2. International AIDS Society (IAS) HIV Pathogenesis and Treat-
ment upto the 5th conference held from 19th-22nd July 2009
3. International Congress onDrug Therapy inHIV infection upto
the 9th meeting on 9th-13th November 2008
4. International Workshops on Adverse Drug Reactions and
Lipodystrophy in HIV upto the 11th workshop on 26th-28th Oc-
tober 2009
5. Conference on Retroviruses and Opportunistic Infections
(CROI) upto the 15th conference on 3rd-6th February 2008
6. Centers for Disease Control and Prevention (CDC) National
HIV Prevention conference upto the meeting on 12th-15th June
2005
7. The International Workshops on HIV Drug Resistance and
Treatment Strategies upto the 5th workshop on 4th-8th June 2001
8. British HIV Association (BHIVA) upto the 17th conference
held on 6th to 8th April 2011
9. European AIDS Clinical Society upto the 11th conference held
on 24th-27th October 2007
10. National HIV/AIDS Update Conference upto the 17th con-
ference on 10th-13th April 2005
• Reference lists
We checked the reference lists of all studies identified by the above
methods for additional relevant records.
Data collection and analysis
We independently screened the results of the search to select po-
tentially relevant studies and to retrieve the full articles (Table 2).
Where there was any uncertainty we obtained the full article. We
independently applied the inclusion criteria using a specially de-
signed eligibility form to the potentially relevant studies. No ran-
domised controlled trials met the inclusion criteria.
R E S U L T S
Description of studies
See: Characteristics of ongoing studies.
No studies were identified that fulfilled the selection criteria. The
PRISMA flowchart in Figure 2 summarizes the results (Figure
2). There is an ongoing study in Kenya that was registered in
the PanAfrican Clinical Trials Register on 19th July 2012. This
register feeds into theWHO International Clinical Trials Registry
Platform (ICTRP).
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Figure 2. PRISMA study flow diagram.
Risk of bias in included studies
No studies were identified that fulfilled the selection criteria.
Effects of interventions
No studies were identified that fulfilled the selection criteria. The
search strategy yielded 12 records, which were all excluded (see
table of excluded studies).
D I S C U S S I O N
In this review no randomised controlled trials on the effectiveness
of interventions against conjunctival squamous cell carcinoma in
HIV-infected individuals were identified. No randomised con-
trolled trials were found, even in theHIV-uninfected populations.
Current practice is based on the results of interventional case se-
ries and case reports (Table 1). The quality of evidence from these
study designs ranks low by various systems for grading evidence.
It is graded level four by the Oxford Centre for Evidence-Based
Medicine (OECBM) recommendations (Phillips 2001) and low-
grade by the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) Working Group (Atkins 2004).
According to GRADE, low means that further research is very
likely to have an important impact on our confidence in the esti-
mate of effect and is likely to change the estimate. These studies
are also mainly from western countries, where the participants are
usually elderlymales, who have a different disease profile from par-
ticipants in developing countries. They have a less aggressive form
of the disease and few are HIV-infected (Ateenyi-Agaba 1995;
Waddell 1996; Lee 1997; Poole 1999; Mahomed 2002; McKelvie
2002). We could not explain why there are no trials, but postulate
that perhaps it reflects differences in research priorities, since the
prevalence of this tumour is low among HIV-infected individuals
living in the western world.
There is a need to conduct randomised controlled trials to provide
unbiased evidence for the effectiveness of currently used interven-
tions for treating conjunctival squamous cell carcinoma. Ideally,
the disease would be studied in its early stages, before it has spread,
since in the later stages the treatment is more costly, can only be
provided in tertiary care centres, and would tend to be individu-
ally tailored depending on the extent of spread. Studies are needed
in the setting where the greatest burden of disease is found. The
typical setting involves young HIV-infected individuals, mostly
females with aggressive disease and HIV co-infections, in the con-
text of high HIV prevalence, high solar exposure, and limited re-
sources.
Investigating the effectiveness of simple surgical excision versus
wide excision with or without adjunctive antimetabolite eye drops
would be relevant as these are relatively simple interventions that
can be easily translated in developing countries. The effect of new
health technologies used in the developed world, such as cryother-
apy, amniotic membrane transplants, and photodynamic therapy,
should also be assessed in RCTs.
Preventive interventions directed against the mutagenic effects of
solar ultraviolet B radiation and the oncogenic viruses associated
with this disease also need to be identified.
There is also an important implication for diagnostic tests for
early disease. Ethical issues that may arise include, for instance,
whether participants should be subjected to the application of
potentially dangerous cytotoxic antimetabolites as an adjunct to
excisionbiopsy before there is histological confirmation of tumour.
Treatment of conjunctival squamous cell carcinomas with topical
mitomycin C and/or radiation has been associated with induction
of atypical cell changes, such as conjunctival DNA-polyploidy
afterward (Cartsburg 2001). More sensitive diagnostic tests, such
as cytology or immunostaining, may thus need to be used pre-
operatively.
Treatment of opportunistic tumours in HIV/AIDS, such as squa-
mous cell carcinoma of the conjunctiva, is part and parcel of HIV
care.Untreated squamous cell carcinomaof the conjunctiva threat-
ens survival. Not paying attention to this disease may compromise
the gains from other care availed to affected individuals.
7Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
92
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current clinical practice in treatment of squamous cell carcinoma
of the conjunctiva is based on case series and case reports. This is
a weak evidence base.
Implications for research
RCTs for treatment of this disease are needed in the settings where
it occurs most frequently. Preventive interventions, such as HPV
vaccination, also need to be identified once scientific knowledge
of the serotypes involved is established. HIV/AIDS research has
not focused on treatment of this tumour.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of ongoing studies [ordered by study ID]
Gichuhi 2012
Trial name or title Adjuvant topical 5fluorouracil (5FU) for ocular surface squamous neoplasia
Methods In this randomized controlled trial tumours involving less than 2 quadrants of the conjunctiva that are
suspected to be OSSN will be surgically excised
Participants Adults with histologically proven OSSN whose tumour excision site has healed
Interventions Topical 1% 5-Fluorouracil in artificial tears vs artificial tears applied 6 hourly for one month
Outcomes Primary: Development of histopathologically confirmed recurrent OSSN anytime during the first year after
the primary surgery
Secondary: Adverse effects of using topical 5-FU 1% four times daily for one month
Starting date 23/8/2012
Contact information sgichuhi@uonbi.ac.ke
Notes
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. 2 Interventions used in treatment of conjunctival squamous cell carcinoma
Intervention Description Reference
Surgical excision Alcohol epitheliectomy for the corneal
component and partial lamellar sclerocon-
junctivectomy with 3 to 4mm margins for
the conjunctival component. Frozen sec-
tions may be used to ensure tumour-free
margins. Modified enucleation involves re-
moving the affected conjunctiva with a
4mmmargin together with the eyeball. Ex-
enteration involves complete removal of or-
bital tissue including the periosteum of the
bony walls. The eyelids may or may not be
spared
Shields 1997 Shields 2004
Cryotherapy Freeze-thaw-freeze-thaw (double freeze-
thaw) applying probe to the excised con-
junctival margin
Peksayar 1989
Chemotherapy
- 5 Fluorouracil (5FU) 1% solution
- Mitomycin C 0.02% or 0.04%
As topical solutions to soak operated site for
2-5 minutes, as subconjunctival injection
intra- or post operatively or as eyedrops to
be applied post-operatively as follows
4 times daily for 1-2 weeks or as pulsed
therapy giving 4 applications for 4 days re-
peated every month for 4-6 cycles
4 times daily for 2 weeks then repeat at 4-
6 weeks intervals depending on response
Yeatts 2000
Midena 2000
Frucht-Pery 1997
Radiotherapy - beta irradiation
- gamma irradiation
- photodynamic therapy
Cerezo 1990
Goldberg 1963
Barbazetto 2004
Amniotic membrane transplants (AMT) Excise tumour with a 3-4 mm tumour-free
margin (so frozen sections needed), apply
cryotherapy to the margin then to close the
defect suture amniotic membrane with 8/0
vicryl sutures to adjacent conjunctiva and
to adjacent cornea using 10/0 nylon sutures
with epithelial side facing up
Gunduz 2005
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Table 1. 2 Interventions used in treatment of conjunctival squamous cell carcinoma (Continued)
Interferon alpha 2b Topical drops or intralesion injection Karp 2001
Cidofovir eyedrops 2mg/ml Applied every 2 hours for 2 weeks then 4
times daily for 2 weeks then 3 times daily
for 2 weeks
Sherman 2002
Table 2. 1 Review methods
Study selection The titles and abstracts of search results are scanned and compared to
predetermined selection criteria for studies. Articles written in foreign
languages are translated to English. Two authors working independently
select trials. The authors are blinded to the trial uthors and institutions
by asking the trial search co-ordinator to block this out when sending
abstracts. Where there is uncertainty about inclusion, the full text of the
article is obtained and read. If additional information is needed about
the trial in question, it is categorized as awaiting assessment until this is
obtained. If differences arise regarding trial inclusion, they are discussed
and if still unresolved, Dr Taryn Young at the South African Cochrane
Centre is asked to take a decision
Data extraction Data are collected and recorded in similar data extraction forms. The fol-
lowing information is extracted; citation details, study eligibility, study
quality and study characteristics. The study characteristics include meth-
ods, participants, interventions and outcomes
Assessment of methodological quality of included studies The methodological quality of the included studies is assessed to deter-
mine validity. Selection bias is checked by assessing whether the gener-
ation of a random allocation sequence and allocation concealment were
performed. Randomization is considered adequate if the allocation se-
quence is generated from a table of random numbers or by computer.
Allocation concealment is deemed adequate if undertaken by means of
sequentially prenumbered sealed opaque envelopes, a centralised system
or prenumbered coded identical containers. In addition, assessment of
blinding, losses to follow-up and whether the analysis was by intention-
to-treat (ITT) is undertaken. The definition of ITT is the requirement
that participants be analyzed in the groups to which they were random-
ized, regardless of which intervention they actually received
Data analysis Measures of treatment effect:The effect measures of choice here are rela-
tive risk (RR) for dichotomous data and hazard ratio (HR) for time-to-
event data with a 95% confidence interval
Dichotomous data include: - number of people who experience local
control in each comparison group
- number of people who experience recurrence during the specified time
periods in each comparison group
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Table 2. 1 Review methods (Continued)
- number of deaths in each comparison group
- number of people who experience adverse events in each comparison
group
- number of people who experience local control in each comparison
group
- number of people who experience recurrence during the specified time
periods in each comparison group
- number of deaths in each comparison group
- number of people who experience adverse events in each comparison
group
Time-to-event data include: - time to recurrence
Dealing with missing data: Participants lost to follow up are censored in
the survival analysis
Assessment of heterogeneity: To identify statistical heterogeneity we look
at the forest plot for overlapping confidence intervals and test it using
the Cochrane Q test with a p-value of 0.10. The impact of heterogeneity
on the meta-analysis is measured using the I-squared test. If I-squared
is greater than 70% we will investigate by checking the trials for data
entry errors and looking for existence of subgroups. Subgroup analysis
by age, sex, geographical location and diagnostic method will be done.
These factors have been shown to influence the occurrence of OSSN
and we anticipate that they may also influence treatment effects. If no
explanation for heterogeneity is found or its correction is not possible,
meta-analysis will not be done
Meta-analysis: A fixed-effect model is used for meta-analysis but when
there is heterogeneity that cannot be readily explained, a random-effects
model is incorporated
Sensitivity analysis: We examine how the magnitude of effect differs
according to study quality or trial size and also the results of per-protocol
analysis with those of intention-to-treat analysis
Assessment of reporting bias: Publication bias is assessed by using a funnel
plot to look for asymmetry
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A P P E N D I C E S
Appendix 1. PubMed search strategy and results
Title: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Database: PubMed (2010 - 2012)
Date: 27 January 2012
Search Query Items found
#13 Search #1 AND #2 AND #11 AND (“2010/10/01”[Date -
Publication] : “2012/01/27”[Date - Publication])
4
#12 Search #1 AND #2 AND #11 23
#11 Search #9 OR #10 2290
#10 Search conjunctival neoplasms[mh] 1729
#9 Search #5 AND #8 1099
#8 Search #6 OR #7 546016
#7 Search carcinoma[tiab] OR carcinomas[tiab] OR neopla-
sia[tiab] OR neoplasm[tiab] OR neoplasms[tiab]
514787
#6 Search carcinoma, squamous cell[mh] 92643
#5 Search #3 OR #4 23573
#4 Search conjunctiva[tiab]ORconjunctivas[tiab]ORconjunc-
tival[tiab]
18906
#3 Search conjunctiva[MeSH Terms] 11829
#2 Search (randomized controlled trial [pt] OR controlled clin-
ical trial [pt] OR randomized [tiab] OR placebo [tiab] OR
drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR
groups [tiab]) NOT (animals [mh] NOT humans [mh])
2499392
#1 SearchHIV Infections[MeSH]ORHIV[MeSH]ORhiv[tw]
OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw]
OR hiv infect*[tw] OR human immunodeficiency virus[tw]
OR human immunedeficiency virus[tw] OR human im-
muno-deficiency virus[tw] OR human immune-deficiency
virus[tw] OR ((human immun*) AND (deficiency virus[tw])
) OR acquired immunodeficiency syndrome[tw] OR ac-
quired immunedeficiency syndrome[tw] OR acquired im-
muno-deficiency syndrome[tw] OR acquired immune-defi-
ciency syndrome[tw] OR ((acquired immun*) AND (defi-
ciency syndrome[tw])) OR “sexually transmitted diseases, vi-
282439
16Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
101
(Continued)
ral”[MH:noexp]
Appendix 2. EMBASE search strategy and results
Title: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Database: PubMed (2010 - 2012)
Date: 10 February 2012
No. Query Results
#13 #1 AND #2 AND #11 AND [humans]/lim AND [embase]/
lim AND [1-2-2012]/sd NOT [10-2-2012]/sd
0
#12 #1 AND #2 AND #11 4
#11 #9 OR #10 2964
#10 ’conjunctiva tumor’/syn 1802
#9 #5 AND #8 1796
#8 #6 OR #7 646277
#7 carcinoma:ab,ti OR carcinomas:ab,ti OR neoplasia:ab,ti OR
neoplasm:ab,ti OR neoplasms:ab,ti
617186
#6 ’carcinoma, squamous cell’/syn 110025
#5 #3 OR #4 56567
#4 conjunctiva:ab,ti OR conjunctivas:ab,ti OR conjunctival:ab,
ti
22041
#3 ’conjunctiva’/syn 51682
#2 random*:ti OR random*:ab OR factorial*:ti OR factorial*:
ab OR cross?over*:ti OR cross?over:ab OR crossover*:ti OR
crossover*:ab OR placebo*:ti OR placebo*:ab OR (doubl*:ti
AND blind*:ti) OR (doubl*:ab AND blind*:ab) OR (singl*:
ti AND blind*:ti) OR (singl*:ab AND blind*:ab) OR as-
sign*:tiORassign*:abORvolunteer*:tiORvolunteer*:abOR
’crossover procedure’/de OR ’crossover procedure’ OR ’dou-
ble-blind procedure’/deOR ’double-blind procedure’OR ’sin-
gle-blind procedure’/de OR ’single-blind procedure’ OR ’ran-
domized controlled trial’/de OR ’randomized controlled trial’
OR allocat*:ti OR allocat*:ab
1186635
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(Continued)
#1 ’human immunodeficiency virus infection’/exp OR ’human
immunodeficiency virus infection’ OR ’human immunode-
ficiency virus’/exp OR ’human immunodeficiency virus’ OR
hiv:ti OR hiv:abOR ’hiv-1’:ti OR ’hiv-1’:abOR ’hiv-2’:ti OR
’hiv-2’:abOR ’human immunodeficiency virus’:tiOR ’human
immunodeficiency virus’:ab OR ’human immunedeficiency
virus’:ti OR ’human immunedeficiency virus’:ab OR ’human
immune-deficiency virus’:ti OR ’human immune-deficiency
virus’:ab OR ’human immuno-deficiency virus’:ti OR ’hu-
man immuno-deficiency virus’:ab OR ’acquired immunod-
eficiency syndrome’:ti OR ’acquired immunodeficiency syn-
drome’:abOR ’acquired immuno-deficiency syndrome’:tiOR
’acquired immuno-deficiency syndrome’:abOR ’acquired im-
mune-deficiency syndrome’:ti OR ’acquired immune-defi-
ciency syndrome’:ab OR ’acquired immunedeficiency syn-
drome’:ti OR ’acquired immunedeficiency syndrome’:ab
371108
Appendix 3. The Cochrane Library search strategy and results
Title: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Database: CLIB (2010 - 2012)
Date: 3 February 2012
ID Search Hits
#1 MeSH descriptor HIV Infections explode all trees 6499
#2 MeSH descriptor HIV explode all trees 2172
#3 hiv OR hiv-1* OR hiv-2* OR hiv1 OR hiv2 OR HIV
INFECT* OR HUMAN IMMUNODEFICIENCY
VIRUS OR HUMAN IMMUNEDEFICIENCY VIRUS
OR HUMAN IMMUNE-DEFICIENCY VIRUS
OR HUMAN IMMUNO-DEFICIENCY VIRUS
OR HUMAN IMMUN* DEFICIENCY VIRUS OR
ACQUIRED IMMUNODEFICIENCY SYNDROME
OR ACQUIRED IMMUNEDEFICIENCY SYNDROME
OR ACQUIRED IMMUNO-DEFICIENCY
SYNDROME OR ACQUIRED IMMUNE-
DEFICIENCY SYNDROME OR ACQUIRED IMMUN*
DEFICIENCY SYNDROME
10597
#4 MeSH descriptor Lymphoma, AIDS-Related, this term only 21
#5 MeSH descriptor Sexually Transmitted Diseases, Viral, this
term only
22
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(Continued)
#6 (#1 OR #2 OR #3 OR #4 OR #5) 10671
#7 MeSH descriptor Conjunctiva, this term only 473
#8 conjunctiva*:ti,ab,kw 1906
#9 (#7 OR #8) 1906
#10 MeSH descriptor Carcinoma, Squamous Cell, this term
only
1818
#11 carcinoma*:ti,ab,kw OR neoplasia:ti,ab,kw OR
neoplasm*:ti,ab,kw
42921
#12 (#10 OR #11) 42921
#13 (#6 AND #9 AND #12) 2
#14 (#6 AND #9 AND #12), from 2010 to 2012 0
Appendix 4. WHO International Clinical Trials Registry Platform (ICTRP) search terms and results
Title: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Database: WHO International Clinical Trials Registry Platform (ICTRP) 2010 - 2012
Date: 10 February 2012
No results were found for: hiv AND carcinoma AND conjunctiva
Appendix 5. National Institutes for Health (NIH) Clinical Trials registry search terms and results
Title: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Database: Clinicaltrials.gov
Date: 10 February 2012
Found no studies with search of: “squamous cell carcinoma” AND conjunctiva AND hiv
WH A T ’ S N E W
Last assessed as up-to-date: 19 February 2007.
Date Event Description
11 December 2012 New citation required but conclusions have not
changed
New comprehensive searches, review updated.
11 December 2012 New search has been performed Updated
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H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 2, 2007
Date Event Description
29 October 2008 Amended Converted to new review format.
19 February 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
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Review of case-series and case-reports of
interventions for ocular surface squamous
neoplasia (OSSN)
Rationale
A Cochrane systematic review of interventions found no randomized controlled trials except
one in Australia. Numerous case reports and case-series formed the evidence base for
treatment of OSSN which is low down in the hierarchy of evidence. We reviewed these case
series to see what could be learned from them.
Methods
In August 2015 using a sensitive search strategy we tried to identify all relevant trials,
regardless of language or publication status using the following search terms; “randomized
controlled trial”, “controlled clinical trial”, “randomized”, “placebo”, “drug therapy”, “randomly”,
“trial”, “conjunctiva*”, “ocular surface”, “carcinoma”, “cancer”, “neoplasia”, “neoplasm”,
“neoplastic”, “dysplasia”, “dysplastic”, “squamous”, “squamous cell”.
We searched electronic databases (PubMed, EMBASE, The Cochrane Library), clinical trial
registries (WHO International Clinical Trials Registry Platform and the US National Institutes
of Health Clinicaltrials.gov), and international conference proceedings of HIV/AIDS and AIDS-
related cancers from the AIDS Education Global Education System (AEGIS). Only series that
reported recurrence as an outcome were included.
Results
The interventions reported in various cases series are summarised in tables 1-10. There is
only one published trial on topical Mitomycin-C (MMC) in a patient group without HIV infection
in Australia. Some case series reported tumour resolution as an outcome and are not included
here. Only five studies involved African patients (Tunisia, Egypt, Uganda, and South Africa).
Sample sizes were variable. With all treatment regimens reported, there were varying doses,
inclusion criteria and follow up times.
Surgery ± Cryotherapy (Table 1)
Surgical excision was the most commonly employed treatment. Small tumours were excised
while more advanced orbital disease needed exenteration to clear all the orbital contents down
to the periosteum of the bone. The margins of the excision varied from 2m to 4mm. Some
surgeons used alcohol epitheliectomy (absolute alcohol) to aid removal of tumour extending
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to the cornea. Some used the bare sclera technique where the tumour was dissected off down
to the sclera leaving the wound uncovered while some closed the resulting defect by mobilising
the surrounding conjunctiva (primary closure) or transplanted either amniotic membrane or
autologous conjunctiva from the same or other eye. Amniotic membranes are obtained from
tissue banks and there are no such facilities in Africa.
Surgical excision may be augmented by cryotherapy where 2-4 freeze-thaw cycles were used
to obliterate residual tumour at the bed and margins. Cryotherapy requires the use of liquefied
gas, either carbon dioxide or nitrous oxide, which is not easily available in most centres in sub-
Saharan Africa. Cryotherapy was the most commonly used adjuvant treatment with surgical
excision. Some articles mentioned local excision without qualifying whether cryotherapy was
used or not. A series consisting of advanced squamous cell carcinoma from Germany worse
than grade 3 using the American Joint Committee on Cancer (AJCC) system reported that
52% of excisions and 20% of exenterations recurred after a median of 24 months.
Surgical excision alone is associated with recurrences of 3.2% to 66.7% 32 months later. The
former involved surgical excision with the corneal extension removed using blade dissection
then wiped with alcohol and using primary closure without cryotherapy. This was a very
experienced surgeon in Uganda. With cryotherapy surgical excision was associated with
recurrences varying from zero at 6.5 years to 52% at 24 months (the latter being the advanced
tumour series aforementioned).
Surgery ± amniotic membrane transplant (Table 2)
Series involving surgery with amniotic membrane transplants reported recurrences ranging
from zero after a mean of 31 months to 12.5% after a mean 17.8 months of follow up. Those
who used the bare sclera technique sometimes applied Weck-cel sponges soaked with
cytotoxic agents such as 5FU or MMC to the tumour bed intraoperatively for periods varying
from 2 minutes to 5 minutes while others would employ this only when complete excision of
the tumour was not deemed possible. Surgical excision with adjuvant chemotherapy was
associated with recurrences varied between zero and 67% but most often in the 30% to 67%
range. In older series local resection would be supplemented by radiation therapy.
Interferon alpha 2b (IFNα2b) (Table 3)
IFN is an immune modulator used on its own or combined with surgical excision and
cryotherapy while in one series IFN was combined with retinoic acid eye drops. Preparations
available include eye drops or an injection. Some used it as primary treatment of presumed
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OSSN or for residual OSSN unresponsive to excision, cryotherapy and MMC. Two
formulations of IFN eyedrops were reported, 1million IU/ml and 3 million IU/ml, used four times
daily for four weeks. Some continued the drops till a month beyond complete clinical
resolution. The injection preparations vary from 6-16 million IU/ml. Some infiltrated it around
the lesion (peri-lesion) while some injected it under the lesion (sub-lesion). Injections were
given every three days for seven doses or three times weekly. Recurrences varied from none
to 33.3% at one year. IFNα2b needs refrigeration and is continued long after clinical resolution. 
It has local and systemic side effects such as conjunctival hyperemia, superficial punctate
keratitis and flu-like symptoms. The cost of the 3 million IU/ml dose of eyedrops was $260 for
a 5 ml bottle and the 1 million IU/ml dose is $120 in 2010 in Bascolm Palmer, Florida, USA.
Treatment for 1 month with IFN 1 million IU/ml drops four times daily for a month cost $179 in
2012 in Wills Eye Hospital, Philadelphia, USA. In Africa this would be too expensive besides
being unavailable.
Cyclosporin A (CsA) (Table 4)
CSA is an immunosuppressant that interferes with the activity of T-lymphocytes. It is prepared
as a 0.05% ophthalmic emulsion and used topically. In one series it was combined with
surgical excision and MMC while in another it was combined only with MMC. Its use allows a
lower concentration of MMC (0.01%) to be used. There were no recurrences reported after
two years of follow up. The ocular surface toxicity observed (punctate keratopathy,
conjunctival hyperemia) and eyelid toxicity were attributed to MMC but it was not clear how
this distinction was made.
Mitomycin C (MMC) (Table 5)
MMC is an antibiotic classified as an alkylating agent causing cross linking of DNA thus
inhibiting DNA synthesis. It is usually used topically as a 0.02% or 0.04% solution applied four
times daily for a week or two followed by one to three weeks off then the cycle is repeated to
make a total of 4 cycles. Most pharmacies compound it for themselves due to a short shelf life
and typically patients have to return after a few weeks to get the next bottle. It is often
combined with surgical excision although some use it on its own. Recurrences range from
zero to 29.4% when used alone; zero to 14% with surgical excision; and zero with IFN. A
caveat here is that the severity of disease treated and surgical margin involvement in these
three groups differs. The most common adverse effect is allergy and conjunctival hyperemia
usually in the second cycle while perhaps the most grievous is persistent epithelial defects
due to presumed limbal stem cell deficiency and corneal or scleral melting.
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5-Fluorouracil (5FU) (Table 6)
5FU belongs to the family of antimetabolites meaning it is a chemical that interferes with cell
metabolism by inhibiting the use of a metabolite which is another chemical needed for normal
metabolism of the cell (typically an enzyme). It is a pyrimidine analogue which works through
inhibition of thymidylate synthetase, an enzyme used to produce one of the intermediate
products along the process of producing thymine, one of the nucleic acids in DNA. Like MMC
it is often used in combination with surgical excision and cryotherapy and is applied
intraoperatively to soak the excision bed or post operatively as eye drops or subconjunctival
injections at the end of surgery. Eyedrops are usually a 1% solution often prepared by diluting
the injection in normal saline or methylcellulose. A treatment course often involves using the
drops four times daily for 2 or 4 weeks. Some have used it in 2-3 week cycles lasting a week
followed by a 1-week drug holiday while others have used it for 4 weeks continuously.
Reported recurrences vary from 2% to 43% when used alone, none with MMC, and zero to
31% with surgery. 5FU is cheap. The cost of 5FU 1% eyedrops four times daily for 4 weeks
in 2016 February was 320 Kenyan shillings (US$ 3.2 or Sterling £ 2.1). A long-term safety
study in Italy reported that there was no difference between the treated eye and the fellow eye
with respect to endothelial cell count, pleomorphism and polymegathism, anterior stromal
keratocyte density, sub-basal nerve plexus fibre number, density, and beadings and central
cornea epithelium thickness. It has been used off-label for a long time so there is widespread
clinical experience and acceptability for it is used in OSSN and other areas of ophthalmology
such as trabeculectomy. Case series report its effectiveness; and regimes with some of the
other interventions are rather complicated. This makes it a feasible alternative for East Africa.
All Trans Retinoic acid (ATRA) (Table 7)
ATRA is a metabolite of vitamin A which mediates development of a healthy ocular surface. A
0.01% topical preparation was reported to be useful in one case that had not responded to
two IFN injections two months apart followed by IFN 1 Million IU/ml four time daily topical use
for a further three months. After a combined approach of IFN four times daily and ATRA
applied every second day for a month the tumour resolved without recurrence.
Anti-vascular endothelial growth factor (anti-VEGF) (Table 8)
Anti-VEGF agents interfere with growth of blood vessels into tumours hence cutting off their
blood supply and nutrition. They may be used alone before surgical excision topically or as
injections. Used alone recurrences were zero to 20% and with surgery zero to 25%.
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Radiotherapy (Table 9)
Brachytherapy plaques are used to deliver radiation to the tumours. This is often used after
surgical excision. In Kenya’s Kenyatta National Hospital, radiotherapy is used after
exenteration but no results have been reported. The source of radiation may be Strontium-90
or Ruthenium-105. Recurrences vary from zero at one year to 13.2% after 39 months.
Others (Table 10)
Thermotherapy, Aloe vera, photodynamic therapy and Urea have been used but these were
usually single case reports. Urea was associated with a 22% recurrence after use by nine
patients.
Discussion
A wide variety of treatments are used for OSSN. Some adjuvant treatments are combined with
surgery and some are not. Some adjuvants are used intraoperatively and others post
operatively. Varying doses of adjuvant agents used for varying durations. Inclusion criteria of
patients differ and potentially different disease phenotypes may be present in different regions.
Recurrences are reported at varying periods after treatment. A number of series reported
recurrences as a whole group despite various combinations of intervention being used.
There was a trend where radiotherapy was used in earlier years then surgery was introduced
and afterwards non-invasive topical treatments became popular, initially with cytotoxic agents
and later with biological agents such as immune modulators and retinoic acid. 5FU was often
used initially then MMC was introduced with no clear rationale why 5FU somehow fell out of
favour. It is unclear whether this was because it is not registered by the FDA as a topical
medication.
Surgery with adjuvant 5FU or MMC was often associated with recurrences of 11% to 67%
about 30 months later. Few series reported the adverse effects of surgery. Series that used
topical agents primarily without surgery did not have histopathology while one used impression
cytology before starting treatment. Treating OSSN without a histopathology report is a problem
because the true diagnosis is not established and factors that may influence recurrence such
as surgical margin involvement during excision are not known.
The cost of interferon is prohibitive and would not be an option for East Africa. Availability of
cryotherapy and agents like mitomycin C is uncommon. 5FU is the most readily available of
the adjuvant agents used in OSSN treatment. 5FU does not have stringent storage conditions
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such as refrigeration and cytotoxics have a low risk of contamination. 5FU is on the WHO
essential medicines list, and is a widely available and low cost option particularly in sub-
Saharan Africa where the highest incidence of OSSN in the world is found.
In conclusion, the results from case series are difficult to compare. As most modes of
treatment such as cryotherapy, amniotic membrane transplants and MMC are unavailable in
most centres in East Africa, we believe that a randomized controlled trial using 5FU is
warranted. Availability of 5FU would make translation of these trial results into clinical practice
feasible.
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Tabulated summary of the review of interventions used in ocular surface squamous neoplasia (OSSN). This will be a
published supplement to the randomized controlled trial reported in Chapter 12.
Table 1: Surgery ± Cryotherapy
Year Country Study
size
Average
age
(years)
M:F
ratio
Intervention Recurrence
2015 Tunisia1 79 61·1 2·56:1 excision 89·8%; margin excision + cryotherapy 46·6%; enucleation
2·5%; exenteration 6·4%
33·3% after 9 months
2015 USA2 43 68·4 7:3 excision + cryotherapy. Alcohol epitheliectomy for corneal extension.
At surgeon's discretion AMT with sutures or glue
7·1% after 1year
2014 Germany3 38 70·6 1·4:1 excision (n=25). If complete excision was not feasible adjuvant IFN was
used (n=14) applied one drop 5 times daily for 6 weeks. If the tumour
invaded deep orbital structures exenteration was done (n=10)
52% of excisions and 20%
of exenterations. Average
time to recurrence 24
months
2014 USA4 98 64·0 1:1 excision alone (n=49) ; excision + cryotherapy (n=41) or intraoperative
MMC (n=1) or sclerectomy (n=8) + AMT (n=14) or conjunctival autograft
(n=1) or primary closure (n=10) or bare sclera (n=24) vs IFN drops
(n=40)or subconj/perilesion IFN injection (n=1) or combined
drops+injection (n=8). The dose was 3 million IU (in 0·5 ml) in all cases
treated with subconjunctival injections. For topical therapy, the dose
was 1 million IU/ml in 35 patients and 3 million IU/ml in 13 patients.
1% in the surgery group
and 3% in the IFN group
after 1yr
2013 Argentina5 4 53·2 1:1 excision + cryotherapy and primary closure None after 6·5 years
2012 Iran6 17 70·7 7·5:1 excision + cryotherapy then Chloramphenicol/Betamethasone drops
QID x 1wk; then MMC 0·04% x7-10 days;
5·9% after 9 months
2006 Uganda7 476 32·0 1:1·2 401 had eye-conserving excision, lamellar sclerectomy if deeply fixed,
corneal dissection with a blade then wiped with alcohol, primary
closure. No cryotherapy.
13 of the 401 (3·2%) after
median follow up of 32
months
2003 Turkey8 57 55·0 1·9:1 excision + cryotherapy before and after the excision 12·3% after 31·7 months
median follow up
2002 Mexico9 287 60·4 1·2:1 Local resection in 258 cases (90%), exenteration in 18 (6%), enucleation
in 7 (2%) and radiation therapy in 2 (1% ). One patient was treated with
5·2% after 7·7 months
median follow up
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local resection and gamma irradiation, and another with local resection
and application of cryotherapy at the surgical margins
2002 India10 5 ? ? Excision + cryotherapy + MMC None at 1 year
2002 Australia11 26 65·1 3·3:1 Excision± cryotherapy (n=19), exenteration (n=6) 27% within 4-15 months
2000 USA12 28 66·6 4:1 19 had Excision alone (E) and 9 had excision+cryotherapy (E+C) overall 5 (17·9%) recurred.
2 in the E+C and 3 in the E
group. Mean follow up
was 13months for primary
lesions and 28months for
recurrent lesions
1999 USA13 60 64·0 2·3:1 27excision+cryotherapy ;
14 excision+cryotherapy+sclerectomy;
8 excision+cryotherapy+mucosal graft; 1 exenteration; 1 enucleation
5% after a median of 56
months follow up
1997 Australia14 79 64·1 5:1 Excision 39% (31 eyes) overall
recurred after a mean 4·6
years follow up
1989 Turkey15 22 ? Excision + cryotherapy before and after excision 9% (time point unclear)
1983 USA16 9 71·0 2:1 Excision + cryotherapy 22% after 9 months
Table 2. Surgery with amniotic membrane transplant (AMT)
Year Country Study
size
age
(years)
M:F
ratio
Intervention Recurrence
2014 Turkey17 21 62·4 1:2 AMT. no touch excision with 2mm margin + double freeze-thaw
cryotherapy for 3 sec ± Alcohol epitheliectomy for corneal extension.
The conjunctival defects were reconstructed up to the limbus with one
sheet of Cryotherapy-preserved single layer AMT—the stromal side
facing down—secured side to side with 8/0 vicryl sutures
None after 31 months
follow up
2011 Lithuania18 2 AMT None after 38 months
follow up
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2008 Brazil19 8 AMT 1 (12·5%)recurred after
17·8 months mean follow
up
2003 Taiwan20 5 64·6 3:2 excised with 3mm margin + AMT with basement membrane facing up. None after mean 27
months follow up
2002 USA21 10 58·6 excised with a 3–4 mm lesion free margin and a superficial keratectomy
was performed if there was corneal infiltration. AMT was placed over
the surgical defect with the basement membrane side facing up and
secured to the adjacent conjunctiva and episclera by interrupted or
continuous 10-0 Vicryl sutures, making sure that its borders were
placed under the conjunctival margin.
1 case (10%) with follow
up period unclear
Table 3. Immune-therapy with Interferon α 2b  (IFNα2b) 
Year Country Study
size
age
(years)
M:F
ratio
intervention Recurrence at
median/mean follow up
Adverse effects
2014 Iran22 5 60·2 4:1 IFNα2b 3 million IU/ml QID x 
4wks
None after median
follow up 10·2 months
No patient developed persistent
epithelial defect, symblepharon,
limbal stem deficiency or systemic
adverse effects related to IFNα2b 
therapy such as malaise, flu like
symptoms, bone pain and fatigue.
2013 USA23 81 ? ? IFNα2b alone (n = 22, 27%) or 
combined with surgery (n = 59,
73%)
5% (4/81) of cases over a
median follow-up of 1
year
Conjunctival hyperaemia (n = 4,
5%), ocular irritation (n = 3, 4%),
superficial punctate keratitis (n =
3, 4%), conjunctival follicles (n = 1,
1%). Systemic side effects included
post injection flu-like syndrome for
1 day (n = 7, 9%).
2012 Australia24 116 ? ? 27 had IFNα2b alone and 89 had
combined IFNα2b + retinoic acid 
0·01%. Patients were prescribed
3·7% in the IFN alone
2·25% with combined
treatment.
Four patients with complete
response developed a mild allergic
papillary conjunctivitis that settled
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IFNα2b drops 1 MIU/ml 4 times
daily and retinoic acid 0·01% once
every second day.
on halving the interferon dose to
0·5 million IU drops and reducing
the frequency to 3 times daily. Side
effects were limited to 1 case of
epithelial microcysts and 1 case of
marginal keratitis.
2012 USA25 18 68·0 1·3:1 1 drop of 1 MIU/ml IFNα2b QID
or subconjunctival 10 MIU/ml of
recombinant IFN injected till the
lesion balooned
None after mean 11
months follow up
Transient flu-like symptoms after
IFNα2b injection (n=3). Corneal 
epithelial defect after 4 months of
using topical IFNα2b (n=2) and 
Conjunctival hyperaemia (n=1). All
symptoms resolved with
conservative measures (e.g.,
acetaminophen, artificial tears,
and ointments)
2012 USA26 20 63·0 2·3:1 Topical IFNα2b 1 million IU/mL
QID continued at least 1 month
beyond complete clinical
resolution
5% (1 case) at 3 months
follow up
Conjunctival hyperaemia (2 [10%]),
follicular hypertrophy (2 [10%]),
giant papillary conjunctivitis (1
[5%]), irritation (1 [5%]), corneal
epithelial defect (1 [5%]), and flu-
like symptoms (1 [5%]); all
resolved within 1 month of
medication discontinuation.
2011 USA27 3 41·0 2:1 IFNα2b drops (1 million units/cc)
QID and IFNα2b sublesional 
injection (5 million units/0·5cc to
8 million units/0·8 cc)
None at 3,6, 69 months
respectively
nausea and chills were minor,
lasting 1 day
2010 USA28 15 64·0 2:1 Thrice weekly perilesional
/subconjunctival 3 MIU of
recombinant IFNα2b in 0·5 ml of 
solution. Ten eyes received
concomitant topical interferon
therapy 4 times daily in addition
to the injections. Later the
injection regime was changed to
6·7% (1 eye of 15)
recurred 4 months after
clinical resolution
Patients were given 1000 mg
acetaminophen after the injection
and every 4 hours as needed to
help ameliorate flulike symptoms
associated with interferon
injections.
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received weekly until clinical
disease resolution
2010 USA29 3 63·7 All
males
pegylated IFNα2β 
subconjunctival/perilesion
injection of 1 µg/kg in the area of
the lesion
1 (33·3%) recurrence
after 7months follow up
No adverse effects.
Acetaminophen 1000mg was given
to prevent flu-like symptoms.
2010 USA30 33 64·4 1:2 IFNα2b drops (1 million
international units (IU)/ml vs 3
million IU/ml) for 1 month after
excision
9% (3 eyes) 20,21 & 28
months later
discomfort and photophobia
2008 USA31 29 66·7 13:1 IFNα2b drops vs no touch
excision +cryotherapy and 8 had
AMT too. 10 received IFNα2b 1 
million IU/ml and 4 received 2
million U/ml, all 4 times per day,
and 1 received 3 million IU/ml
thrice daily. Those whose lesion
failed to regress within 2 months
of therapy crossed over to
surgery. IFNα2b was continued 
until 4 months after clinical
resolution
None a t 35·6 months Not described
2006 Australia32 10 73·4 2:1 topical IFN-α2b (1 million IU/ml) 
four times a day until clinical
resolution of the lesion or until
the lesion appeared
nonresponsive
None at 55 weeks follow
up
Not described
2006 Australia33 3 69·3 1:2 IFNα2b 3Mill IU/ml every 3 days
for 7 doses
None after 22·7 months
follow up
Not described
2005 USA34 2 69·0 All
males
IFNα2b drops 1 million units/ml)
QID
None after 3 and 6
months follow up
respectively
Not described
2004 USA35 7 68·7 6:1 recombinant topical IFNalpha2b
drops (1 million IU/ml) 4 times
daily until lesion resolution noted
2 (33·3%) patients had
another recurrence of
Not described
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noted at 1 year and 2
months, respectively.
2002 Japan36 1 73·0 Female subconj IFNα2b x2 then drops for
12wks (cryotherapy had been
done twice before and failed)
Not described
1999 USA37 6 64·3 2:1 single
subconjunctival/perilesional
injection of 3 MIU/ml
recombinant IFNα2b in 0·5 ml 
and then IFNα2b drops (1 
MIU/ml) four times a day
None after 7·2 months
follow up
Not described
1976 USA38 1 24 Male dinitrochlorobenzene (DNCB).
Initial sensitization with topical
DNCB 2000µg on volar aspect of
forearm. Then 30-50 µL of DNCB
2mg/ml solution in acetone
applied to the tumour surface.
Repeated topical treatment a
week later for 5 cycles
None after 3 years follow
up
Not described
Table 4. Immune-therapy with cyclosporin A (CSA)
Year Country Study
size
age
(years)
M:F
ratio
intervention Recurrence Adverse effects
2009 Egypt39 10 65·0 2:1 wide surgical excision + topical
cyclosporine A (0·05%) and
topical mitomycin C (0·01%) QID x
12 weeks after surgery
None after a mean 2
years follow up
Epithelial toxicity (punctate
keratopathy) occurred in 3 eyes,
ocular irritation and mild
conjunctival hyperemia in 5 eyes,
and lid toxicity in 2 cases during
the treatment with mitomycin C
2006 Turkey40 2 65·0 All male Combined CSA and MMC. CSA
(0·05%) ophthalmic emulsion QID
None after 18 months
follow up
In this study they lowered the
concentration of MMC to 0·01%
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for 12 weeks, and topical MMC
(0·01%) QID was combined with
CSA at the second, fourth, and
sixth weeks
and combined it with CSA to
prevent potential ocular surface
side effects
Table 5. Chemotherapy with mitomycin C (MMC)
Year Country Study
size
age
(years)
M:F
ratio
intervention Recurrence Adverse effects
2014 Australia41 135 69·0 3·5:1 MMC 0·04% 4 times daily for 1
week, followed by 3 weeks off
treatment. IFNα2b 1 MIU/mL 4 
times daily if previous treatment
with MMC had failed or unable to
tolerate MMC due to side effects.
Again, this treatment was
continued until an end point was
reached. Endpoint was resolution
or failure.
Overall 19 (14·1%)
recurred. The mean time
to recurrence was 17·2
months (range, 4 to 61
months). 14 recurrences
(15·1%) were in patients
treated only with MMC
(n = 93), 4 recurrences
(20·0%) were in patients
treated with both MMC
and IFNα2b (n=20), and 
only 1 recurrence (4·6%)
was in patients treated
only with IFNα2b (n= 22). 
Adverse effects occurred in 76
(58·9%) patients using MMC and in
14 (30·4%) patients using IFNα2b. 
The most common were
conjunctival hyperemia or
irritation (MMC, n=63 [48·8%]; IFN,
n=13 28·2%]), localized allergic or
toxic reactions (defined as
papillary conjunctivitis, lid
swelling, or both; MMC,n = 12
[9·3%]) and punctal stenosis
(MMC, n = 7 [5·4%]). There was
one case of corneal erosion in
each of the MMC and IFN groups.
Patients occasionally had more
than 1 adverse effect. There were
no cases of limbal stem cell
deficiency identified. Most side
effects were mild and were
tolerated by patients. Side effects
significant enough to result in
cessation of treatment before
clinical resolution occurred in 12
(8·4%) of 143 eyes; all
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were with MMC.
2012 Turkey42 28 64.5 7:3 combined excision, cryotherapy,
and intraoperative mitomycin-C
(EXCRIM) using adjuvant 0.02 %
mitomycin-C (MMC)
0% over mean 49months 7 (21 %) had delayed epithelial
healing. Two of eight patients (25
%) with squamous cell carcinoma
(SCC) had positive lateral margins.
2011 USA43 32 70·3 4:1 Excision vs Excision + MMC.
intraoperative MMC use involved
applying a Weck cel sponge
soaked with either 0·02% or
0·04% MMC to the
subconjunctival surface at the
edge of the surgical excision for
1–3 minutes. Postoperatively, 1
drop of topical MMC 0·02% was
given TID for 2 weeks. In most
cases, 3 cycles of 2 weeks on and
2 weeks off were used with a
punctal plug inserted before
treatment
66·7% for excision alone,
7·7% for excision + MMC
after a mean of 31·7
months follow up
Discomfort during the 2nd or 3rd
treatment cycle occured in all
patients
2010 Australia44 91 66·0 3:1 Excision + cryotherapy then MMC
0·04% (0·4 mg/ml) four times a
day was used on a week-on
week-off basis for two to three
cycles (one cycle of treatment=1
week on+one week off)
12·5% after a mean 56·8
months follow up
A localised allergic reaction was
seen in 23% of patients during the
second or third cycle of treatment
but settled rapidly on cessation of
treatment in all. Of these patients,
one developed a secondary levator
disinsertion ptosis requiring
surgical correction. 15% of patients
developed epiphora, most of
which settled following simple
syringing of the involved
nasolacrimal system. Two patients
with diffuse disease developed a
corneal epithelial defect but no
stromal melt. There were no
incidences of severe complications
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such as hypotony, corneo-scleral
melt or limbal stem cell failure.
2010 UK45 24 63·0 ? MMC as primary treatment or
surgical adjuvant. 0·04% MMC
four times a day for 3 weeks on, 3
weeks off, 3 weeks on, with
topical steroid and lubricants
throughout
67% after a mean 50
months of follow up
hyperemia, allergy, epiphora,
discharge, mild
keratoconjunctivitis, uveitis,
corneal abrasion, corneal oedema,
pyogenic granuloma, nose bleed.
The most common short term
complication was allergy, 64% of
which occurred in the second 3-
week cycle. The most common
long term complication was
continuing mild
keratoconjunctivitis
2009 Iran46 17 58·7 2·4:1 2-3 alternate 7-day courses of
0·04% mitomycin-C in artificial
tears. 14 patients (82·4%)
received 2 courses of MMC one
week apart, and only 3 patients
(17·6%) received 3 MMC courses
5 (29·4%) recurrences
over a mean follow up of
30·8 months
All patients reported some degrees
of mild to moderate eye redness
and irritation that were controlled
by artificial tear, mild
corticosteroid drops, and warm
compress. There were no cases of
scleral melting or any systemic
complications
2006 Spain47 1 82·0 Female Short term MMC 0·02% (2 cycles)
followed by long term interferon
1 MIU/ml QID until tumour
disappearance (took 75 days to
disappear)
None after 1 year no clinical evidence of limbal stem
cell deficiency
2004 USA48 1 52·0 Female 0·02% MMC for 14 days in the
first cycle, 12 days in the second
cycle, and 3 days in the third cycle
followed by topical interferon
alfa-2b 1 x 106 U/mL for 11 days
due to intolerance to MMC.
Resolution lasted 10
months. Recurrence not
explicitly mentioned in
Not described
2004 Australia49 27 64·0 2·7:1 excised with 2mm margin +
cryotherapy (where available) +
None after 27 months
mean follow up
5 patients developed granuloma
following excision of OSSN, all of
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Chloramphenicol and Prednefrine
Forte eye drops four times daily
until wound healing + at least two
1 week courses of topical MMC
0·04% four times a day, after
complete epithelial healing. Each
course was followed by 1 week
free of MMC
which resolved rapidly with
continued topical steroid
treatment. Eight patients received
two courses because of allergy to
MMC with redness, swelling, and
significant itching, which
developed late in the second
course. All MMC allergy symptoms
resolved rapidly following
discontinuation of treatment.
2002 USA50 10 66·0 2·3:1 Mitomycin C 0·04% four times
daily was applied for a median of
three cycles
None after a median 15
months follow up
temporary local irritation,
erythema, chemosis
2002 Israel51 5 58·4 2:3 MMC, 0·02% or 0·04%, four times
daily for 14 days. Second and
third identical cycles of MMC
were applied at 3- to 4-week
intervals. Wide excision of the
conjunctiva was done 4 to 6
weeks after the final cycle of
MMC
None after a mean 23·8
months follow up
1 case of conjunctival hyperaemia
seen from day 8
2002 Greece52 7 73·8 3:4 During excision of the lesion,
mitomycin-C 0·02% was applied
intraoperatively for 5 minutes. In
two cases, excision was combined
with conjunctival limbal autograft
14% ( n=1) after a mean
of 16 months follow up
Not described
2002 UK53 11 66·7 2:9 Preoperative topical and
intraoperative local mitomycin C.
MMC 0·04% eye drops QID in two
weekly courses preoperatively
and/or a single intraoperative
application of 0·4 mg/ml. 7
patients had additional limited
local excision of the residual
None after a mean of 9·5
months follow up
1 developed a reaction to the
drops during the second
fortnightly course of MMC drops
but treatment was continued
under steroid cover. 1 persistent
epithelial defect following both
courses of topical mitomycin C
drops
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tumour mass and 1 had
cryotherapy.
2001 Germany54 9 ? ? mitomycin C eye drops 0·02%
(MMC) after excision
11% (1 patient) 14
months after surgery and
after 2 MMC-cycles.
self-limited conjunctivitis
1999 USA55 4 ? ? MMC 0·02% TID x2wk None after a mean of 20
months follow up
mild discomfort, redness,
photophobia, and punctate
epithelial keratopathy that
subsided on discontinuation of the
medication
1997 UK56 7 ? ? one drop of MMC 0·04% QID for 7
days in alternate weeks
None after 9 months
follow up
transitory ocular discomfort,
conjunctival injection, tearing,
photophobia, and punctate
epithelial keratopathy
Table 6. Chemotherapy with 5-Fluorouracil (5FU)
Year Country Study
size
age
(years)
M:F
ratio
intervention Recurrence Adverse effects
2015 Australia57 38 70·0 6:1 1% 5FU in N/saline QIDx 2wks or
0·04% MMC in N/saline x2-3
cycles each cycle lasting 1 wk
followed by 1 wk drug holiday.
Some pts had excision with a
2mm margin + cryotherapy
31% (10 patients)
required further
treatment for disease
persistence or
recurrence; 7 on MMC
and 3 on 5FU
5-FU 1% resulted in drug-related
complications in seven of 12 cases
(58·3%), and included a single case
of focal paracentral corneal
stromal melt. MMC 0·04% resulted
in transient drug related
complications in 23 of 39 (59%)
cases
2014 Australia58 153 65·5 7:3 89 on 5FU 1% QID x 2 wks and 64
on MMC 0·04% QID for 2-3 1-
week cycles.
2% (n=) 2 on 5FU; 0 on
MMC. Mean follow up
33·6months on 5FU and
57·9months on MMC
Not described
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2011 Australia59 65 66·3 3:1 a single cycle of 5FU 1% in
N/saline QID x 2wk
1·5% (1 case) after a
median follow up 23
months
37 (57%) patients had short-term
complications. Lid toxicity 32
(49·2%); epiphora 5 (7·7%);
superficial keratitis 6 (9·2%);
corneal epithelial defect 1 (1·5%);
ectropion 1 (1·5%). Four patients
were unable to complete the
course of 5-FU 1% because of local
toxicity
2011 Italy60 41 65·5 1·7:1 1% 5-FU QID x4 weeks (one
course). 22 patients (53·7%) had
5-FU as a sole treatment, and 19
patients (46·3%) as adjuvant
and/or debulking therapy
7·3% (3 tumours) treated
with 5-FU alone recurred
during a follow-up of
89·7 months
Clinical confocal microscopy
showed no long-term difference
between the treated eye and
fellow (control) eye in: endothelial
cells count, pleomorphism and
polymegathism, anterior stromal
keratocyte density, sub-basal
nerve plexus fibre number,
density, and beadings and central
cornea epithelium thickness
2010 Yemen61 15 50·8 1:4 subconjunctival 5FU (5mg) at the
end of surgery + 1% 5-FU eye
drops QID x 4days then repeated
at 30 day intervals x6 cycles. All
had 6 months therapy
1/15 (6·7%) recurred mild temporary local irritation
2000 USA62 7 74·0 All male 1% 5-FU in methylcellulose was
administered four times daily for
2 to 4 days for each cycle. The
number of initial treatment cycles
was two to six, with the time
between cycles being 30 to 45
days.
3 recurrences (43%) No adverse effects noted
2000 Italy63 8 70·0 3:1 1% 5FU drops alone QID x4wks
without surgery or radiotherapy
1 patient (12·5%) with a
mean 27 months follow
up
Acute transient toxic
keratoconjunctivitis was observed
in all treated cases; it was
controlled with topical therapy.
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1995 USA64 6 61·0 2:1 excision +5FU or 5FU alone 1 recurred (16·6%) after
30 months
Punctate epithelial keratopathy,
epithelial defect
Table 7. Retinoic acid
Year Country Study
size
age
(years)
M:F
ratio
intervention Recurrence Adverse effects
2010 Australia65 1 64·0 Female topical all-trans retinoic acid
(ATRA), 0·01%, 1 eyedrop applied
every second day x9mo. After
there was no response from 2
intralesional injections of 3 Mill IU
of recombinant IFN in 0·5 mL, 2
months apart, followed by topical
interferon alfa-2b (1 Mill IU/mL) 4
times a day.
No recurrence Not described
Table 8. Anti-vascular endothelial growth factor (VEGF)
Year Country Study
size
age
(years)
M:F
ratio
intervention Recurrence Adverse effects
2015 Turkey66 6 66 2:1 topical 5mg/mL bevacizumab QID
x 8 weeks
None after 6 months
follow up
Not described
2014 Turkey67 10 60·5 bevacizumab (Avastin) 25mg/ml
x 7·8wks (range 5-14) then
excision biopsy+cyro+AMT
None after 6 months
follow up
Not described
2009 Egypt68 10 45·0 2:1 subconj Avastin (bevacizumab) 20% after 12 months
follow up
Not described
2009 USA69 4 51·5 ? Subconjunctival injections of
ranibizumab 0·5 mg were given
every 2 or 4 weeks if the tumour
regressed or remained stable.
1 recurred (25%) and 1
did not regress (25%)
No adverse ranibizumab-related
ocular or systemic side effects.
Specifically, there were no local or
systemic allergies and no corneal
124
epitheliopathy, perforation,
conjunctival hyperaemia, scleral
thinning, uveitis orcataract
formation.
Table 9. Radiotherapy, Thermotherapy
Year Country Study
size
age
(years)
M:F
ratio
intervention Recurrence Adverse effects
2015 S. Africa70 69 42·0 1:1 60 Gray Sr-90 brachytherapy in
four divided doses after resection
with a 2 mm margin. No
cryotherapy or alcohol
debridement
8 (11·6%) after a median
27 months follow up
Five patients developed a dry eye,
which was treated with
ocular lubricants
2011 Spain71 1 61·0 Male Orthovoltage was administered
with direct field radiation focused
on the tumor. The patient
received 500 cGy in 2
sessions/week for 2 weeks (2000
cGy) and then 7 sessions 300 cGy
daily (2100 cGy).
No recurrence after 1
year follow up
Not described
2009 France72 15 63·7 4:1 proton beam therapy and surgery 2 patients (13·2%). Mean
follow-up was 39.1
months
Not described
2009 Australia73 11 60·8 1:3·7 Plaque brachytherapy. A 10- 15-
mm-diameter circular Iodine-125
plaque was applied under
assisted local or general
anaesthesia during surgery
(excised with histological
confirmation using a technique
involving minimal lateral
clearance and avoidance of deep
scleral dissection)
None after 23·4 months
mean follow up
Not described
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1995 Germany74 2 58·5 All male Brachytherapy with Ruthenium
105-applicator for radiation (after
prior surgery). The applicator was
fixed to the sclera adjacent to the
corneal limbus. A 100 Gy
radiation dose was delivered with
2mm tissue penetration.
None after 2 years follow
up
Not described
1993 Austria75 1 local excision and brachytherapy
with ruthenium-106. A total dose
of 320 Gy was delivered to the
tumour bed
None after 22 months Not described
1990 Spain76 12 strontium-90 source on cup-
shaped applicators of different
sizes according to the extension
of the tumor. Surface dose
ranged from 60 Gy in a single
treatment to 140 Gy in 7
fractions, depending on the
thickness of the lesion.
1 (8·3%) recurred in a
follow up period ranging
from 2-15 years
Cataracts
1988 Australia77 146 123 were treated with a
strontium-90 source, 10 with a
radon "ring," and 7 with
superficial X ray therapy. of the
123, 107 received 30 Gy, 14
received 40 Gy (pre 1960) and
one patient each received 20 and
25 Gy incident dose
3 (2·3%)developed local
recurrence
complications were very
uncommon. 3 patients developed
unsightly conjunctival
telangiectasia, 2 patients
developed a persistent scleral
ulcer and 2 patients developed
clinically significant cataracts.
Table 10. Others
Year Country Study
size
age
(years)
M:F
ratio
intervention Recurrence Adverse effects
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2015 USA78 1 64·0 Female Aloe vera drops TID None Not described
2004 USA79 3 70·7 2:1 Photodynamic therapy
1-3 treatments of verteporfin (6
mg/m2 body surface area,
intravenously). All tumours
irradiated 1 min after injection
using a diode laser with an
emission wavelength of 695 nm,
applying a light dose of 50 J/cm2.
None after 8·6 months
follow up
minimal temporary local irritation
in two patients, and small
conjunctival haemorrhages and
mild transient chemosis in the
three eyes directly after
treatment. One patient had
infusion-related back pain.
2002 USA80 1 52·0 Female Cidofovir drops
6-week course of cidofovir
eyedrops (2·5 mg/ml) one drop
q2h x2wk then QIDx2wk then TID
x2wk
None after 24 months
follow up
Not described
1979 Greece81 9 Urea local application 22% Not described
We included studies that reported recurrence as an outcome.
MIU- million international units
? means unreported or unclear
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Kenya – an introduction to the research setting
5.1 Geography of Kenya
Kenya sits astride the equator in East Africa (Figure 5.1). The climate is tropical; hot and humid
at the Indian ocean coast and Lake Victoria basin, temperate in the highlands and very hot
and dry in the north and eastern parts of the country. The long rains occur from March to May
and a short rains from October to December. June and July are the coldest months of the year
while January and February are the hottest.
Figure 5.1 Map of Africa showing Kenya highlighted in a red circle in East Africa.
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5.2 Demography
The population in 2014 was estimated at 43.0 Million.1 From the last Kenya Population and
Housing Census in 2009, the total population was 38.6 Million representing a 35% increase
from the previous census in 1999.2 There were 19.2 Million males and 19.4 Million females
(male: female ratio of 1:1). The majority (26.1 Million, 68%) of the population was rural while
about one third (12.5 Million, 32%) lived in urban areas. The population pyramid shows that
Kenya’s population is mainly youthful (Figure 5.2).
Figure 5.2 Kenya population pyramid in 2009.
Based on the 2009 census about 65% of the population had only primary or incomplete
secondary education, and another 10% had never attended school.
5.3 HIV
HIV/AIDS is a huge burden in Kenya. In 2013 the prevalence of HIV in the 15-49 years age
group was estimated at 6.0% and approximately 1.6 Million people were living with HIV.3 The
peak age affected is 35-39 years among women and 45-49 years among men. (Figure 5.3)
The prevalence was higher among women (7.6%) compared to men (5.6%). The top 4
counties with the highest HIV prevalence among adults in Kenya are found around Lake
Victoria. (Table 5.1). Two of our study centers (Sabatia and Kikuyu) were located in these
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areas. (Figure 5.4) The areas with the highest prevalence include western Kenya and the Lake
Victoria region, Nairobi and pockets along the Indian Ocean coast (Figure 5.5)
Table 5.1 Counties in Kenya with the highest HIV prevalence among adults in 2013.3
County HIV prevalence in adults (%)
Homa Bay 25.7
Siaya 23.7
Kisumu 19.3
Migori 14.7
Kisii 8.0
Nairobi 7.6
Mombasa 7.4
These figures were generated by the National Aids Control Council (NACC) in Kenya using the Estimation and
Projection Package (EPP) and Spectrum software recommended by the UNAIDS reference group with data from
antenatal clinic surveillance, population based surveys such as the Kenya AIDS Indicator Survey II (KAIS 2012)
and other program data.
Figure 5.3 HIV prevalence by age and sex in the KAIS 2012 survey.4
NOTE: HIV prevalence is highest in the 35-39 years and 45-49 years age groups in women and men respectively
Abbreviation: KAIS – Kenya AIDS Indicator Survey
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Figure 5.4 Map of Kenya showing study sites and the HIV prevalence in those
counties in 2012.
3.1%
4.7%
3.8%
4.9%
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Figure 5.5. Map showing HIV prevalence in Kenya (2012) in different provinces under
the now-replaced provincial system.4
NOTE: Nyanza region and Nairobi have the highest prevalence. Two of our study centers (Kenyatta
National Hospital and PCEA Kikuyu Eye Unit) serve Nairobi and its environs. Sabatia Eye Unit serves
Western and Nyanza regions.
5.4 Kenya eye health system
The Kenya eye care program started as a small project of the Royal Commonwealth Society
in 1956. In 1966 the first National Prevention of Blindness Committee was formed. Later as it
grew it was absorbed into the Ministry of Health and in 2001 it was upgraded to a full Division
of the Ministry of Health and Sanitation after the launch of VISION 2020. The eye health
delivery system now comprises of: Government, non-governmental, Mission and private
facilities at various levels. There is an electronic eye health information system which is part
of the health management information system (HMIS) of the Ministry of Health that collates
data from all eye clinics except the private practices.
In 2012 there were 87 ophthalmologists, 92 Ophthalmic Clinical Officers specialised as
Cataract Surgeons (OCO/CS), 43 OCO, 67 Ophthalmic Nurses (ON) and 34 Ophthalmic
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Assistants (OA).5 Eye care workers are unevenly distributed with the highest numbers being
in urban and non-arid areas. The University of Nairobi (UON) trains ophthalmologists while
the Kenya Medical Training Centre (KMTC) in Nairobi trains OCO/CS and OCO and nurses.
Training of OCOs started in 1959, Ophthalmologists in 1978 and ON in 2003. A number of
Mission hospitals and NGO clinics train OA. UON has the capacity to train 10 ophthalmologists
per year of which about 5 are from other African countries while KMTC can train 10 OCO/CS
and 16 ON per year.
The prevalence of blindness in people aged 50 years and older from a rapid assessment of
blindness study in Nakuru district of Kenya, a predominantly rural area, was 2.0% (95%CI;
1.5%-2.4%), while that of visual impairment was 5.8% (95%CI; 4.8%-6.8%).6 Cataract is the
leading cause of blindness and refractive error for MSVI. The cataract surgery rate in 2010
was 589 operations/million population/year far below the Vision 2020 goal of 3000.5 This is
attributed to lack of resources, lack of awareness by blind persons, high cost of treatment and
limited access to services.
5.5 Research Partners
5.5.1 Study centres
The study centres for this project were selected by obtaining data from the Kenya Ophthalmic
Services electronic eye health information system to show the centres that reported the
highest number of conjunctival excision between 2008 and 2011. The top 4 were:-
• Sabatia Eye Unit (219 cases/year) in the western highlands bordering Lake Victoria
300km from Nairobi and 20km from Kisumu
• PCEA Kikuyu Eye Unit (118 cases/year) about 25 kilometres (km) from Nairobi in Central
Kenya
• Homa Bay District Hospital (94 cases/year) in Nyanza on the shores of Lake Victoria
• Kitale District Hospital (83 cases/year) in the north Rift Valley 490km from Nairobi
Kenyatta National Hospital (KNH) Eye Clinic in Nairobi which did not submit data in that
period but is the national referral hospital was also chosen.
The location of the centres is shown in Figure 5.4.
Initially data collection started in PCEA Kikuyu Eye Unit and KNH in July 2012 but by October
2012 the recruitment at KNH had been rather slow due to a sudden increase in user fees in
KNH from KSh. 1500 for a conjunctival excision to KSh. 5000 earlier that year. We wrote to
the ethics committees in Nairobi and London School of Hygiene & Tropical Medicine to request
for a protocol amendment to include the other 3 centres above. We thus added Sabatia and
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Kitale hospitals but for logistical reasons (difficult to transport pathology specimens to Nairobi)
Homa Bay district hospital was not activated.
From the foregoing description of Kenya, it is seen that the centres are located in the areas
with the largest ethnic groups and highest HIV prevalence in the country.
5.5.2 Laboratories
i) MP Shah Hospital in Nairobi - histopathology
ii) The Kenya Aids Vaccine Institute (KAVI) Institute for Clinical Research laboratory at
the University of Nairobi - HIV and CD4 testing and frozen tissue storage (serum for
vitamin A and fresh frozen tumour samples).
iii) The Tropical Diseases Research Centre’s (TDRC) Nutrition Unit in Ndola Hospital,
Zambia - vitamin A analysis.
iv) The University College London (UCL) Institute of Ophthalmology, Department of Eye
Pathology at the Moorfields Eye Hospital in London - Immunohistochemistry
v) The London School of Hygiene & Tropical Medicine - DNA extraction from tumour
specimens
vi) Genome Institute of Singapore – HPV genotyping
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Chapter 6. Overview of project design
6.1 Research Questions
i) Are HIV infection, low CD4 lymphocyte count, HPV infection, vitamin A deficiency,
ultraviolet light exposure, cigarette smoking and occupation risk factors for OSSN?
ii) Is CD4 T lymphocyte count (in HIV positive individuals) associated with the severity of
OSSN?
iii) In patients with conjunctival tumours, what is the safety, sensitivity and specificity of
Toluidine blue dye 0.05% as a point-of-care diagnostic test for OSSN?
iv) Why do patients with OSSN present late and from their perspective what can be done to
reduce the delay?
v) Does adjuvant chemotherapy with topical 1% 5FU applied four times daily for one month
reduce the recurrence rate over a period of one year more than surgical excision alone?
6.2 Objectives
6.2.1 Broad Objectives
i) To improve the understanding of the epidemiology, aetiology and pathophysiology of
OSSN in East Africa.
ii) To develop a diagnostic algorithm based on clinical signs and vital staining of the
conjunctiva.
iii) To understand why patients with OSSN present late with advanced disease.
iv) To determine whether the recurrence of OSSN can be reduced through the use of
adjuvant topical chemotherapy.
6.2.2 Specific objectives
i) To determine if HIV infection, low CD4 lymphocyte count, HPV infection, vitamin A
deficiency, ultraviolet light exposure, cigarette smoking and occupation are risk factors for
OSSN in Kenya and describe the expression patterns of the SLRP family members.
ii) To determine the sensitivity and specificity of Toluidine blue dye 0.05% vital staining in
patients with conjunctival tumour for diagnosis of OSSN with histology as the gold
standard.
iii) To develop a diagnostic algorithm based on clinical signs and vital staining of the
conjunctiva to guide the management of possible OSSN in resource-limited settings.
141
iv) To describe the barriers to care, the care-seeking pathway of patients with OSSN and
possible solutions from the patients’ perspective.
v) To conduct a randomised controlled trial to determine the efficacy and safety of adjuvant
topical 5FU 1% eye drops applied 4 times daily for one month after surgical excision of
OSSN tumours which involve less than 2 quadrants of the conjunctiva by evaluating the
one-year recurrence rate and mean time-to-recurrence of OSSN; and both immediate and
delayed adverse effects of this therapy.
6.3 Methods/design
Participants passed through the following study sequence:
i) Case-Control Study: confirmed cases of OSSN were compared with controls. Clinical
features were recorded and various risk factors evaluated: HIV, CD4, vitamin A, HPV
types, ultraviolet exposure and occupational history. (Figure 6.1)
ii) Evaluation of Toluidine Blue (ToB) vital staining of conjunctival tumours as a point-of-care
test in the diagnosis of OSSN compared to histopathology as the gold standard.
iii) A narrative of the care-seeking pathway OSSN cases took.
iv) A randomised controlled trial to determine whether OSSN recurrence can be reduced by
adjuvant topical 5FU chemotherapy following excision. (Figure 6.2)
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Figure 6.1 Case-control study outline.
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Figure 6.2 Randomised controlled trial outline.
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6.4 Project timeline
Figure 6.3 Project timeline
Activity 2011 2012 2013 2014
2015 20
16
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1
Fellowship result
Finalize full protocol
1st term courses in London
(LSHTM)
Ethics committee submission
Ethics committee feedback
received
Protocol review and
resubmission to ethics
Write SOPs
Equipment procurement
Staff recruitment
Protocol training
Pilot phase
Modify SOPs
Participant recruitment
Participant follow up
PhD Upgrade Report &
seminar
Laboratory testing
Data analysis
Write up (review papers were
published first)
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During the project period certain untoward events occurred in Kenya that affected the timeline:
a) There were national elections held in March 2013 and by six months before that tension was
already rising high nationwide during campaigns. There was a lot of anxiety in the populace
at large related to major inter-ethnic violence that took place after the previous elections in
December 2007. People residing in areas where they were considered ‘outsiders’ migrated
back to their rural homes where they felt safer. From December 2012, about 50 or so
participants who had surgical excisions and were enrolled in the study did not return for their
results and we lost the opportunity to enrol them in the case-control study and trial. Some of
the participants who had been enrolled also missed their visits or were lost to follow up
completely.
b) In the year 2011, for example, a total of 21 industrial strikes were reported involving 13,499
employees with up to 175,329 man-days lost mainly affecting health workers, school teachers
and university academic staff.1 Nationwide industrial action by health workers from August
2011 to December 2011 and another in September 2012 paralysed services in the health
facilities from where we were receiving referrals to the study centres. There were additional
strikes by health workers and teachers in 2012 and 2013. In March 2014 teaching and non-
teaching staff in public universities went on strike. In one case, blood samples for 20 study
participants that were stored in the freezers of a district hospital laboratory neighbouring
Sabatia Eye Unit went missing and were never found again. We resorted to direct courier of
subsequent samples to Nairobi which considerably raised costs.
c) There was a sudden increase in user fees at KNH that slowed down recruitment. Time was
lost as we had to get the necessary ethical approval for additional study centres. We thus
started recruitment in Sabatia in January 2013 and in Kitale in February 2013. Recruitment in
the other centres had started about 8 months before (KNH in June 2012 and Kikuyu in July
2012).
d) The first batch of 16 tumour specimens from one centre (Kitale) arrived at the pathology
laboratory autolysed. It was suspected to be related to poorly constituted formalin which was
subsequently replaced.
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Abstract
Background
Clinical features of Ocular Surface Squamous Neoplasia (OSSN) and benign conjunctival lesions
overlap. Toluidine blue (ToB) 0.05% vital staining of OSSN has a high sensitivity (92%) but low
specificity (31%). This study was conducted to determine whether an algorithm combining clinical
features and vital staining increased the specificity.
Methods
Clinical features of participants presenting with conjunctival lesions in Kenya were evaluated and
lesions excised for histopathology to confirm the diagnosis. Participants were randomly divided into
two sets: “development” and “validation” sets. Using the development set, clinical criteria that had
the strongest association with OSSN were analysed using logistic regression, a specificity-based
and sensitivity-based model. Using the best combination of features in the three models, receiver
operator characteristic curves were plotted, cut-off determined, best model chosen and repeated in
the validation set. An algorithm showing the probability of OSSN with features at the cut-off was
developed.
Results
Out of 496 participants OSSN was confirmed in 187 (38%). The regression-based model had the
highest area under the curve (79.8%). The best cut-off was using 3 out of 8 features; prior excision,
corneal involvement, feeder vessels, dark blue ToB staining, papillary or gelatinous tumour surface,
severe inflammation, anti-retroviral therapy and temporal or circumlimbal tumours. At this cut-off
sensitivity was 89%, specificity 50%, and 65% of lesions were correctly classified. This specificity
was higher than any blue ToB staining (31%) but lower than clinical photo-examination (60%).
Conclusion
This algorithm may assist clinicians decide about the need for surgery but cannot replace
histopathology.
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Introduction
Ocular surface squamous neoplasia (OSSN) is a relatively common, aggressive disease in Africa.
Compared to other parts of the world, it more frequently affects younger adults, particularly those
living with HIV, and has a higher incidence in women.1 Late presentation with large tumours is not
infrequent and the outlook of treatment limited by high recurrence rates.2-4 The gold standard for
diagnosis of OSSN remains histopathology.5 However most practitioners in Africa depend on their
clinical impression and lesions are often excised without histopathology due to a shortage of
pathologists, logistical problems of sending the specimens to distant histopathology service centres
and the added cost thereof.6 7 This means that it is difficult to know what the lesion was exactly and
whether the margins were involved or not. In some countries without such resource constraints,
treatment decisions are also being made without an excision biopsy for histopathology being
performed.8 Studies from East Africa have found an overlap in the clinical features of OSSN and
benign lesions, making it difficult to distinguish between them.9 10 In addition, different histological
grades of OSSN show overlapping phenotypes.9 10 Clinical examination of a series of conjunctival
lesions from photographs had a positive predictive value of 54%.9
We have previously reported the use of Toluidine blue (ToB) 0.05% vital staining in Kenya to assist
in the diagnosis of OSSN and found that although any blue staining was sensitive for OSSN (92%)
it lacked specificity (31%).11 The test was however easily interpreted by different examiners
(kappa=0.76). Dark royal blue staining had a sensitivity of 64% and specificity of 67%. Other studies
have reported that vital staining for OSSN has high sensitivity and relatively low specificity. In Brazil,
toluidine blue 1% had high sensitivity of 100% and a specificity of 50% while in South Africa
methylene blue 1% had a sensitivity of 92% and a specificity of 50%.12 13 Therefore, vital staining
alone cannot currently be relied upon to guide treatment decisions.
In the African setting a clinical diagnostic algorithm may help support the clinician’s impression of
OSSN to distinguish lesions that should be excised from those that can be followed up. We
conducted this study to develop an algorithm that combined ToB staining with other clinical features.
The key qualities sought were: simplicity, for clinicians to use easily; specificity, as we have a test
with high sensitivity already (any blue ToB stain) but it has an unacceptably low specificity (31%);
sensitivity (using dark blue ToB stain has a higher specificity of 67% but the sensitivity is only 64%).11
Methods
Ethical Approval
This study was approved by the Kenyatta National Hospital – University of Nairobi Ethics and
Research Committee and the London School of Hygiene & Tropical Medicine Ethics Committee. It
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adhered to the tenets of the Declaration of Helsinki. All participants gave informed written consent
to take part.
Study population
The participants were part of an integrated set of studies on the epidemiology and management of
OSSN in Kenya. They were recruited between July 2012 and July 2014 in four eye care centres:
Kenyatta National Hospital in Nairobi, PCEA Kikuyu Eye Unit about 25 kilometres (km) from Nairobi
in Central Kenya, Kitale district hospital in the north Rift Valley 490km from Nairobi and Sabatia Eye
Hospital 300km from Nairobi in western Kenya near Lake Victoria. Adult patients (≥18 years)
presenting to these clinics with any conjunctival lesion (first presentation or a recurrence) and
scheduled for surgery were recruited.
Participant examination methods have been published elsewhere.9 Briefly, a comprehensive history
was taken, clinical examination at the slit lamp was performed to record features of the lesions, vital
staining done with ToB 0.05% and digital photographs of the lesions taken before and after staining.11
Lesions were excised and sent for histopathology. One pathologist examined all the histology slides.
OSSN was defined as any lesion with mild, moderate or severe conjunctival intraepithelial neoplasia
(CIN I, II, III respectively); any who had carcinoma-in-situ (CIS); or invasive squamous cell
carcinoma. Benign lesions included pterygium, actinic keratosis, papillomas, pyogenic granulomas,
nevi and rhinosporidiosis. During the post-operative visit about 3-4 weeks later, participants found to
have OSSN were offered HIV testing and a CD4 count if positive.
Generation of development and validation datasets
The original dataset, consisting of observations of both OSSN and benign lesions, was split into two
datasets, one for the purposes of developing the diagnostic test and the other for validating it. This
was done by setting a “seed” (in order to make the random allocation reproducible). Each individual
was allocated a random number between 0 and 1. They were then sorted by this random number
and split into a development set (consisting of 75% of the participants) and a validation set
(consisting of the remaining 25%). This, and all other statistical analysis, was performed using Stata
version 12.1 (StataCorp, College Station, Texas, USA).
Model construction and validation
Using the development dataset, univariable analysis was conducted to find which features were
associated with OSSN. Multivariable logistic regression analysis was used to estimate odds ratios
(ORs) and 95% confidence intervals (CIs). The likelihood ratio test was used to assess statistical
significance of associations. Variables that were associated with OSSN in the univariable analyses
at a level of p<0.05 were included in the multivariable analysis and then those with p<0.2 were
retained in the model. We took the features selected by the logistic regression model and for each
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patient created a “diagnostic score” which was the number of features observed. We then plotted a
ROC curve to identify the most appropriate “cut-off” to classify a lesion as OSSN or not.
In addition to the regression-based model, specificity-based and sensitivity-based models were also
developed. The specificity-based model which aimed to reduce the proportion of false positives was
developed using a similar method to a Zimbabwe study that created an algorithm for verbal autopsy
of HIV.14 The positive likelihood ratio (LR) for a range of features from the history and clinical
examination findings was calculated in the development dataset to examine their strength of
association with OSSN. Features with a LR ≥1.92 (corresponding to a significant chi-squared test on 
1 degree of freedom at p<0.05) were retained for further analysis. The selected features were then
ordered from the highest specificity to lowest and the following steps followed:
1) Take the feature with the highest specificity
2) Classify all observations where this feature is present as OSSN+
3) Calculate sensitivity and specificity of diagnostic test using this feature
4) Recalculate the specificity of all remaining features using only the observations not
classified as OSSN+
5) Take the feature with the highest specificity in the remaining list of variables
6) Classify all observations where this feature is present as OSSN+
7) Calculate sensitivity and specificity of diagnostic test
This iterative process was repeated until all the variables had been incorporated. For the sensitivity-
based model, the same method was used except that the selection of features to be included was
based on the highest sensitivity. These features from the specificity-based and sensitivity-based
models were then applied to the development dataset and used to plot a modified receiver operator
characteristic (ROC) curve to visualise the effect that adding each feature had on the sensitivity and
specificity and to choose a cut-off point which optimised the two. We modified the typical ROC curve,
which shows different cut-offs for the same parameter, usually a continuous variable, by creating an
ordered categorical variable in which different categories consisted of various combinations of
features. For example, category 1=feature A, 2= feature A + feature B, 3= feature A + feature B +
feature C and so on.
The results of the models from the development set were then applied to the validation set and ROC
curves plotted. To choose the best model among the three, the ROC that was closest to the upper
left hand corner of the plot was used. The cut-off value from the ROC curve was also selected by
choosing the point closest to the upper left hand-corner of the plot and specificity above 50%.
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Algorithm development
Finally, an algorithm was built from the development dataset as a probability tree using identified
features from the best model, in the case of the regression model starting with the ones with the
highest odds ratios.
Results
There were 496 participants with conjunctival lesions. The development dataset included 372
participants and validation dataset 124. Histologically confirmed OSSN was present in 187 (38%)
participants: 139/372 (37%) of the development dataset and 48/124 (39%) of the validation dataset.
Model Development
The features from the history, clinical examination and laboratory testing that were evaluated are
listed in the Supplementary Table. Those that were associated with OSSN at the 5% significance
level on univariate analysis are shown in Table 9.1. In the multivariable logistic regression model
eight variables were considered significant predictors of OSSN (Table 9.2).
The three ROC curves (regression, sensitivity and specificity models) generated from the
development dataset are shown in Figure 9.1. The best cut-off for the specificity-based model was
the presence of any one of the following features; symblepharon, fornix involvement, history of prior
excision, anti-retroviral therapy (ART) use, severe inflammation or dark ToB vital stain. The best cut-
off for the sensitivity-based model was the presence of a papillary-gelatinous surface. For the
regression-based model, the best cut-off was the presence of any 3 of the 8 features listed in Table
9.2. With this cut-off in the regression model the sensitivity was 89% and specificity 50%. The curve
from the regression-based model had the highest area under the curve (79.8% vs 77.9% for the
specificity-based and 58.0% for the sensitivity-based).
Model Validation
The ROC curves from application of the three models to the validation dataset are shown in the
Supplementary Figure. The curve from the regression-based model had the highest area under the
curve (73% vs specificity 57% and sensitivity 58%). The cut-off giving the point closest to the top left
of the plot was 3, which means those individuals with 3 or more of the 8 selected features are
classified as OSSN. Using 2 features as a cut-off had a high sensitivity (94%) but low specificity
(26%) while 4 features, though with a higher specificity (74%), had a low sensitivity (56%), making 3
the best compromise. With 3 features the sensitivity was 83% and specificity 54%. The odds ratios
for many of the variables in Table 9.2 were not statistically significant in the validation dataset
because of sample size limitations.
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A comparison of the performance, using the validation dataset, of the three models with ToB staining
and clinical assessment from photographs is shown in Table 9.3. The regression-based model was
more accurate (65%) than the specificity (57%) or sensitivity (50%) models. It offered the best
compromise with false positives at 46% (instead of 69% with any blue staining) and false negatives
at 17% (twice those of any blue staining but dark blue staining had four times as many false negatives
at 36%). Clinical photograph examination had a higher sensitivity (86% vs 83%), specificity (60% vs
50%) and accuracy (70% vs 65%) than the regression model.
Diagnostic Algorithm
Applying this to the four clinical features with the highest odds ratios from the multivariable regression
model we constructed the diagnostic probability tree shown in Figure 9.2 to show the probability of
OSSN in an individual patient with specific combinations of features in this dataset.
Discussion
Earlier studies from the East African region have found that the diagnosis of OSSN on clinical
grounds can be unreliable, due to an overlap in clinical features of OSSN with other ocular surface
lesions.9 In addition, we have previously reported the use of toluidine blue vital staining, which we
found to have a high sensitivity but low specificity.11 In this study we developed and evaluated several
models to try to identify a combination of variables that most reliably distinguishes OSSN from other
pathology.
We found that a simple logistic regression model, with a classifier threshold of 3 or more out of 8
features associated with OSSN from history, clinical examination and ToB vital staining provided the
best balance (of the options tested) between reasonable sensitivity (89%) and improved specificity
(50%) over using ToB alone.11 The sensitivity and specificity in the regression model compares well
with the quoted values in the clinical features we previously reported (86% sensitivity and 60%
specificity) although we do not know which specific features the examiners were using or how they
interpreted them when looking at the photographs.9 A high sensitivity is a critical requirement when
dealing with a serious disease like OSSN. However, the moderate specificity remains problematic,
as this is likely to result in more patients having surgery for suspected OSSN who turn out not to
have this disease.
The probability tree algorithm is a simple tool that clinicians may also find helpful in assessing
patients with ocular surface lesions. Tracing the presence or absence of certain features leads to a
probability score for the diagnosis of OSSN. However, it should be emphasised that this algorithm
pertains to this specific dataset. It is not a substitute for careful clinical assessment and judgment,
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which should continue to form the basis for decisions around the need for surgical excision or other
treatment.
Formal diagnostic algorithms have not previously been evaluated in the management of OSSN,
although it seems likely that most clinicians implicitly go through a similar process when forming a
clinical impression. The results of our previous study in Kenya found that individual clinical features
were not specific for OSSN, being found in variable proportions in malignant and benign lesions.9
However, when clinicians were asked to provide an overall categorisation of OSSN or not OSSN
their sensitivity and specificity were similar to the performance of the model we describe here. This
suggests that clinicians who are experienced in examining such patients are integrating the
information provided by the combination of clinical features to draw similar conclusions about the
nature of the pathology.
This study had several limitations. Firstly, as with many diagnostic tests, there is a trade-off between
sensitivity and specificity. Secondly, it can be difficult to standardize the assessment of some clinical
features such as the degree of inflammation. Although histopathology is the gold standard for
diagnosis it is still open to individual interpretation. Some non-OSSN lesions such as pterygia and
actinic keratosis have been shown in several studies to share some histological and etiological
features with OSSN.15-17 Extrapolation of these results or direct comparison with other populations
of OSSN patients requires caution as the pattern of disease in this population appears quite distinct
from that seen in more temperate regions.
In conclusion, ToB staining is less specific and predictive than clinical examination by an
Ophthalmologist but it may be useful for other health care workers screening patients for the disease,
and when there is no ToB staining, to reassure that the disease is unlikely to be malignant. We
developed a simple model with various combinations of clinical features that could identify a high
proportion of OSSN cases and give an indication of the probability of disease. This could be used to
estimate the risk of OSSN. However, it is context-specific and given the clinical overlap between
OSSN and non-OSSN lesion, this should not be regarded as a substitute for histological assessment.
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Table 9.1. Univariate analysis of the development dataset, showing variables that were
associated with OSSN with a p-value <0.05. Ranked in descending order of odds ratios.
Variable OSSN
N=139
Benign
N=233
Crude
OR
(95%CI) p-value
n (%) n (%)
Feeder vessels 124 (91.2) 148 (64.1) 5.80 (3.02-11.11) <0.001
Prior excision of
present lesion
28 (20.1) 12 (5.2) 4.65 (2.28-9.48) <0.001
ART use 53 (41.4) 26 (13.4) 4.57 (2.65-7.86) <0.001
Any toluidine blue
staining
99 (90.8) 144 (69.2) 4.40 (2.15-8.98) <0.001
No formal education 14 (10.1) 6 (2.6) 4.24 (1.59-11.30) 0.004
Fornix involvement 9 (6.5) 4 (1.7) 3.95 (1.19-12.07) 0.03
Papillary or gelatinous
surface
126 (92.0) 173 (74.9) 3.84 (1.94-7.61) <0.001
Dark royal blue
Toluidine staining
72 (66.1) 71 (34.1) 3.75 (2.30-6.12) <0.001
Severe inflammation 50 (36.5) 36 (15.5) 3.14 (1.91-5.17) <0.001
Corneal involvement 92 (67.2) 96 (41.4) 2.90 (1.86-4.51) <0.001
Temporal or
circumlimbal tumour
48 (34.5) 41 (17.6) 2.47 (1.52-4.01) <0.001
Any inflammation 122 (89.1) 179 (76.8) 2.45 (1.32-4.55) 0.004
Leukoplakia 95 (69.9) 116 (50.0) 2.32 (1.48-3.63) <0.001
Age group, n(%) y
18-29 15 (10.8) 42 (18.0) 1.00 (REF) 0.01
30-39 49 (35.3) 103 (44.2) 1.33 (0.67-2.63)
40-49 47 (33.8) 52 (22.3) 2.53 (1.25-5.14)
50-59 19 (13.7) 23 (9.9) 2.31 (0.99-5.39)
60-69 3 (2.2) 10 (4.3) 0.84 (0.20-3.47)
70-79 6 (4.3) 3 (1.3) 5.60 (1.24-25.25)
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Table 2. Multivariable logistic regression analysis of predictors of OSSN identified using the development dataset and applied to the
validation dataset.
Variable Development set (N=372) Validation set (N=124)
Adjusted OR (95%CI) p-value Adjusted OR (95%CI) p-value
Prior excision of the present lesion 4.51 (1.64-12.42) 0.004 0.55 (0.09-3.23) 0.51
Corneal involvement 3.66 (1.93-6.95) <0.001 3.28 (1.13-9.55) 0.03
Feeder vessels 3.38 (1.32-8.62) 0.01 2.57 (0.75-8.79) 0.13
Dark royal blue Toluidine staining 3.08 (1.61-5.88) 0.001 2.56 (0.92-7.14) 0.07
Papillary or gelatinous tumour surface 2.98 (1.09-8.09) 0.03 1.57 (0.46-5.39) 0.47
Severe inflammation 2.91 (1.39-6.10) 0.005 1.20 (0.40-3.63) 0.74
ART use 2.32 (1.10-4.89) 0.03 1.27 (0.41-3.91) 0.67
Temporal or circumlimbal tumour 2.21 (1.09-4.45) 0.03 1.84 (0.55-6.13) 0.32
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Figure 9.1. Receiver operator characteristic (ROC) curves plotted from the three models using the
development dataset: (A) Specificity-based model; (B) Sensitivity-based model; (C) Regression-based
model. The area under the curve is shown under each plot eg 0.7792=77.92%. The cut-off point is the point
at which we make the OSSN vs non-OSSN distinction. Read the curves from the origin of the x and y axis. For
instance in (A) the options are using symblepharon alone, then the next is using symblepharon or fornix, then
symblepharon or fornix or prior excision and so on such that the last point refers to a cut-off point where we
use any one of symblepharon or fornix involvement or prior excision or ART use or severe inflammation or
dark ToB staining. For (B) the cut-off point was papillary/gelatinous surface. For (C) similarly we read it from
the origin and use either all 8 features listed in Table 9.2, or 7 features or 6 features and so forth with the last
option being the use of only 1 feature. The cut off was any 3 of the 8 features listed in Table 9.2.
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(B) Sensitivity-based model
(C) Regression-based model
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Table 9.3. Performance of different diagnostic tools for diagnosing OSSN in the validation dataset and Toluidine blue data and photograph
examination from a previous study.9 11
Diagnostic tool Sensitivity Specificity PV+ PV- Correctly
classified
F+
rate
F-
rate
LR+ LR-
Toluidine blue (any blue) 92% 31% 41% 88% 52% 69% 8% 1.33 0.26
Toluidine blue (dark royal blue) 64% 67% 50% 78% 66% 33% 36% 1.95 0.53
Clinical examination of photographsa 86% 60% 54% 88% 70% 40% 14% 2.15 0.23
Regression based modelb 83% 54% 53% 84% 65% 46% 17% 1.81 0.31
Specificity based modelb 75% 45% 47% 73% 57% 55% 25% 1.38 0.55
Sensitivity based modelb 85% 31% 44% 77% 50% 69% 15% 1.22 0.50
NOTE: Abbreviations; PV means predictive value, F+ means false positive, F- means false negative, LR means likelihood ratio
a This was the median score of 6 examiners looking at lesion photos without vital staining
b This is at the best cut-offs shown in the ROC curves we plotted.
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Figure 9.2. Probability-tree algorithm for determining the probability of OSSN in the specific data set presented in this study. This uses the
features most strongly associated with OSSN added in the order shown in table 9.2. The probability of OSSN at each level is shown in the circles.
NOTE: + means present and - means absent. To illustrate the use this algorithm, we first ask whether there is history of prior excision of the present lesion or not. If present, the
probability of OSSN is 70% and if not it is 30%. Next we determine the presence of corneal involvement. If the patient had prior excision and the cornea is involved the risk of OSSN is
77%. We can further determine the presence of feeder vessels in this patient. If present, the risk of OSSN increases to 95%.
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Supplementary Table: All the features evaluated for inclusion in the algorithm.
Clinical feature Sensitivity Specificity LR(+)
History
Age group 4.3% 98.7% 3.35
Female gender 66.2% 33.5% 1.00
Any formal education 89.9% 2.6% 0.92
Outdoor occupation 65.0% 43.0% 1.14
History of any smoking 30.2% 74.0% 1.16
Current smoking 14.5% 90.4% 1.52
Ocular pain 10.8% 86.7% 0.81
Ocular redness 5.8% 94.4% 1.03
Prior lesion excision 20.1% 94.8% 3.91
Allergic conjunctivitis history 0.7% 97.9% 0.34
HIV infection 80.2% 7.4% 0.87
ART 41.4% 86.6% 3.09
Clinical Examination
Inflammation (any) 89.1% 23.2% 1.16
Inflammation (mod/severe) 36.5% 84.5% 2.36
Leukoplakia 69.9% 50.0% 1.40
Erythroplakia 15.3% 84.1% 0.97
Pigment 51.8% 57.8% 1.23
Papilliform/ gelatinous surface 92.0% 25.1% 1.23
Feeder vessels 91.2% 35.9% 1.42
Corneal involvement 67.2% 58.6% 1.62
Symblepharon 2.9% 99.1% 3.38
Fornix involvement 6.5% 98.3% 3.76
ToB stain (any blue) 90.8% 30.8% 1.31
ToB stain (dark royal blue) 66.1% 65.9% 1.94
NOTE: Abbreviations; LR(+) likelihood ratio of a positive test; ToB- toluidine blue; ART- antiretroviral therapy
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Supplementary Figure: Receiver operator characteristic (ROC) curves plotted from the three
models using the validation dataset: (A) Specificity-based model; (B) Sensitivity-based
model; (C) Regression-based model.
LEGEND: The area under the curve is shown under each plot eg 0.7792=77.92%. The cut-off point is the point at which
we make the OSSN vs non-OSSN distinction. Read the curves from the origin of the x and y axis. For instance in A) the
options are using symblepharon alone, then the next is using symblepharon or fornix, then symblepharon or fornix or prior
excision and so on such that the last point refers to a cut-off point where we use any one of symblepharon or fornix
involvement or prior excision or ART use or severe inflammation or dark ToB staining.
For (B) the cut-off point was papillary/gelatinous surface
For (C) similarly we read it from the origin and use either all 8 features listed in table 9.2 or 7 or 5 and so forth with the
last option being the use of only 1 feature. it was any 3 of the 8 features listed in table 9.2.
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(C) Regression-based model
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ABSTRACT
Introduction
In East Africa, ocular surface squamous neoplasia (OSSN) is a relatively common aggressive
disease affecting younger adults and more women than in other parts of the world. Studies
have implicated HIV, human papilloma virus (HPV) and solar radiation as risk factors. The aim
of this study was to determine modifiable risk factors of OSSN in Kenya using disease-free
controls.
Methods
Adults with conjunctival lesions were recruited at four eye care centres in Kenya and excision
biopsy performed. An equal number of controls having surgery for conditions not affecting the
conjunctiva and unrelated to ultraviolet light were group-matched to cases by age group, sex
and eye care centre. Associations of risk factors with OSSN were evaluated using
multivariable logistic regression to estimate odds ratios (ORs) and 95% confidence intervals
(95%CI). Continuous variables were compared using the t-test or the Wilcoxon-Mann-Whitney
U test depending on their distribution.
Results
A total of 131 cases and 131 controls were recruited. About two-thirds of participants were
female and the mean age of cases and controls was 42.1 years and 43.3 years respectively.
Risk factors for OSSN were HIV infection without antiretroviral therapy (ART) use (OR=48.30;
95%CI 7.53-309.90) and with ART use (OR=19.02; 95%CI 6.55-55.26), longer duration of
exposure to the sun in the main occupation (6.9 hrs/day vs 4.6 hrs/day, OR=1.23; 95%CI 1.08-
1.39) and a history of allergic conjunctivitis (OR=80.20; 95%CI 8.62-746.29). Wearing hats
was protective (OR=0.21; 95%CI 0.07-0.63).
Discussion
Measures to prevent and control HIV, prevent sun exposure such as wearing hats, and control
allergic conjunctivitis are recommended.
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Background
Ocular surface squamous neoplasia (OSSN) is a spectrum of disease in the conjunctiva and
cornea that ranges from intraepithelial neoplasia to invasive squamous cell carcinoma. It
usually presents as a unilateral tumour on the eye, centred around the corneal limbus (the
junction between the cornea and conjunctiva).1
The epidemiology, aetiology and pathophysiology of OSSN are not well understood. There
appears to be two disease patterns: a milder form in temperate climates and a more
aggressive one in sub-Saharan Africa (SSA). In SSA both males and females have equal
incidence rates, although in prevalence series females constitute 60-70%, in contrast to other
regions where males predominate.2,3 It is unclear why the prevalence is not 1:1 in African
series. The presentation of OSSN in SSA also is relatively more aggressive, with a short
history of 3 to 8 months compared to one year in temperate climates4-7, and younger age of
onset (30-40 years in SSA compared with 60-70 years in temperate climates).2,3,8 Current
evidence suggests that multiple factors may combine to drive the disease process. Case-
control studies and cancer registry data implicate ambient solar ultraviolet radiation (UVR)
among other factors. The risk of OSSN is higher in those who spend more time outdoors and
the incidence worldwide varies with latitude peaking at 16° South, particularly in the sunny
areas of Eastern and Southern Africa, and also Australia.2,9-11 This may be related to the
Earth’s 23° tilt and elliptical orbit which brings it closer to the sun during the southern summers
(perihelion) than during the northern summer (aphelion).12 The TP-53 gene mutation, which is
associated with UV radiation, has been found more frequently in OSSN tissue.11,13
There is a strong association between OSSN and HIV in SSA, and incidence rose sharply with
the onset of the HIV pandemic.14 However, about 30% of people with OSSN in SSA are not
infected with HIV, suggesting that other factors also contribute.2 The association between
human papilloma virus (HPV) and OSSN is inconclusive.15-20 This is probably because of
variations in methodology and the specific HPV types that have been looked for.2
The importance of vitamin A in maintaining the health of the ocular surface is established and
its deficiency leads to goblet cell loss, desquamation and keratinization of the ocular surface.21
Vitamin A deficiency (serum retinol <30 µg/dL or <1.05 µmol/L) is common in HIV patients.22
The potential role of vitamin A deficiency in OSSN has not previously been investigated.
Cigarette smoking although associated with many cancers has not been conclusively shown
to be associated with OSSN.2
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To date, case-control studies investigating risk factors for OSSN have enrolled individuals with
conjunctival lesions suspected to be OSSN, which were excised and sent for histopathology.
Individuals with OSSN were classified as “cases” and those with benign lesions as
“controls”.6,11,13,23 However, these are probably not appropriate controls, as benign conjunctival
lesions may have some risk factors in common with OSSN. For example, pterygia, actinic
keratosis and papillomas, the most common benign lesions, may also be associated with solar
UV radiation, p53 gene mutation, and human papillomavirus infection.24-27
The aim of this study was to investigate the role of multiple risk factors (HIV infection, vitamin
A, cigarette smoking, ultraviolet light exposure and occupation), which are preventable or
modifiable, by comparing OSSN cases to disease-free controls presenting at four eye care
centres in Kenya.
Methods
Ethical Approval
This study was approved by the Kenyatta National Hospital – University of Nairobi Ethics and
Research Committee and the London School of Hygiene & Tropical Medicine Ethics
Committee. All participants gave informed written consent to take part. It adhered to the tenets
of the Declaration of Helsinki.
Study design
A frequency matched case-control study design was used, with a 1:1 case to control ratio.
Matching was by age (10-year age groups) and sex, as both are strong constitutional factors
associated with OSSN. Cases of OSSN (subsequently confirmed by histology to have OSSN)
were compared with controls who had no conjunctival lesion, attending for routine ophthalmic
surgery that involved incision of the conjunctiva. Controls were recruited at the same
ophthalmic clinics after cases were enrolled.
Study setting
Cases were recruited between July 2012 and July 2014 while controls were enrolled between
January 2014 and May 2015 in four eye care centres in Kenya namely; Kenyatta National
Hospital (KNH) Eye Clinic, Nairobi; PCEA Kikuyu Eye Unit (KEU), Kikuyu near Nairobi;
Sabatia Eye Hospital (SEH), Vihiga about 350 kilometres north-west of Nairobi near Lake
Victoria; and Kitale District Hospital (KDH) in the North Rift Valley. These are busy eye units
that receive referrals from surrounding areas (Table 10.1).
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Study population, inclusion & exclusion criteria
Both cases and controls were recruited from people attending the eye clinic. Adult patients
(aged >18 years) with any histologically confirmed OSSN tumour (first presentation or
recurrence) were included as cases. Controls were adult patients scheduled for ocular surgery
that involved a conjunctival incision for a disease not involving the conjunctiva and unrelated
to ultraviolet light. History of prior surgery in the index eye was an exclusion criterion for
controls. Eligible participants who gave written informed consent to participate were enrolled.
Demographic and Occupational Data
Data on age, sex, marital status and educational history were collected. Questions included:
residential history (regions lived in for >1 year), lifetime occupational history (including whether
based mainly indoors or outdoors), hours of sun exposure on an average day, patterns of
wearing hats, caps or sunglasses, and cigarette smoking history. Participants with regular
partners who smoked cigarettes were classified as passive smokers.
Clinical examination
For potential cases (participants with conjunctival lesions) a detailed clinical and slit lamp
examination was performed, to document clinical features of the tumours. High-resolution
digital photographs were taken. For potential controls the ocular surface was examined at the
slit lamp before surgery to exclude any conjunctival lesions.
Surgical excision & histopathology
All lesions were excised under local infiltration anaesthetic using an operating microscope with
a 3mm clear margin. Specimens were placed directly into buffered formalin and subsequently
examined at the histopathology laboratory at the MP Shah Hospital, Nairobi. All the histology
slides were stained with haematoxylin and eosin and examined by one pathologist (TO). For
controls a 2mm by 2mm piece of conjunctiva was excised and immediately placed in RNALater
tissue collection RNA stabilization solution (Ambion Inc, Austin, Texas, USA) for further
molecular studies.
HIV / CD4 Count Assays
Individuals with a confirmed diagnosis of OSSN were tested for HIV and CD4 cell count four
weeks after the surgery when they returned for results. Controls were tested for HIV and CD4
at the time of surgery. Pre-test counselling was provided individually to all participants by a
counsellor. Venous whole blood was tested at the Kenya Aids Vaccine Institute (KAVI) for
Clinical Research laboratory at the University of Nairobi for HIV initially using Vironostika
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antigen/antibody kit (Biomerieux, Marcy l'Etoile, France) then later the Alere Determine HIV-
1/2 Ag/Ab (Alere, CITY, USA) and Trinity Unigold (Trinity Biotech, Jamestown, USA) when
Vironostika became unavailable. CD4 count was measured using FacsCount (Becton
Dickinson, Franklin Lakes, USA). Samples from Sabatia Eye Hospital and Kitale District
Hospital were tested for HIV using Alere Determine HIV-1/2 Ag/Ab (Alere, CITY, USA) and for
CD4 count using FacsCount (Becton Dickinson, Franklin Lakes, USA). We also asked about
antiretroviral (ART) use.
Serum vitamin A assays
Blood samples collected without EDTA were immediately wrapped in aluminium foil to prevent
degradation from light. They were transported to the KAVI laboratory in a cool box within an
hour from nearby centres (KNH and KEU) or couriered on ice packs from more distant centres
(SEH and KDH). On arrival samples were immediately centrifuged at 2500 revolutions per
minute for 10 minutes in a dimly lit room, aliquoted into cryovials, labelled, re-wrapped in
aluminium foil and stored in a freezer at -800C. Samples were batched and shipped on dry ice
to the Tropical Diseases Research Centre’s Nutrition Unit in Ndola, Zambia. Retinol was
quantified using high performance liquid chromatography.28 The quantitation of retinol was
done using the SHIMADZU Prominence HCT2010 HPLC (Kyoto, Japan). Individuals with
serum retinol <30µg/dl were considered vitamin A deficient.
Sample size determination
This case-control study was nested within a randomised controlled trial of post-operative 5-
fluorouracil eye drops to reduce recurrent OSSN. The sample size of 131 cases and 131
controls provides 90% power to detect a difference in prevalence of a given exposure of 40%
in controls and 60% in cases.
Statistical Analysis
Data were managed in an Access database (Microsoft), cleaned and transferred into STATA
version 12.1 (StataCorp, College Station, Texas, USA) for analysis. In this analysis we
compared the cases and controls for the proportions with HIV/ART status, vitamin A
deficiency, cigarette smoking and for levels of UV radiation exposure. We also compared
cases and controls for the mean or median for CD4 count, number of cigarettes smoked daily
and serum retinol levels. CD4 counts were graded by the WHO criteria.29 All analyses were
adjusted for age, sex and study centre. Multivariable logistic regression analysis was used to
estimate odds ratios (ORs) and 95% confidence intervals (CIs). The likelihood ratio test was
used to assess statistical significance of associations. Variables that were associated with the
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outcome on univariable analyses at a level of p<0.05 were included in the multivariable
analysis and then those with p<0.2 were retained in the model.
Results
Five potential cases and six potential controls declined to participate. Two hundred and sixty-
two participants were recruited: 131 cases and 131 controls frequency-matched by age group,
sex and centre. About two-thirds were females (72% of cases and 65% of controls, p=0.23).
The mean age and standard deviation (SD) of cases and controls were 42.1 years (SD=13.1)
and 43.3 years (SD=13.2), respectively (p=0.43). The controls all had surgery for conditions
without primary conjunctival pathology: lacerations (n=41), traumatic cataract (n=39), vitreous
haemorrhage (n=29), retinal detachment (n=18) and squint surgery (n=4).
After adjusting for the matching variables, OSSN was significantly associated with lower
education level (OR=4.24, 95%CI 1.33-13.53 for no education vs more than secondary),
history of allergic conjunctivitis (OR=30.8, 95%CI 4.05-233) and outdoor occupations
(OR=1.73, 95%CI 1.03-2.91; Table 10.2). There was a strong association with HIV infection
(OR=19.0, 95%CI 8.87-40.5) and lower CD4 count (OR=38.16, 95%CI 8.15-178.7 for CD4
<200 cells/mm3 compared with CD4>500 cells/mm3). Participants living with HIV but not on
ART were at the greatest risk (OR=39.4, 95%CI 8.35-185) compared with HIV non-infected
participants, Table 10.2.
Independent risk factors for OSSN are shown in Table 10.3. Participants were who HIV
positive and not on ART were at the greatest risk (adjusted OR=48.30, 95%CI 7.53-309.9
compared with HIV negative participants), and there was also a very strong association with
history of allergic conjunctivitis (adjusted OR=80.20, 95%CI 8.62-746.29). The duration of
exposure to the sun per day in their occupations was higher among cases than controls (6.9
hours/day vs 4.6 hours/day, p<0.001). There was also a strong independent protective effect
of wearing a hat or cap outdoors (OR=0.21, 95%CI 0.07-0.63).
Discussion
OSSN appears to be a disease driven by multiple risk factors. In this study we set out to
examine several of these in a large case-control study in Kenya nested within a randomised
controlled trial, and confirmed established risk factors such as exposure to ultraviolet radiation
and HIV-infection and some potential new ones such as allergic conjunctivitis.
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This study design has several strengths compared with previous case-control studies. Most
notably, previous studies have used controls with benign lesions which are on the causal
pathway for OSSN, and this is likely to under-estimate the magnitude of their effects. For
example, HIV is an established risk factor for OSSN, but we found a much stronger association
of HIV and OSSN than previously reported in a meta-analysis of six case-control studies in
East and Southern Africa (summary OR=6.17; 95%CI: 4.83-7.89).2 Five of those studies were
conducted in the era before ART programs were available or scaled up in the region while one
was conducted in 2010 when ART was available in Ugandan public hospitals and did not
report on ART use.30 HIV is also associated with more severe OSSN disease. A study in India
that compared HIV infected OSSN patients with HIV negative OSSN patients found that HIV
infection was associated with larger tumours and a higher incidence of extension to the
cornea, sclera and orbit but there was no data reporting ART use.31 Although we had CD4
data on only 59 cases and 76 controls, it was intriguing that CD4 count was not a significant
risk factor after multivariable adjustment. There may have been confounding with ART as
those with low CD4 counts would be started on treatment and their CD4 count would
subsequently rise. We observed that those on ART had higher mean CD4 counts than those
who were not. (see footnote table 10.3). There was also was an overlap in the confidence
intervals between HIV infected people on ART and not on ART suggesting that ART did not
seem to significantly change the effect of HIV infection on OSSN. This is further supported by
the observation that OSSN is still common in Africa despite availability of ART programs for
over a decade. Perhaps the effect of HIV on OSSN may not be through CD4 counts but rather
a yet to be understood pathway. HIV-associated premature ageing may play a role in the
aetiology as advancing age increases cancer risk.32
Another aspect of our study design is that we enrolled controls after cases had been recruited.
There may be systematic differences between incident and prevalent OSSN cases which are
difficult to identify in previous case-control studies that enrolled cases and controls
concurrently.
Our study also focused on modifiable risk factors in order to identify strategies for prevention.
We found a similar effect for duration of solar ultraviolet exposure outdoors to a study in
Uganda (adjusted OR=1.7; 95% CI: 1.2-2.4 for cases exposed to 2-4 hours and OR=1.8; 95%
CI: 1.1 - 3.1 for those exposed to ≥5 hours daily).11 The association between OSSN and UV
radiation has been shown by results from cancer registries and the previously mentioned case-
control study in Uganda.2,11,33 The latter had two types of controls per case; patients attending
the eye clinic for reasons other than OSSN, and patients originally recruited as cases but
whose histology was non-OSSN.11 UV radiation affects the nasal limbus more than other parts
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of the eye which explains why there is a higher proportion of both benign and malignant
conjunctival lesions nasally than temporally.2,34,35 Although cases had worked for a shorter
period at their current occupations (10 years vs 15 years, p=0.04), they were more likely to
have outdoor occupations than controls (65% vs 50%) and had longer daily exposure to the
sun at work (p<0.001). The association we observed between less education and OSSN could
have been due to those less educated people (particularly less than secondary school level)
having jobs with greater sun exposure (means range from 6.5 – 8.4 hours/day) than controls
(4.6 hours/day) but it persisted on adjustment suggesting residual confounding or an
independent effect. The observed protective effect of wearing of hats while outdoors is
consistent with UV radiation being a risk factor of OSSN. The earlier Uganda study did not
find hats protective (OR=1.3; 95%CI 0.8 - 2.2).11 We did not find sunglasses protective similar
to the same Uganda study.
We found a relatively high prevalence of history of allergic conjunctivitis among cases (21.5%)
which contrasts with previous studies. The aforementioned case-control study in Uganda
reported no OSSN cases with allergic conjunctivitis, and a descriptive study in Tanzania found
a prevalence of 1.9%.11,36 The Uganda study examined for allergy in the nasal quadrant of the
conjunctiva but they were unlikely to find allergy in adults in their 30s and 40s as typically the
onset is in childhood and is rare after the age of 30 years. Allergic conjunctivitis is common in
Africa. Studies in Ghana and Nigeria found allergic conjunctivitis in up to 40% of school
children and 33% of University students respectively.37,38 The disease also tends to be quite
severe with limbal hypertrophy as shown in a Rwandan study where 98% of school children
with vernal keratoconjunctivitis (VKC) had limbal disease.39 Though not fully understood,
limbal stem cells may be the progenitors in the pathophysiology of OSSN.40 It is unclear
whether allergic conjunctivitis or its treatment with steroids is the cause per se. One hypothesis
may be that chronic allergic conjunctivitis is associated with a milieu of inflammation mediators
which increases the probability of DNA errors during mitosis of stem cells at the limbus. Using
corneal confocal microscopy, a study found that patients with VKC had more cells with a high
nuclear to cytoplasm ratio (26.4% vs 7.5%), more activated cells (59% vs 10%) and
inflammatory cells (75.4% vs 0) compared to controls.41 On the contrary the other hypothesis
may be that prolonged steroid use causes immunosuppression (like HIV might) which
predisposes to OSSN.
This study had various weaknesses. Selection bias may be present if potential controls with a
less serious disease than OSSN were not inclined to participate. The refusal rates were
however not different for cases at 5/273 (1.8%) and 6/273 (2.2%) for controls. Recall bias
could not be ruled out as cases are more likely to remember about exposures more than
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controls. We had considerable missing data on HIV, CD4 count and vitamin A as not all
excised cases returned post operatively for testing. The classification of occupations is not
ideal. We would have preferred one that classifies occupations by possible exposure to
carcinogens. Existing systems such as Kenya National Occupational Classification System
(KNOCS) which is derived from the International Standard Classification of Occupations
(ISCO) are designed for economic purposes not epidemiological studies.42
In conclusion we identified modifiable risk factors. HIV control interventions are now available,
exposure to UV radiation can be reduced and indeed we found that wearing of hats was
protective, while allergic conjunctivitis can be treated more aggressively in younger people. In
addition, the results of this study corroborate what is known about the pathophysiology of
OSSN where the limbus stem cells appear to be the main focus of disease. However, the
latency period between first exposure to these risk factors and causation of OSSN is still not
known. The role of CD4 count in OSSN still remains to be elucidated and why OSSN usually
affects one eye is still an enigma. Measures to control HIV, prevent sun exposure such as
wearing hats, and control allergic conjunctivitis are recommended.
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Table 10.1 Study Centres and the 2013 HIV prevalence in their catchment
areas42
Study centre Countyb HIV prevalence (%)
Kenyatta National Referral Hospital a Nairobi 8.0
Machakos 5.0
Kajiado 4.4
PCEA Kikuyu Hospital Kiambu 3.8
Muranga 5.2
Nyeri 4.3
Embu 3.7
Kirinyaga 3.3
Sabatia Eye Hospital Vihiga 3.8
Kakamega 5.9
Bungoma 3.2
Kisumu 19.3
Homa Bay 25.7
Siaya 23.7
Migori 14.7
Kitale District Hospital Trans Nzoia 5.1
Turkana 7.6
West Pokot 2.8
Note: The prevalence data refers to adults of age 15 - 49 years. The national prevalence was 6.0%.
a The national referral hospital receives patients from further afield including counties that may be
listed under other study centres.
b the first county listed is where the study centre is located.
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Table 10.2 Univariable analysis of potential risk factors for ocular surface squamous neoplasia. This analysis is adjusted
for age group, sex and study centre.
Exposure Cases
(N=131)
Controls
(N=131)
Crude OR (95% CI) P value
Marital status, No. (%) 0.12
Single 22 (16.8) 26 (19.9) 1 [Reference]
Married 83 (63.4) 89 (67.9) 1.12 (0.56 - 2.26)
Divorced or Separated 8 (6.1) 6 (4.6) 1.55 (0.45 - 5.31)
Widowed 18 (13.7) 10 (7.6) 1.88 (0.67 - 5.30)
Highest education level, No. (%) 0.01
More than secondary 13 (9.9) 33 (25.2) 1 [Reference]
Completed secondary school 33 (25.2) 35 (26.7) 2.26 (1.01 - 5.06)
Some secondary school 12 (9.2) 14 (10.7) 2.00 (0.72 - 5.51)
Completed primary school 41 (31.3) 25 (19.1) 3.55 (1.55 - 8.12)
Some primary school 19 (14.5) 17 (13.0) 2.43 (0.94 - 6.30)
None 13 (9.9) 7 (5.3) 4.24 (1.33 - 13.53)
Residential area (Province) 0.15
Central 27 (20.6) 34 (26.0) 1 [Reference]
Coast 1 (0.8) 1 (0.8) 1.25 (0.07 - 21.10)
Eastern 13 (9.9) 9 (6.9) 1.81 (0.67 - 4.87)
Nairobi 28 (21.4) 42 (32.1) 0.83 (0.41 - 1.70)
North-Eastern 2 (1.5) 0 -
Nyanza 14 (10.7) 7 (5.3) 1.79 (0.59 - 5.41)
Rift Valley 36 (27.5) 28 (21.4) 0.97 (0.39 - 2.41)
Western 10 (7.6) 10 (7.6) 0.75 (0.23 - 2.41)
Duration of residence in home province,
median (IQR),y
24 (10 - 39) 28 (14 - 40) - 0.33a
History of allergic conjunctivitis b 28 (21.5) 1 (0.9) 30.78 (4.05 - 233.75) <0.001
Location of current occupation, No. (%)b 0.01
Indoor 45 (34.9) 62 (48.1) 1 [Reference]
Outdoor 84 (65.1) 67 (51.9) 1.73 (1.03 - 2.91)
Duration in current occupation, median
(IQR),y
10 (5 - 20) 15 (7 - 23) - 0.04 a
Sun exposure per day in current occupation,
mean (SD), h
6.9 (3.8) 4.6 (3.2) 1.22 (1.12 - 1.32) <0.001c
Hat or cap worn outdoors, No. (%)b 19 (15.0) 32 (24.8) 0.60 (0.30 - 1.20) 0.04
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Sunglasses worn outdoors, No. (%)b 10 (7.9) 16 (12.4) 0.66 (0.28 - 1.55) 0.06
Cigarette smoking (past), No. (%)b 0.05
No 93 (71.5) 90 (70.3) 1 [Reference]
Passive (spouse/partner smokes) 17 (13.1) 21 (16.4) 1.10 (0.47 - 2.56)
Yes 20 (15.4) 17 (13.3) 1.12 (0.54 - 2.34)
Cigarette smoking (current), No. (%)b 0.02
No 115 (89.2) 111 (88.1) 1 [Reference]
Passive (spouse/partner smokes) 4 (3.1) 9 (7.1) 0.55 (0.15 - 2.00)
Yes 10 (7.8) 6 (4.8) 1.63 (0.55 - 4.77)
Duration of cigarette smoking, mean (SD), y 13.5 (8.6) 12.7 (10.0) - 0.79 c
No. of cigarettes smoked daily, median
(IQR), y
9 (5 - 20) 7 (5 - 10) - 0.60 a
HIV infection d, No. (%) 62 (74.7) 14 (13.6) 18.96 (8.87 - 40.51) <0.001
HIV infection & ART use e, No. (%) <0.001
HIV- 21 (16.0) 89 (67.9) 1 [Reference]
HIV +/ ART- 17 (13.0) 2 (1.5) 39.37 (8.35 - 185.64)
HIV+ / ART+ 40 (30.5) 12 (9.2) 14.50 (6.42 - 32.74)
No HIV or ART data 53 (40.5) 28 (21.4) 7.22 (3.69 - 14.11)
CD4 count f, median (IQR), cells/mm3 251 (118 - 670) 796 (619 -1063) - <0.001a
CD4 WHO category, No.(%),cells/mm3 <0.001
  ≥500 20 (15.3) 64 (48.9) 1 [Reference]
350 - 499 6 (4.6) 9 (6.9) 2.42 (0.75 - 7.82)
200 - 349 11 (8.4) 1 (0.8) 39.63 (4.73 - 332.14)
<200 22 (16.8) 2 (1.5) 38.16 (8.15 - 178.70)
No CD4 data 72 (55.0) 55 (42.0) 3.87 (2.07 - 7.23)
Vitamin A deficiency (<30 µg/dL) g, No. (%) 5 (8.8) 5 (5.8) 1.25 (0.30 - 5.23) 0.50
Serum retinol, median (IQR), µg/dL 44.9 (37.6 - 56.2) 51.0 (39.7 - 64.7) - 0.03 a
Abbreviations: SD, standard deviation; IQR, interquartile range
a Wilcoxon-Mann-Whitney U test
bThere were missing data on allergic conjunctivitis (24 participants), occupational location (4), hat or sunglasses use (6), cigarette smoking (7)
c t test
d The denominator here is 83 cases and 103 controls who were tested for HIV
e We used the combined HIV/ART variable because the effect of HIV would be related to ART use
f There were 59 cases and 76 controls who had a CD4 test
g The denominator here is 57 cases and 86 controls who had a vitamin A test
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Table 10.3 Multivariable logistic regression analysis for being an OSSN case.
Exposure Adj ORa (95% CI) P value
HIV infection & ART use a <0.001
HIV- 1 [Reference]
HIV +/ ART- 48.30 (7.53 - 309.90)
HIV+ / ART+ 19.02 (6.55 - 55.26)
No HIV or ART data 9.37 (3.76 - 23.34)
History of allergic conjunctivitis 80.20 (8.62 - 746.29) <0.001
Sun exposure in current occupation 1.23 (1.08 - 1.39) 0.001
Hat or cap worn outdoors 0.21 (0.07 - 0.63) 0.01
Highest education level 1.24 (0.95 - 1.63) 0.12
a We used the combined HIV/ART variable because the effect of HIV would be related to ART use.
The mean (SD) CD4 count with respect to HIV and ART was; HIV- was 926(298) cells/mm3; HIV+/ART-
was 258(196) cells/mm3; HIV+ / ART+ was 314(225) cells/mm3; missing HIV/ART data was 136 (101)
cells/mm3.
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Chapter 11. Delay along the care-seeking
pathway of patients with ocular surface
squamous neoplasia in Kenya
195
RESEARCH PAPER COVER SHEET
PLEASE NOTE THAT A COVER SHEET MUST BE COMPLETED FOR EACH RESEARCH PAPER INCLUDED
IN A THESIS.
SECTION A – Student Details
Student
Principal Supervisor
Thesis Title
If the Research Paper has previously been published please complete Section B, if not please move to
Section C
SECTION B – Paper already published
Where was the work published?
When was the work published?
If the work was published prior to
registration for your research degree,
give a brief rationale for its inclusion
Have you retained the copyright for the
work?* Choose an item.
Was the work subject to
academic peer review?
Choose an
item.
*If yes, please attach evidence of retention. If no, or if the work is being included in its published format, please
attach evidence of permission from the copyright holder (publisher or other author) to include this work.
SECTION C – Prepared for publication, but not yet published
Where is the work intended to be
published?
Please list the paper’s authors in the
intended authorship order:
Stage of publication Not yet submitted
SECTION D – Multi-authored work
For multi-authored work, give full details of your role in
the research included in the paper and in the preparation
of the paper. (Attach a further sheet if necessary)
Student Signature: Date:
Supervisor Signature: Date:
196
Delay along the care-seeking journey of patients with ocular surface
squamous neoplasia in Kenya
Authors:
Stephen Gichuhi MBChB, M.Med 1, 2, Joy Kabiru MBChB, M.Med 3, Alain M’bongo Zindamoyen
MBChB, M.Med 3, Hilary Rono MBChB, M.Med 4, Ernest Ollando MBChB, M.Med 5, Joseph Wachira
MBChB, M.Med 6, Rhoda Munene MBChB, M.Med 6, Timothy Onyuma MBChB, M.Med 7, Mandeep S.
Sagoo PhD, FRCOphth 8, 9, 10, David Macleod MSc1,11, Helen A. Weiss MSc, PhD1,11 and Matthew J.
Burton PhD, FRCOphth1, 9
Affiliations:
1International Centre for Eye Health, London School of Hygiene and Tropical Medicine, Keppel Street,
London, WC1E 7HT, UK
2Department of Ophthalmology, University of Nairobi, P.O Box 19676-00202, Nairobi, Kenya 3PCEA
Kikuyu Eye Unit, PO Box 45, Kikuyu, Kenya
4Kitale District Hospital, PO Box 98-30200, Kitale, Kenya
5Sabatia Eye Hospital, PO Box 214-50311, Wodanga, Kenya
6Kenyatta National Hospital, PO Box 20723-00202, Nairobi, Kenya
7MP Shah Hospital, Department of Pathology, PO Box 14497-00800, Nairobi, Kenya
8UCL Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL, UK
9Moorfields Eye Hospital, 162 City Road, London, EC1V 2PD, UK
10St. Bartholomew’s Hospital, W Smithfield, London EC1A 7BE, London, UK
11 MRC Tropical Epidemiology Group, London School of Hygiene and Tropical Medicine, Keppel
Street, London, WC1E 7HT,
Corresponding Author:
Stephen Gichuhi
International Centre for Eye Health
London School of Hygiene & Tropical Medicine
Keppel Street, London WC1E 7HT
United Kingdom
Tel. +44 (20) 7636 8636 ext. 8257
stephen.gichuhi@lshtm.ac.uk
Email contacts
Stephen Gichuhi, Stephen.Gichuhi@lshtm.ac.uk
Joy Kabiru, joykabiru@yahoo.com
Alain M’bongo Zindamoyen, zindamoyen@yahoo.com
Hilary Rono, hkrono@yahoo.com
Ernest Ollando, eollando@yahoo.com
Joseph Wachira, drjwachira@gmail.com
Rhoda Munene, drmmunene@gmail.com
Timothy Onyuma, tonyuma@mpshahhosp.org
Mandeep S. Sagoo, mandeep.sagoo@moorfields.nhs.uk
David Macleod david.macleod@lshtm.ac.uk
Helen A. Weiss, helen.weiss@lshtm.ac.uk
Matthew J. Burton, matthew.burton@lshtm.ac.uk
Financial support
SG received funding from the British Council for Prevention of Blindness (BCPB) fellowship programme.
MJB is supported by The Wellcome Trust (Grant Number 098481/Z/12/Z). HAW and DM are supported
by the MRC and DFID (Grant Number G0700837). The funding organizations had no role in the design
or conduct of this research.
Conflict of interest
None of the authors have any proprietary interests or conflicts of interest related to this submission.
This submission has not been published anywhere previously and is not simultaneously being
considered for any other publication.
197
Running head
Delayed care for ocular surface squamous neoplasia - Kenya
Word count: Abstract 249; Text 3554
198
ABSTRACT
Purpose
To assess referral pathway and treatment delay for patients with ocular surface squamous
neoplasia (OSSN) in Kenya.
Methods
Adults with conjunctival lesions presenting to four eye centres were asked about their
occupations, when they noticed the growth, health facilities visited in seeking care, cost of
consultation, surgery, medicines and histopathology and dates at each step. The time-to-
presentation was divided into quartiles and correlates analysed using ordinal logistic
regression.
Results
We evaluated 158 first-time presenters with OSSN. Most were women (102 [65%]), living with
HIV (78/110 tested [71%]), with low to medium income (127 [80%]). Most of the HIV patients
(49/78 [63%]) were in antiretroviral care programs. About half (88/158, [56%]) presented
directly to the study centres while the rest were referred. Indirect presenters sought care earlier
than direct presenters (median 2.0 months vs 5.5 months) and travelled a shorter distance to
the first health facility (median 20km vs 30km) but had surgery later (median 12.5 months vs
5.5 months). Visits beyond the first health facility for indirect presenters markedly increased
delay (median 7.3, 29.0, 37.9, and 32.0 months for 1-4 facilities, respectively). Delay was
associated with number of health facilities visited (adjusted ordered OR=9.12; 95%CI 2.83-
29.4, p<0.001) and being female (adjusted ordered OR=2.42; 95%CI 1.32-4.44, p=0.004).
Conclusions
Referral delays definitive treatment for OSSN. Women were more likely to experience delay.
Despite regular contact with the health system for those with known HIV infection, delays
occurred. Early detection and referral of OSSN in the HIV service, might reduce delays.
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INTRODUCTION
Ocular surface squamous neoplasia (OSSN) usually presents as a defined lesion of the
conjunctiva and/or cornea. In temperate countries it presents as a rare, slow-growing tumour
mostly affecting elderly men. In contrast, in sub-Saharan Africa (SSA) OSSN is more common
than in other global regions (1.38 and 1.18 cases/100000/year in males and females
respectively in Africa vs 0.18 and 0.08 cases/100,000/year in males and females respectively
worldwide). It is also more aggressive in SSA, predominantly affects people living with HIV
(PLWH), and occurs with similar frequency in men and women.1, 2 A study from Kenya found
that people with no formal education were at higher risk of OSSN and presented with larger
tumours than more educated individuals.3 Late presentation with large tumours and orbital
spread is not uncommon in Africa.4-6 Surgery is the mainstay of treatment and if it is provided
in a timely manner, outcomes can be very good with very low recurrence rates.7
The Kenya health care referral system is organized into six levels.8 The first level comprises
community units run by community health workers. Services here focus on health promotion
and treatment of minor ailments. Dispensaries form the second level. The third level comprises
health centres with basic outpatient care, minor surgical services, basic laboratory services,
maternity care, and limited inpatient facilities. They also coordinate the community units under
their jurisdiction. Levels 4 and 5 are secondary-care hospitals providing curative services, and
some training centres. Level 6 are tertiary referral facilities that offer specialised care and
training to health workers. There are also a number of private and mission hospitals.
In Africa, accessing eye health services is a major challenge. A study in the Kibera slums and
Dagoretti area of Nairobi found that the main barriers to utilization of eye health services were
a lack of a perceived need for treatment (49% of respondents), lack of money (33% of
respondents), while a small proportion (8%) did not know where to obtain help.9 A study from
Tanzania found that for eye trauma cases an injury at the weekend, use of topical treatment,
and visiting other facilities were independently associated with delay of more than 24 hours in
accessing specialist eye care. Circular journeys were common where patients repeatedly
visited health facilities that were unable to treat the injury.10
Cancer is a growing problem in Africa. The age-standardised incidence rates for most cancers
increased by more than 10% in most African countries between 1990 and 2013.11 A literature
review of current cancer prevention approaches revealed that the major impediments to good
care include a lack of awareness, limited human and financial resources, limited vaccine use
(with regard to human papilloma virus), inadequacy of cancer registries, fear, cultural reasons
(such as examination by doctors of the opposite sex) and competing health demands.12 A
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study from Rwanda examined health system delays in breast cancer presentation and
diagnosis of more than 6 months and found that low levels of education and consulting a
traditional healer before a nurse or doctor were the main predictors of delay after adjusting for
sociodemographic and clinical characteristics.13 Visiting 5 or more health facilities before the
diagnosis was associated with even longer delay in that study. The experiences of breast
cancer, Kaposi’s sarcoma and lymphoma patients in the only oncology centre in Cameroon
show that 35% of patients waited >6 months after the first sign of disease before presenting
to the health system, while diagnosis was made >3 months after presentation in 47% of
cases.14 In the Cameroon study the total delay between first sign of cancer and a correct
diagnosis was >6 months for 63% of patients. There are few data on access to eye cancer
services. This study was conducted to describe the presentation and referral “journey” that
OSSN patients travel in Kenya, describing the time spent, identifying the points of delay and
determining the factors associated with delay.
MATERIALS AND METHODS
This study was conducted in Kenya between July 2012 and July 2014. We used Ministry of
Health records to identify four eye centres that performed the highest number of conjunctival
excision biopsies between 2008 and 2011. The centres were Kenyatta National Hospital in
Nairobi, PCEA Kikuyu Eye Unit (25 km from Nairobi in Central Kenya), Kitale district hospital
in the north Rift Valley (490km from Nairobi) and Sabatia Eye Hospital (300km from Nairobi)
in the western highlands bordering Lake Victoria. These centres receive referrals from
surrounding health facilities.
The study was approved by the Kenyatta National Hospital – University of Nairobi Ethics and
Research Committee and the London School of Hygiene and Tropical Medicine Ethics
Committee. It adhered to the tenets of the Declaration of Helsinki. All participants gave
informed written consent to take part in the study before enrolment.
We prospectively recruited consecutive adult patients (≥18 years) presenting to the four 
centres with any conjunctival lesion (first presentation or recurrence) suspected to be OSSN
and scheduled for surgical excision. A detailed history was taken using a structured
questionnaire before surgery. Participants were asked when they had first noticed the ocular
lesion. To document the referral route taken prior to presentation, participants were asked to
list the health facilities they had visited, their location, dates visited, advice given and total cost
of clinical care to the patient (consultation, tests, surgery and medications). The first facility
the patient visited was denoted to as Facility 1, the second one visited (either as a result of
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formal referral from the first or self-initiated referral) was denoted Facility 2 and so on. A
comprehensive clinical examination was conducted at the slit lamp, including measurement of
the longest lesion diameter using the slit lamp beam and scale. Participants underwent
surgical excision under local anaesthesia. A histopathologist examined all the tissue
specimens at MP Shah Hospital laboratory, Nairobi. Individuals who had histologically
confirmed OSSN were offered a HIV test; if this was positive they were offered a referral for
care and a CD4 count test. The detailed description of clinical assessment, surgery, tissue
handling and testing have been previously published.3
Treatment “delay” was defined as the time between becoming aware of the lesion and having
surgery. For the purpose of this analysis we only included individuals who had histologically
confirmed OSSN. As recurrence after a prior excision is likely to influence health-seeking
behaviour and the journey followed, we excluded those with recurrent lesions from this
analysis.
Data on the other health facilities visited by patients prior to presentation to one of the four
study centres (location, health system level, ownership etc.) were obtained from the Kenya
Ministry of Health web-based master facility list (http://www.ehealth.or.ke/facilities/) accessed
on 15th November 2015. Information about the availability of ophthalmic surgical facilities (eye
operating theatre) at each of these other health facilities was obtained from the Kenya Ministry
of Health, Department of Ophthalmic Services (DOS). One-way distances travelled by road
from the patients’ home town to the various health facilities and study centres were estimated
using Google Maps following the roads that public vehicles would use.
We compared patients who presented directly to one of the four centres (“direct presenters”)
with those who had visited other health facilities prior to presenting to a study centre (“indirect
presenters”). Characteristics of the two groups were compared using the chi-squared test for
proportions, and the t-test or Mann-Whitney U-test as appropriate for continuous variables.
We traced the care seeking journey to describe the time taken, and the advice given at each
stage. To investigate factors associated with delayed presentation we subdivided the total
time in the range from awareness to surgery into quartiles and created an ordered categorical
outcome variable. Ordinal logistic regression was used to estimate odds ratios (OR) and 95%
confidence intervals (95%CI).
The likelihood ratio test was used to assess which factors from the univariable analysis would
be included in the multivariable regression model. Variables that were associated with delay
at a level of p<0.1 in the univariable model were included in an initial multivariable model. The
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final multivariable model included variables which were independently associated with the
outcome (p<0.05). All statistical analyses were performed using Stata version 12.1
(StataCorp, College Station, Texas, USA).
RESULTS
500 individuals with conjunctival lesions enrolled in this study and underwent surgical excision.
Of these, 191 (38.2%) were diagnosed with OSSN by histopathology. Among these, 158
(83%) had new lesions and 33 (17%) had recurrent lesions (at least one prior excision at the
same site).
The care-seeking journey of the 158 patients with new lesions was analysed: 88 (55.7%)
presented directly to study centres and 70 (44.3%) presented indirectly via one or more other
health facilities (Figure 11.1). Overall, the mean age was 41.9 years (SD 12.0) and the majority
were females (102 [65%]). Education levels were variable, 125 (79%) had completed primary
school or above, and 67 (42%) had completed secondary school. The majority worked mostly
outdoors (101 [65%]). Most occupations were low or middle income in nature (127 [80%]) and
were predominantly in the agricultural sector. HIV status and CD4 count were obtained for
patients who returned after surgery (110 [70%]. Of these, 78 (71%) were HIV positive, of whom
49 (63%) were already on antiretroviral therapy (ART).
The numbers of individuals taking different routes to the study centres and the time spent
along each stage on the care-seeking journey is illustrated in Figure 11.1. Most indirect
presenters (56, [80%]) visited one other health facility before going to the study centres.
Overall, despite having a shorter time to first presentation, indirect presenters took longer to
receive surgery than direct presenters (5.5 vs 9.6 months, p=0.001). The additional time in
getting from the first health facility to the study centre was largely responsible for this
difference. The longest delay in the whole care pathway occurred when patients went from
the first facility to a second one (median 6.1 months, IQR 3.1-12.2). Referral beyond the first
facility markedly increased delay.
The demographic and clinical characteristics of participants, by type of presentation, are
shown in Table 11.1. There was little evidence of a difference between direct and indirect
presenters by age, marital status, education, occupation or HIV status. There was weak
evidence that indirect presenters were more likely to be female than direct presenters (71%
vs 59%; p=0.11). There was evidence that the main presenting symptom was different
(p=0.03) between the two groups, with pain more common in the direct presenters (17.1% vs
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2.9%). At the time of presentation at the study centres for surgery the median tumour diameter
in both directly and indirectly presenting patients was 6mm (p=0.52) and the histological
spectrum of OSSN was similar between the groups (p=0.87). Kikuyu Eye Unit and Kenyatta
National Hospital had a significantly larger proportion of referrals than the other two study
centres (p<0.001). Direct presenters travelled a longer distance to the first health facility (study
centre) than indirect presenters (median 30km vs 20 km, p=0.003).
The median cost of care was similar in the two groups at 3800 (IQR 3800-4800) Kenyan
Shillings (KSh) for direct presenters and 3880 (IQR 3800-4100) KSh for indirect presenters.
Costs incurred along the indirect route were mainly a subsidised consultation fee charged in
government hospitals as most of the participants studied did not receive surgery there plus
the cost at the study centre. Costs at the study centres (including consultation, surgery, post-
operative medication and histopathology) were: Kikuyu Eye Unit 3800KSh, Kenyatta National
Hospital 4000KSh, Sabatia 4800 KSh and Kitale 3500 Ksh. All histology was done at MP Shah
Hospital to reduce inter-observer variation in the diagnosis. Tissue specimens from Sabatia
and Kitale hospitals were sent to Nairobi for histopathology using a courier service which
added to the costs.
The level of the health facility and the availability of an operating theatre at the place where
patients presenting indirectly first went to are shown in Table 11.2. For 24 patients it was not
possible to determine whether surgical facilities were available, mostly because the patient
could not correctly name the facility. The most common points of entry into the health system
for indirect presenters were at level 5 county referral hospitals (22 [31.4%]) and private clinics
(13 [18.6%]). It is noteworthy that for the majority of facilities an operating theatre was available
(37 [53%]). All four of the study centres have a dedicated ophthalmic operating theatre.
The advice given to indirectly presenting patients at the other facilities is shown in Table 11.3.
At each point patients were referred, advised to re-attend for follow up or advised to have
surgery. It is not clear why some health facilities with operating theatres did not offer surgery.
Regardless of the advice, all patients eventually went to the study centres at various time
points. From the first facility visited, 32 patients were formally referred to a study centre. Of
these, 29 (91%) followed this advice and went directly to a study centre within a median of 2.3
months (IQR 1.2–3.9), while three patients went via other clinics first and reached a study
centre (at 1, 3 and 42 months). Out of the 31 advised to re-attend for follow up, only one
returned to the same facility seven months later and was then referred to one of the study
centres for surgery. The other 30 either self-referred to a study centre (20 [65%]) and received
surgery with a median time of 6.1 months (IQR 3.0–11.9) or to another clinic (10 [32%]). The
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five who were advised to have surgery all went to the study centres within a median (IQR)
duration of 5.6 (2.3 – 11.5) months.
There was a modest linear relationship between duration of symptoms and the lesion size
(Figure 11.2) for direct presenters (p=0.01), but not indirect presenters (p=0.41). For the direct
presenters, those who present later tended to have a larger lesion, with an expected increase
in size of 0.09mm per month (95% CI 0.03-0.16). There is little evidence that the relationship
between symptom duration and tumour size was different in direct and indirect presenters
(p=0.33). Delay was associated with larger tumour size at presentation (OR 1.07, 95%CI 1.01-
1.13, p=0.02). The median (IQR) tumour diameter was 5.6 (4.2-7.0), 5.0 (4.2-7.1), 6.4 (4.2-
11.5) and 7.6 (5.4-10.0) millimetres (mm) in the following delay categories; 0.4-3.2, 3.3-7.0,
7.1-15.6 and 15.7-190.5 months respectively.
Analysis of the predictors of delay is shown in Table 11.4. On multivariable ordered logistic
regression, the number of health facilities visited in the care pathway followed and being
female are associated with increased delay. Participants who followed an indirect path were
twice as likely to be in a higher delay group than those in the direct pathway (adjusted OR=2.3,
95%CI 1.5-3.7; p<0.001). Similarly, females were twice as likely to be in a higher delay group
than males (adjusted OR=2.1; 95% CI 1.15-3.81, p=0.02).
DISCUSSION
This study identified various challenges along the journey to treatment for new patients with
OSSN. Firstly, referral significantly delayed surgery and delay was associated with larger
tumours at the time of surgery. Patients in the indirect route initially presented earlier than
those who went directly to study centres perhaps because it was a shorter distance and the
cost of care was lower. However, surgery was more delayed in the indirect route compared to
the direct (5.5 months vs 9.6 months, p=0.001), particularly if the patients visited more than
one health facility. This correlates well with the finding that the number of facilities visited
before was an important predictor of delay in receiving surgery.
Secondly, we found being female was another important predictor of delay. Gender disparities
in access to health care services have also been identified in East Africa for other ocular
diseases such as eye trauma and cataract with females having relatively more difficulty.10, 15
A study on access to cataract surgery in Tanzania found that some women needed to seek
permission from their husbands before going to hospital or may rather put up with the adversity
of poor eye health for fear of being seen as a burden in the family.15 Women are less likely
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than men to be the financial decision makers with regard to seeking health care. In addition,
they may have other responsibilities to consider before going to hospital such as child care
and home upkeep. Although there is limited information on gender-specific utilization of cancer
services in Africa, particularly for OSSN, we hypothesize that women with household and
child-care responsibilities have more difficulty attending health facilities, particularly if distant
referrals are made.
With respect to the patients reported advice and treatment provided at facilities other than the
four study centres there is an intrinsic limitation in that we do not know how many other (if any)
people had excisions in the other health facilities who never came to one of the study centres.
There is no reporting of this to the central Ministry of Health. However, it would appear that
advising follow up for suspicious lesions needs to be supported by more than just a clinical
impression. At the first health facility level, 20 of 31 patients who were advised to return for
follow up went to the study centres and had surgery within median 6 months (mean 13 months)
and were found to have OSSN (Table 11.3). Only one patient at the first facility took the follow
up advice and by the time of review seven months later was referred for surgery and was
found to have OSSN. While we have no information on how the lesions looked at earlier time
points, they may have appeared either benign or were suspicious of malignancy and
progressed rather rapidly within a few months, underscoring two things, that OSSN in East
Africa is an aggressive disease and that distinguishing OSSN from benign lesions clinically is
challenging as they can look very similar.3
It is still unclear what drives the decision to present to a first health facility once the person
become aware of the tumour. Perhaps it is more the absolute size rather than the rate of
growth or combination of the two. We found only a modest difference in growth rates between
direct and indirect presenters. It is likely that the duration and growth rates will vary. Pain
maybe an important driver of the decision; we found that pain was more common among the
direct presenters (p=0.02).
The majority of participants were living with HIV and were already in contact with HIV care and
treatment programs. Despite this, they still experienced delay. There could be various
explanations for this. Firstly, awareness about OSSN among HIV health workers may be
limited. Secondly, patients on ART may find it particularly challenging to seek care for OSSN.
Over half (44/81 [54%]) the patients on ART had advanced or severe immunosuppression and
thus at high risk for comorbidities such as tuberculosis.16 Thirdly, due to stigma around HIV
they may not feel safe or comfortable in other health facilities. A recent study in rural western
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Kenya found that cervical cancer stigma was highly correlated with HIV stigma (correlation
coefficient 0.72).17
We did not find income or level of formal education a barrier to presentation despite most of
our patients (80%) being in the low to medium income group. The majority worked in farming.
Most employment (83%) nationwide is in the informal sector so it is difficult to know the real
earnings as they are not captured in tax systems.18 In Kenya half of healthcare expenditure
(51.1%) is paid for out-of-pocket.19 The gazetted monthly basic minimum wages for the
agricultural industry during the study period was an average of KSh 5704 in 2012 rising to KSh
6503 in 2013 and remained the same in 2014 which was comparable to the fees charged at
the study centres.20 However the opportunity cost of lost income during the care-seeking
period for the patient and other adults involved in supporting this care could not be estimated.
A study in Kenya found that households spend over 10% of their annual income on healthcare
payments with the poor spending more than 33%.21 The mean annual total spending per
household (both inpatient and outpatient) was KSh 16,000 (£114) in urban areas and KSh
5600 (£40) in rural areas. Only about 7% of Kenyans have private health insurance.20 The
National Health Insurance Fund (NHIF) run by the government is the dominant insurance
provider. The maximum contribution was KSh 320 (about £2) per month until April 2015 when
it was increased to KSh 1700 (£12) per month. NHIF used to pay for the inpatient bed charge
only, therefore day surgery (the norm for OSSN surgery) would not be covered. This situation
has now been reviewed. The cost of travel is not captured in this analysis. Usually most
patients in Kenya would travel to hospitals accompanied by a relative or friend, further
increasing the cost of care.
This study had several weaknesses. It did not address the availability of eye surgeons or other
surgeons skilled enough and adequately equipped with the right surgical instruments to excise
conjunctival lesion as a cause of referral and hence delay. This data was not available to us.
The presence or absence of an operating theatre is probably not the determining factor for
referral - it is likely to be the availability of an appropriately skilled surgeon. Our analysis of the
flow through the health system did not address why the patients did what they did. To answer
this would require a qualitative study.
In conclusion, women and those who visited more health facilities were at increased risk of
delay. We observed various health system delays. Referral beyond the first point of contact
was a major cause of delay. It is also unclear why patients who are in regular contact with the
health system through HIV care programs have delayed presentation. There is need to
evaluate if health education about OSSN and the ocular effects of HIV infection particularly
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among HIV care workers is a barrier to the provision of timely intervention. Systematic OSSN
screening could be considered in HIV care programmes. Patients with pain presented more
rapidly. The cost to the patient of treating OSSN (excluding transport casts) was equivalent to
a month’s wages. It has been suggested that cancer care programs could learn from HIV
programs by mainstreaming cancer into the health system together with advocacy and
improved health worker training.22
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Figure 11.1 The care-seeking journey followed by 158 new patients with ocular
surface squamous neoplasia and the time taken in months for each step.
NOTE: median(IQR), mean(SD).
The term Facility in this figure refers to the sequence of facilities visited rather than the hierarchical position of the
facility in the health system. For instance, Facility 1 refers to the first facility a patient visited. Facility 2 is the
second facility a patient who was referred from the first facility went to and so on.
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Figure 11.2 Scatterplots showing the change in tumour size against the time between
becoming aware of the tumour and having surgery.
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Table 11.1 Demographic and clinical characteristics of 158 OSSN patients who either
presented directly or indirectly via other health facilities to the study centres
Demographic feature Direct presenters
N=88
Indirect presenters
N=70
p-
value a
n (%) n (%)
Age in years, mean (SD), y 42.5 (12.0) 41.1 (12.0) 0.47c
Sex, No. (%) 0.11
Male 36 (40.9) 20 (28.6)
Female 52 (59.1) 50 (71.4)
Marital status, No. (%) 0.21
Single 16 (18.2) 9 (12.9)
Married 55 (62.5) 49 (70.0)
Divorced or Separated 3 (3.4) 6 (8.6)
Widowed 14 (15.9) 6 (8.6)
Highest education level, No. (%) 0.25
Completed secondary or higher 33 (37.5) 34 (48.6)
Completed primary or some secondary 33 (37.5) 25 (35.7)
None or some primary 22 (25.0) 11 (15.7)
Location of primary occupation, No. (%) 0.66
Indoor 29 (33.0) 26 (37.1)
Outdoor 57 (64.8) 44 (62.9)
Missing data 2 (2.2) 0 0
Employment 0.23
Unemployed/no regular income 5 (5.7) 8 (11.4)
Low to middle income 69 (78.4) 58 (82.9)
High income 10 (11.4) 4 (5.7)
Missing data 4 (4.6) 0 0
HIV infection/ART use, No. (%) 0.42
HIV- 15 (25.0) 17 (34.0)
HIV+/ART- 15 (25.0) 14 (28.0)
HIV+/ART+ 30 (50.0) 19 (380)
CD4 count in cells/mm3, median(IQR) 344 (148 – 802) 219 (120 – 670) 0.42d
HIV-associated immunodeficiency by CD4
count in cells/mm3, No. (%)
0.28
  None or not significant (≥500)  15 (37.5) 14 (34.2)
Mild (350-499) 5 (12.5) 3 (7.3)
Advanced (200-349) 9 (22.5) 5 (12.2)
Severe (<200) 11 (27.5) 19 (46.3)
Main symptom, No. (%) 0.03
Lump 53 (60.2) 48 (68.6)
Pain 15 (17.1) 2 (2.9)
Redness 6 (6.8) 8 (11.4)
Others 14 (15.9) 12 (17.1)
Tumour diameter in mm, median(IQR) 6.0 (4.3 – 8.5) 6.0 (4.2 – 10.0) 0.52d
Histopathology, No. (%) 0.87
CIN I (mild dysplasia) 5 (5.7) 4 (5.7)
CIN II (moderate dysplasia) 13 (14.8) 9 (12.9)
CIN III (severe dysplasia) 19 (21.6) 13 (18.6)
Carcinoma-in-situ 0 0 1 (1.4)
SCC – poorly differentiated 1 (1.4) 1 (1.4)
SCC – moderately differentiated 45 (51.1) 35 (50.0)
SCC – well differentiated 5 (5.7) 7 (10.0)
Study Centre, No. (%) <0.001
Kikuyu Eye Unit 42 (47.7) 55 (78.6)
Kenyatta National Hospital 4 (4.6) 9 (12.9)
Sabatia Eye Hospital 25 (28.4) 3 (4.3)
Kitale District Hospital 17 (19.3) 3 (4.3)
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Distance from home to study centre or to
1st health facility in km, median(IQR) b
30 (20 – 89) 20 (5 – 56) 0.003 d
Cost of care in KSh, median (IQR) 3800 (3800-4800) 3880 (3800-4100) 0.01d
Abbreviations: ART – antiretroviral therapy; CIN – conjunctival intraepithelial neoplasia; SCC- squamous cell
carcinoma; KSh – Kenyan shillings
a testing whether the distribution of each demographic feature is the same in direct and indirect presenters
b 1 patient had missing data on distance, 48 missing data on HIV and 77 on CD4 count
c t-test with unequal variances
d Mann-Whitney U-test
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Table 11.2 The type of health facilities represented by Facility 1 in the care-seeking
journey. This shows where indirect presenters first entered the health system and the
availability of operating theatres in those clinics.
Health facility Operating theatre available TOTAL
None General
theatre
Eye unit
theatre
Unknown n(%)
Dispensary or Health Centre 1 0 0 5 6 (8.6)
District or sub-district hospital 0 3 - 2 5 (7.1)
County referral hospital 0 5 17 0 22 (31.4)
Private clinic 2 0 8 3 13 (18.6)
Mission hospital 0 1 3 2 6 (8.6)
Outreach eye camp 6 0 0 0 6 (8.6)
Facility not identified 0 0 0 12 12 (17.1)
TOTAL, N(%) 9 (12.9) 9 (12.9) 28 (40.0) 24 (34.3) 70 (100.0)
NOTE: General theatre refers to an operating theatre that is shared by all departments. Eye unit theatre means
the eye unit has its own operating theatre.
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Table 11.3 Advice given to 70 new patients with OSSN at each health facility along the indirect care-seeking journey and whether the
health facility had an operating theatre.
Step in journey Advice given Total patients
seen
Follow up
n(%)
Surgery Offered
n(%)
Referred
n(%)
Facility 1 31 (44.3) 5 (7.1) 32 (45.7) 70 a
Theatre available 13 4 18 37
No theatre 1 0 2 3
missing information 17 1 12 30
Facility 2 3 (21.4) 2 (14.3) 9 (64.3) 14
Theatre available 1 1 7 9
No theatre 0 0 1 1
missing information 2 1 1 4
Facility 3 1 (33.3) 1 (33.3) 1 (33.3) 3
Theatre available 0 0 1 1
No theatre 0 0 0 0
missing information 1 1 0 2
Facility 4 0 0 1 (100) 1
Theatre available 0 0 0 0
No theatre 0 0 0 0
missing information 0 0 1 1
a There was missing data on the advice given to 2 patients at the first facility
The term Facility in this figure refers to the sequence of facilities visited rather than the hierarchical position of the facility. For instance, Facility 1 refers to the first facility a
patient visited. Facility 2 is the second facility a patient who was referred from the first facility went to and so on.
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Table 11.4 Predictors of delay in presentation of 158 new patients with ocular surface squamous neoplasia, sub-divided into
quartiles.
Factor 0.4 – 3.2
months
(N=38)
3.3 – 7.0
months
(N=41)
7.1 – 15.6
months
(N=40)
15.7 – 190.5
months
(N=39)
Univariate
ordered
proportional OR
(95% CI)
p- value Adjusted ordered
proportional OR
(95% CI)
p- value
Distance from home to first health
facility or study centre, mean(SD) km
71 (102.0) 63 (82.3) 44 (49.6) 66 (96.3) 1.00 (0.99-1.00) 0.54 -
Total cost of care, mean (SD) Ksh 4102 (596.0) 4000 (496.3) 4218 (1594.7) 4289 (835.9) 1.00 (0.99-1.00) 0.32
Care pathway followed, No (%) <0.001 <0.001
Direct 27 (30.7) 25 (28.4) 19 (21.6) 17 (19.3) 1.00 (REF) 1.00 (REF))
1 facility visited 11 (19.6) 15 (26.8) 18 (32.1) 12 (21.4) 1.56 (0.85-2.83) 1.38 (0.75-2.54)
2 or more facilities visited 0 1 (7.1) 3 (21.4) 10 (74.1) 12.93 (3.79-44.06) 13.03 (3.78-44.94)
Sex, No. (%) 0.01
Male 18 (32.1) 18 (32.1) 12 (21.4) 8 (14.3) 1.00 (REF) - 1.00 (REF)
Female 20 (19.6) 23 (23.6) 28 (27.5) 31 (30.4) 2.29 (1.27-4.15) 0.006 2.31 (1.25-4.24)
Age, mean(SD) y 42 (13.0) 40 (11.8) 46 (13.6) 39 (8.3) 0.99 (0.97-1.02) 0.69 -
Marital status, No. (%) 0.59 -
Single 2 (8.0) 11 (44.4) 3 (12.0) 9 (36.0) 1.00 (REF)
Married 28 (26.9) 24 (23.1) 31 (29.8) 21 (20.2) 0.60 (0.28-1.31)
Divorced or Separated 1 (11.1) 5 (55.6) 1 (11.0) 2 (22.2) 061 (0.17-2.26)
Widowed 7 (35.0) 1 (5.0) 5 (25.0) 7 (35.0) 0.81 (0.27-2.45)
Highest education level, No. (%) 0.23 -
Completed secondary or higher 14 (20.9) 19 (28.4) 15 (22.4) 19 (28.4) 1.00 (REF)
Completed primary or some
secondary
12 (20.7) 16 (27.6) 14 (24.1) 16 (27.6) 1.01 (0.54-1.89)
None or some primary 12 (36.4) 6 (18.2) 11 (33.3) 4 (12.1) 0.55 (0.26-1.17)
Occupation, No. (%) 0.95 -
High income 3 (21.4) 3 (21.4) 6 (42.9) 2 (14.3) 1.00 (REF)
Low-Medium income 31 (24.4) 35 (27.6) 30 (23.6) 31 (234) 0.96 (0.37-2.48)
Unemployed 4 (30.8) 3 (23.1) 3 (23.1) 3 (23.1) 0.82 (0.21-3.12)
HIV infection & ART use, No. (%)a 0.07 -
HIV- 11 (34.4) 10 (31.3) 6 (18.8) 5 (15.6) 1.00 (REF)
HIV+/ART- 6 (20.7) 11 (37.9) 8 (27.6) 4 (13.8) 1.41 (0.58-3.40)
HIV+/ART+ 11 (22.5) 9 (18.4) 12 (24.5) 17 (34.7) 2.57 (1.13-5.88)
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Main symptom, No. (%) 1.07 (0.94-1.21) 0.32
Lump 24 (23.8) 24 (23.8) 29 (28.7) 24 (23.8)
Pain 7 (41.2) 5 (29.4) 2 (11.8) 3 (17.7)
Redness 4 (28.6) 4 (28.6) 2 (14.3) 4 (28.6)
Others 3 (11.5) 8 (30.8) 7 (26.9) 8 (308)
a There were 48 participants with missing HIV/ART data
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Chapter 12. Topical 5-Fluorouracil (5FU)
following surgery for ocular surface squamous
neoplasia (OSSN) in Kenya: a randomised,
double-blind, placebo-controlled trial
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Topical ﬂ uorouracil after surgery for ocular surface 
squamous neoplasia in Kenya: a randomised, double-blind, 
placebo-controlled trial
Stephen Gichuhi, Ephantus Macharia, Joy Kabiru, Alain M’bongo Zindamoyen, Hilary Rono, Ernest Ollando, Joseph Wachira, Rhoda Munene, 
John Maina, Timothy Onyuma, Mandeep S Sagoo, Helen A Weiss, Matthew J Burton
Summary
Background Ocular surface squamous neoplasia (OSSN) is an aggressive eye tumour particularly aﬀ ecting people 
with HIV in Africa. Primary treatment is surgical excision; however, tumour recurrence is common. We assessed the 
eﬀ ect of ﬂ uorouracil 1% eye drops after surgery on recurrence.
Methods We did this multicentre, randomised, placebo-controlled trial in four centres in Kenya. We enrolled patients 
with histologically proven OSSN aged at least 18 years. After standard surgical excision, participants were randomly 
allocated to receive either topical ﬂ uorouracil 1% or placebo four times a day for 4 weeks. Randomisation was stratiﬁ ed 
by surgeon, and participants and trial personnel were masked to assignment. Patients were followed up at 1 month, 
3 months, 6 months, and 12 months. The primary outcome was clinical recurrence (supported by histological 
assessment where available) by 1 year, and analysed by intention to treat. The sample size was recalculated because 
events were more common than anticipated, and trial enrolment was stopped early. The trial was registered with 
Pan-African Clinical Trials Registry (PACTR201207000396219).
Findings Between August, 2012, and July, 2014, we assigned 49 participants to ﬂ uorouracil and 49 to placebo. 
Four participants were lost to follow-up. Recurrences occurred in ﬁ ve (11%) of 47 patients in the ﬂ uorouracil group 
and 17 (36%) of 47 in the placebo group (odds ratio 0·21, 95% CI 0·07–0·63; p=0·01). Adjusting for passive smoking 
and antiretroviral therapy had little eﬀ ect (odds ratio 0·23; 95% CI 0·07–0·75; p=0·02). Adverse eﬀ ects occurred 
more commonly in the ﬂ uorouracil group, although they were transient and mild. Ocular discomfort occurred in 
43 of 49 patients in the ﬂ uorouracil group versus 36 of 49 in the placebo group, epiphora occurred in 24 versus ﬁ ve, 
and eyelid skin inﬂ ammation occurred in seven versus none.
Interpretation Topical ﬂ uorouracil after surgery substantially reduced recurrence of OSSN, was well-tolerated, and its 
use recommended.
Funding British Council for Prevention of Blindness and the Wellcome Trust.
Copyright © Gichuhi et al. Open Access article distributed under the terms of CC BY.
Introduction
Ocular surface squamous neoplasia (OSSN) covers a range 
of conjunctival and corneal diseases, from intra-epithelial 
dysplasia to invasive squamous cell carcinoma.1 Risk 
factors for OSSN include ultraviolet radiation, HIV 
infection, and human papillomavirus infection.2 In 
temperate regions, OSSN is uncommon, usually growing 
slowly, and most often aﬀ ects elderly men. By contrast, in 
sub-Saharan Africa, OSSN is more common and 
aggressive.3 It aﬀ ects younger adults, predominately 
women (around two-thirds of cases), and is strongly 
associated with HIV infection (in about 70% of cases). 
OSSN has a wide range of clinical phenotypes and late 
presentation with invasive orbital disease is not uncommon 
(ﬁ gure 1). Surgical excision is the mainstay of treatment, 
although primary chemotherapy has also been used 
(appendix). OSSN often recurs after surgery. The highest 
recorded recurrence is 67%.4 Recurrence is a particular 
problem in sub-Saharan Africa, where it typically occurs in 
30–40% of patients.4–7 In temperate climates, recurrence 
typically occurs in 5–25% of patients (appendix). Surgical 
outcomes seem to be aﬀ ected by delays in diagnosis, 
tumour size, histological grade, ocular location, scleral 
invasion, excision margin involvement, prior excision, and 
coexisting xeroderma pigmentosum.5,8,9 Several adjunctive 
treatment regimens are used during or after surgery to 
reduce recurrence: cryotherapy, topical chemotherapy 
(mitomycin and ﬂ uorouracil), interferon alfa-2b, retinoic 
acid, and radiotherapy (appendix p 1, 3, 7, 11, 13, 14). Most 
data on adjuvant treatment are case series. There is one 
previous randomised trial, from Australia, which assessed 
the eﬀ ectiveness of topical mitomycin and there are no 
trial data on interventions for people with HIV.10,11 Radical 
surgery (enucleation or exenteration) is usually needed for 
advanced disease.12
The antimetabolite ﬂ uorouracil is often used in 
ophthalmology, particularly for its anti-scarring properties 
during surgical procedures (trabeculectomy, pterygium 
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excision, and lacrimal surgery).13 Eye drops containing 1% 
ﬂ uorouracil have also been used for several years to treat 
patients with OSSN after tumour excision (appendix 
p 11), on the basis of case series, which suggest that 
ﬂ uorouracil reduces tumour recurrence and is safe.14–20 
However, there are no data from trials. Fluorouracil is 
widely available and relatively cheap in sub-Saharan 
Africa, therefore, if shown to be an eﬀ ective adjuvant, it 
would be a deliverable intervention.
We assessed whether use of ﬂ uorouracil 1% eye drops 
could reduce recurrence of OSSN following surgical 
excision in Kenya.
Methods
Study design and participants
We did a double-blind, parallel-group, randomised, 
placebo-controlled trial at four centres in Kenya: Kenyatta 
National Hospital Eye Clinic in Nairobi, PCEA Kikuyu 
Eye Unit in central Kenya, Sabatia Eye Hospital in 
western Kenya, and Kitale District Hospital in the north 
Rift Valley.
We enrolled consecutive patients presenting with 
suspicious conjunctival lesions. Entry criteria were: 
histologically proven OSSN involving two or fewer 
quadrants; attendance for follow-up within the ﬁ rst 
2 months after excision; healing of the excision site; and 
age at least 18 years. Exclusion criteria were: previous 
treatment with topical antimetabolite drugs such as 
ﬂ uorouracil or mitomycin to the same eye or systemic 
cytotoxic drugs; extensive disease requiring more radical 
surgery than a simple excision; and pregnant or 
breastfeeding mothers. Patients were not enrolled if they 
did not think that they could return for follow-up.
All participants gave written informed consent before 
enrolment. Ethics approval was granted by the Kenyatta 
National Hospital/University of Nairobi ethics and 
research committee and the London School of Hygiene 
& Tropical Medicine ethics committee. Approval was also 
obtained from the Kenya Pharmacy and Poisons Board to 
produce and use the active intervention drops because 
they are not commercially available.
An independent data and safety monitoring board 
oversaw the study, conﬁ rmed data integrity, and approved 
the results and report for release. Trial personnel received 
good clinical practice training and certiﬁ cation. This 
study adhered to the tenets of the Declaration of Helsinki.
Randomisation and masking
Participants were randomly assigned (1:1) to either 
ﬂ uorouracil 1% or placebo eye drops. The ﬂ uorouracil 
eye drops were prepared by dilution of ﬂ uorouracil 
Research in context
Evidence before this study
Ocular surface squamous neoplasia (OSSN) is an eye cancer, 
common in people with HIV. A Cochrane systematic review 
from 2013 showed no evidence from trials for the eﬀ ectiveness 
of interventions used in this population. We searched electronic 
databases (PubMed, Embase, The Cochrane Library), clinical trial 
registries (WHO International Clinical Trials Registry Platform 
and the US National Institutes of Health ClinicalTrials.gov), and 
international conference proceedings of HIV/AIDS and 
AIDS-related cancers from the AIDS Education Global Education 
System for studies published up to Aug 31, 2015, irrespective of 
language or publication status. We used the terms “randomized 
controlled trial”, “controlled clinical trial”, “randomized”, 
“placebo”, “drug therapy”, “randomly”, “trial”, “conjunctiva*”, 
“ocular surface”, “carcinoma”, “cancer”, “neoplasia”, “neoplasm”, 
“neoplastic”, “dysplasia”, “dysplastic”, “squamous”, and 
“squamous cell”. We found only one trial, on topical mitomycin 
in a non-HIV-infected population in Australia. We identiﬁ ed 
some case series and case reports (appendix). Only series that 
reported recurrence as an outcome were included.
Added value of this study
Our study provides the ﬁ rst evidence from a trial of the 
eﬀ ectiveness of ﬂ uorouracil as adjunctive treatment for 
OSSN. Our results show that the simple and relatively 
inexpensive use of 4 weeks of ﬂ uorouracil 1% eye drops after 
surgical excision substantially reduced the relative risk of 
recurrence compared with placebo and was safe. There were 
transient side-eﬀ ects, such as watery eye, discomfort when 
taking the drops, and eyelid skin inﬂ ammation but these were 
mostly mild and resolved in a few weeks after completion of 
4 week treatment.
Implications of all the available evidence
Recurrence is a huge issue in the management of this common 
and aggressive eye disease. Fluorouracil does not need stringent 
storage conditions and cytotoxics have a low risk of 
contamination. It is on the WHO Essential Medicines List, and is 
a widely available and low-cost option, particularly in 
sub-Saharan Africa, which has the highest incidence of OSSN in 
the world. Translation of these trial results into clinical practice 
is therefore feasible. 
Figure 1: Ocular surface squamous neoplasia
Moderately diﬀ erentiated conjunctival squamous cell carcinoma, (A) moderate size, (B) large lesion involving the 
cornea, limbus, and extending to the fornix. Fornix involvement is often associated with orbital spread.
A B
221
Articles
www.thelancet.com/lancetgh   Vol 4   June 2016 e380
50 g/L solution for injection in hydroxypropyl 
methylcellulose 0·7% artiﬁ cial tear eye drops. The 
placebo was the same hydroxypropyl methylcellulose 
0·7% artiﬁ cial tear eye drops.
The randomisation sequence was generated by 
computer by the trial statistician using Stata (version 12). 
The permuted block size (known only to the statistician) 
varied randomly between two and four, and 
randomisation was stratiﬁ ed by surgeon. The allocation 
sequence was transferred to the manufacturing 
pharmacy, where an independent pharmacist applied 
labels with sequential code numbers to the appropriate 
eye drop bottles. Participants, clinicians, and study 
personnel were masked to the allocation: the bottles, 
liquid content, and packaging had identical appearances. 
The supervising clinician at each of the four study centres 
issued the trial drug to participants. The allocation 
followed the order of enrolment.
Procedures
Lesions involving two or fewer quadrants of the 
conjunctiva were fully excised with a 4 mm clear margin 
by the no-touch technique, with use of an operating 
microscope and under local anaesthesia.21 Absolute 
alcohol was applied to any corneal component of the 
tumour to loosen it and facilitate dissection. The 
conjunctival component was dissected down to bare 
sclera. Cryotherapy was not applied, because it is not 
generally available in sub-Saharan Africa. Topical 
adrenaline, and where necessary mild diathermy, were 
used for haemostasis. The conjunctiva around the defect 
was undermined and mobilised for primary closure. 
Specimens were placed on suture-pack polystyrene, to 
keep the tissue ﬂ at and oriented for the pathologist, and 
ﬁ xed in 10% neutral buﬀ ered formalin. All 
histopathological tests were done centrally and reported 
by a single pathologist. Combined gentamicin 0·3% and 
prednisolone acetate 1% eye drops were applied four 
times per day for 3–4 weeks after surgery. Patients were 
reviewed after about 4 weeks to conﬁ rm wound healing 
and for recruitment into the trial.
Participants were asked to self-administer one drop of 
their allocated medication four times a day to the aﬀ ected 
eye for 4 weeks. Each participant was given a 28 day 
medication diary to monitor treatment. They were asked 
to record each dose taken or missed. The record card had 
a similar diary for adverse eﬀ ects (pain or burning 
sensation, excessive tears, and redness).
Participants underwent a detailed ophthalmic 
examination with a slit-lamp biomicroscope before 
surgery and at about 1 month after surgery. After 
enrolment, follow-up visits were scheduled for 1 month, 
3 months, 6 months, and 12 months after randomisation. 
Participants were telephoned 1 week before their 
appointments to remind them. Individuals who missed 
follow-up visits were contacted by telephone. At each 
follow-up visit, a symptom history was taken and a 
detailed ophthalmic examination was done for evidence 
of recurrent disease. On each examination, high-
resolution digital images of the surface of the eyes were 
taken. In addition, we assessed whether the lacrimal 
drainage system was blocked using the dye disappearance 
test. Fluorescein dye was applied in both eyes in the 
inferior conjunctival fornix and the tear ﬁ lm observed 
with the cobalt blue light of the slit lamp after 5 min for 
clearance of the dye. The presence of dye after this time 
was considered positive, indicating a functional or 
anatomical blockage.
HIV status was initially tested by ELISA using 
Vironostika antigen/antibody kit (Biomerieux, France) 
then later changed to rapid tests with Alere Determine 
HIV-1/2 Ag/Ab (Alere, USA) and Unigold (Trinity Biotech, 
USA). CD4 count was measured with FacsCount (Becton 
Dickinson, USA). Serum retinol concentration was 
quantiﬁ ed by high-performance liquid chromatography 
(SHIMADZU Prominence HCT2010, Japan).
When an obvious regrowth was found, re-excision for 
treatment and histopathology was advised. If a small 
potentially suspicious change was observed, it was 
initially photographed, the size measured, and the 
participant examined more frequently than the scheduled 
study visits. If on subsequent visits the lesion had 
progressed, the lesion was re-excised and sent for 
histopathology; the date of recurrence was recorded as 
the ﬁ rst time the possible regrowing lesion was noticed.
Outcomes
The primary outcome was clinical recurrence of the 
lesion at any time during the ﬁ rst year of follow-up, 
conﬁ rmed by histological assessment where available. 
The secondary outcomes were time to recurrence, 
cofactors of recurrence, and adverse events.
Primary outcome events were assessed and conﬁ rmed 
centrally by an ophthalmologist, who had either directly 
examined all patients at Kenyatta National Hospital and 
Kikuyu Eye Unit, or reviewed the clinical images from 
Sabatia Eye Hospital and Kitale District Hospital, 
supported by histopathological results. For cases where 
histopathology was not available, mostly because the 
participant did not return for the repeat surgery, the 
images of recurrent lesions were reviewed by two 
consultant ophthalmologists experienced in OSSN in 
east Africa to conﬁ rm clinical recurrence. Adverse eﬀ ects 
were monitored by reviewing the medication diary with 
the participant and asking about discomfort and tearing.
Statistical analysis
Case series of the use of surgical excision with or without 
adjuvant ﬂ uorouracil treatment have reported 
recurrences in 3·2–43% of patients.7,19,22,23 Assuming a 
recurrence of 20% in the control group and 10% in the 
treatment group, power of 80%, and a two-sided α of 5%, 
the target sample size was initially calculated to be 
219 participants in each group. 1 year into the study, we 
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noted that recruitment was slow but recurrences were 
more common overall than anticipated, so after review 
by the trial steering committee in discussion with the 
data safety and monitoring board, a pragmatic decision 
was made to revise the sample size assuming that 30% of 
patients in the placebo group and 5% in the treatment 
group would have disease recurrence. As such, a sample 
size of 43 participants in each group would provide 80% 
power to detect an absolute diﬀ erence in recurrence rates 
of 25%.
The analysis was predeﬁ ned. We compared the two 
groups for balance in terms of predeﬁ ned factors that 
could have a bearing on aetiology or recurrence: age, sex, 
smoking history, outdoor occupation, HIV status, CD4 
count, vitamin A concentration, tumour size, prior 
excision, and histological grade.3,5,8,9 The primary analysis 
of the primary outcome and the safety analysis were 
done by intention to treat. Data were managed in 
Microsoft Access, cleaned, and transferred into Stata 
(version 12.1) for analysis.
We calculated the numbers of events, person-months, 
and rate of recurrence in each group. We estimated the 
eﬀ ect size as the odds ratio (OR) for recurrence, estimated 
by logistic regression, with 95% CIs. We adjusted the 
crude OR for the seven surgeons as a random eﬀ ect and 
for additional baseline factors that were greater in one 
group than the other.24 We analysed the eﬀ ect of the 
intervention on time to recurrence with Kaplan-Meier 
survival curves, and we used Cox regression to estimate 
hazard ratios and 95% CIs, adjusting for substantial 
baseline imbalances. To assess whether survival was the 
same by treatment group, we used the log rank test. We 
report the risk of any adverse eﬀ ects at any follow-up in 
the treated eye by group.
The trial is registered with the Pan-African Clinical 
Trials Registry, number PACTR201207000396219.
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
Between August, 2012, and July 2014, 496 patients with 
conjunctival lesions had surgical excision followed by 
histopathological tests. 187 of these patients had OSSN 
and 309 had other pathological disease types. For all 
participants with OSSN, only one eye was involved. 
89 (48%) of 187 patients were ineligible. Therefore, we 
enrolled 98 patients (ﬁ gure 2). 49 patients were assigned 
to receive ﬂ uorouracil eye drops and 49 were assigned to 
placebo. 58 of 98 patients were enrolled at Kikuyu Eye 
Unit, 20 at Sabatia Eye Hospital, 12 at Kitale District 
Hospital, and eight at Kenyatta National Hospital. The 
ﬁ nal follow-up visits were scheduled for 12 months, 
although we included data from up to 13 months for late 
participants. Follow-up was completed in July, 2015. 
Four individuals without a recorded recurrence (two from 
each group) did not complete a full year of follow-up.
The main reasons for exclusion were: inability to return 
for regular follow-up (n=41), extensive disease requiring 
radical surgery (n=24), not returning at all after surgery 
(n=16), or returning more than 2 months after surgery 
(n=3; ﬁ gure 2). There were no signiﬁ cant diﬀ erences 
between the enrolled and non-enrolled patients in terms 
of age, sex, smoking, HIV infection, or stage of OSSN 
(excluding larger tumours; data not shown).
The mean age of all participants was 41·0 years 
(SD 11·3) and most were female. Baseline characteristics 
were reasonably balanced between the two groups with 
the exception of past passive cigarette smoking and use 
of antiretroviral therapy, which were more common in 
the placebo group than in the ﬂ uorouracil group, and 
therefore were adjusted for in the primary analysis 
(table 1).
By the end of follow-up, recurrent lesions had 
developed in 22 eyes of 22 participants. The 
four participants who did not complete a full year of 
follow-up were excluded from the primary analysis of 
clinical recurrence of the lesion by 1 year. Lesion 
recurrence was signiﬁ cantly less common in the 
 Figure 2: Trial proﬁ le
OSSN=ocular surface squamous neoplasia.
496 patients assessed for eligibility
187 OSSN conﬁrmed
98 randomly assigned
49 allocated to and received ﬂuorouracil 49 allocated to and received placebo
47 included in the analysis 47 included in the analysis
2 lost to follow-up 2 lost to follow-up
309 did not have OSSN
89 excluded
 41 anticipated diﬃculty with follow-up
 24 had extensive disease >two quadrants
 16 did not return after surgery
 3 returned more than 2 months after surgery
 1 prior use of mitomycin eye drops
 1 pregnant
 1 breastfeeding
 1 declined consent
 1 sphenoid wing meningioma (referred)
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ﬂ uorouracil group (ﬁ ve [11%] of 47 patients) than in the 
placebo group (17 [36%] of 47 patients; crude OR 0·21, 
95% CI 0·07–0·63; p=0·01). This eﬀ ect remained 
signiﬁ cant when adjusted for use of antiretroviral 
therapy and passive cigarette smoking (OR 0·23, 95% CI 
0·07–0·75; p=0·02). The relative risk of recurrence was 
reduced by 70·7% and the absolute diﬀ erence was 
25·6%. Treatment with ﬂ uorouracil after surgery for 
four patients would therefore prevent an estimated one 
recurrence (number needed to treat 3·9, 95% CI 
2·4–11·8).
16 of 22 recurrent lesions underwent repeated surgical 
excision and recurrent OSSN was conﬁ rmed by 
histopathology in all cases. Re-excision was not done for 
six recurrent cases: four participants in the placebo group 
did not return for repeat surgery or further follow-up 
after the recurrence was noted, and two participants in 
the placebo group died before re-excision could be done 
(one from a presumed myocardial infarction and one 
from HIV-related complications). The images of these 
cases were reviewed by two ophthalmologists experienced 
in OSSN in east Africa. All were judged to be recurrent 
OSSN disease on clinical grounds, in the context of 
previous histologically conﬁ rmed OSSN.
There was a signiﬁ cant diﬀ erence in the recurrence 
rate between the two groups over the follow-up period 
(hazard ratio [HR] 0·24, 95% CI 0·09–0·66; p=0·01; 
ﬁ gure 3), which changed slightly after adjusting for 
smoking and use of antiretroviral therapy (HR 0·32, 
95% CI 0·11–0·95; p=0·04). The test for proportional 
hazards assumption showed that the assumption of 
proportionality was appropriate (p=0·59). Median 
tumour-free survival was 7·3 months (IQR 2·3–13·5) in 
the ﬂ uorouracil group and 4·8 months (3·0–7·6) in the 
placebo group but the diﬀ erence was not statistically 
signiﬁ cant (p=0·23).
Sensitivity analysis, assuming the four participants 
who did not complete 1 year of follow-up did not have a 
Fluorouracil 
group (n=49)
Placebo group 
(n=49)
Sex
Male 17 (35%) 14 (29%)
Female 32 (65%) 35 (71%)
Age (years) 39·1 (9·2) 42·9 (13·0)
Marital status*
Single 6 (12%) 11 (22%)
Married 32 (65%) 28 (58%)
Divorced or separated 4 (8%) 2 (4%)
Widowed 7 (14%) 7 (14%)
Formal education (years)*
Tertiary (>12) 5 (10%) 4 (8%)
Secondary completed (12) 18 (37%) 20 (41%)
Some secondary (8–12) 4 (8%) 6 (12%)
Primary completed (8) 13 (27%) 11 (22%)
Some primary (<8) 6 (12%) 4 (8%)
None 3 (6%) 3 (6%)
Past cigarette smoking*
No 41 (84%) 32 (67%)
Yes 5 (10%) 4 (8%)
Passive (spouse or partner smokes) 3 (6%) 12 (25%)
Current cigarette smoking†
No 44 (90%) 41 (87%)
Yes 3 (6%) 0 (0%)
Passive (spouse or partner smokes) 2 (4%) 6 (13%)
Cigarettes smoked daily 9 (6) 13 (13)
Years of cigarette smoking 10·7 (6·8) 16·2 (7·4)
Location of current occupation*
Indoors 20 (41%) 19 (40%)
Outdoors 29 (59%) 29 (60%)
Wears hat or cap outdoors† 8 (16%) 6 (13%)
Wears sunglasses outdoors† 4 (8%) 4 (9%)
HIV infection‡ 29 (63%) 31 (71%)
Use of antiretroviral therapy§ 10 (22%) 19 (42%)
CD4 count (cells per μL)¶ 444 (370) 460 (421)
Serum retinol concentration (μg/L)|| 489 (157) 529 (215)
Vitamin A deﬁ ciency (serum retinol 
<300 μg/L)||
3 (6%) 3 (6%)
Tumour diameter (mm) 5·9 (2·6) 6·3 (2·4)
Prior excision 8 (16%) 9 (19%)
Histological grading of tumours
CIN 1 4 (8%) 4 (8%)
CIN 2 13 (27%) 8 (16%)
CIN 3 11 (22%) 14 (29%)
Carcinoma in situ 0 (0%) 1 (2%)
Poorly diﬀ erentiated squamous cell 
carcinoma
1 (2%) 1 (2%)
Moderately diﬀ erentiated 
squamous cell carcinoma
17 (35%) 18 (37%)
Well diﬀ erentiated squamous cell 
carcinoma
3 (6%) 3 (6%)
Surgical margin involvement 21 (43%) 19 (39%)
(Table 1 continues in next column)
Fluorouracil 
group (n=49)
Placebo group 
(n=49)
(Continued from previous column)
Stage of OSSN**
T1N0M0 15 (31%) 9 (18%)
T2N0M0 10 (20%) 9 (18%)
T3N0M0 23 (47%) 31 (63%)
T3N1M0 1 (2%) 0 (0%)
Data are n (%) or mean (SD). *Data missing for one participant in the placebo 
group. †Data missing for two participants in the placebo group. ‡Data missing for 
three participants in the ﬂ uorouracil group and ﬁ ve in the placebo group. 
§Data missing for three participants in the ﬂ uorouracil group and four in the 
placebo group. ¶Data missing for eight participants in the ﬂ uorouracil group and 
11 in the placebo group. ||Data missing for ten participants in the ﬂ uorouracil 
group and 13 in the placebo group. **As per the American Joint Committee on 
Cancer. CIN=cervical intra-epithelial neoplasia. OSSN=ocular surface squamous 
neoplasia. 
Table 1: Baseline characteristics 
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recurrence in the ﬁ rst year, made little diﬀ erence to the 
results (crude OR 0·21, 95% CI 0·07–0·64, p=0·01; 
adjusted OR 0·25, 95% CI 0·08–0·79, p=0·02; HR 0·25, 
95% CI 0·07–0·67, p=0·01; adjusted HR 0·33, 95% CI 
0·11–0·97, p=0·04) and the number needed to treat 
remained at four (4·1, 95% CI 2·5–12·5).
Tumour size at baseline was a signiﬁ cant cofactor of 
recurrence (crude OR 1·27, 95% CI 1·04–1·54, p=0·02). 
Participants who had a recurrence had signiﬁ cantly 
larger mean tumour diameter (7·3 mm, SE 0·26) than 
did patients who did not have a recurrence (5·8 mm, 
SE 0·66; p=0·01). There was no eﬀ ect modiﬁ cation by 
tumour size or rate of tumour growth before surgery, 
deﬁ ned as tumour diameter divided by duration between 
noticing the growth and time of surgery, assuming a 
linear rate (likelihood ratio test p=0·49). The mean 
growth rate was 1·6 mm per month (SE 0·61) in patients 
who had a recurrence and 1·7 mm per month (SE 0·22) 
in patients who did not. Surgical margin involvement 
was not a signiﬁ cant cofactor for recurrence (crude 
OR 1·28, 95% CI 0·49–3·33, p=0·62) and nor was having 
invasive carcinoma rather than carcinoma in situ at 
baseline (crude OR 1·09, 95% CI 0·42–2·81, p=0·87).
Adverse eﬀ ects were more common in the ﬂ uorouracil 
group than in the placebo group, as shown by analysis of 
the time to ﬁ rst adverse event (p=0·005; table 2). Epiphora 
(watery eye) was more common in the ﬂ uorouracil group 
than in the placebo group and the dye disappearance test 
became transiently positive in six patients in the 
ﬂ uorouracil group at 1 month. None of the participants 
with epiphora had a positive dye disappearance test at 
1 year. Ocular discomfort was more common in the 
ﬂ uorouracil group than in the placebo group at 1 month 
(p=0·004). In one (2%) patient, discomfort was suﬃ  cient 
to discontinue treatment after 3 weeks. After the 1 month 
visit, no participants reported ocular discomfort.
Seven participants, all in the ﬂ uorouracil group, 
developed inﬂ ammation or irritation of the eyelid skin 
after about 2–3 weeks of treatment. This was attributed 
to overﬂ ow spillage of the eye drop onto the skin. All skin 
changes fully resolved within 1 month. We advised all 
further enrollees to apply drops while holding a piece of 
tissue paper against the lid; subsequently, no episodes of 
eyelid skin irritation occurred.
Discussion
We showed that 4 weeks of treatment with topical 
ﬂ uorouracil 1% after surgical excision substantially 
reduced the 1 year recurrence of OSSN tumours. The 
study was done in a region with a relatively high 
incidence of OSSN, which is often associated with HIV 
infection, and where patients often present late with 
advanced disease. Tumour recurrence has been a major 
problem in managing this disease. Most of our 
participants were relatively young, and women 
outnumbered men, the typical demographic pattern in 
Africa.3 The whole range of OSSN disease was 
represented, enabling us to draw a general conclusion 
about the eﬀ ectiveness of the intervention.
This study was the ﬁ rst randomised controlled trial of 
topical ﬂ uorouracil as adjunctive treatment for OSSN. 
Figure 3: Kaplan-Meier analysis of time to recurrence
Number at risk
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Placebo
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0 0·5 1·0 1·5
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Fluorouracil 
group 
(n=49)
Placebo 
group 
(n=49)
p value
Epiphora ·· ·· ··
1 month 24 (49%) 5 (10%) <0·001
3 months* 3 (6%) 2 (4%) 0·66
6 months† 1 (2%) 0 (0%) 0·32
12 months† 4 (8%) 0 (0%) 0·04
Positive dye disappearance test ·· ·· ··
At baseline 0 (0%) 1 (2%) 0·32
1 month 6 (12%) 1 (2%) 0·05
3 months* 1 (2%) 0 (0%) 0·32
6 months† 0 (0%) 0 (0%) -
12 months† 0 (0%) 0 (0%) -
Discomfort in the treated eye 
at 1 month‡
·· ·· 0·004
Occasional discomfort 21 (43%) 30 (61%) ··
Discomfort for <5 min 12 (24%) 3 (6%) ··
Discomfort for ≥5 min 4 (8%) 2 (4%) ··
Discomfort making 
treatment diﬃ  cult
6 (12%) 1 (2%) ··
Eyelid inﬂ ammation at 1 month 7 (14%) 0 (0%) <0·001
Any adverse event ·· ·· 0·005§
1 month 34 (69%) 19 (39%) ··
3 months 10 (20%) 9 (18%) ··
6 months 5 (10%) 1 (2%) ··
12 months 7 (14%) 6 (12%) ··
*48 patients in the ﬂ uorouracil group and 47 in the placebo group because of loss 
to follow-up. †47 participants in each group because of loss to follow-up. 
‡No participant reported any discomfort at 3 months, 6 months, or 12 months. 
§Computed with the stratiﬁ ed log-rank test for equality of survivor functions.
Table 2: Adverse events 
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However, our results are consistent with those of non-
randomised case series of adjuvant ﬂ uorouracil, which 
have reported similarly low proportions of recurrence.14–20 
Some investigators have reported the eﬀ ectiveness of 
ﬂ uorouracil as primary treatment in presumed OSSN 
lesions without surgical excision and histopathological 
assessment.14 We chose to test ﬂ uorouracil in this setting 
because it is cheap and readily available with a history of 
use and wide acceptance for other types of ophthalmic 
surgery. Fluorouracil is on WHO’s list of essential drugs. 
It does not require stringent storage conditions such as 
refrigeration. Therefore, the translation of this result into 
clinical practice, given the resource limitations of the 
Kenyan health system and other similar settings, is 
realistic. Because surgical cryotherapy is not routinely 
available, topical ﬂ uorouracil is therefore an alternative 
strategy to prevent recurrence.
The only other randomised study of treatment for 
OSSN was a placebo-controlled, crossover trial of topical 
mitomycin for 48 patients from Australia.10 However, that 
study has several distinct diﬀ erences to our study, which 
probably limit the relevance to settings such as Kenya. 
First, only partial incisional biopsy samples were taken 
for diagnosis; the tumours were not excised. Given the 
advanced and aggressive disease in Africa, complete 
surgical removal of the lesion is the preferred approach. 
Second, the casemix was diﬀ erent: patients with 
squamous cell carcinoma were excluded from the 
Australia study, the population group was older than ours 
(mean age 67 years), predominantly male (75%), and 
probably not infected with HIV (no data were provided). 
Although the lesions regressed clinically on treatment 
with mitomycin, more than half of patients had persistent 
OSSN on repeat histological assessment of the lesion site 
1 year after treatment.
Overall, the use of topical ﬂ uorouracil was associated 
with transient side-eﬀ ects: watery eye, discomfort when 
taking the drops, and eyelid skin inﬂ ammation. However, 
these were mostly mild and resolved after the completion 
of treatment. A transiently positive dye disappearance 
test indicates temporary reversible obstruction of the 
nasolacrimal duct, a known complication of ﬂ uorouracil 
treatment.18 The most signiﬁ cant adverse eﬀ ect was the 
eyelid skin inﬂ ammation. This was reliably prevented by 
protecting the skin with a tissue while applying the drops 
to catch any overﬂ ow. Epiphora was reported by 10% of 
participants at 1 month in the placebo group and 61% 
reported occasional discomfort at 1 month. We think that 
these eﬀ ects were not caused by the placebo, which was a 
bland lubricant, but rather related to having recently had, 
often extensive, excision surgery to remove a tumour. It 
is quite common for excision of conjunctival lesions, 
OSSN or other pathology such as a pterygium, to result 
in a degree of ocular surface inﬂ ammation and irritation 
that can persist for several weeks. Such eﬀ ects are 
especially common in young people of African origin, 
who are more likely to scar and have inﬂ ammation than 
are older white patients.25 Overall, we think that these 
side-eﬀ ects can be partly mitigated, do not usually 
represent a problem after cessation of treatment, and are 
outweighed by the beneﬁ t of the reduced tumour 
recurrence.
Adjunctive ﬂ uorouracil probably works through its 
eﬀ ect on residual OSSN cells that are left after surgical 
excision. It interferes with DNA and RNA processes 
through several active metabolites.26 Fluorodeoxyuridine 
monophosphate inhibits thymidylate synthase, blocking 
thymidylate production, and thus DNA replication. 
Rapidly dividing neoplastic cells are much more 
vulnerable to thymidine depletion than are normal cells. 
Fluorodeoxyuridine triphosphate is misincorporated into 
DNA and ﬂ uorouridine triphosphate is misincorporated 
into RNA. These diﬀ erent metabolites disrupt crucial 
cellular mechanisms, triggering apoptosis.
We were able to follow up participants to 1 year. This 
was attributable to two factors. First, we excluded people 
who said that they would be unlikely to return for follow-
up. Second, the study team were careful to build and 
maintain good relationships with study participants, and 
actively communicated with those who missed follow-
up visits.
Our study has several limitations. First, recruitment 
was slower than anticipated, resulting in a smaller study 
than originally anticipated. The initial study size was 
based on previously reported recurrence rates from 
several case series, with heterogeneous inclusion criteria, 
treatment regimens, and follow-up.4,7,19,22,23,27,28 However, 
the higher than expected recurrence rate and high 
retention enabled us to have good power with a smaller 
sample size. In common with other studies from Africa, 
the recurrence rate in both groups was higher than that 
reported in many case series from temperate countries. 
This diﬀ erence is possibly because OSSN in this 
population, with a high proportion of patients who are 
HIV positive, is more aggressive and patients probably 
present later with more advanced disease.
Second, not all the cases of clinical recurrence had re-
excision and histopathological tests done. However, all 
suspected recurrences for which histopathological 
results were available were conﬁ rmed as recurrent 
OSSN, which suggests that our clinical judgment in this 
situation is highly concordant with the pathology.
Third, we excluded a high proportion of potential 
participants. The most common reason for exclusion was 
that the patient was unlikely to return for follow-up. 
Excluding those who did not think they could return 
helped us achieve good follow-up among those who were 
enrolled in the trial. However, there was no systematic 
diﬀ erence between participants and excluded patients in 
terms of age, sex, HIV status, smoking status, or OSSN 
grade (when those with large lesions requiring alternative 
radical surgery were excluded). This ﬁ nding suggests 
that our results can be generalised. The participants who 
were lost to follow-up attended at least the ﬁ rst visit after 
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randomisation and were recurrence-free at that point. 
The challenge of ensuring high follow-up rates in 
Kenyans with HIV has been reported previously.29
Fourth, we excluded individuals with very large 
tumours that required either enucleation or exenteration. 
This exclusion could reduce the generalisability of the 
ﬁ ndings. However, such patients are not suitable for less 
radical surgery and topical chemotherapy, as the tumour 
is already invading the deeper tissues of the orbit. Finally, 
there were some diﬀ erences in adverse events by group, 
which could have led to unmasking. However, we think 
that this is unlikely: discomfort was common and similar 
in each group at 1 month, and eyelid inﬂ ammation, 
positive dye disappearance test, and epiphora after 
1 month were uncommon.
In conclusion, 4 weeks of topical ﬂ uorouracil 1% after 
surgical excision of OSSN substantially reduced the 
1 year recurrence of tumours. The treatment is safe, 
generally well tolerated, and easy to use. Fluorouracil is 
widely available, aﬀ ordable, and easy to formulate into 
eye drops. It is suitable in settings without cryotherapy. 
Fluorouracil eye drops are an eﬀ ective and realistic 
intervention to improve outcomes for people with OSSN.
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General discussion and future work
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Chapter 13. Discussion
Ocular surface squamous neoplasia is a complex multifaceted problem. (Figure 13.1) This
project aimed to address some of the knowledge gaps in this complex web. The most
prominent problems we see with regard to OSSN in sub-Saharan Africa are a high incidence,
recurrences after surgery and delayed presentation. This discussion will take a logical
framework approach examining each problem in turn and delving into the underlying causes
as shown in Figure 13.1.
The systematic review we conducted on the epidemiology of OSSN confirmed that the
incidence in Africa is the highest in the world and that women here were at similar risk as men
unlike other regions of the world where male disease predominated. The case-control study
we conducted showed that in the Kenyan setting this situation is driven by a combination of
modifiable risk factors all which are more common in Africa than in other parts of the world,
namely, HIV, exposure to solar UV radiation outdoors and allergic conjunctivitis. We also
identified that wearing hats was protective. The role of HPV remains unclear as studies show
a lot of variation. It is also still unclear why the incidence is equally high in both males and
females but prevalence seems higher in females. It may be related to HIV being a strong risk
factor for OSSN. Females have a higher biological susceptibility to HIV and other sexually
transmitted infections (STI) which may contribute to the high incidence.1 Women survive
longer with HIV than men perhaps from better ART compliance and acceptance which would
explain the high prevalence.2 The pathophysiology review implicated the limbal stem cells as
the possible nidus of neoplastic transformation in OSSN. The nasal limbus is particularly
susceptible to UV radiation. The finding of allergic conjunctivitis as a risk factor is new yet
consistent with the limbal stem cells being the origin of OSSN. The findings of this review
closely reflect what the case-control study found. Knowledge on how the risk factors interact
and the lead time between exposure and disease is evolving. However it is still not clear why
OSSN is often unilateral. Possible entry points for prevention would therefore need to focus
on women especially in prevention and control of HIV, wearing hats while outdoors and
effective control of allergic conjunctivitis in children and adolescents. A better understanding
of the pathophysiology would also highlight more options for therapeutic intervention focusing
on stem cells and genetic modification rather than just the rapidly dividing tumour cells that
current therapies seem to target.
229
Figure13.1. The OSSN problem tree. This diagram illustrates the negative aspects of the existing situation at the top and
the cause-and-effect relationships between them in a logic-frame approach.
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Recurrences highlight the need for effective treatments and the need to provide this in a timely
fashion. The trial we conducted provides a feasible local option. The value of experience is
demonstrated by a surgeon in Uganda who reported very low recurrence rates (3.2%).3
Without trial evidence of an effective treatment for OSSN it would be difficult for health policy
makers to make robust recommendations and health promotion messages would be
hampered if they highlighted a disease whose treatment remained unclear.
Various factors may be responsible for delayed presentation of OSSN. The absence of a
screening or early detection program is hampered by various factors. OSSN does not meet
most of the criteria for screening described by Wilson and Jungner in 1968 and now adopted
by the WHO.4 (Table 13.1) Early diagnosis is a particularly challenging. We also found that a
single histological type would show varying phenotype among affected patients. There is much
geographic variation worldwide in the phenotype of OSSN, the male to female ratio, age and
HIV association (Chapters 1 & 7). Clinical distinction between OSSN and other benign
conjunctival lesions is difficult (Chapter 7). They have similar features and this could partly be
related to a common pathophysiological pathway. Similar UV-related mutations of the p53
tumour suppressor gene and HPV have been observed in OSSN and benign lesions that some
of the latter are considered pre-malignant. 5, 6 Toluidine blue vital staining is challenged by
high false positives and was not as specific as a clinical assessment by a trained
ophthalmologist as we saw in the examination of photographs but it may have value for
screening performed by other health care workers (Chapter 8 & 9). The dye is easy to
reconstitute from commercially available powder which would make it widely available in sub-
Saharan Africa.
The diagnosis is further complicated by various other issues. Firstly, histopathology though
the gold standard for diagnosis is not without pitfalls. It is not widely available in sub-Saharan
Africa. Secondly, it is subjective and prone to inter- and intra-individual variation.7 Tissue
specimens are generally small as most tumours were 6.8mm wide (Chapter 7). Tissue
preparation and sectioning sometimes causes shearing off the superficial layers which can
lead to misinterpretation of the depth and margin involvement (see Figure 2b&h in Chapter 3).
Thirdly, the terminology ‘ocular surface squamous neoplasia’ has been described as
conceptually friendly but clinically perilous because it may refer to intraepithelial neoplasia
(which some surgeons may call pre-malignant) or invasive squamous cell carcinoma or both.8
The American Joint Committee on Cancer recognizes squamous cell carcinoma but does not
use the term OSSN. Fourthly, distinctions within the continuum of OSSN such as different
degrees of intraepithelial neoplasia and invasive carcinoma may not be clinically relevant to
management, bearing no association with response to treatment. Finally, the histological
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descriptions of OSSN appear bent towards conjunctival disease and do not address corneal
disease – whether primary or secondary involvement. Indeed even what we call benign is
considered by some to be pre-malignant.
At program level there are competing priorities in sub-Saharan Africa. The incidence of OSSN
is low compared to leading cancers such as breast, cervix, lung and prostate. It is not a leading
cause of blindness so it receives no attention from eyecare programs. Although strongly
associated with HIV, it is not in the radar screen of HIV care programs. We found that most
of our patients experienced delay despite already being enrolled in HIV care programs.
Although we now have evidence of the efficacy of 5FU, it is not registered as an eye
medication. It is an injection registered for gastrointestinal cancer treatment but has been used
off-label in ophthalmology for a long time. This leaves OSSN as an orphan disease.
There are also geographical variations in cost of treatment of OSSN. A recent US study found
that surgical treatment was more expensive than medical treatment with interferon therapy
(mean, $17 598; SD, $7624) vs mean, $4986; SD, $2040).9 In Africa surgery can be delivered
for a small fraction of the US cost. In the Kenyan context 5FU is affordable, available and
effective. The cost of a 4-week treatment course of 5FU eyedrops is 320 Kenyan shillings
(US$ 3.2 or Sterling £ 2.1). OSSN patients tended to have low education so advocacy is
difficult. It is therefore hard to find a champion for the disease unlike other cancers that may
affect famous people and get attention.
In the prevailing circumstances, it was difficult to put together a health promotion message
without evidence of effective treatment or suitable early diagnosis.
This project provided information to fill in some of the gaps and we plan some future work to
gain more new information. The planned future work will help to increase our understanding
of the pathophysiology and at program level, evidence for the effectiveness of a health
education tool to improve the referral of OSSN patients in the country. However, wide
geographical variation in disease patterns and risk factors may make joint mitigation efforts
worldwide difficult.
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Table 13.1 Wilson & Jungner criteria for screening and how OSSN performs on
each.
Criteria OSSN situation
1 The condition should be an important health
problem
Incidence compared to leading
cancers is low. Competing priorities
in the health sector
2 There should be an accepted treatment for patients
with recognized disease
Yes
3 Facilities for diagnosis and treatment should be
available
Inadequate
4 There should be a latent or early symptomatic
stage
Early stage exists
5 There should be a suitable test for examination Histopathology
6 The test should be acceptable to the population Requires surgery but on the whole
acceptable
7 The natural history of the condition, including
development from latent to declared disease,
should be understood
Unclear
8 There should be an agreed policy on who to treat
as patients
Not in place yet
9 The cost of case finding (including diagnosis and
treatment of patients diagnosed) should be
economically balanced in relation to possible
expenditure on medical care as a whole
Unclear
10 Case finding should be a continuing process and
not a ‘once and for all’ project
No program in place yet
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Chapter 14. Future work
The following future work is planned.
i) Stem cells study – we conducted immunohistochemistry staining of different histological types
of OSSN and some benign lesions for stem cell markers. Various stains reported to stain stem
cells in other tumours were used. The objective was to study the stem cell patterns if any in
OSSN. A manuscript is in preparation.
ii) Human papilloma virus (HPV) serotypes in OSSN – we extracted viral DNA from a set of
OSSN lesions for genome sequencing to study what types of HPV may be involved in OSSN.
Most other studies have used diagnostic kits that focused on cervical cancers. We hope our
study will reveal a wider array of genotypes of HPV. The sequencing component is still
ongoing.
iii) OSSN sequencing – we have held preliminary discussions with the Sanger Institute in
Cambridge to study the genetic mutations in OSSN tumours. The aim is to further explore the
gene mutations in OSSN that may be associated with UV radiation, HIV, HPV and smoking.
iv) Health Education and Early Detection (HEED) study – I have obtained a post-doctoral
fellowship grant (£90,000) from the Queen Elizabeth Jubilee Trust Fund through the
Commonwealth eye health consortium (http://cehc.lshtm.ac.uk/ ) to conduct a pilot project to
promote early awareness and early referral of OSSN in Kenya.
v) Validation study to see the effectiveness of the algorithm for screening by other health workers
(non-Ophthalmologists).
vi) Make 5FU available in Kenya as effectiveness has been demonstrated. We would need to
work with the Kenya Pharmacy and Poisons Control Board and the manufacturer who
produced it for the study.
vii)Long-term follow up of 5FU trial participants – we continue following up our trial participants
with the aim of reporting 3-year results.
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Appendices
1. Diagnosing ocular surface squamous neoplasia in East Africa: case-control study of clinical
and in vivo confocal microscopy assessment.
2. Ocular rhinosporidiosis mimicking conjunctival squamous papilloma in Kenya – a case report
3. Ethics committee approvals
4. RCT registration, regulatory authority approval and protocol
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Diagnosing Ocular Surface Squamous
Neoplasia in East Africa
Case-Control Study of Clinical and In Vivo Confocal
Microscopy Assessment
Marie B. Nguena, MMed,1 Jan G. van den Tweel, MD, PhD,2 William Makupa, MMed,1
Victor H. Hu, PhD, MRCOphth,1,3 Helen A. Weiss, MSc, PhD,4 Stephen Gichuhi, MBChB, MMed,3,5
Matthew J. Burton, PhD, FRCOphth1,3
Objective: To examine the reliability of clinical examination and in vivo confocal microscopy (IVCM) in dis-
tinguishing ocular surface squamous neoplasia (OSSN) from benign conjunctival lesions.
Design: Case-control study.
Participants: Sixty individuals with conjunctival lesions (OSSN and benign) and 60 age-matched controls
with normal conjunctiva presenting to Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
Methods: Participants were examined and photographed, and IVCM was performed. Patients with
conjunctival lesions were offered excisional biopsy with histopathology and a human immunodeﬁciency virus
(HIV) test. The IVCM images were read masked to the clinical appearance and pathology results. Images were
graded for several speciﬁc features and given an overall categorization (normal, benign, or malignant). A group of
8 ophthalmologists were shown photographs of conjunctival lesions and asked to independently classify as
OSSN or benign.
Main Outcome Measures: Comparison of the histopathology diagnosis with the clinical and IVCM
diagnosis.
Results: Fifty-two cases underwent excisional biopsy with histopathology; 34 were on the OSSN spectrum,
17 were benign, and 1 was lymphoma. The cases and controls had comparable demographic proﬁles. Human
immunodeﬁciency syndrome infection was more common in OSSN compared with benign cases (58.8% vs.
5.6%; odds ratio, 24.3, 95% conﬁdence interval [CI], 2.8e204; P ¼ 0.003). Clinically, OSSN lesions more
frequently exhibited feeder vessels and tended to have more leukoplakia and a gelatinous appearance. Overall,
the ophthalmologists showed moderate agreement with the histology result (average kappa ¼ 0.51; 95% CI,
0.36e0.64). The masked grading of IVCM images reliably distinguished normal conjunctiva. However, IVCM was
unable to reliably distinguish between benign lesions and OSSN because of an overlap in their appearance
(kappa ¼ 0.44; 95% CI, 0.32e0.57). No single feature was signiﬁcantly more frequent in OSSN compared with
benign lesions. The sensitivity and speciﬁcity of IVCM for distinguishing OSSN from benign conjunctival lesions
were 38.5% and 66.7%, respectively.
Conclusions: In East Africa, conjunctival pathology is relatively common and can present signiﬁcant diag-
nostic challenges for the clinician. In this study, neither clinical examination nor IVCM was found to reliably
distinguish OSSN from benign conjunctival pathology because of an overlap in the features of these groups.
Therefore, IVCM cannot currently replace histopathology, and management decisions should continue to rely on
careful clinical assessment supported by histopathology as indicated. Ophthalmology 2014;121:484-491 ª 2014
by the American Academy of Ophthalmology.Ocular surface squamous neoplasia (OSSN) is the most
common malignant ocular surface disease in Africa.1e3 It
ranges from small areas of conjunctiva intra-epithelial
neoplasia (CIN) to large invasive squamous cell carcinoma
(SCC).4 There has been a marked increase in the incidence
of this disease in East Africa over the last couple of decades,
attributed to human immunodeﬁciency virus (HIV)/
AIDS.3,5e7 The disease now presents at a younger age
than previously and affects more women than men.
Although HIV positivity is a well-deﬁned major risk factor484  2014 by the American Academy of Ophthalmology
Published by Elsevier Inc.
237for OSSN, approximately half of all cases in East Africa are
HIV positive and the role of other etiologic factors needs to
be deﬁned.4,7 Data from case-control studies suggest that
damage from ultraviolet light exposure in equatorial regions
may be important.7 Human papilloma virus has been
postulated to be involved, but its contribution remains
uncertain despite several studies.8
One of the challenges facing clinicians managing OSSN
is distinguishing early neoplastic from benign lesions
(Fig 1A, B). This is a particular problem in East Africa,ISSN 0161-6420/14/$ - see front matter
http://dx.doi.org/10.1016/j.ophtha.2013.09.027
Figure 1. Photographs of a pterygium and various grades of ocular surface squamous neoplasia: pterygium (A), conjunctiva intra-epithelial neoplasia (CIN)
1 (B), CIN 3 (C), carcinoma in situ (D), squamous cell carcinoma (SCC) grade 1 (E), SCC grade 2 (F), SCC grade 3 (G), and SCC with orbital invasion
(H).
Nguena et al  Diagnosing OSSN in East Africawhere benign conjunctival changes (pterygium, pingeculum)
are relatively common. There is probably an overlap in
the clinical features of these different benign lesions
and OSSN, with no signs being exclusive to OSSN,
although this has not been formally evaluated. Some
features have been reported to be more common in
advanced cases of OSSN.4 Histopathology is necessary
to conﬁrm a diagnosis of OSSN. However, pathology
services are generally scarce in East Africa outside larger238centers. As a result, many lesions are excised without
pathologic analysis.
The standard approach for treating suspected OSSN is an
excisional biopsy, often with cryotherapy to the conjunctival
margin and sometimes with topical chemotherapy.9,10 An
initial incisional biopsy is usually performed for larger
lesions to make a diagnosis to plan treatment. In recent
years, there has been a move to consider primary topical
chemotherapy for suspected OSSN without a tissue485
Ophthalmology Volume 121, Number 2, February 2014diagnosis.11 Given the potential uncertainty of diagnosis
based on clinical signs alone, several groups have
investigated whether in vivo confocal microscopy (IVCM)
can help distinguish cases of OSSN.12e16 These reports of
relatively few cases (26 in the whole literature) have tended
to conclude that IVCM may be helpful in making a diag-
nosis of OSSN. Several speciﬁc features, such as irregular
cell size, hyper-reﬂectivity, prominent bright nucleoli
(“starry night appearance”), and mitotic ﬁgures, have been
singled out as potential markers for OSSN.13
We report a prospective study of patients with conjunc-
tival lesions presenting to an ophthalmic unit in Tanzania.
We investigate the diagnostic accuracy of the clinical
examination and whether certain features help to distinguish
OSSN from benign lesions. Second, we evaluate the utility
of IVCM in identifying OSSN in a masked study of
conjunctival lesions.Methods
Ethical Approval
This study adhered to the tenets of the Declaration of Helsinki. It
was reviewed and approved by the Kilimanjaro Christian Medical
Centre (KCMC) Ethics Committee, Tanzania.Study Design and Participants
In this case-control study, we compared individuals with
conjunctival lesions (“cases,” either benign or OSSN) with indi-
viduals with clinically normal conjunctiva (“controls”). Recruit-
ment of both cases and controls was conducted at the Department
of Ophthalmology, KCMC Hospital, Moshi, Tanzania, from May
to November 2011. Cases were consecutive individuals presenting
with a conjunctival lesion that on clinical grounds required surgical
excision. For each case, we recruited a control presenting for
a condition that was not affecting the ocular surface and who had
healthy conjunctiva on slit-lamp examination (e.g., cataract). These
control participants were age-matched to the corresponding case
(5 years). All participants were aged 18 years or older. The study
was explained to eligible study subjects, and written informed
consent was obtained before enrollment. All enrolled patients with
conjunctival lesions received counseling and were offered testing
for HIV, which is standard of care at KCMC. Patients with
a positive HIV test result were referred to the Comprehensive
Treatment Center.Clinical Assessment
Patients with conjunctival lesions were asked about symptoms
(ocular pain, irritation, itchiness, redness, decreased vision, prop-
tosis, and discharge). Participants were asked where they lived
within Tanzania and their main occupation. The surface of the eye
was carefully examined with a slit lamp for conjunctival
pathology. We recorded lesion location and size and the presence
of speciﬁc features, including ﬁbrovascular tissue (Fig 1A, B),
leukoplakia (Fig 1C), gelatinous appearance (Fig 1D), feeder
vessels (Fig 1D), papilliform structure (Fig 1F), limbal
involvement, and orbital invasion (Fig 1H). The lesions were
photographed using a digital single lens reﬂex camera with
a macro lens.486
239In Vivo Confocal Microscopy Examination
In vivo confocal microscopy examination of the bulbar conjunctiva
was performed using the Heidelberg Retina Tomograph 3 in
combination with the Rostock Corneal Module (Heidelberg Engi-
neering GmbH, Dossenheim, Germany). A sterile, disposable
polymethylmethacrylate cap was mounted on the head of the
confocal microscope, and a drop of topical anesthetic (proparacaine
0.5%) was instilled into the inferior fornix of the eye before the
examination. For cases, the lesion and surrounding areas were
scanned. For controls, the temporal or nasal inter-palpebral
conjunctiva was scanned. Representative images of the examined
conjunctiva were obtained using the “volume scan” mode, which
collects a series of 40 parallel images 2 mm apart; both surface
(starting at the epithelium) and deeper sets of scans were
performed.
All confocal images were graded over a 2-day period, after
recruitment had been completed. Two ophthalmologists (M.B.N.,
M.J.B.) jointly examined all the images; they were masked to the
case/control status, clinical features, and histopathology results.
The grading of the images was based on separately examining each
of the 40 parallel images in each of the volume scan stacks. The
following features, which are said to be potentially discriminating
in previous studies, were evaluated: variable epithelial cell size,
hyperreﬂectivity, presence of mitotic cells, and prominent bright
nucleoli (“starry night appearance”) (Fig 2).13 An overall
provisional categorization based on the IVCM ﬁndings was
made: (1) normal, (2) abnormal benign, or (3) abnormal malignant.
Surgical Treatment
Lesions were treated surgically. Small to medium-sized lesions that
were clinically suspicious for OSSN were fully excised using the
“no touch technique” with a 3- to 4-mm margin of healthy-looking
tissue. Surgical sponges saturated with 5-ﬂuorouracil were applied
to the excision site for 5 minutes followed by irrigation with normal
saline. 5-Fluorouracil treatment was not used if the case was thought
to be benign pathology, such as a pterygium. Incisional biopsies
were performed for large lesions to obtain tissue for histology
assessment. If malignant pathology was conﬁrmed, radical surgery
(enucleation or exenteration) was then offered to the patient. Biopsy
tissue was not collected from the normal controls.
Histopathology
Biopsy specimens from the cases were immediately placed in 10%
formaldehyde solution. These were mounted in parafﬁn wax, and
5-mm sections were cut perpendicular to the conjunctival surface
and stained with hematoxylineeosin. All specimens were exam-
ined by a single pathologist (J.G.T.). Ocular surface squamous
neoplasia was classiﬁed using the standard deﬁnitions for mild
(CIN I), moderate (CIN II), and severe (CIN III) dysplasia, carci-
noma in situ, and invasive SCC.17 Squamous cell carcinoma was
subdivided by the degree of differentiation: well (I), moderate
(II), and poor (III).
Clinical Diagnosis Study
To evaluate the ability of clinicians to correctly distinguish
between benign and malignant conjunctival lesions, we showed
a group of 8 ophthalmologists (3 consultants and 5 residents)
a series of 43 photographs of lesions for which a histologic diag-
nosis also was available by the time this component was con-
ducted. This included a mixture of benign and neoplastic
pathologies. They were asked to independently write down their
diagnosis and whether they thought it was benign or malignant.
Figure 2. In vivo confocal microscopy images of conjunctival ocular surface squamous neoplasia. A, Small hyper-reﬂective cells. B, Large hyper-reﬂective
cells of variable size. C, Possible mitotic ﬁgure (arrow) and prominent basal cell nucleoli. D, Amorphous, possibly keratinized material. Scale bar 50 mm.
Nguena et al  Diagnosing OSSN in East AfricaData Analysis
Data were entered into Access 2007 (Microsoft Corp., Redmond,
WA) and analyzed using Stata 11.0 (StataCorp LP, College
Station, TX). Demographic characteristics of cases and controls
were compared by conditional logistic regression. For the purpose
of analysis, occupation was condensed to “indoors” or “outdoors”
and region of residence to “Kilimanjaro region” and “outside
Kilimanjaro region.” The Wilcoxon rank-sum test was used to
compare the ages between cases and control because the distribu-
tion was skewed. The frequency of clinical signs and symptoms in
benign and neoplastic lesions was compared using the Fisher exact
test.
The Kappa statistic was used to assess the agreement between
the categorized tissue diagnosis (benign or OSSN), and clinical
diagnosis made from photographs by the 8 ophthalmologists
(benign or OSSN). To calculate an average value, the kappa
statistics for each grader were transformed to Z scores using the
Fisher Z transformation, averaged, and then back-transformed to
a kappa statistic. The clinical and IVCM features were analyzed in
relation to the histologic diagnosis. Associations between the tissue
diagnosis and the presence of speciﬁc clinical or IVCM features240were assessed by the Fisher exact test. Agreement between the
categorized tissue diagnosis (normal, benign, or malignant) and the
masked IVCM grading (normal, benign, or malignant) was
assessed by a weighted Kappa statistic.Results
Study Participants
Sixty individuals with conjunctiva lesions (cases) and 60 age-
matched controls with healthy ocular surfaces were recruited.
The cases and controls had comparable demographic proﬁles: age,
sex, region of origin, and occupational history (Table 1).
Diagnoses
Five cases declined surgical excision of their lesions, and a further
3 cases had surgical excision without histopathology, leaving 52 of
60 cases with a histologic diagnosis (Table 1). For 34 cases, the
histologic diagnosis was on the OSSN spectrum, 17 had benign
lesions, and 1 case had lymphoma. Of the 8 cases without487
Table 2. Symptoms and Clinical Signs by Histologic Diagnosis
OSSN Cases Benign Cases* P Valuey
Symptom
Irritated red eye 21 (61.7%) 8 (44.4%) 0.26
Discharge 20 (58.8%) 11 (61.1%) 1.00
Foreign body sensation 14 (41.1%) 10 (55.5%) 0.39
Decreased vision 8 (23.5%) 3 (16.6%) 0.73
Pain 5 (14.7%) 5 (27.7%) 0.29
Proptosis 5 (14.7%) 1 (5.5%) 0.65
Itchy 2 (5.8%) 1 (5.5%) 1.00
Mean duration
(mos, 95% CI)
3.7 (2.4e5.8) 8.8 (3.9e19) 0.029
Sign
Feeder vessel 30 (88.2%) 11 (61.1%) 0.034
Limbal involvement 26 (76.4%) 9 (50.0%) 0.07
Leukoplakia 15 (44.1%) 3 (16.6%) 0.07
Gelatinous 13 (38.2%) 2 (11.1%) 0.055
Pedunculated 4 (11.7%) 2 (11.1%) 1.00
Papilliform 2 (5.8%) 1 (5.5%) 1.00
Orbital invasion 2 (5.8%) 0 (0.0%) 0.54
Fibrovascular tissue 1 (2.9%) 7 (44.4%) 0.001
CI ¼ conﬁdence interval; OSSN ¼ ocular surface squamous neoplasia.
*Including 1 lymphoma case.
yP values calculated using Fisher exact test for variables except duration,
which was calculated by Wilcoxon rank-sum test.
Table 1. Demographic Characteristics and Diagnoses of Study
Participants
Characteristics
Cases Controls
Total P Value*N ¼ 60 N ¼ 60
Female 30 (50%) 36 (60%) 66 (55%) 0.28
Region (Kilimanjaro) 35 (58.3%) 39 (65.0%) 74 (61.6%) 0.45
Occupation (outdoor) 35 (58.3%) 30 (50.0%) 65 (54.1%) 0.34
Age (yrs)
Mean 43.5 43.7 43.6 0.95
Range 23e80 21e75 21e80
Histologic diagnosis
CIN I 2 (3.3%) e e
CIN II 3 (5.0%) e e
CIN III 5 (8.3%) e e
CIS 5 (8.3%) e e
SCC I 12 (20.0%) e e
SCC II 4 (6.6%) e e
SCC III 3 (5.0%) e e
Lymphoma 1 (1.6%) e e
Pterygium 5 (8.3%) e e
Pingueculum 3 (5.0%) e e
Papilloma 3 (5.0%) e e
Other benign lesions 6 (10.0%) e e
No histopathology 8 (13.3%) e e
Control diagnosis
Normal examination e 26 (43.3%) e
Diabetic retinopathy e 10 (16.6%) e
Cataract e 9 (15.0%) e
Glaucoma e 3 (5.0%) e
Astigmatism e 6 (10.0%) e
Hyperopia e 1 (1.6%) e
Presbyopia e 3 (5.0%) e
Optic atrophy e 1 (1.6%) e
Myopia e 1 (1.6%) e
CIN ¼ conjunctiva intra-epithelial neoplasia; CIS ¼ carcinoma in situ;
SCC ¼ squamous cell carcinoma.
*P value from conditional logistic regression for sex, region, and occupation
and from Wilcoxon rank-sum test for age.
Table 3. Human Immunodeﬁciency Virus Test Results by Tissue
Diagnosis of Conjunctival Lesions
Tissue Diagnosis HIV Positive OR 95% CI P Value
Benign lesions* 1/18 (5.6%) 1 e e
CIN 7/15 (46.7%) 14.9 1.56e142 0.019
SCC 13/19 (68.4%) 36.8 3.93e344 0.002
CI ¼ conﬁdence interval; CIN ¼ conjunctiva intra-epithelial neoplasia;
HIV ¼ human immunodeﬁciency virus; OR ¼ odds ratio; SCC ¼ squa-
mous cell carcinoma.
*Including 1 lymphoma case.
Ophthalmology Volume 121, Number 2, February 2014histology, the clinical diagnosis was OSSN in 6, pterygium in 1,
and pingeculum in 1. Biopsy tissue was not collected from
control participants with clinically normal conjunctiva. The most
common clinical diagnoses of controls were normal examination
results, diabetic retinopathy, and cataract (Table 1).
Symptoms and Signs
Among individuals with conjunctival lesions, there was no
difference in the frequency of various symptoms between benign
and OSSN cases (Table 2). However, OSSN cases had a shorter
time to presentation, suggesting a more symptomatic or rapidly
evolving lesion (3.7 vs. 8.8 months; P ¼ 0.03). Several clinical
signs were more frequently found in eyes with OSSN (with
borderline statistical signiﬁcance): feeder vessel, leukoplakia, and
gelatinous appearance (Fig 1, Table 2). A ﬁbrovascular
appearance was more frequent among benign lesions. The OSSN
lesions tended to be larger than benign lesions, although this
difference was not signiﬁcant (Wilcoxon rank-sum P ¼ 0.8).
Human Immunodeﬁciency Virus and Conjunctival
Lesions
Among the 52 cases (benign and OSSN) with a tissue diagnosis,
there was a strong association between HIV and OSSN (58.8%)488
241compared with benign cases (5.6%) (odds ratio, 24.3; 95% conﬁ-
dence interval [CI], 2.8e204; P ¼ 0.003) (Table 3). Human
immunodeﬁciency virus infection also tended to be more frequent
in people with SCC compared with CIN (68.4% vs. 46.7%;P¼ 0.2).
Reliability of the Clinical Diagnosis
Eight ophthalmologists were shown a consecutive series of 43
images of conjunctival lesions and asked to classify them into 2
broad categories of benign and neoplastic. Their diagnoses were
compared with the histopathology results, and kappa statistics were
calculated: average kappa statistic 0.51 (95% CI, 0.36e0.64). Two
ophthalmologists had “fair” agreement (kappas of 0.21 and 0.40), 3
ophthalmologists had “moderate” agreement (0.41e0.60), and 3
ophthalmologists had “substantial” agreement (0.61e0.80). The
correct diagnosis was made in 56% to 86% of the cases.
In Vivo Confocal Microscopy
In vivo confocal microscopy was attempted on all 120 cases and
controls, and the scans were graded in a masked manner. Three
controls were excluded because of inadequate IVCM images.
Histopathology results were available for 52 of 60 cases. The
archived IVCM images from 8 of 52 of the cases were not of
Table 4. In Vivo Confocal Microscopy Features by Disease Group,
Based on Masked Grading
IVCM Features
Controls
Benign
Cases*
OSSN
Cases P
Valuey
P
ValuezN/57 (%) N/18 (%) N/26 (%)
Hyper-reﬂective
cells
<0.001 0.9
None 54 (94.7%) 7 (38.3%) 12 (46.1%)
<50% 3 (5.3%) 7 (38.8%) 8 (30.7%)
>50% 0 (0.0%) 4 (22.2%) 6 (23.1%)
Variation in cell
size
<0.001 0.5
Uniform 55 (96.4%) 9 (50%) 17 (65.3%)
Mild 1 (1.7%) 6 (33.3%) 4 (15.3%)
Marked 1 (1.7%) 3 (16.7%) 5 (19.2%)
Starry night
appearance of
basal cells
0.001 0.8
Nil 57 (100%) 14 (77.7%) 22 (84.6%)
Few to many 0 (0.0%) 2 (11.1%) 1 (3.8%)
Amorphous
material
0 (0.0%) 2 (11.1%) 3 (11.5%)
IVCM ¼ in vivo confocal microscopy; OSSN ¼ ocular surface squamous
neoplasia.
*Including 1 lymphoma case.
yP value is for the comparison of normal controls with all cases (benign and
malignant combined) by Fisher exact test.
zP value is for the comparison of benign with malignant cases, by Fisher
exact test.
Table 5. Comparison of the Overall Classiﬁcation from the
In Vivo Confocal Microscopy Based on Masked Grading (Normal,
Benign, or Malignant) versus the Final Histologic Diagnosis
Tissue Diagnosis
IVCM Diagnosis
TotalNormal Abnormal Benign Malignant
Normal control 50 7 0 57
Benign lesion 4 8 6 18
Malignant lesion 5 11 10 26
Total 59 26 16 101
IVCM ¼ in vivo confocal microscopy.
Grey shading highlights where there was agreement.
Nguena et al  Diagnosing OSSN in East Africasufﬁcient quality for masked grading. Therefore, the analysis of
IVCM was limited to 101 participants: 44 cases (with both histo-
pathology and adequate scans) and 57 controls.
The IVCM images were examined for the presence of speciﬁc
features: hyper-reﬂective cells, variation of cell size, mitotic cells,
and “starry night” appearance of the basal layer (Fig 2, Table 4).
Several lesions showed marked surface changes on IVCM with
extensive, hyper-reﬂective material with large irregular cellular
structure. A possible mitotic cell was observed in only 1 lesion (Fig
2C). Among the 57 controls with IVCM images, 3 had some
hyper-reﬂective cells and 2 showed some variation in epithelial
cell size. For each of the graded features, there were statistically
signiﬁcant differences in their frequency between the normal
controls and cases (benign and malignant combined). However, we
found no evidence for a difference in the frequency of these IVCM
features between benign and malignant conjunctival lesions.
Each set of IVCM images was given an overall classiﬁcation by
the masked readers: normal, benign abnormal, or malignant. The
comparison of this overall IVCM classiﬁcation with the histopa-
thology diagnosis is shown in Table 5. Agreement was found to be
moderate with an unweighted kappa score of 0.44 (95% CI,
0.32e0.57). The linear weighted kappa score was 0.54 (95% CI,
0.40e0.67). The sensitivity and speciﬁcity of IVCM for
distinguishing OSSN from benign conjunctival lesions were 38.5%
(95% CI, 0.21e0.59) and 66.7% (95% CI, 0.41e0.86), respectively.
Discussion
Timely detection and treatment of OSSN are challenges in
East Africa, with many patients only presenting when the
lesion is already established. The reasons for this are many:
Access to eye care services outside the major urban centers
is generally limited; therefore, patients may delay traveling242for treatment until the lesion is more obvious and symp-
tomatic. When patients do present, there can be further delay
in making the diagnosis of OSSN because initially it may be
thought to be a benign lesion. Delayed or missed diagnosis
can have considerable effects on ocular morbidity and even
mortality.
In this study based in an East African ophthalmic referral
center, OSSN was a common cause of conjunctival
pathology, with presentation rates comparable to those in
previous reports from this unit.3,4 Time between onset of
symptoms and presentation was shorter for OSSN than for
benign lesions, possibly because OSSN develops more
rapidly. However, some individuals with OSSN had noticed
a problem many months earlier. Strategies are needed to
raise general awareness that growths on the eye need prompt
attention. This is particularly important in people who have
a known diagnosis of HIV, but this needs to be done in
a way that minimizes stigma.
There is an overlap in the clinical signs of (early) OSSN
and some benign lesions (Fig 1A, B). However, a number of
features tended to be more frequent in cases of OSSN:
feeder vessels, gelatinous appearance, and leukoplakia.
These and other signs could form the basis of a diagnostic
algorithm to assist the clinician in identifying OSSN
cases, and they warrant further study in a larger data set.
Overall, the 8 ophthalmologists, most of whom had seen
many cases of OSSN previously, achieved only moderate
agreement with the histologic diagnosis. There was a wide
range in their diagnostic accuracy, suggesting that if the
key features that point to a diagnosis of OSSN can be
identiﬁed and emphasized in training, there should be
scope to improve the detection rate.
The prevalence of HIV infection in OSSN cases was
comparable to that in previous studies from the region.4
Human immunodeﬁciency virus seems to be a risk factor
for developing more severe disease, being more frequent
among cases with SCC than CIN. There was no difference
in the time between the onset of symptoms and the
presentation between SCC and CIN, suggesting that HIV
infection permits a more rapid progression in the disease.
In vivo confocal microscopy is a potentially useful tool in
the management of several external eye diseases. It has been
particularly helpful in the diagnosis of acanthamoeba and
ﬁlamentary fungal keratitis.18 We have also found the
technique informative in the study of conjunctival scarring489
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IVCM clearly distinguished between normal conjunctiva
and lesions (benign or malignant). A few clinically normal
controls had some minor changes on IVCM, which might
be attributable to solar radiation damage. In contrast, it
was not possible to reliably distinguish between OSSN
and benign conjunctival lesions because there seems to be
an overlap in the IVCM features of these various
conditions. We did not identify any features that were
exclusive to OSSN. Of particular note was the ﬁnding that
there were several cases of OSSN that were classiﬁed as
normal on IVCM.
Our conclusion that IVCM does not reliably distinguish
OSSN from other conjunctival pathology contrasts with
earlier reports that suggest it may be possible to use it for
this purpose.12e16 However, these earlier reports, mostly
from Europe (where the disease spectrum is different), have
tended to be of relatively few cases. Moreover, with the
exception of 1 series of 4 cases, benign lesion controls have
not been recruited for comparison. Finally, the assessment
of the images was not masked in all but 1 of the previous
studies.16 Without systematic masked comparison with
benign lesions, it is difﬁcult to know how useful the
observed features are. Studies of the IVCM appearance of
pterygium have reported hyper-reﬂective epithelial cells,
a feature previously said to be associated with OSSN.20,21
This is the ﬁrst time IVCM has been used in Africa to
study OSSN. Overall, the disease tends to be more advanced
and aggressive in this context, and clinical/IVCM features
may show signiﬁcant variation from studies of Caucasian
patients with disease largely unassociated with HIV. Further
validation is needed using masked grading of OSSN and
other conjunctival pathology in other settings.
Study Limitations
First, histopathology was not available for all conjunctival
lesions because the patient declined surgery or the surgeon
did not send a sample for analysis. Second, it was not
always possible to obtain IVCM scans of sufﬁcient quality
for the masked grading, usually because the patient was
unable to tolerate the examination. Third, the masked
analysis was limited to the set of stored volume scans; in
practice, the formation of a diagnostic impression with
IVCM is based on a continuous, dynamic examination in
which the examiner is not masked to the clinical appearance
of the eye. A limitation of current IVCM technology is that
it is not possible to identify exactly where on the lesion the
scan is collected from; therefore, it is not possible to put it in
exact correspondence with ﬁndings from histopathology.
Finally, the conclusions of this study may not be general-
izable to the use of IVCM to detect OSSN in other settings if
the distribution of disease stage is different.
In conclusion, ocular surface squamous neoplasia
remains a major clinical challenge in the East African
context. A simple and cheap diagnostic test to help distin-
guish benign from malignant pathology would be of
considerable utility in the East African context, where
pathology services may not be readily available.490
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http://www.biomedcentral.com/1471-2415/14/45CASE REPORT Open AccessOcular rhinosporidiosis mimicking conjunctival
squamous papilloma in Kenya – a case report
Stephen Gichuhi1,2*, Timothy Onyuma3, Ephantus Macharia4, Joy Kabiru4, Alain M’bongo Zindamoyen4,
Mandeep S Sagoo5,6 and Matthew J Burton2,5Abstract
Background: Ocular rhinosporidiosis is a chronic granulomatous infection caused by a newly classified organism
that is neither a fungus nor bacterium. It often presents as a benign conjunctival tumour but may mimic other
ocular conditions. It is most often described in India. In Africa cases have been reported from South Africa, Kenya,
Tanzania, Malawi, Uganda, Congo and Ivory Coast.
Case presentation: A 54 year old man was seen in Kenya with a lesion that resembled a conjunctival papilloma.
We report resemblance to conjunctival papilloma and the result of vital staining with 0.05% Toluidine Blue.
Conclusion: Ocular rhinosporidiosis occurs in East Africa. It may resemble conjunctival squamous papilloma. Vital
staining with 0.05% Toluidine blue dye did not distinguish the two lesions well.
Keywords: Ocular rhinosporidiosis, Rhinosporidium seeberi, Conjunctival papilloma, Toluidine-blue, AfricaBackground
Rhinosporidiosis is a chronic granulomatous infection of
the mucous membranes (nasal, oral, ocular and rectal)
caused by Rhinosporidium seeberi [1]. This is an unusual
unicellular pathogen that is difficult to culture and
whose taxonomic classification has been controversial. It
has been variously hypothesized to be a cyanobacterium
(prokaryote), a eukaryotic Mesomycetozoa or a fungus
[2]. Currently it is domiciled in the Mesomycetozoea
class (also known as the DRIP clade, or Ichthyosporea).
The term Mesomycetozoea derives from “Meso-” (in the
middle of ), “-myceto-” (fungi) and “-zoea” (animals).
This is a heterogeneous group of microorganisms at the
animal-fungal boundary. The Mesomycetozoea are a
small group of protists, which are mostly parasites of
fish and other animals.
Rhinosporidiosis affects both adults and children and
is commonly seen in otolaryngology. The largest re-
ported case series of rhinosporidiosis consisting of 462
cases in India found that the disease mainly occurs in
the nose and nasopharynx (81.1%) while the eye was af-
fected in 14.2% [3]. Another series of 34 cases from* Correspondence: sgichuhi@uonbi.ac.ke
1Department of Ophthalmology, University of Nairobi, Nairobi, Kenya
2London School of Hygiene and Tropical Medicine, London, UK
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246India also found nasal and nasopharyngeal involvement
in 85% while the eye was affected in 9% of cases [4]. A
case involving multiple parts of the body; the nares, mul-
tiple areas of the skin, the external urethral meatus,
glans of penis and the perineum has been reported in
India [5].
Ocular rhinosporidiosis affecting the conjunctiva was
first described in India in 1912 [6]. Currently most pub-
lished reports on rhinosporidiosis of the eye have been
reported from Asia mainly from India, Sri Lanka, Nepal
and Bangladesh. In Africa it has been reported in South
Africa, Malawi, Zambia, Kenya, Uganda, Tanzania,
Congo, Ivory Coast, and Cameroon [7-13]. None of the
cases in Africa were initially diagnosed as ocular rhinos-
poridiosis, perhaps a sign of its rarity.
How the disease is acquired remains an enigma. Rhi-
nosporidiosis has been associated with migrants from
endemic areas [14-16]. Although it is an infectious dis-
ease, as lesions are always associated with the presence
of the pathogen, there is limited data on how it might be
transmitted [15]. It is presumed to be acquired through
traumatized nasal mucosa and spread to other sites by
autoinoculation. As most rhinosporidiosis lesions arise
from the nose, it is feasible that ocular involvement may
occur by spreading from the nose through the lacrimall Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Pre-operative clinical photographs. A & B – shows the ocular rhinosporidiosis lesion in the region of the right medial canthus.
C & D - shows squamous papilloma in the left medial canthus area from another patient for comparison. Both lesions are shown before and after
vital staining with 0.05% Toluidine Blue.
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however unproven.
Ocular rhinosporidium most often presents as a polypoid
mass of the palpebral conjunctiva [17]. It may also present
as a lacrimal sac diverticulum [18], recurrent chalazion
[19], conjunctival cyst [20], chronic follicular conjunctivitis
in contact lens wearers [21], peripheral keratitis [22], scleral
melting [23], ciliary staphyloma [24] or simulate a tumour
of the eyelid [25] or periorbital skin [26]. Large conjunc-
tival lesions may cause mechanical ectropion [27]. Lacrimal
sac disease may present with bloody tears [16].
In a series of 63 cases from India that included nasal,
nasopharyngeal and ocular disease, routine haematology
tests did not show any abnormality and while cytologyFigure 2 Photomicrograph of ocular rhinosporidiosis stained
with Haematoxylin & Eosin (H & E ×10) showing multiple
sporangia within the conjunctival stroma (block arrows).
247of smears obtained via fine needle aspiration or cytology
has a role in diagnosis, the mainstay remains histology
[28]. Vital staining with Toluidine blue has been de-
scribed for diagnosis of conjunctival tumours but not for
rhinosporidiosis [29].
The treatment is surgical excision with or without cau-
tery at the base and recurrence is described as rare [30].
Scleral melting may be treated with a tectonic corneal graft
[31]. There are reports that the following agents are effect-
ive in vivo: imidocarb diproprionate, diminazine aceturate,
cycloserine, dapsone, trimethoprim-suphadiazine, ketoco-
nazole, sodium stibogluconate, and amphotericin B [32].
Dapsone is the most commonly reported drug and com-
bination therapy to prevent drug resistance is recom-
mended. A laboratory study in India found that biocidesFigure 3 Multiple sporangia with a reactive mixed
inflammatory cell infiltrate (H & E ×20).
Figure 4 Sporangium at higher magnification filled with
endoconidia and surrounded by plasma cells and lymphocytes
(H & E ×40).
Figure 6 Ulcerated surface epithelium (open arrows) with a
fibrin plaque and granulation tissue on the basal side of the
ulcer (H & E ×20).
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nol, chlorhexidine, cetrimide, thimerosal, 70% ethanol, iod-
ine in 70% ethanol, 10% formalin, povidone-iodine, sodium
azide and silver nitrate caused metabolic inactivation with
or without altered structural integrity of the endoconidia of
Rhinosporidium seeberii but no human trials have been
reported [33]. Human anti-rhinosporidial antibody is not
directly protective against the endoconidia [34].Case presentation
A 54-year-old male presented to the eye clinic at the
PCEA Kikuyu Hospital on the outskirts of Nairobi with
a 16 month history of a painless lump on the surface of
the right eye. Concerned about the appearance, he at-
tributed the lesion to a foreign body that entered that
eye while he was trimming a hedge.Figure 5 Burst sporangium with discharged microsporangia
surrounded by an inflammatory cell infiltrate (H & E ×40).
248No other family member or neighbour had a similar dis-
ease. Social history included living in Homa Bay district
on the shores of Lake Victoria from birth to 18 years age,
then Kapsabet, a highland area in the Rift Valley until the
age of 26 years, followed by Nairobi. He had resided in a
low-income area of Nairobi for the past 11 years. Occupa-
tional history included working as a gardener for the last
10 years and a cook for 5 years prior to that. Although he
grew up in a lakeside area, he had not dived or swum in
stagnant water in the recent past.
On examination he had a pedunculated 6×11 mm wide
fleshy mass at the medial canthus of the right eye (Figure 1),
which was pink with some intrinsic pigmentation. It had a
papilliform surface with vascular tufts and some epithelial
ulceration. There was no discharge or conjunctival injec-
tion. The mass was not attached to the lid but arose from
the plica semilunaris. On vital staining with 0.05%
Toluidine Blue it was coloured deep blue except at the
ulcerated surface, similar to the staining of a papilloma.
The clinical diagnosis was of conjunctival papilloma and
surgical excision under local anaesthetic was undertaken.
Histological analysis revealed multiple sporangia in the
conjunctival stroma, an ulcerated squamous epithelium
covered by a fibrin plaque whose underlying tissue
showed granulomatous tissue, mixed inflammatory cellsFigure 7 Post-operative photographs showing no recurrence
6 months after excision of ocular rhinosporidiosis.
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numerous thick walled sporangia filled with nucleated
basophilic endoconidia (Figures 2, 3, 4, 5 and 6). A diag-
nosis of ocular rhinosporidiosis was made.
There was no recurrence 6 months after excision was
performed (Figure 7).
Conclusions
Ocular rhinosporidiosis occurs in East Africa. It may re-
semble conjunctival squamous papilloma. Although tolui-
dine blue has been used as a vital stain of conjunctival
lesions, in this case, it was unable to distinguish between
an infective and neoplastic cause.
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19 January 2012
Stephen Gichuhi
Dear Stephen
Study Title: A double-masked randomised placebo-controlled trial of adjuvant
topical 5-fluorouracil (5FU) treatment following surgical excision of
ocular surface squamous neoplasia
LSHTM ethics ref: 6097
Department: Infectious and Tropical Diseases
The Committee reviewed the above application.
Documents reviewed
The documents reviewed were:
Document Version Date
LSHTM ethics application n/a 19/01/12
Protocol V1.0 19/01/12
Information Sheet V1.0 19/01/12
Consent form V1.0 19/01/12
Provisional opinion
The Committee would be content to give a favourable ethical opinion of the research, subject to receiving a
complete response to the request for further information set out below.
The Committee delegated authority to confirm its final opinion on the application to the Chair.
Further information or clarification required
Please provide a reference for the 20% recurrence rate - the document mentions 30-66% recurrence
within 2 years only currently.
Clarify why 5-fluorouracil was selected over mitomycin or interferon - was this simply an issue of cost?
When submitting your response to the Committee, please send revised documentation where appropriate
underlining or otherwise highlighting the changes you have made and giving revised version numbers and dates.
If the Committee has asked for clarification or changes to any answers given in the application form, please do
not submit a revised copy of the application form; these can be addressed in a covering letter to the Committee.
Yours sincerely,
Professor Andrew J Hall
Chair
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Prof. Andrew J. Hall
Study Title: A double-masked randomised placebo-controlled trial of adjuvant
topical 5-fluorouracil (5FU) treatment following surgical excision of
ocular surface squamous neoplasia
LSHTM ethics ref: 6097
Department: Infectious and Tropical Diseases
Thank you for your letter dated 19th January 2012 requesting further information and clarification.
Regarding the 20% recurrence rate, operationally, published rates mostly vary between 30-60%
(summarised in the appendix attached) and involve a surgical technique in which the tumour is
excised and the sclera left bare. The lowest rate is 3.2% from a surgeon in Uganda who is probably
the most experienced in East Africa.  In our study we will have fairly experienced surgeons and the
surgical technique will involve primary closure of the excision site by mobilizing adjoining conjunctiva
or using a conjunctival autograft. We think this would reduce the recurrence rate to below 30%. In
addition, if we used 30% for sample size calculation, we would require a smaller sample but 20%
would increase the sample size. We chose to use a more conservative estimate.
With respect to the choice of 5FU, this was based on the fact that it is less costly, has lower ocular
toxicity and is more easily available in East Africa. This would make translation of the trial results
easier in the East African eye care setting. In addition, there is no published trial evidence that either
5FU, Mitomycin C or Interferon is better than the other for the treatment of ocular surface squamous
neoplasia.
Yours sincerely,
Stephen Gichuhi
Encs. Summary of published recurrence rates
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24 July 2012
To Whom It May Concern:
re: Adjuvant topical 5fluorouracil (5FU) for ocular surface squamous neoplasia
As project manager for the Pan African Clinical Trial Registry (www.pactr.org) database, it
is my pleasure to inform you that your application to our registry has been accepted. Your
unique identification number for the registry is PACTR201207000396219.
Please be advised that you are responsible for updating your trial, or for informin g us of
changes to your trial.
Additionally, please provide us with copies of your ethical clearance letters as we must
have these on file (via email, post or fax) at your earliest convenience if you have not
already done so.
Please do not hesitate to contact us at +27 21 938 0506 or email aabrams@mrc.ac.za
should you have any questions.
Yours faithfully,
Amber Abrams
www.pactr.org Project Manager
+27 021 938 0506
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1. Title
A double-masked randomised placebo-controlled trial of adjuvant topical 5-
fluorouracil (5FU) treatment following surgical excision of ocular surface
squamous neoplasia.
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3. Collaborating institutions
i) London School of Hygiene & Tropical Medicine
ii) University of Nairobi
iii) Kenyatta National Hospital
iv) PCEA Kikuyu Hospital Eye Unit
v) UCL Institute of Ophthalmology & UCL Cancer Institute
vi) Sabatia Eye Unit
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4. Funding agency
Funding has been provided by the British Council for Prevention of Blindness (BCPB) to
Dr Stephen Gichuhi to conduct this project as a PhD fellowship, registered at the
London School of Hygiene & Tropical Medicine (LSHTM).
5. Summary
In East Africa, ocular surface squamous neoplasia (OSSN) is a relatively common
aggressive disease affecting younger adults. Treatment usually involves surgical
excision, however, recurrent disease is quite common (up to 30-66% by 30 months
afterwards) and there have been no randomised controlled trials to investigate how to
reduce this. For a long time topical 5-fluorouracil (5FU) has been widely used as
adjuvant therapy following surgical excision, with many case reports and series in the
literature. However, it has not been formally tested in a randomised controlled trial and
so we currently do not know if it is effective in preventing recurrent tumours, particularly
in the context where more expensive adjuvants or surgical equipment are not readily
available.
We propose to conduct a randomised controlled trial to determine whether OSSN
recurrence can be reduced by adjuvant topical 5FU chemotherapy following excision.
Following surgical excision of histopathologically confirmed OSSN, participants will be
randomised to either 5FU eyedrops, or placebo drops to be taken four times a day for 1
month. Patients will be followed for one year to assess the effect. The primary outcome
measure is histopathologically confirmed recurrent OSSN.
6. Background
Ocular surface squamous neoplasia (OSSN) is a spectrum of disease that ranges from
non-invasive intra-epithelial dysplasia of the conjunctiva and cornea (CCIN), through to
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invasive squamous cell carcinoma (SCC).1 In recent decades OSSN has undergone an
epidemiological shift. In more temperate countries, it remains a rare, slow growing
tumour of elderly males.2 In contrast, in tropical countries, particularly in Eastern Africa,
it is now more common, more aggressive, affects younger people and slightly more
women than men.3-6 Patients often present late with advanced tumours.5 It seems likely
that much of this increased burden of disease is attributable to the HIV/AIDS epidemic.7
Even though OSSN is not a target condition within Vision 2020, a WHO initiative to
prevent avoidable blindness by the year 2020, it frequently leads to a poor quality of life,
visual disability and death. In September 2010 the “International Agency for Prevention
of Blindness (IAPB)/Vision2020 Workshop on Research for Global Blindness
Prevention” identified specific research priorities.8 It was recognised that for Africa there
was a need for research on HIV-related conditions to better define the epidemiology and
determine context-specific management approaches.
Reliable prevalence and incidence estimates of the numbers of individuals affected have
been difficult to ascertain and vary considerably. At one extreme, in one study from
Kenya based in HIV testing clinics, 7.8% of HIV-infected adults were found to have
conjunctival tumours which were found to be OSSN on histopathology.5 The Kenyan
national HIV prevalence is 7.4%% (2.22 million) so it was suggested that over 170,000
Kenyans might have some degree of OSSN.9 In contrast, a relatively low annual
incidence estimate of 2.2/100,000 has been suggested in a study from Tanzania, based
on the number of cases being operated in eye units.6 From the clinical perspective
OSSN represents a significant component of the ophthalmic “work-load” in East Africa
and is associated with a high level of morbidity for the patient, as exenteration is often
needed for those with late presentation or recurrent disease. However, OSSN receives
little or no attention from either ophthalmic or HIV care programs.
The epidemiology, aetiology and pathophysiology of OSSN in East Africa is not well
understood. There is an association with HIV; however, a significant proportion (about
30%) of people with OSSN are not infected with HIV, suggesting that other factors also
contribute to the excess burden of disease in this region.7, 10-12 The interaction between
CD4 T-lymphocyte levels in HIV+ individuals and OSSN has not been described. The
relationship between human papilloma virus (HPV) and OSSN remains unclear; some
studies have reported associations and others have not.13-18 This is probably because of
variations in methodology and the specific HPV types that have been looked for. There
are 120 genotypes of HPV.19 Some are cutaneous and others mucosal. Cutaneous
types are more frequently found in OSSN than the mucosal types.16, 20 Generally only a
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very limited sub-set of the many different HPV types have been investigated. It seems
plausible that ultraviolet (UV) solar radiation also plays a role; the risk is higher with
increasing time spent in daylight and a specific mutation associated with UV radiation
has been found more frequently in OSSN tissue.21, 22 The importance of vitamin A in
maintaining the health of the ocular surface is well known. About 40-50% of HIV-infected
adults have low levels of vitamin A (serum retinol <30 µg/dL or <1.05 µmol/L).23, 24 The
potential role of vitamin A deficiency in OSSN has not previously been investigated.
A Cochrane systematic review found no randomised controlled clinical trials of any
interventions for the treatment of OSSN.25 Most tumours are surgically excised. Very
large tumours that have spread to the orbit are usually managed by exenteration
(removal of the eye and orbital content). However, results in terms of OSSN recurrence
rates are very variable. Although one series by a very experienced surgeon reported low
recurrence rates,12 under routine operational conditions in Africa and elsewhere the
recurrence rates are much higher: reports generally range between 30% and 66% 30
months afterwards.5, 26, 27 Recurrences start as early as one month later within the first
year after excision. 26, 28, 29
To try to reduce recurrence rates various adjuvant chemotherapy treatments are
sometimes used: mitomycin-C (MMC), 5-fluorouracil (5FU) or interferon (IFN) α-2B.27, 28,
30, 31 5FU is less toxic and less costly than MMC while IFN is the most expensive and
difficult to obtain.31 5FU is one of the most commonly used antimetabolites in
ophthalmic practice, used for its anti-scarring properties in a wide variety of surgical
operations such as trabeculectomy, pterygium surgery and lacrimal surgery.32 5FU is a
pyrimidine analogue first synthesized in 1957 by Duschinsky et al.33 It is a pro-drug with
two active metabolites that have cytotoxic effects.34 One of them, 5- fluoro-2’-
deoxyuridine-5’-monophosphate (FdUMP), binds to the enzyme thymidylate synthetase
which is critical for the synthesis of thymidylate, resulting in the inhibition of DNA
synthesis. The other, 5-uorouridine-5’-triphosphate (FUTP) interferes with RNA
synthesis.35 The primary antineoplastic mechanism of action of 5FU is thought to be
through FdUMP. This mechanism is cell-cycle specific, affecting only those cells in the S
(synthesis) stage.32, 35 Various reports show that therapy with topical 5FU has been used
for a long time in different parts of the world but the effectiveness of this practice has not
been formally tested in a randomised trial.28, 31, 36-39 The first report was in 1995.36 In one
study, topical 1% 5FU was used alone, without concurrent surgery or radiotherapy.37
Case-series study of the long-term efficacy and safety of topical 5FU 1% given alone or
as adjuvant therapy following surgical excision reported recurrence rates of <10% and
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no evidence of long term toxicity or morbidity except rarely epiphora (excessive watering
of the eyes) thought to be due to scarring of the tear drainage passage.39, 40 Adjuvant
therapy is however rarely used in sub-Saharan Africa, although 5FU is available and
affordable. Randomised controlled trials are needed to identify the optimal treatment for
this condition to minimise recurrence rates, visual loss and death from conjunctival
squamous cell carcinoma in the East African setting.
7. Rationale
Ocular surface squamous neoplasia is a common and often difficult to treat disease in
ophthalmic practice in East Africa. Recurrent tumours often complicate the treatment.
There is a need for interventions to reduce recurrence rates. Post-operative 5FU drops
have been used for many years to treat patients following tumour excision, although
there is no trial data on this. There is a need for a randomised controlled trial (RCT) to
determine whether this is effective and should become standard practice. If this trial has
a positive outcome, 5FU eye drops are cheap and easily available. They do not have
stringent storage conditions and have low risk of contamination. Patients can also apply
it for themselves. Provision of this intervention on a public health scale is therefore
feasible.
8. Research question
In adults with primary OSSN, does adjuvant chemotherapy with topical 1% 5FU applied
four times daily for one month reduce the recurrence rate over a period of one year than
surgical excision alone?
9. Objectives
a) Broad Objective
To determine whether the recurrence of OSSN can be reduced through the use of
adjuvant topical chemotherapy.
b) Primary Objective
To compare the one-year recurrence rate of OSSN with or without adjuvant topical
5FU 1% eye drops applied 4 times daily for one month after surgical excision of OSSN
tumours which involve less than 2 quadrants of the conjunctiva.
c) Secondary objectives
280
version2 19/10/2012
9
i) To compare the mean time-to-recurrence of OSSN with or without adjuvant topical
5FU 1% eye drops applied 4 times daily for one month after surgical excision of
OSSN tumours which involve less than 2 quadrants of the conjunctiva.
ii) To determine the co-factors of recurrence of OSSN with or without adjuvant topical
5FU 1% eye drops applied 4 times daily for one month after surgical excision of
OSSN tumours which involve less than 2 quadrants of the conjunctiva.
iii) To determine the adverse effects of adjuvant topical 5FU 1% eye drops applied four
times daily for one month after surgical excision of OSSN tumours.
10. Study design and Methodology
Overview:
This trial is part of an integrated set of studies that will investigate the epidemiology,
aetiology, pathophysiology, diagnosis and treatment of OSSN. Figure 1 below illustrates
how patients will flow through the various components of the trial. A case-control study
component which will be examining the epidemiology, aetiology, pathophysiology and
diagnosis is being submitted in for review in a companion application to this one.
a) Study design
A double-masked randomised placebo-controlled trial of adjuvant topical 5-fluorouracil
(5FU) treatment following surgical excision of OSSN will be conducted. Tumours
involving two or less quadrants of conjunctiva that is suspected to be OSSN will be
surgically excised under local anaesthetic. All the surgeons involved in this study would
undergo standardisation training to ensure uniform good quality surgery is performed
using the “no touch” technique.41 An experienced pathologist will examine the excision
specimen for evidence of OSSN within one week of excision. Patients will be reviewed
in the clinic four weeks after the surgery to confirm that the excision site has healed.
Those with a histopathology report of OSSN will be invited to participate in the RCT.
Those who give consent will be enrolled and randomised to one of two treatment arms;
1% 5FU or placebo eye drops applied four times daily for four weeks starting after the
excision site has healed. The participants will be followed up for one year (at 1, 3, 6, and
12 months after intervention allocation).
The primary outcome will be the recurrence of the tumour at any time during the first
year of follow up defined as histological confirmation of OSSN from a re-excision biopsy.
The mean time-to-recurrence; co-factors of recurrence; and rate of “clinical recurrence”
(defined in secondary objective iii) of OSSN will also be investigated in a secondary
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analysis of the primary outcome. The secondary outcome will be adverse effects of 5FU
eye drops.
Figure 1. Randomised controlled trial.
b) Study population
This study will be conducted in 5 eye centres namely;
i) Kenyatta National Hospital eye clinic
ii) PCEA Kikuyu Eye Unit in Kenya
iii) Sabatia Eye Unit
iv) Kitale District Hospital
v) Homa Bay District Hospital
These are busy eye units with a weekly operating list in the minor theatre where
conjunctival tumours are excised or incision biopsies taken. The hospitals have access to
Voluntary Counselling and Testing (VCT) facilities and Comprehensive Care Centres
(CCC) for HIV that can offer adequate care and support for study participants who are
HIV infected.
Conjunctival
tumour ≤2 
Quadrants
Examination /
Photograph /
Investigations
Excision of
whole tumour
Pathology
OSSN
RCT
5-FU Placebo
Not OSSN
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Inclusion criteria:
1. Histologically proven ocular surface squamous neoplasia (OSSN)
2. Healed excision site.
3. At least 18 years of age.
Exclusion criteria:
1. Prior treatment with topical antimetabolite drugs such as 5FU, Mitomycin C (MMC) to
the same eye or systemic cytotoxic drugs.
2. Patients that may need more radical surgery than a simple excision eg. intraocular
extension or features suggestive of metastasis such as fornix or regional lymph node
involvement.
3. Pregnant or breastfeeding mothers.
c) Intervention arms
Surgical excision under infiltration local anaesthesia will be performed in the standard
technique of dissecting down to bare sclera. The widest diameter of the tumour will be
measured in millimetres with a pair of callipers. A 4mm-wide margin beyond the visible
edge of the tumour will be used as the incision line. The “no-touch” excision technique
described by Shields et al will be used.39 The excised tissue specimen will be immediately
fixed with 10% neutral buffered formalin in a specimen bottle labelled with the study
number and sent to the histopathology laboratory with a structured request form similarly
labelled. An additional elliptical piece of conjunctiva about 2x2mm wide next to the tumour
will be excised and sent fresh for SLRP and HPV studies. The defect left at the surgical
bed will be closed by mobilizing a conjunctival flap or tenon’s capsule flap from the
adjoining area or placing a conjunctival autograft. After excision, all participants will be
treated with oral analgesics and combined Gentamicin 0.3% and prednisolone acetate
1% eye-drops four times daily until wound healing is complete.
Individuals will be randomly allocated to one of two arms in the trial: (1) topical 5-
fluorouracil 1% drops; (2) topical placebo drops. The interventions will be packaged into
plastic eye drop bottles. Patients will be asked to self-administer the drops four times a
day to the affected eye for four weeks.
a. Topical 5-fluorouracil 1% will be reconstituted from locally available 5FU
injection 250mg/5ml Fluracedyl (Pharmachemie Ltd) by a pharmaceutical
manufacturer in Kenya (Ivee Aqua EPZ Ltd.) and diluted in Hydroxypropyl
Methylcellulose 0.7% (Ivyomoicell® Ivee Aqua EPZ Ltd, to a concentration of
1%.
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b. The placebo will be the same diluent solution used to make up the 5FU drops,
namely Hydroxypropyl Methylcellulose 0.7% (Ivyomoicell® Ivee Aqua EPZ
Ltd.).
d) Randomisation
A random allocation sequence will be generated on computer by a statistician at the
London School of Hygiene and Tropical Medicine (LSHTM) using STATA software (Stata
Corporation, College Station, TX, USA). Random permuted blocks will be used. The block
size will be randomly varied to prevent guessing the intervention assignment. Separate
randomisation lists will be prepared for each surgeon. The lists will be used by one
research staff member to label and allocate treatment bottles. The allocation sequence will
be concealed from the other investigators as only this staff member and the statistician will
handle the randomisation list.
e) Masking
The participants, the surgeon, the ophthalmologist performing the clinical examinations
and the pathologist examining the recurrence specimens will be masked to the treatment
arm allocation. The bottles of eye drops will appear similar and only identified by code
numbers. The ID number on the bottle will not provide a clue as to whether it is 5FU or
placebo. The pharmacy will not know the content of each bottle. The pharmaceutical
manufacturer will have a code generated by the statistician to use in making the eye
drops. Unmasking of an individual’s treatment will be performed on recommendation of the
data safety and monitoring board (DSMB).
f) Follow up
After the wound has healed participants will be allocated to the intervention arm then
followed-up at 1 month, 3 months, 6 months and 12 months after the date of intervention
allocation. They will be carefully examined for signs of recurrent tumours and
photographed on each occasion.
g) Primary end point and analyses
Primary analysis of primary endpoint:
The primary outcome will be the clinical recurrence of the tumour at any time during the
first year of follow-up, and where available confirmed by histology. During follow up, if the
outcome assessor notices a possible recurrence, it will be re-excised and sent for
histopathology. We will compare the proportion of recurrences at one year in the two
intervention arms. Intention-to-treat analysis will be used. The measure of effect will be the
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odds ratio with 95% confidence intervals. Kaplan-Meier analysis will be used to plot the
survival curves for both arms up to the final visit at one year.
Secondary analysis of primary endpoint
I. mean time-to-recurrence of OSSN
The time-to-recurrence will be the number of person-months between surgery and the
date the recurrence was first noted clinically. Person-months will be calculated for each
arm and the two compared. Cox regression will be used to assess the impact of the
intervention on time-to-recurrence. The hazard ratio will be estimated with Cox
regression, adjusting for substantial baseline imbalances if appropriate.
II. Co-factors of recurrence
Factors that may influence the primary outcome will be analysed. This will include HIV
infection, CD4 count, age and sex of participant, use of highly active anti-retroviral
therapy (HAART), HPV infection and serum vitamin A levels. Effect modification by the
surgeon, size of initial OSSN tumour, and rate of growth will be analysed. The association
between any of these co-factors and the primary outcome will be reported using odds
ratios and their 95% confidence intervals.
h) Secondary outcome
The main secondary outcome will be to assess the safety of using topical 5-fluorouracil 1%
four times daily for one month. We would monitor adverse events. The most commonly
reported adverse effect is epiphora but we would monitor all other events as shown below.
DEFINITIONS - The following definitions shall be adopted for safety reporting:
Adverse Event (AE): any untoward medical occurrence in a clinical trial participant
administered a medicinal product and which does not necessarily have a causal
relationship with this treatment. An AE can therefore be any unfavourable and unintended
sign (including an abnormal laboratory finding), symptom, or disease temporally associated
with the use of an investigational medicinal product (IMP), whether or not considered
related to the IMP.
Adverse Reaction (AR): all untoward and unintended responses to an IMP related to any
dose administered. All AEs judged by either the reporting investigator or the sponsor as
having reasonable causal relationship to a medicinal product qualify as adverse reactions.
The expression reasonable causal relationship means to convey in general that there is
evidence or argument to suggest a causal relationship.
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Unexpected Adverse Reaction: an AR, the nature or severity of which is not consistent with
the applicable product information (eg investigator’s brochure for an unapproved
investigational product or summary of product characteristics (SmPC) for an authorised
product). When the outcome of the adverse reaction is not consistent with the applicable
product information this adverse reaction shall be considered as unexpected. Side effects
documented in the SmPC which occur in a more severe form than anticipated are also
considered to be unexpected.
Serious Adverse Event (SAE) or Serious Adverse Reaction: any untoward medical
occurrence or effect that at any dose
• Results in death
• Is life-threatening – refers to an event in which the subject was at risk of death at
the time of the event; it does not refer to an event which hypothetically might have
caused death if it were more severe
• Requires hospitalisation, or prolongation of existing inpatients’ hospitalisation
• Results in persistent or significant disability or incapacity
• Is a congenital anomaly or birth defect
Medical judgement shall be exercised in deciding whether an AE/AR is serious in other
situations. Important AE/ARs that are not immediately life-threatening or do not result in
death or hospitalisation but may jeopardise the subject or may require intervention to
prevent one of the other outcomes listed in the definition above, shall also be considered
serious.
Suspected Unexpected Serious Adverse Reaction (SUSAR): any suspected adverse
reaction related to an IMP that is both unexpected and serious.
CAUSALITY - Most adverse events and adverse drug reactions that occur in this study,
whether they are serious or not, will be expected treatment-related toxicities due to the
drugs used in this study. The assignment of the causality will be made by the investigator
responsible for the care of the participant using the definitions in the table below.
If any doubt about the causality exists the local investigator shall inform the study site
coordinator who will notify the Chief Investigators. The pharmaceutical companies and/or
other clinicians may be asked to advise in some cases.
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In the case of discrepant views on causality between the investigator and others, all parties
will discuss the case. In the event that no agreement is made, the Kenya Pharmacy and
Poisons Board and the Kenyatta National Hospital Ethics Review Committee will be
informed of both points of view.
Table 1. Assignment of causality of adverse events and adverse drug reactions.
Relationship Description
Unrelated There is no evidence of any causal relationship
Unlikely There is little evidence to suggest there is a causal relationship
(e.g. the event did not occur within a reasonable time after
administration of the trial medication). There is another
reasonable explanation for the event (e.g. the participant’s
clinical condition, other concomitant treatment).
Possible There is some evidence to suggest a causal relationship (e.g.
because the event occurs within a reasonable time after
administration of the trial medication). However, the influence of
other factors may have contributed to the event (e.g. the
participant’s clinical condition, other concomitant treatments).
Probable There is evidence to suggest a causal relationship and the
influence of other factors is unlikely.
Definitely There is clear evidence to suggest a causal relationship and
other possible contributing factors can be ruled out.
Not
assessable
There is insufficient or incomplete evidence to make a clinical
judgement of the causal relationship.
REPORTING PROCEDURES - All adverse events shall be reported. Depending on the
nature of the event the reporting procedures below shall be followed. Any questions
concerning adverse event reporting shall be directed to the study coordinator in the first
instance. A flowchart is given in appendix 4 to aid in the reporting procedures.
i) Non serious Adverse Reactions (ARs)/Adverse Events (AEs)
All such events, whether expected or not, shall be recorded in the toxicity section of the
relevant case report form and sent to the study coordinator within one month of the form
being due.
ii) Serious Adverse Reactions (SARs)/Serious Adverse Events (SAEs)
Fatal or life threatening Serious Adverse Events (SAEs), Serious Adverse Reactions
(SARs) and Suspected Unexpected Serious Adverse Reactions (SUSARs) shall be
reported on the day that the local site is aware of the event. The SAE form asks for nature
of event, date of onset, severity, corrective therapies given, outcome and causality (i.e.
unrelated, unlikely, possible, probably, definitely). The responsible investigator shall sign
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the causality of the event. Additional information shall be sent within 5 days if the reaction
has not resolved at the time of reporting.
iii) SAEs
An SAE form shall be completed and sent to the study coordinator for all SAEs within 24
hours. However, relapse and death due to ocular surface squamous neoplasia and
hospitalisations for elective treatment of a pre-existing condition will not need reporting as
SAEs.
iv)SUSARs
In the case of serious, unexpected and related adverse events, the staff at the site shall:
Complete the SAE case report form & send it immediately (within 24 hours, preferably by
email), signed and dated to the study coordinator together with relevant treatment forms
and anonymised copies of all relevant investigations.
Or
Contact the study coordinator by phone and then send the completed SAE form by email to
the study coordinator within the following 24 hours as above.
The study coordinator will notify the Kenya Pharmacy and Poisons Board and Kenyatta
National Hospital Ethics Review Committee of all SUSARs occurring during the study
according to the following timelines; fatal and life-threatening within 7 days of notification
and non-life threatening within 15 days. All investigators will be informed of all SUSARs
occurring throughout the study.
Investigators shall report any SUSARs and /or SAEs as required by and Kenyatta National
Hospital Ethics Review Committee.
Contact details for reporting SAEs and SUSARs
Please send SAE forms to: Dr. Stephen Gichuhi on sgichuhi@uonbi.ac.ke
Tel: 0722873059 (Mon to Fri 09.00 – 17.00)
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i) Sample size
A power-based sample size calculation will be used. We anticipate a 20% OSSN
recurrence rate by one year after surgery in the placebo arm. From a programmatic
perspective in the East African setting we consider that adjuvant 5FU would be a
worthwhile intervention if it halved the recurrence rate to 10%. Using Stata IC 11 to
calculate sample size, a sample of 438 cases of OSSN (219 in each arm) would have
80% power and 95% confidence to detect a relative reduction in the risk of recurrence of
50% from 20% to 10% in the 5FU arm at one year. Including 15% extra for loss to
follow-up would make a total of 504, 252 in each arm.
j) Recruitment, consenting and retention procedures
Together the study centres surgically treat about 7 new cases of OSSN each week on
designated operating lists (about 360/year). Therefore we anticipate that we will be able
to comfortably recruit the necessary sample size within 15 months.
Participants for the trial will be recruited from a concurrent case-control study that will be
going on at the two centres. The project will be publicised using flyers and
announcements at various forums that ophthalmologists and ophthalmic clinical officers
meet and also eyecare institutions to encourage referrals. The websites of eye care
professional associations and also the East Africa Journal of Ophthalmology (EAJO) will
also carry the announcement.
During the case-control study participants with conjunctival tumours will have clinical
examinations, digital photographs, surgical excision and histology done. After excision,
they will be treated with oral analgesics and combined Gentamicin 0.3% and
Prednisolone acetate 1% eye-drops four times daily until wound healing is complete.
Usually this takes 3-4 weeks. In the interim period, histology reports will be ready. The
reports that indicate OSSN will be flagged and the patients noted for potential
recruitment into the trial. Their medical records will be checked to screen for eligibility.
During the review visit, the clinician will discuss treatment options and refer the patient
to a research nurse who will give more details about the study. The informed consent
process will be conducted by an ophthalmic research nurse trained in the procedures
involved in the study. The study information sheet will be given to them, read to them in
an appropriate language and discussed by the research nurse. Any questions will be
answered. The study information sheet will include questions to test understanding. For
illiterate patients, the study will be explained in an appropriate language with
illustrations. Enrolment into the study will be dependent on witnessed informed consent,
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which will be recorded on a consent form marked by the patient (signature or thumb
print). Those who give consent will be enrolled into the study and given a study number.
A record of potentially eligible people who decline to participate will be kept for reporting
purposes.
To aid participant retention in the study locator information and telephone contacts will
be collected and updated on every visit. Contact information of a next of kin or other
person who may be contacted in case the participant is unreachable will be requested.
Participants will provide a sketch map of their area of residence. A research nurse will
remind participants about their appointments one week before via telephone. If the
participant does not make a clinic visit within a week of their expected date of
appointment they will be rang again and a convenient date set up within the next week.
If they are unreachable on phone after a reasonable number of attempts, the next of kin
will be contacted. If the latter is unavailable after a reasonable number of attempts, a
home visit will be made by the research nurse
k) Data collection procedures
Initial data will have been collected during the case-control study. A structured case
record form (CRF) will be used in an interview to collect socio-demographic data and an
occupational, medical and care-seeking history. The following will be done during the
case-control phase of the study.
Examination: The eyes will be examined using a stereoscopic biomicroscopic slit lamp.
The clinical features of the tumour will be noted (in particular, leukoplakia, redness,
whether the surface is gelatinous, fornix involvement, feeder vessels and regional lymph
node involvement). The size of the tumour will be estimated by measuring its widest
diameter and the maximum diameter perpendicular to the first one using the slit lamp
scale. Intraocular extension will be assessed using ocular ultrasound. Fornix
involvement will be assessed clinically and with orbital ultrasound. A line drawing of the
tumour will be made in the case record form (CRF). Digital photographs of the tumour
will be taken in primary gaze and with the tumour centred. The area of the tumour will be
measured in square millimetres from the photographs using Image J software (NIH,
Bethesda, USA).
Histopathology: Since the PCEA Kikuyu Eye Unit laboratory has no facility for
histology they have an arrangement where tissue specimens are usually transferred to
the Department of Pathology MP Shah hospital where one of the co-investigators
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reports them (FSR). The tissue will be embedded in paraffin and cut into sections for
haematoxylin and eosin staining and the slide examined by a histopathologist. The
laboratory diagnosis will be recorded on the request form and sent to the clinic record. A
participant will be considered to have OSSN if histology shows any stage of dysplasia or
invasive squamous cell carcinoma.
After the participant is enrolled in the trial, the clinical information from the case-control
study will be maintained. The following will be done at the first post operative and all
follow up visits.
Examination: The eyes will be examined using a stereoscopic biomicroscopic slit lamp;
initially to document that the excision site is healed and subsequently to check for
recurrent tumours. The eye will be photographed on each visit as outlined earlier.
Presence of epiphora will be assessed by taking history and doing the fluorescein dye
disappearance test in both eyes.
If a recurrence is noted, the procedures above for surgery and histopathology will be
followed.
l) Management of other health conditions
Patients who are HIV-infected will be referred to the Comprehensive Care Center (CCC)
in the hospital for appropriate care. Adverse effects associated with the study drugs will
be appropriately treated.
m) Quality assurance
The LSHTM will be the sponsor of this trial. We will hire staff with experience in clinical
trials. All study staff will be trained and a pilot phase conducted. Data management
quality procedures involving checking case record forms (CRFs) before and after filling
and other subsequent procedures are described in the data management section further
below.
A data safety and monitoring board (DSMB) will be constituted. The DSMB in
consultation with the Trial Steering Committee will determine if an interim analysis is
required to monitor if a significant difference in recurrence rates is reached at an earlier
than anticipated stage or if additional recruitment is required. The DSMB will monitor
reports of any adverse events, such as moderate to severe ocular surface or skin
inflammation.
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The laboratories to be used have been certified for good laboratory clinical practice
(GCLP). The laboratories participate in External Quality Assurance (EQA) of their
processes. An extra histology slide will be prepared from each tissue specimen to be
examined at the Institute of Ophthalmology, part of University College London (UCL) for
peer review.
The guidelines of the Kenyatta National Hospital-University of Nairobi Ethics Review
Committee (KNH/UON/ERC) and LSHTM on trial monitoring and reporting will be
followed. Protocol deviations will also be reported to the DSMB.
After approval by the KNH/UON/ERC this protocol will be submitted to the Kenya
Pharmacy and Poisons Board for registration of the 5FU eye drops to ensure they
conform to good manufacturing practices (GMP).
A Material Transfer Agreement (MTA) between the laboratories involved in the project
will be prepared and approved by the Kenya Ministry of Medical Services Department of
standards and regulatory services prior to any sample transfer.
n) Training procedures
Protocol training will be provided for all staff who will work on the project. In addition
they will be given training updates in good clinical practice (GCP) and research ethics.
They will be required to obtain GCP certification and update them regularly. The
surgeons will undergo training to standardize the excision procedure.
11. Ethical considerations
The principles of GCP and in particular the ethical principles of the Declaration of
Helsinki will be followed in this trial. Only participants who freely give written consent will
be enrolled into the study. The rights, safety and well being of participants will be
assured. The protocol will be submitted for ethics review at KNH/UON/ERC & LSHTM.
The investigators and research staff will have the appropriate education, training and
experience. Accurate data handling, protection and confidentiality will be ensured.
Quality assurance systems will be instituted as described in section (m) above. The
sponsor will monitor trial activities and provide insurance.
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12. Data management
Data clerks supervised by a data manager will check the case record forms (CRFs) to
ensure full completion. Where data is missing, the CRF will be flagged on the database
and clinic register for supplementary interviews to be conducted during the next follow
up visit. The key unique identifier variable will be the study number. This will appear on
all pages of the CRF, specimen containers and laboratory request forms. When reports
are received from the laboratory, the results will be entered onto the CRF. The serial
number of the source documents (laboratory reports, medical records, digital
photographs) will be noted in the CRF.
Data will be transferred from CRF to a MS Access database with an interface that
appears similar to the CRF to minimize errors in data entry. The database will be
designed with must-enter variables, logic checks, legal values and specified range
checks built into the program to enable interactive checking during data entry.
Interactive checking allows the data clerk to be prompted on the screen if an erroneous
value is entered. After data entry, batch checking will be done. Batch checking will also
apply the standard checks (range, legal values etc) as well as consistency checks.
Verification of data entry will be done using the double entry method. This will involve
data being entered twice into two separate files by two different data clerks. The two
files will then be compared (using EpiData) and any discrepancies checked against the
CRFs and/or source documents. The clean dataset will then be transferred from MS
Access to Stata version IC 11 software (Stata Corporation, College Station, TX, USA)
for analysis. In the end all CRFs and laboratory reports will be filed and boxed (box 5
Figure 2) in order of study number.
All CRFs received from the interviewers and clinicians will be recorded in a register and
put in a box (Box 1 in figure 2). They will be manually checked for errors and if there is
no query they will be put in a box labelled 2 for the first entry. After the first entry, the
CRFs will be put in a box labelled 4 and taken for the second entry. The principal
investigator will compare the first and second entry. Any CRF with a query will be
marked and put in a special query box (Box 3 in Fig. 2).
On site, after the photographs are taken, the picture will be reviewed for clarity. Unclear
pictures will be repeated. The picture serial number from the camera will be noted on
the CRF. Pictures will be downloaded in computer in which photo databank
management software is installed and backed up at the end of each day. Similarly MS
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Access and Stata databases will be backed up daily on compact discs. Antivirus scans
will be run daily on the computers.
Figure 2. Flow chart for data handling
CRF/ Photos / Histology
report from clinic/lab
Check records
Recorded in study register
BOX 3BOX 1
Query
Return to interviewerCheck manually for queries.(missing data, inconsistencies)
No Query
BOX 2
Query
1st Data entry into Access file
No Query BOX 4 Query
2nd Data entry into Access file
No Query Query
Data manager compares 1st &
2nd data entry
No Query
Save and back-up Access file
Query
No Query
Use Stat Transfer to import Access
file into Stata IC 11. Merge files,
clean, save and back-up. (ossn.dat)
BOX 5
All CRFs and lab reports filed
sorted by study number
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13.Study limitations and how to minimize them
Delayed recruitment of the required sample size and loss to follow up during the trial may
be a challenge. Measures to facilitate recruitment and retention are outlined in section (j)
above. In addition, a 15% loss to follow up contingency has been built into the sample
size calculation (section i).
14. Timeline
Research fellowship to start from Q4 2011 and run for three years.
Table 2. Project timeline
Activity
2011 2012 2013 2014
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
Scholarship result
Finalize full protocol
Ethics committee
submission
Write SOPs
Equipment
procurement
Staff recruitment
Protocol training
Pilot phase
Modify SOPs as
needed
Participant
Recruitment Phase
Follow-up Phase
PhD Upgrade
Data analysis
Write up
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16.Appendix
Appendix 1 Statistical analysis plan
1) Participant flow
A summary of the flow of participants through the different phases of the trial; enrolment,
allocation, follow up and analysis will be made following the 2010 CONSORT flowchart
(Schulz et al 2010 http://www.consort-statement.org/consort-statement/overview0/).
This will show the numbers eligible, consenting to take part, randomised, who received the
intended treatment by arm. For each follow-up time-point the numbers seen, censored,
defaulting, and permanently lost-to-follow-up will also be shown by arm. The numbers
excluded at each stage and reasons for their exclusion will be noted such as reasons for
declining to take part, not completing treatment, not having re-excision surgery, or
discontinuing follow-up.
2) Summary of the baseline characteristics of the trial population
A table will show a summary of baseline characteristics of the trial population such as total
number involved further subdivided by study centre, age and sex.
3) Comparison of treatment groups with respect to baseline variables thought to be
associated with main outcome
The following characteristics of participants at baseline will be tabulated by arm:
a) Socio-demographic factors: age, sex.
b) Behavioural factors: smoking, outdoor occupation, wearing hats/caps.
c) Clinical status: HIV status, HPV infection, CD4 count, serum vitamin A levels, tumour
size and histological grade.
Categorical variables will be reported as numbers and proportions while continuous
variables will be reported as mean and standard deviations if normally distributed or medians
and interquartile range if their distribution is skewed. We will eyeball for differences between
groups with respect to these variables but avoid any formal tests of the null hypothesis for no
between-group differences since it will be assumed to hold if randomization was done
properly. If one arm has appreciably more severe cases than the other – by chance – the
primary analysis will be adjusted during multivariable regression.
4) Primary analysis of the primary outcome measure by intention to treat
Definition of primary end-point
The primary outcome will be the clinical recurrence of the tumour at any time during the first
year of follow-up, and where available confirmed by histology. Where histology is not
available, photographs recurrent lesions will be reviewed by two consultant ophthalmologists
experienced in OSSN in East Africa.
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Justification of primary outcome:
The aim of adjuvant therapy is to reduce the rate of recurrence and therefore increase
tumour-free survival after surgical excision.
a) We will present an estimated effect of treatment on recurrence of the tumour at any
time during the first year of follow up defined as clinical recurrence of OSSN OSSN
from a re-excision biopsy. The numbers of events (recurrences in the first year) and
risk of recurrence in both arms will be shown in a table. The odds of recurrence will
be compared using the odds ratio (OR) and its 95% confidence interval adjusting for
surgeon. The null hypothesis will be no treatment effect. The number needed to treat
will also be estimated.
b) We hope to achieve no less than 85% follow up and have adjusted sample size for
this. If follow up is not as good as expected, sensitivity analysis will be conducted to
examine the possible effect of losses to follow up to see if these may affect the
treatment effect estimate.
5) Primary analysis adjusted for baseline variables
It is expected that the important baseline characteristics that are known to affect the risk of
recurrence will be balanced between the two arms through randomisation. If the arms are
found to be substantially imbalanced an appropriately adjusted logistic regression model will
be used.
6) Secondary analysis of the primary outcome
a) Effect of the intervention on time-to-first-recurrence.
The time-to-first-recurrence variable is an estimate of the tumour-free survival period. The
numbers of events, person-months and rate of recurrence in each arm will be shown.
Kaplan-Meier analysis will be used to plot the survival curves for both treatment arms up to
the final visit at 1 year. The Mantel-Cox hazard ratio will be used to assess the impact of the
intervention on time-to-first-recurrence. The hazard ratio will be estimated with Cox
regression, adjusting for substantial baseline imbalances if appropriate.
b) Risk factors for recurrence
A multivariate logistic regression model will be used to identify potential explanatory factors
for recurrent tumour at one year, in addition to the randomised adjuvant therapy allocation.
Baseline factors which will be examined in this model of recurrent tumour will include:
i) Age
ii) Sex
iii) HIV status
iv) Mean CD4 count
v) HAART
vi) HPV infection
vii) Smoking
viii) Serum Vitamin A level
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c) Effect modification
We will assess effect modification of the intervention on recurrence at one year with the
following factors by including an interaction term with treatment arm in the logistic regression
model.
i) Pre-operative tumour size – proxy measure will be the estimated area measured
from digital photographs
ii) Rate of tumour growth – estimated as a function of tumour size above and time in
months since the participant noticed the tumour. We hypothesize that tumours
with a high rate of growth have a higher propensity to recur.
iii) Operating surgeon
7) Analysis of adverse effects (secondary outcome)
A secondary outcome will be the prevalence of epiphora (watering of the eyes) at 12
months. The prevalence of any epiphora and a positive dye disappearance test at any follow
up visit in the treated eye will be described by arm.
8) Sensitivity analysis
Where expert opinion is unable to be unequivocally certain about the recurrence, sensitivity
analysis will be conducted, categorizing these as non-OSSN.
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Appendix 2 – Flow chart for reporting of safety events
Safety event as defined in
SOP observed in participant
Record in CRF
Fill Adverse Event
Reporting Form on
computer
Email to study
coordinator
Print copy of
email for file
File hard copy
IF UNABLE TO FILL ON COMPUTER,
FILL HARD COPY
Ring study
coordinator to report
event
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